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ABSTRACT 
 
Andrew W. Roberts: Optimizing the Public Health Benefit of a Medicaid Controlled Substance Lock-In 
Program 
(Under the direction of Joel F. Farley and Asheley C. Skinner) 
 
 
 Medicaid controlled substance lock-in programs (MLIP) have garnered increased attention for 
their potential role in combating prescription drug abuse. MLIPs are purported to enhance care 
coordination for high-risk beneficiaries by restricting access to a single prescriber and pharmacy for 
controlled substance service coverage. However, the MLIP evidence base is largely non-existent. The 
purpose of this dissertation was to examine two threats to MLIP effectiveness: lock-in circumvention 
through out-of-pocket purchases and lack of standardized MLIP eligibility criteria. Our aims were to 
investigate: 1) the effect of enrollment in the North Carolina (NC) MLIP on controlled substance 
circumvention behavior, 2) prescription-level characteristics of circumvented opioid analgesics, and 3) 
optimal claims-based measures of high-risk opioid use for assessing MLIP eligibility. 
 We used a retrospective cohort of NC MLIP enrollees and linked NC Medicaid claims and 
Controlled Substances Reporting System data from 10/1/2009-9/30/2012. Generalized estimating 
equations estimated the effect of MLIP enrollment and covariates on circumvention behavior (Aim 1). 
Subjects were 3.6 times more likely to obtain a controlled substance prescription through circumvention 
after MLIP enrollment. Generalized linear models estimated the association of MLIP enrollment with 
circumvention of opioids with high-risk prescription-level attributes (Aim 2). Mean prescribed daily 
opioid dose and the likelihood of a circumvented prescription containing a Schedule II opioid product or a 
long-acting opioid product did not increase after MLIP enrollment. 
 Medicaid claims data for cross-validation cohorts of opioid users in NC Medicaid were used to 
test and validate optimal measures of high-risk opioid use (Aim 3). The highest performing dichotomous 
  iv 
predictors of overdose were selected using survival receiver operating characteristic models and bivariate 
Cox model fit. The best measures were ≥5 opioid claims and ≥12 daily milligram morphine equivalents 
over 60 days, but these exhibited low sensitivity in capturing subjects with overdose. 
 MLIP enrollment induced people to circumvent Medicaid to obtain controlled substance 
prescriptions, negating the underlying purpose of the MLIP intervention. Also, current MLIP eligibility 
assessment strategies performed poorly in selecting beneficiaries at highest risk for preventable overdose. 
Reducing MLIP circumvention and optimizing eligibility criteria to better capture highest risk individuals 
are necessary to bolster MLIP public health benefit. 
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CHAPTER I:  INTRODUCTION 
 
 
1.1 OVERVIEW 
 The past two decades have given rise to an epidemic of prescription drug abuse in the United 
States. Nearly 16 million people over the age of 12 report using a prescription medication for nonmedical 
(e.g. recreational) purposes in the previous year.1 Over 10% of nonmedical users newly initiated these 
behaviors within the previous year. This epidemic is largely fueled by a four-fold increase in the 
manufacture and prescribing of controlled substance medications since 1999.2 The drastic rise in the 
availability and nonmedical use of prescription drugs—particularly controlled substances—has resulted in 
recent alarming trends in abuse and overdose-related outcomes. Controlled substance overdose is now the 
second-leading cause of unintended death in the United States behind automobile accidents.3 Between 
1999 and 2008, the prescription drug overdose death rate increased 400%, reaching a peak of over 20,044 
fatalities in 2008.4 Emergency department visits related to nonmedical controlled substance use nearly 
tripled between 2004 and 2010.5 Additionally, researchers estimate that nonmedical controlled substance 
use results in a societal economic burden of $50-$70 billion annually.2,6 Figure 1.1 depicts the recent 
increases in controlled substance prescribing, overdose deaths, and healthcare utilization.2 
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Figure 1.1: Rates of opioid sales, deaths, and substance abuse treatment admissions (1999-2010) 
 
Source: Centers for Disease Control and Prevention. Prescription painkiller overdoses in the US. November 2011; 
http://www.cdc.gov/vitalsigns/painkilleroverdoses/. 
 
 Much of the controlled substances used for nonmedical purposes are obtained through entirely 
legal prescribing and dispensing processes.7,8 The Centers for Disease Control and Prevention (CDC) 
estimate that nearly 85% of abused controlled substances were originally prescribed to the nonmedical 
user or to a friend or relative.1 The fact that legal distribution channels are a major source of abused 
medications creates an opportunity to mitigate the nonmedical use of controlled substances through policy 
intervention. Two of the most common policy strategies for identifying and preventing nonmedical 
controlled substance use occur on the state level: prescription drug monitoring programs (PDMP) and 
Medicaid lock-in programs (MLIP). Although the focus of this dissertation lies on evaluating the MLIP 
policy strategy, it is important to first understand the role of PDMPs for the purpose of establishing the 
current policy context in which MLIPs operate and also to lay a foundation for detailing this dissertation’s 
novel analytic approach, which leverages the breadth of PDMP data. 
 PDMPs are electronic databases that automatically aggregate patient-, prescription-, prescriber-, 
and pharmacy-specific information for controlled substance prescriptions dispensed by community 
pharmacies in a state. They are currently employed in 47 states.9 Prescribers and pharmacists can access 
the PDMP data to view a patient’s controlled substance-seeking behaviors preceding the patient encounter 
in order to inform safe healthcare decisions in light of suspected nonmedical use. Currently, the primary 
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limitations of PDMPs include low utilization by providers and lack of interstate cooperation between state 
PDMP systems.10 When accessed by providers, though, the evidence indicates that PDMPs reduce 
unnecessary controlled substance prescribing, prevent doctor- and pharmacy-shopping behaviors, and 
inform higher quality medical decision-making of controlled substance use.11-14  
 In a prior publication, I found that at least 46 states also operate MLIPs.15 MLIPs work by, first, 
identifying Medicaid beneficiaries exhibiting “high risk” controlled substance-seeking behaviors.16 
Individual state MLIPs typically define high risk controlled substance use through assessment of the 
number controlled substance prescriptions received, as well as prescribers and pharmacies used in a given 
time period. Medicaid beneficiaries that exceed a state’s threshold for high-risk controlled substance use 
based on claims review are “locked in” to specific providers—usually one prescriber and pharmacy. This 
means that during periods of MLIP enrollment, Medicaid will only pay for a beneficiary’s controlled 
substance-related services if they were accessed through the designated lock-in providers.  
 The MLIP is intended to reduce prescription drug abuse burden in the Medicaid population by 
creating better care coordination among providers caring for patients with high-risk controlled substance 
use. Better care coordination is thought to ultimately prevent nonmedical use behaviors and adverse 
outcomes for the high-risk Medicaid beneficiaries enrolled in the program. Unlike PDMPs, however, the 
body of evidence supporting the MLIP policy strategy’s public health benefit in combating nonmedical 
prescription drug use is minimal. There has been little to no peer-reviewed research, to date, examining 
the effect of MLIPs on substance abuse and overdose-related outcomes. There are also noted limitations 
of the MLIP intervention that may potentially undermine the current and future benefits of MLIPs in 
improving care coordination and outcomes from high-risk controlled substance use.  
 The purpose of this dissertation was to provide rigorous examination of two key MLIP 
limitations. The first limitation is the ability of MLIP enrollees to circumvent the lock-in provider 
restrictions by purchasing controlled substance prescriptions completely out of pocket. The second 
limitation is a stark lack of knowledge concerning measures of high risk controlled substance use that 
most effectively identify Medicaid beneficiaries who benefit most from MLIP intervention. To my 
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knowledge, findings from this dissertation represented one of the first attempts to establish an MLIP 
evidence base. It is hoped this new knowledge will be leveraged to inform MLIP optimizations that 
enhance the public health benefit of this policy strategy in fighting the prescription drug abuse epidemic. 
1.2 SPECIFIC AIMS 
 In October 2010, North Carolina (NC) Medicaid implemented the Recipient Management Lock-
In Program (further referred to as the NC MLIP). The NC MLIP enrolled beneficiaries meeting at least 
one of the following eligibility criteria assessed over a period of two consecutive months: ≥7 opioid 
prescription claims, ≥7 benzodiazepine prescription claims, and/or ≥4 unique prescribers of these 
medications.17 NC MLIP enrollees were locked in to one prescriber and one pharmacy for a period of 12 
months. The recent introduction of this program to the controlled substance abuse policy landscape in 
North Carolina—which has operated a PDMP called the Controlled Substances Reporting System 
(CSRS) since 2005—created a unique opportunity to contribute a rigorous MLIP examination to the peer-
reviewed literature and inform state-level policy efforts to curb nonmedical prescription drug use.  
 The research evaluating the NC MLIP conducted herein was investigated under the umbrella of a 
parent project. The parent project was an interdisciplinary collaboration of researchers across the 
University of North Carolina at Chapel Hill. It was funded by the Centers for Disease Control and 
Prevention (CDC) [PI: Asheley Skinner, Grant No. CDC U01 CE002160-01]. The aims of the parent 
project represented initial population-level policy evaluation questions. It included a qualitative process 
evaluation of NC MLIP administration and quantitative investigations of the population-level effect of the 
NC MLIP on the number of controlled substance prescription fills and overdose events in the NC 
Medicaid population.  
 This dissertation project utilized the parent project team’s rich data resources to develop research 
questions examining known MLIP policy limitations of MLIP circumvention and lack of consensus on 
optimal MLIP eligibility criteria. Specifically, this dissertation addressed the following research 
questions: (1) To what extent did NC MLIP enrollees adhere to program restrictions, and what patient 
characteristics predicted circumvention behavior? (2) Are certain opioid analgesic prescriptions more 
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likely to be circumvented than others? and (3) What are the most effective claims-based measures for 
identifying high-risk beneficiaries for potential enrollment in the MLIP?  
 This dissertation used a novel dataset linking Medicaid claims data with records from the North 
Carolina CSRS, the state’s PDMP surveillance database. Because the PDMP captures data for all 
controlled substance prescriptions dispensed in the state regardless of payer, this merged dataset allowed 
observation of an MLIP enrollee’s complete controlled substance-seeking behavior, whether or not they 
adhered to the lock-in restrictions.  
 The specific aims of this dissertation were: 
  Aim 1: To examine the effect of the NC MLIP, as well as patient-level characteristics, on 
controlled substance circumvention behaviors. 
 Controlled substance circumvention occurs when NC Medicaid beneficiaries purchase an opioid 
or benzodiazepine prescription entirely out of pocket without submitting a prescription claim to the 
Medicaid benefit. Although this behavior constitutes fraud when a Medicaid beneficiary is enrolled in the 
MLIP, circumvention can easily happen in situations where the MLIP enrollee visits a pharmacy and fails 
to inform the pharmacy of their Medicaid coverage. Also, a pharmacy may inappropriately allow the 
enrollee to pay the full cash price for the medication out of pocket despite knowledge of active Medicaid 
coverage. Circumvention of the MLIP restrictions has serious consequences for the intended public health 
impact of MLIPs. For MLIP enrollees that circumvent the program with the intent of abusing or diverting 
controlled substances, the ability to circumvent Medicaid fails to prevent access to these medications. For 
MLIP enrollees with legitimate medical need of controlled substances, circumvention may reflect the 
MLIP causing undue access barriers to necessary medications. In either case, circumvention undermines 
the ability of MLIPs to confer enhanced provider care coordination of these high-risk patients and it 
wastes state resources used to operate the MLIP. 
 The purpose of Aim 1 was to isolate the effect of the NC MLIP on circumvention behaviors and 
identify predictors of lock-in circumvention behavior in the NC MLIP population. This evidence will 
provide some of the first evidence of the prevalence and extent of circumvention in an MLIP population. 
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This will inform opportunities for targeted improvements in MLIP design and operation. Analyses for 
Aim 1 utilized the novel Medicaid-CSRS linked dataset. This dataset allowed identification of 
circumvention behavior. Circumvention was defined as the presence of an opioid or benzodiazepine 
prescription fill record in the CSRS dataset that lacked a corresponding prescription fill record in the 
Medicaid claims data. The study sample was a longitudinal cohort of adult NC MLIP enrollees with 
continuous NC Medicaid coverage. A retrospective cohort design with repeated monthly measures was 
used. We described patient-level characteristics of the study cohort and compared circumvention behavior 
trends across NC MLIP enrollment status through bivariate analyses. Generalized estimating equation 
(GEE) modeling estimated the relationship between NC MLIP enrollment, as well as select patient-level 
characteristics, with the likelihood and extent of circumvention at the person-month level. GEE leveraged 
the repeated monthly measures to account for time trends and control for within-subject correlation. The 
first GEE model utilized multivariable logistic regression to estimate the effect of MLIP enrollment and 
patient predictors on engaging in any circumvention behavior. The second GEE model examined the 
effect of MLIP enrollment and patient predictors on the number of circumvention fills obtained.  
  Aim 2:  To investigate prescription-level characteristics of opioid analgesics obtained by NC 
MLIP enrollees through circumvention. 
  Aim 1 examined whether enrollment in an MLIP induced circumvention behavior and how often 
NC MLIP enrollees engaged in circumvention. However, this knowledge alone does not fully capture the 
global implications of circumvention for the public health impact of MLIPs. It is also necessary to 
understand the characteristics of controlled substance prescriptions MLIP enrollees obtain through 
circumvention. The risk of prescription overdose and mortality from nonmedical use, particularly related 
to opioid analgesics, is largely a function of the potency and the amount of the opioid agent ingested.18 
Higher potency opioids and larger amounts of opioids more readily contribute to adverse clinical 
outcomes compared to weaker opioid agents and reduced quantities. Therefore, certain opioid products 
used in medical practice in the United States present a greater potential for overdose outcomes. For 
example, opioid products classified as Schedule II agents by the Drug Enforcement Agency (DEA) 
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represent a group of opioids with the highest potency. Schedule II products include agents such as 
morphine, oxycodone, fentanyl, and methadone. Additionally, long-acting, or extended-release, opioid 
preparations have greater potential to contribute to overdose due to larger amounts of opioids contained 
within each dosing unit, as compared to short-acting products. Long-acting opioids include products such 
as Oxycontin tablets, transdermal fentanyl patches, and extended-release morphine capsules and tablets. 
Aside from Schedule II and long-acting qualities, the strength of a prescription opioid product and the 
prescribed quantity also play a major role in a prescription’s abuse and overdose potential. 
  The purpose of Aim 2 was to examine the effect of NC MLIP enrollment, as well as patient 
predictors, on prescription-level characteristics of opioid fills received through circumvention. 
Specifically, three prescription-level opioid characteristics were investigated: receipt of a Schedule II 
product vs. non-Schedule II, receipt of a long-acting opioid vs. short-acting opioid, and the amount of 
opioid product received in a prescription (measured as prescribed average daily milligram morphine 
equivalents). Collectively, these three outcomes capture the abuse potential of individual prescriptions 
received by NC MLIP enrollees. Analyzing trends in these prescription-level characteristics among 
circumvented opioid fills provided valuable knowledge for the extent to which circumvention behavior 
might contribute to downstream overdose outcomes, whether NC MLIP enrollment induced changes in 
utilization of certain opioid products, and prescription-level characteristics that may signal attractiveness 
for MLIP circumventers. 
  Aim 2 utilized the linked Medicaid claims-CSRS dataset, as well as the same cohort of adult NC 
MLIP enrollees with continuous NC Medicaid coverage. A retrospective cohort study design was used for 
the study period of 10/1/2009 through 9/30/2012. Prescription-level characteristics of opioid fills were 
described and compared across MLIP enrollment status through bivariate analyses. Multivariable analyses 
involved a series of generalized linear models estimating the pre/post effect of NC MLIP enrollment on 
likelihood of receiving a Schedule II opioid, the likelihood of receiving a long-acting opioid, and 
differences in average daily milligram morphine equivalents prescribed. The unit of analysis was the 
prescription. GLM models included patient-level characteristics implemented in Aim 1. The primary 
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GLM analysis of these outcomes was performed in the sample of circumvented opioid fills. They were 
also performed in the Medicaid-covered opioid prescription fill sample and the combined sample of 
opioid fills from both payment sources in order to observe comprehensive trends in opioid utilization. 
  Aim 3: To identify and validate the most effective measures of high-risk opioid analgesic use in 
the NC Medicaid population.  
 Defining high-risk controlled substance use in the context of NC MLIP eligibility currently 
involves assessment of the number of controlled substance-related prescription fills and prescribers used 
in a given time period. However, when looking at MLIP eligibility criteria used across state Medicaid 
programs, there exists a remarkable lack of standardization with regard to the specific measures and 
thresholds used for assessing MLIP eligibility. And currently, there are no peer-reviewed studies in the 
literature providing evidence for the most effective strategy to define high-risk controlled substance use in 
the context MLIPs as it relates to notable meaningful public health outcomes.  
 Aim 3 analyses filled this gap in the MLIP literature by rigorously evaluating the effectiveness of 
various opioid exposure measures in predicting relevant clinical outcomes from high-risk opioid use. 
Results from this aim help establish best practices in MLIP design by informing strategies for identifying 
beneficiaries most likely to benefit from program enrollment from a public health perspective. Aim 3 
employed a retrospective cohort design using Medicaid claims data from 10/1/2008 through 9/30/2010. 
The study cohort included adult NC Medicaid beneficiaries who recorded an opioid prescription claim in 
the first year of the study period. Survival receiver operating characteristic (ROC) modeling was 
employed to examine the discriminatory capability and optimal thresholds of four opioid exposure 
measures in predicting an outcome event during a follow-up period of up to one year. Opioid exposure 
measures included: number of opioid claims received, number of unique community and outpatient 
pharmacies used to obtain opioids, average daily opioid dose, and average daily acetaminophen (APAP) 
dose from opioid/APAP combination products. All opioid exposure measures were assessed over a 60-
day period following the index opioid prescription fill. The primary outcome was unintentional opioid 
overdose, and secondary outcome measures were unintentional APAP overdose, unintentional overdose 
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of any drug product, diagnosed opioid use disorder, and any diagnosed substance use disorder. High 
performing opioid exposure measures and their optimal thresholds identified in a randomly selected 
testing sample were validated in the remaining subjects. Performance of optimal measures in predicting 
the Aim 3 outcomes was assessed through descriptive analysis, Cox proportional hazard models, and 
Kaplan-Meier estimation. 
1.3 SIGNIFICANCE  
 Medicaid lock-in programs represent a highly prevalent state-level strategy for combating the 
ongoing epidemic of prescription drug abuse in the United States. These policies are poised to reduce 
nonmedical controlled substance use and its consequences among Medicaid beneficiaries—a patient 
population known to experience greater rates of prescription drug abuse and overdose-related death.19-22 
In fact, multiple academic and governmental sources, including the Office of the President of the United 
States, have explicitly identified MLIPs as a key tool moving forward in this fight.23,24 However, rigorous 
evaluations of MLIPs are largely absent from the literature. Any meaningful application of MLIPs in 
large-scale efforts to mitigate nonmedical use will require a deep understanding of what constitutes an 
effective MLIP design and how lock-in enrollment impacts patient outcomes.  
 Findings from this dissertation project contribute significantly to this field by rigorously 
examining two important and previously uninvestigated MLIP limitations that may currently undermine 
the public health benefit of this policy. The first MLIP limitation is the problem of Medicaid 
circumvention. Circumvention negates the intended effect of MLIP restrictions because it reflects a 
failure to regulate access to inappropriate use of controlled substances and obviates the care coordination 
that adherence to provider lock-in restrictions would provide. From a public health perspective, 
circumvention is also problematic because Medicaid agencies have previously been unable to observe and 
respond to this phenomenon in the MLIP population. Aims 1 and 2 of this dissertation provide new and 
valuable knowledge to MLIP stakeholders regarding two key aspects of circumvention behavior. Aim 1 
focused on characterizing the prevalence and likelihood of NC MLIP enrollees to circumvent Medicaid to 
obtain controlled substances. Aim 2 further rounded out our understanding of circumvention in the NC 
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MLIP population by investigating prescription-level characteristics of opioid analgesics obtained through 
circumvention. Aim 2 findings characterized whether certain opioid prescriptions were more attractive for 
circumvention and provided new understanding of the level of risky opioid use occurring outside the 
current reach of MLIP administrators. Both Aims 1 and 2 also identified patient-level predictors of their 
respective outcomes. This information will inform targeted MLIP design modifications and educational 
interventions of providers to improve adherence to MLIP restrictions and, ultimately, improve the quality 
of care and patient outcomes for Medicaid beneficiaries engaging in risky controlled substance use.  
 The second key MLIP limitation is reflected in the absence of any semblance of accepted 
definitions of high-risk controlled substance utilization in MLIP eligibility criteria. The findings from 
Aim 3 will help illuminate the most effective strategy or strategies for defining high-risk controlled 
substance use within the context of MLIP enrollment criteria. Validated MLIP eligibility criteria are 
necessary to ensure enrollment of beneficiaries most likely to benefit from this policy intervention. This 
information—along with lessons learned from using a novel dataset merging claims and PDMP data—
will be invaluable in future efforts to create much-needed interoperable prescription drug abuse 
monitoring tools that aggregate multiple relevant data sources across state lines.8,10,25-28 Lastly, the need 
for the evidence provided by this dissertation project concerning the effectiveness and optimal design of 
MLIPs is made all the more urgent by the recent and ongoing influx of millions of patients into the 
healthcare system as a result of expanded insurance coverage under the Affordable Care Act. Millions of 
newly insured Americans will gain coverage through Medicaid programs. With more Medicaid 
beneficiaries, MLIPs will have a greater potential impact on reducing nonmedical controlled substance 
use among this patient population that has borne a substantial brunt of the prescription drug abuse 
epidemic.  
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CHAPTER II:  BACKGROUND, LITERATURE REVIEW, AND CONCEPTUAL MODEL 
 
 Chapter II is presented in three sections. The first section provides background information 
regarding controlled substance pharmaceuticals; trends in the nonmedical use of prescribed controlled 
substances; prescription drug monitoring program and Medicaid lock-in program policy strategies for 
mitigating nonmedical controlled substance use; and a description of North Carolina’s PDMP and MLIP. 
The second section comprises a rigorous review of the literature evaluating MLIP-related outcomes and is 
followed by identification of gaps in the literature that motivate the research questions in Aims 1 and 2. 
The second section also reviews the body of evidence examining definitions of high-risk controlled 
substance use in prescription claims data, which provides a foundation for the investigations of Aim 3. 
The third section of Chapter II outlines a conceptual framework upon which analyses of the dissertation 
aims are based. 
2.1 BACKGROUND 
2.1.1 Introduction 
 This section details necessary background knowledge and establishes the public health and policy 
context in which the dissertation were developed. It provides a comprehensive overview of issues 
pertaining to controlled substances, including regulation, utilization trends, and the major policy strategies 
currently used to address nonmedical controlled substance use in the United States and in North Carolina, 
specifically. 
2.1.2 Overview of Controlled Substances 
 The Controlled Substances Act of 1970 granted the Drug Enforcement Agency (DEA) and the 
United States Food and Drug Administration (FDA) the power to classify pharmaceuticals with no 
acceptable medical use or with the potential for abuse and dependency as controlled substances.29 
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Controlled substances are classified into Schedules, ranging from Schedule I to Schedule V.30 The 
schedule decision is primarily informed by the degree of a drug product’s abuse potential. Designation as 
a controlled substance imposes stricter regulations on the accessibility of these medications. For example, 
Schedule II prescriptions cannot have refill authorizations and must be presented to the pharmacy in a 
hardcopy paper form. Table 2.1 describes characteristics of each controlled substance Schedule, as well as 
common medication classes and products in each.  
Table 2.1: Summary of federal controlled substance schedules 30,31  
Schedule Description Major drug classes Primary use Example generic drug products 
(Brand) 
I No accepted medical use. High  
abuse potential and severe  
psychological or physical 
dependence 
Illicit street drugs Recreation Marijuana, heroin, LSD 
II High abuse potential but less than  
Schedule I drugs. Potential for 
severe psychological or physical 
dependence. 
Opioid analgesics 
Stimulants 
Pain 
ADHD 
Oxycodone HCL (Oxycontin, 
Percocet);  
fentanyl (Duragesic); Amphetamine 
salts (Adderall); methylphenidate HCL 
(Ritalin) 
III Less abuse potential than Schedules  
I and II but more than Schedule IV.  
Moderate to low potential for  
psychological or physical 
dependence. 
Opioid analgesics Pain Hydrocodone combination products 
(Vicodin); codeine products with 
<90mg/dose (Tylenol #3) 
IV Low abuse potential. Low risk of  
dependence. 
Benzodiazepines 
Sedative/hypnotics 
Muscle relaxants 
Anxiety 
Insomnia 
Muscle 
spasms 
Alprazolam (Xanax); diazepam 
(Valium) 
Zolpidem tartrate (Ambien) 
Carisoprodol (Soma) 
V Lower abuse potential than 
Schedule IV. 
Codeine-based  
antitussives 
Cough <200mg/mL codeine preparations 
(Robitussin AC) 
Note: LSD=lysergic acid diethylamide; ADHD=attention deficit hyperactivity disorder; HCL=hydrochloride; mg=milligram; 
mL=milliliter 
 
 
2.1.3  Controlled Substance Use Behaviors 
  The increased abuse potential of controlled substances, along with their accessibility through 
legal channels, makes them prime targets for undesirable medication use behaviors among patient 
populations and the public at large.32 A constellation of terminology exists to describe ways in which 
individuals consume controlled substances outside of their intended purpose or directions for use. These 
include nonmedical use, misuse, abuse, dependence, addiction and pseudoaddiction.33 Table 2.2 provides 
definitions for each concept, as developed by the Substance Abuse and Mental Health Services 
Administration (SAMHSA).  
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Table 2.2: Controlled substance utilization pattern definitions 
Concept Definition 
Nonmedical use Use of prescription drugs that were not prescribed by a medical professional (i.e., 
obtained illicitly) or use for the experience or feeling a drug causes.  
Misuse Incorrect use of a medication by patients, who may use a drug for a purpose other than 
that for which it was prescribed, take too little or too much of a drug, take it too often, 
or take it for too long 
Abuse A maladaptive pattern of substance use, leading to clinically significant impairment or 
distress as manifested by one or more behaviorally based criteria 
Dependence Increasing tolerance for a drug, withdrawal signs and symptoms when a drug  
is discontinued, or the continued use of a substance to avoid withdrawal 
Addiction Increasing tolerance for a drug, withdrawal signs and symptoms when a drug  
is discontinued, or the continued use of a substance to avoid withdrawal 
Pseudoaddiction Drug-seeking and other behavior that is consistent with addiction but actually  
results from inadequate pain relief 
33 
 
 Nonmedical use represents the broadest definition of “risky” controlled substance utilization, 
allowing for the fact that these substances could have been obtained through legal means or through 
diversion.33 In this context, diversion means any method for distributing controlled substances, or 
obtaining controlled substances with the intent to distribute them, through illegal channels; this includes 
theft; forgery of prescriptions; receipt from friends or family members; or doctor- and pharmacy-
shopping.34 Shopping behaviors refer to visiting multiple providers to illicitly obtain large quantities of 
controlled substances.35 Misuse behaviors are a subset of nonmedical use in which the medications were 
prescribed to the misusing individual. Abuse refers to patterns of nonmedical use or misuse that have 
escalated to the point of causing impairment or significant adverse health outcomes, such as overdose.36 
2.1.4 Nonmedical Controlled Substance Use—Prevalence and Trends 
 Utilization of controlled substances grew exponentially in recent decades.37-39 In fact, the 
manufacture and sales of opioid analgesics quadrupled from 1999 to 2010.2 Not only did the number of 
prescriptions for controlled substances increase during this time compared to non-controlled 
medications,40 but the average quantity of opioid analgesics per prescription rose substantially as well.41,42 
In 2012, Kenan et al’s analysis of a large, nationally-representative controlled substance claims database 
found that the average size of oxycodone and hydrocodone prescriptions increased 69% and 67%, 
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respectively, between 2000 and 2010.41 This growth has been driven in large part by a substantial, yet 
clinically controversial,43,44 increase in the prescribing of opioid analgesics to treat chronic non-cancer 
pain (CNCP) diagnoses.45-48 Controlled substances are now among the most commonly prescribed 
medications in this country; hydrocodone combination products have been the most frequently dispensed 
drug in the United States since the mid-2000s, with alprazolam, zolpidem, and oxycodone also ranking in 
the top 25.49  
 With the drastic increase in the controlled substance prescribing, it is not surprising that 
nonmedical use of controlled substances is highly prevalent in the United States.50 The annual National 
Survey on Drug Use and Health (NSDUH), sponsored by SAMHSA, found that 6.8 million people over 
the age of 12 reported nonmedical use of prescription drugs in the past month—mostly involving opioid 
analgesics.1 Nearly 16 million people reported nonmedical use in the past year. In addition, 750,000 
Americans newly initiated nonmedical use of prescription drugs in 2012, alone. Estimates report four to 
six percent of adults use medications for nonmedical purposes at some point in their lifetime.1,51-53 While 
the NSDUH shows relatively stable incidence of reported nonmedical use over the past decade, other 
evidence shows an increasing trend. In 2013, Roland, et al found that diagnosed opioid abuse doubled 
among privately insured patients between 2005 and 2010.54 Research also suggests a significant shift in 
preference from illicit street drugs to the nonmedical use of controlled substances for recreational 
purposes.55,56 A 2013 national survey reported that nearly 30% of law enforcement agencies believe 
controlled substances pose the greatest drug threat, up from 10% three years prior.57 
2.1.5 Nonmedical Controlled Substance Use—Clinical Outcomes 
 The high prevalence of nonmedical controlled substance use translates into significant adverse 
health consequences—primarily overdose events and overdose-related mortality.58-60 Overdose events 
involving opioid analgesics can result in death due to fatal respiratory depression, especially in the 
presence of other intoxicants.61 Acute overdose of opioid/APAP combination products—as well as 
prolonged ingestion of greater than four grams of acetaminophen daily from these products—may also 
lead to death from APAP-induced liver toxicity.62 Additionally, benzodiazepines are commonly 
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implicated in multi-substance overdose deaths due to its contribution to fatal respiratory depression.63 
However, acute benzodiazepine overdoses rarely cause death when they are the single intoxicant.64 In 
2008, there were over 20,000 deaths due to prescription drug overdoses in the United States; 75% of these 
were tied to opioid analgesics.2,4 This represented a four-fold increase in the prescription drug overdose 
death rate since 1999.4 Controlled substance overdoses are now the second-leading cause of unintended 
death in the United States behind motor vehicle accidents.3 
2.1.6 Nonmedical Controlled Substance Use —Healthcare Utilization Outcomes 
 In addition to clinical outcomes, nonmedical controlled substance use is associated with increased 
utilization of costly healthcare services.37,39,54 SAMHSA’s Drug Abuse Warning Network found that, in 
2011, 1.2 million emergency department visits stemmed from nonmedical prescription drug use.5 Of 
these, nearly one-third were directly tied to nonmedical use of opioid analgesics and over half involved 
multiple pharmaceutical agents. Between 2004 and 2011, the incidence of nonmedical use-related 
emergency department visits increased 183%.5 In 2011, White and colleagues found that opioid abusers 
were up to nine times more likely to be hospitalized, three times more likely to utilize emergency 
services, and they received up to four times as many prescription services compared non-abusing opioid 
users.65 As previously shown in Figure 1.1, there is a striking increase in utilization of healthcare services 
and deaths resulting from nonmedical use observed over the past decade.20 
2.1.7 Nonmedical Controlled Substance Use —Economic Outcomes 
 Not surprisingly, the dramatic rise in nonmedical controlled substance use creates substantial 
economic burdens on patients, payers, and society, in general.28 It is reported that opioid abusers incur 
anywhere from three to seven times higher healthcare costs than non-abusers.50,54,66,67 In 2011, White et al 
found that this translated to $15,000-$20,000 in excess annual healthcare costs per opioid abuser; annual 
out-of-pocket costs were $1,000 higher for caregivers of opioid abusers compared to those taking care of 
non-abusers.65 Multiple efforts have been made in the literature recently to quantify the total societal cost 
of nonmedical use of controlled substances. Estimates range from roughly $25 billion in unnecessary 
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costs annually68,69 up to $53 billion per year.6 The CDC reports this figure could actually be in excess of 
$72 billion annually.2 
2.1.8 Nonmedical Controlled Substance Use —Trends in North Carolina 
 The effects of the nonmedical controlled substance use epidemic have been felt in North 
Carolina, specifically. Currently, rates of controlled substance sales, reported nonmedical use, and 
nonmedical use-related fatalities are in line with national averages.4,70 Most of the increase in nonmedical 
use fatalities were concentrated in rural Western North Carolina71, which is consistent with other literature 
investigating nonmedical use trends in Appalachian regions.72,73 Since 1997, the number of annual deaths 
in North Carolina due to controlled substance overdose increased around 200-300%74,75, claiming a total 
of 7,100 lives by 2008.71 Opioid analgesics and benzodiazepines were implicated in roughly 90% of these 
prescription overdose fatalities. Controlled substance overdoses in North Carolina were on pace to 
imminently (or perhaps already) surpass vehicular accidents as the leading cause of injury-related deaths 
in the state.74  
2.1.9 Addressing Nonmedical Use Through Policy 
 Nonmedical users often obtain controlled substances through entirely legal processes involving 
licensed prescribers and pharmacies.7,8,76 Results from the National Survey on Drug Use and Health found 
that over 80% of controlled substances used for nonmedical purposes originated as a prescription written 
for either the nonmedical user or one of their friends or family members.1 Because the majority of 
misused and abused controlled substances are distributed through legal channels, this provides 
policymakers and payers with opportunities to combat nonmedical use through policy and regulatory 
strategies. In fact, numerous Federal entities have been on a crusade in recent years to draw attention to 
the epidemic of nonmedical prescription drug use. The US Department of Health and Human Services’ 
Health People 2020 campaign explicitly identified reduction of nonmedical controlled substance use as an 
objective.77 Publications from the US Government Accountability Office28, CDC78,79, and Centers for 
Medicare and Medicaid Services80 urge policymakers and researchers to develop and implement smart 
policies for the identification and provision of appropriate care for nonmedical users, in addition to 
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infusing collaboration across local, regional, state, and Federal levels. A 2011 landmark report from the 
Office of the President of the United States, “Epidemic: Responding to America’s Prescription Drug 
Abuse Crisis,” recommended a four-pronged policy approach: improve patient and provider education 
about nonmedical use; proper medication disposal; stronger enforcement against “pill mill” prescribers; 
and smarter tracking and monitoring of controlled substance utilization behaviors.23 
 The attention drawn by the alarming trends of nonmedical controlled substance use in the US, 
coupled with the added momentum from Federal urging to address this problem, has led to many policy 
and practice changes in recent years. For example, many community-based organizations were created to 
provide direct comprehensive support and education to hard-struck areas.81,82 Prescription drug take-back 
initiatives have proliferated, which remove unused or unwanted pharmaceuticals from peoples’ homes 
that may have been misused or diverted otherwise.83 84,85 In clinical practice, significant efforts have been 
made to reduce prescription forgery14,86, increase prescribing of abuse-deterrent opioid formulations87, and 
integrate substance abuse screening instruments into regular practice.88 Some of the most robust efforts to 
reduce nonmedical use of controlled substances happen through state-level policy strategies, namely 
prescription drug monitoring programs and, the policy strategy that is the focus of the proposed 
dissertation, Medicaid controlled substance lock-in programs. 
2.1.10 Prescription Drug Monitoring Programs 
 Although this dissertation does not directly evaluate PDMPs, it is important to provide 
background on this strategy to fully understand the policy landscape in which MLIPs operates and to 
highlight how integrating PDMP and payer data—which is used for Aim 1 analyses—enhances the 
monitoring of risky controlled substance use. 
 PDMPs are electronic databases that aggregate controlled substance dispensing records in a state. 
They collect detailed information for controlled substance prescriptions dispensed by all community 
pharmacies within state lines regardless of the source of payment—out-of-pocket or payer-covered. Most 
states collect records for drugs in all Schedules II-V.89 PDMPs records typically include patient-, 
prescription-, prescriber-, and pharmacy-level information for each prescription. Prescribers, pharmacists, 
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and, in some cases, law enforcement agencies, are then able to register with the PDMP and access its data 
through online portals to view past controlled substance utilization patterns for patients under their care. 
The National Alliance for Model State Drug Laws identifies five primary purposes for implementing 
PDMPs: “(1) to support access to legitimate medical use of controlled substances, (2) to help identify and 
deter or prevent drug abuse and diversion, (3) to facilitate and encourage the identification, intervention 
with, and treatment of persons addicted to prescription controlled substances, (4) to help inform public 
health initiatives through outlining of use and abuse trends, and (5) to help educate individuals about 
PDMPs and prescription drug use, abuse, diversion, and addiction.”89  
 The concept of tracking state-level controlled substance dispensing dates back to the 1930s in 
California.10 However, the introduction of two federal grant programs90 in 2002 and 2005, as well as 
improved technology contributed to a recent proliferation of PDMPs. Currently, 49 states have enacted 
PDMP legislation and 47 operate active PDMPs.9  
 PDMPs form the cornerstone of the Office of the President’s 2011 initiative to improve the 
tracking and monitoring of controlled substance use.23 Despite some conflicting findings91, the available 
body of evidence generally indicates that PDMPs can successfully reduce controlled substance utilization, 
shopping behaviors, and improve prescribing practices.11-14,92-94 The primary limitations facing PDMPs at 
this date are limited provider engagement with the programs95-97, lags in data availability, and lack of 
data-sharing capabilities across state lines and with other key data streams like prescription insurance 
claims data.26 
2.1.10.1 North Carolina Controlled Substances Reporting System 
  In 2005, the state of North Carolina passed PDMP legislation establishing the CSRS, which was 
later implemented in 2007.98 Prescribers and pharmacists are granted access to the CSRS, which collects 
records for all Schedule II through Schedule V controlled substances. CSRS data aggregates detailed 
patient-, prescriber-, pharmacy-, and prescription-level for each controlled substance prescription 
dispensed from community pharmacies within the State of North Carolina. Currently, however, the CSRS 
does not contain a field indicating the source of payment for the controlled substance prescription. North 
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Carolina pharmacies report controlled substance claims data to the CSRS weekly.99 A recent internal 
evaluation of providers’ experience with the CSRS found that 86% of provider respondents were 
registered with the program, and over 93% of providers had accessed the CSRS at least once in the 
previous three months.100 
2.1.11 Medicaid Lock-In Programs 
 In addition to operating PDMPs, the vast majority of states (n=46) also operate controlled 
substance lock-in programs designed to identify, correct, and prevent high-risk nonmedical use behaviors 
in their Medicaid populations.15 (Medicaid was established in 1965 by Title XIX of the Social Security 
Act as a joint state and federally funded health insurance program for the poor and disabled.101) This is 
not surprising given Medicaid beneficiaries are particularly susceptible to nonmedical controlled 
substance use behaviors and its consequences.102 The rate of controlled substance prescribing among 
Medicaid beneficiaries increased two- to three-fold over the past 15 years.19,22,48 In fact, literature has 
shown Medicaid beneficiaries are up to twice as likely to receive an opioid analgesic prescription than 
privately insured or uninsured populations, when controlling for demographic and clinical 
characteristics.21,103 Notably, Washington Medicaid beneficiaries had a six-fold risk of opioid-related 
death, accounting for half of all such events despite making up only 22% of the state’s population.20 
 MLIPs—sometimes referred to as patient review and restriction programs—attempt to mitigate 
these trends by enrolling beneficiaries that exhibit controlled substance utilization patterns indicative of 
nonmedical use. Once identified, MLIP administrators restrict their access, or “lock” them in, to specific 
providers as a stipulation for Medicaid coverage of controlled substance-related services. The purpose of 
operating an MLIP is multifactorial.15  First, restricting beneficiaries, for example, to one prescriber and 
one pharmacy for their opioid prescriptions allows those providers to establish heightened levels of care 
coordination, deliver higher quality care, and ultimately improve health outcomes. Also, MLIPs are 
intended to prevent doctor- and pharmacy-shopping behaviors, which would mitigate the diversion of 
Medicaid-covered controlled substance prescriptions to other parties for nonmedical use. Lastly, states 
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stand to enjoy substantial economic savings from a reduction in unnecessary controlled substance-related 
services and avoidance of downstream clinical outcomes from nonmedical controlled substance use. 15 
 The legal foundation for MLIPs was established in 42 CFR 431.54(e). These rules provide a 
general framework for MLIPs16: 
(e) If a Medicaid agency finds that a recipient has utilized Medicaid services 
at a frequency or amount that is not medically necessary, as determined in 
accordance with utilization guidelines established by the State, the agency 
may restrict that recipient for a reasonable period of time to obtain Medicaid 
services from designated providers only. The agency may impose these 
restrictions only if the following conditions are met: 
(1) The agency gives the recipient notice and opportunity for a hearing (in 
accordance with procedures established by the agency) before imposing the 
restrictions. 
(2) The agency ensures that the recipient has reasonable access (taking into 
account geographic location and reasonable travel time) to Medicaid services 
of adequate quality. 
(3) The restrictions do not apply to emergency services furnished to the 
recipient. 
 
The Federal rules only stipulate that MLIPs must inform candidates of the lock-in decision prior to their 
MLIP enrollment, must ensure reasonable access to quality Medicaid services, and must not impede 
access to emergency medical services. The rest of the program design decisions are left up to state 
Medicaid agencies. These decisions include the MLIP enrollment criteria, qualifying medication classes, 
which provider(s) MLIP enrollees get locked in to, and the duration of the lock-in period. Most MLIPs 
restrict enrollees to either one pharmacy or one pharmacy plus one prescriber. The lock-in period 
typically lasts from 12 to 24 months, with some states employing longer subsequent lock-in periods if the 
nonmedical use behaviors do not resolve after the initial enrollment term. In addition, most states define 
their MLIP eligibility criteria using threshold measures of numbers of controlled substance prescription 
claims and number of controlled substance prescribers and pharmacies used. However, considerable 
variability exists in how state MLIP administrators utilize these measures to define their criteria for 
“excessive” use of controlled substance services (Table 2.3).15  
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Table 2.3: Enrollment criteria for states with publicly available Medicaid lock-in eligibility details (as of 2/22/14)a 
State 
Assessment 
periodb Prescription criteria Prescriber criteria 
Pharmacy 
criteria Other criteria 
Alaska Monthly for 2 
consecutive 
months 
Receipt of prescriptions with frequency ≥2 
standard deviations of mean; 
Receipt of prescriptions from ≥1 prescribers 
in total average daily doses exceeding those 
recommended in Facts & Comparisons 
  Provider referral 
Colorado 3 months ≥3 drugs in the same therapeutic category; 
≥16 prescriptions 
 ≥3 pharmacies Provider referral 
Idaho 60 days ≥6 benzodiazepine claims; 
≥8 opiate claims;  
≥3 tramadol claims; 
≥480 tramadol tablets; 
≥6 months of continuous muscle relaxant use 
Use of "multiple" 
prescribers 
Use of 
"multiple"  
pharmacies 
"Excessive" ED use; 
Drug dependence or abuse 
history; 
Provider referral 
Kentucky 2 consecutive 
180-day periods 
≥10 different prescription drugs; ≥5 prescribers ≥3 pharmacies ≥4 ED visits for non-emergency; 
≥3 different EDs used for  
non-emergency 
Massachusetts 3 months ≥11 Schedule II-IV prescription fills; AND ≥4 prescribers; OR ≥4 pharmacies  
Michigan 3 months ≥5 claims for CS or muscle relaxants; 
"Aberrant" CS utilization patterns over 1 year 
≥2 prescribers for  
duplicate services 
≥3 pharmacies ≥3 ED visits; 
Repeat ED use with no follow-up; 
Repeat ED use for non-
emergency 
Nevada 60 days ≥9 CS claims 
  
 
New 
Hampshire 
(any three 
criteria) 
90 days ≥3 drugs in same drug class; 
Same/similar drug received from different  
pharmacies within 2 days; 
100 units per prescription per 7-day supply 
≥3 prescribers ≥3 pharmacies ≥2 ED visits 
 
New Jersey NR ≥2 prescription fills "in excess of what any 
one prescriber would intend" 
Use of "multiple" 
prescribers 
Use of 
"multiple"  
pharmacies 
Presentation of forged or altered  
prescription 
North Carolina 2 consecutive 
months 
≥6 benzodiazepine claims; 
≥6 opiate claims 
≥3 prescribers  Provider referral 
Oregon 6 months “Exhibit patterns of drug misuse” Use of "multiple" 
prescribers to obtain 
same/similar drugs 
≥3 pharmacies  
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Utah 12 months ≥6 CS prescription fillsc  ≥3 prescribers ≥4 pharmacies ≥4 primary care providers visited; 
≥4 specialists visited; 
≥5 ED visits for non-emergency 
Virginia 3 months Exceed 200% max therapeutic dose of drug 
class or 100% max therapeutic dose of drug 
class from ≥2 prescribers for period ≥4 weeks; 
Duplicate prescription fills within 2 days on 
two separate occasions; 
≥2 CS prescriptions from ≥2 pharmacies or ≥2 
prescribers for period ≥4 weeks; 
≥24 prescriptions; 
≥12 CS prescriptions 
≥3 prescribers; 
≥2 physician visits 
for similar diagnoses 
within 2 days 
≥3 pharmacies ≥3 ED visits for non-emergency; 
Provider referral; 
Pattern of non-compliance 
Washington 
(any two 
criteria) 
3 months ≥10 prescriptions; 
CS prescriptions from ≥2 prescribers  
(automatic eligibility if this criterion met) 
≥4 prescribers ≥4 pharmacies Similar services from ≥2 
providers 
on same day; 
≥10 office visits; 
≥2 ED visits (automatic eligibility); 
“At risk” fraudulent behavior 
(automatic eligibility) 
West Virginia 60 days Suboxone therapy in last 30 days; 
≥6 claims within single class with abuse 
potential; 
≥6 claims from ≥3 classes with abuse potential; 
≥16 claims for all drugs with abuse potential; 
"Doctor shopping" involving ≥6 claims for 
drug 
with abuse potential from ≥3 prescribers filled 
at ≥2 pharmacies 
≥3 prescribers of 
drugs 
with abuse potential 
 History of dependence; 
History of poisoning/overdose 
Wyoming NR  ≥2 prescribers ≥2 pharmacies  
Note: CS=controlled substance; ED=emergency department; NR=not reported. Information in this table reflects evidence identified in published literature and publicly 
available sources online. 
a. Eligibility for lock-in enrollment contingent on meeting one individual criterion listed within the state, except where noted as otherwise. 
b. Assessment of individual lock-in enrollment criteria occurs over the designated time period in this column, except where noted with criterion as otherwise. 
c. CS utilization criteria for Utah Medicaid Restriction Program assessed over time period shorter than 12 months, but exact duration unavailable 
 
Table from: Roberts AW, Skinner AC. Assessing the Present State and Potential of Medicaid Controlled Substance Lock-In Programs. J Manag Care Pharm. 
May 2014;20(5):439-446c.  
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 Unlike the PDMP policy strategy, there is limited peer-reviewed evidence available to inform our 
current understanding of optimal MLIP design and the effectiveness of MLIPs in achieving positive 
effects on nonmedical controlled substance use. Available literature pertaining to MLIP-related outcomes 
and MLIP enrollment criteria design are discussed in Sections 2.2 and 2.3, respectively. 
2.1.11.1 North Carolina Medicaid Recipient Management Lock-In Program 
 North Carolina Medicaid implemented their MLIP, the Recipient Management Lock-In Program, 
in October of 2010.17,104 North Carolina Medicaid beneficiaries are eligible for MLIP enrollment if they 
meet at least one of the following criteria based on retrospective utilization review of NC Medicaid claims 
data and are not being treated for cancer:  
• Fill ≥7 opioid analgesic prescriptions in a period of two consecutive months; 
• Fill ≥7 benzodiazepine prescriptions in a period of two consecutive months; 
• Receive opioid or benzodiazepine prescriptions from four or more unique prescribers in a period 
of two consecutive months; 
• Referred for enrollment from a provider or the North Carolina Division of Medical Assistance. 
 
 The North Carolina Division of Medical Assistance (DMA) administers the NC MLIP but 
contracts with a third-party vendor, Affiliated Computer Services (ACS), to manage program enrollment. 
ACS retrospectively applies the NC MLIP enrollment criteria to the most recent 60 days of Medicaid 
claims data to identify beneficiaries eligible for lock-in. Roughly 3,000 to 4,000 Medicaid beneficiaries 
meet the inclusion criteria at any given time.105 They then rank those eligible for the MLIP by severity of 
controlled substance seeking-behavior, which is assessed through clinical pharmacist review and a 
proprietary algorithm that considers number of prescriptions received, providers used, and controlled 
substance costs incurred. ACS then provides DMA with the prioritized list of eligible Medicaid 
beneficiaries, at which point DMA conducts another clinical drug utilization review and begins the MLIP 
enrollment process for the finalized list of eligible individuals.  
 MLIP enrollees are notified of their lock-in status through a mailed letter and have a 30-day 
period in which to designate one preferred lock-in pharmacy and one preferred lock-in prescriber. Once 
enrolled, individuals are locked in to their preferred prescriber and one pharmacy—or assigned a 
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prescriber and pharmacy if no preference is designated—for North Carolina Medicaid coverage of 
services involving benzodiazepine and opioid analgesic medications. The initial enrollment period lasts 
12 months, at which point enrollees are evaluated for release from the MLIP or for re-enrollment.  
 DMA phased in NC MLIP implementation by enrolling roughly 200 eligible NC Medicaid 
beneficiaries into the MLIP each month beginning in October 2010. For example, in the first six months 
of MLIP implementation, the number of lock-in beneficiaries increased from 58 to 954.105  
 
2.2 LITERATURE REVIEW—MLIP Outcomes and Evaluations 
2.2.1 Section Overview 
 Despite the majority of state Medicaid agencies operating controlled substance lock-in programs, 
relatively little is known about the effectiveness of this policy strategy in mitigating the nonmedical use 
of prescribed controlled substances or its effect on a broad range of utilization, economic, and clinical 
outcomes. This section provides a comprehensive review of all available evidence for the effects of 
Medicaid lock-in programs. In sections 2.2.2 through 2.2.4, we summarize the landscape of evidence for 
the effect of MLIP policies on general economic, utilization, and clinical outcomes found in the peer-
reviewed literature, two doctoral dissertations, and unpublished MLIP grey literature. We utilized 
PubMed, Google Scholar, and Web of Science databases to conduct the review of relevant published 
literature prior to May 2014. We searched the grey literature using Google, Google Scholar, and 
comprehensive review of individual state Medicaid agency websites prior to May 2015. This non-
published evidence was largely comprised of publicly accessible reports and presentations developed 
from internal MLIP administrator evaluations. For both the published and grey literature searches we used 
free-text and Boolean operator strategies with key search terms, such as “Medicaid,” “controlled 
substance,” “lock in,” “restriction,” “recipient management,” and individual state names and state MLIP 
monikers. We also identified relevant sources of evidence through secondary review of article 
bibliographies to ensure complete capture of evidence.  
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 Then in sections 2.2.5 and 2.2.6, we explicitly discuss the limited available evidence for the effect 
of MLIPs on circumvention behavior outcomes, which are the specific MLIP outcomes investigated in 
Aims 1 and 2, respectively. Section 2.2 closes with a summary of the body of MLIP outcomes evidence 
and identification of major gaps in the literature that informed the development of the research questions 
posed in both the parent project and Aims 1 and 2 of this dissertation. 
2.2.2 General MLIP Outcomes—Peer-Reviewed Literature 
 The first MLIP evaluation was conducted in Missouri by Singleton in 1971, the year after its 
implementation.106 At the time, Missouri Medicaid beneficiaries were identified for MLIP enrollment 
through a combined automated and manual patient review focusing on aberrant shopping behaviors and 
excessive quantities of prescriptions received. Missouri MLIP enrollment reached nearly 6,000 
beneficiaries per quarter in 1970. Singleton only analyzed economic outcomes among this sample, but he 
estimated the MLIP would result in nearly $11 million in savings to the state annually. 
 Another early MLIP evaluation was conducted in Hawaii’s Medicaid program in 1984 by 
Chinn.107 Hawaii’s MLIP restricted enrollees to any combination of a primary care physician, pharmacy, 
clinic group, or hospital. Beneficiaries qualified for MLIP enrollment by displaying aberrant prescriber, 
pharmacy, or controlled substance use. Chinn identified 270 individuals enrolled in Hawaii’s MLIP 
between July 1977 and December 1983. Fifty (21%) of the enrollees were found to be compliant with the 
MLIP restrictions for 12 months following enrollment, as identified by “fair hearings” taking place 
between MLIP administrators and enrollees. Fair hearings with all 270 enrollees identified “very few” 
beneficiaries that continued pre-enrollment levels of Medicaid services abuse. Chinn also estimated that 
the MLIP resulted in $909,922 in total savings to the state for the year of 1983, alone. 
 A 1998 peer-reviewed presentation abstract from Blake et al. described the results of an 
investigation into the Louisiana Medicaid lock-in program’s effect on pharmacy provider continuity, 
prescription utilization, and prescription expenditures. The authors performed a pre-post examination of a 
retrospective cohort of 1,490 Louisiana Medicaid lock-in enrollees using segmented regression analyses 
to analyze trends following MLIP implementation.108 The authors found a significant increase in the total 
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number of prescriptions filled at a single pharmacy following enrollment in the MLIP. The total number 
of unique drug products received per enrollee, utilization of Schedule II narcotics, and total prescription 
expenditures all decreased significantly following MLIP enrollment. Further unpublished findings related 
to Blake’s analyses are reported in Section 2.2.3 below. 
 Hladilek and colleagues conducted a broad overview of quality initiatives employed in the 
Wisconsin fee-for-service Medicaid population in 2004.109 One such quality initiative they studied was 
the Recipient Lock-In Program (RLP), which was implemented six years prior and had an enrollment of 
62 to 250 beneficiaries over that time. Although their evaluation primarily focused on the efficiency of 
communicating notices of beneficiary qualification for RLP enrollment to providers and patients, they 
also looked at utilization and economic outcomes. Their analyses, which were based on 1997 data, found 
that RLP enrollment was associated with a 24% decrease in prescription expenditures and similar 
decrease in emergency room visits and inpatient hospitalizations. A cost benefit analysis found that for 
each dollar invested in administering the RLP, the state saved $6.16, which validated a prior return-on-
investment analysis.110 
 Oklahoma Medicaid administrators also published a summary of results of an evaluation of their 
Pharmacy Lock-In Program in a 2009 issue of the Journal of the Oklahoma State Medical Association.111 
The article states that lock-in enrollment significantly improved healthcare-seeking behaviors of Medicaid 
beneficiaries, including narcotic medication use, doctor- and pharmacy-shopping behaviors, and 
emergency department use. The average number of monthly narcotic claims per Oklahoma Medicaid 
member steadily decreased from 2.5 immediately preceding MLIP implementation to slightly over one fill 
per month one year following the program start date. Further unpublished results from this evaluation are 
detailed in Section 2.2.4. 
 The most recent peer-reviewed published data regarding MLIP-related outcomes comes from a 
paper presented by Kachur, et al., at the 2013 AcademyHealth Annual Research Meeting.112 The authors 
identified 111 adult beneficiaries of the Medicaid Managed Care Organization (MCO) in Maryland 
initially enrolled in the state’s MLIP between March 2008 and February 2011. MLIP enrollees were 
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locked in to a single prescriber and pharmacy. The authors utilized a comparator group of 2,248 Medicaid 
MCO beneficiaries not enrolled in the MLIP but were identified as exhibiting opioid overuse by the 
health plan. The Medicaid MCO defined overuse as eight or more opiate prescriptions written by three or 
more prescribers during the previous six months. The authors used bivariate analyses to investigate 
demographic and disease burden differences between groups, and retrospective difference-in-difference 
methods were used to estimate the differential effect of MLIP enrollment on opiate utilization and 
healthcare utilization between study groups for six-month periods prior to and following enrollment. 
 MLIP enrollees were slightly younger at 37.4 years of age, on average, compared to 42.1 years 
for the non-MLIP beneficiaries.112 Both groups were roughly 70% female. MLIP enrollees were more 
likely to reside in suburban (44.1%) and urban settings (34.2%), as opposed to the comparator group, of 
which 40% lived in rural settings. Disease burden was similar between the groups, with about 30% of 
each sample having at least five diagnosed chronic conditions. Following MLIP enrollment, study 
subjects displayed a significant decrease in mean number of opiate prescribers (2.29 vs. 0.85), mean 
number of opiate prescriptions (3.18 vs. 1.53), and per-member-per-month opiate costs ($157 vs. $153). 
Difference-in-difference analyses indicated these differences remained significant when considering 
comparison group trends. Kachur and colleagues also found significant decreases in utilization of primary 
care providers and emergency care, as well as total healthcare expenditures. However, these were 
insignificant in difference-in-difference analyses. MLIP enrollment had no impact on receipt of substance 
abuse treatment services.  
2.2.3 General MLIP Outcomes—Doctoral Dissertation Findings 
 Two doctoral dissertations evaluating Medicaid lock-in programs were identified in the ProQuest 
Dissertations & Theses Full Text database.113  
 In 1997, Blake completed a comprehensive evaluation of Louisiana Medicaid’s lock-in 
program.114 This investigation included 1,490 MLIP enrollees and assessed utilization and economic 
outcomes for the 12-month periods before and after enrollment in the MLIP. Study subjects were 48 years 
of age, on average, and mostly female, White, and residing in metropolitan areas. Louisiana MLIP 
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enrollees also had poor health status. Three-fourths of the study sample received Supplemental Security 
Income disability benefits. The mean number of comorbidities per enrollee was 24.5, defined as unique 
five-digit International classification of Diseases, Ninth Revision (ICD-9) diagnosis codes during the pre-
enrollment period.  
 Major findings from Blake’s dissertation work were previously discussed in Section 2.2.2 with 
regard to the conference presentation abstract published by Blake, et. al.108 In short, using an interrupted 
time series design, Blake found the Louisiana MLIP reduced polypharmacy, Schedule II narcotic 
prescription fills, inpatient days, physician office visits, diagnostic tests, pharmacy costs, and total 
healthcare costs. The program also improved provider continuity, with the number of enrollees using a 
single physician increasing from 52% in the pre-MLIP period to 83% in the post-MLIP period and use of 
a single pharmacy increasing from 63% to 92%. 
 Beaubien completed dissertation work in 2005 that examined of the effect of a Northeastern 
Medicaid managed care organization lock-in program on pharmacy and healthcare utilization.115 This 
portion of the project identified a retrospective cohort of 307 Medicaid MCO beneficiaries enrolled in the 
MLIP in the calendar year of 2001. Similar to previously discussed studies, the Northeastern MLIP 
enrollees were predominantly female with a mean age of 44 years. Beaubien employed a pre-post design 
using enrollees’ pharmacy and medical claims data available for one year periods prior to and following 
lock-in enrollment. The MLIP was associated with a 17% reduction in controlled substance prescription 
claims. The number of medical claims from both outpatient office visits and emergency department visits 
were consistent before and after MLIP enrollment. The number of medical claims originating from an 
inpatient hospital setting increased 16% following MLIP enrollment. Beaubien partially attributes the 
observed trends partially, however, to underlying historical trends seen in the general Medicaid 
population. 
2.2.4 General MLIP Outcomes—Unpublished MLIP Evaluation Data 
 Multiple sources of MLIP evaluation data were identified through comprehensive search of the 
grey literature. Most of these sources took the form of commissioned reports or presentation materials that 
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communicate results from internal state MLIP evaluations. First, a recent evaluation of the North Carolina 
Medicaid Recipient Management Lock-In Program is highlighted. Then, additional unpublished MLIP 
evidence is reported, grouped by economic, utilization, and clinical MLIP outcomes. 
2.2.4.1 General MLIP Outcomes—Internal North Carolina MLIP Report 
 The State of North Carolina commissioned a report in 2011 to evaluate the impact of their MLIP, 
implemented in October 2010, on healthcare utilization and outpatient pharmacy costs.105 The evaluation 
assessed changes in outcome measures between the six month period before the MLIP start date—April 
through September 2010—and the six month period following—October 2010 through March 2011. 
Because enrollment of qualifying beneficiaries into the MLIP was steadily phased in at a rate of roughly 
200 additional enrollees monthly, this evaluation captured a total of 2,909 person-months of exposure to 
the MLIP policy. They also utilized a comparator group of beneficiaries meeting the state’s criteria for 
MLIP enrollment but were not yet enrolled into the program during the study period.  
 The report estimated the MLIP was associated with $279,500 in total gross outpatient pharmacy 
savings in the first six months of MLIP implementation.105 Fourteen percent of MLIP enrollees incurred 
no pharmacy costs to North Carolina Medicaid following their lock-in, which accounted for almost 40% 
of the estimated savings. (The authors do not speculate about the lack of subject observation in Medicaid 
claims data following lock-in, but this finding could indicate circumvention behaviors that will be 
investigated in Aims 1 and 2of this dissertation). A total of 55% of the estimated $279,500 in total 
pharmacy savings were attributed to reduced claims for MLIP qualifying medications, including opioid 
analgesics and benzodiazepines. The MLIP resulted in a mean reduction of 2.8 total prescription claims 
per enrollee and a mean reduction in controlled substance claims per enrollee of 2.0 fills. Utilization of 
inpatient, outpatient, emergency, and radiology services were unchanged among MLIP enrollees during 
the post-implementation period. Subsequent internal evaluations found that 2.3 million fewer opioid 
analgesic tablets were dispensed in the first three months of MLIP implementation, with a total of $5.2 
million in savings to the state in its first year.116 
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2.2.4.2 General MLIP Outcomes—Unpublished Economic Findings 
 Much of the grey literature—and for that matter, peer-reviewed literature—focus on MLIPs’ 
economic impact on state expenditures. The State of Washington conducted two large-scale evaluations 
of its MLIP; one in 2005 that assessed the first three years of the program’s operations when enrollment 
increased from 200 to 3,000 beneficiaries117 and again in 2012 with a cost-effectiveness analysis when 
enrollment topped out at 3,800 individuals.118 The state studied a nine month pre-MLIP and six month 
post-MLIP observation period and reported monthly savings of $1.5 million due to its MLIP117, with a 
return on investment of $6.61 for each dollar spent administering the MLIP. 118  
 In addition, presentation materials from Best and colleagues also describe findings from an 
unpublished randomized controlled trial that was conducted in 2008 and included economic outcomes.118 
The study assigned 503 qualifying Washington Medicaid beneficiaries to MLIP enrollment and 188 
beneficiaries meeting enrollment criteria to an observation-only control group.118 The researchers 
employed a difference-in-difference intention to treat analysis looking at changes in outcomes between 
pre- and post-enrollment observation periods of 12 months. Enrollment in the Washington MLIP was 
associated with significant decreases in physician, emergency care, planned hospitalization, and total 
Medicaid costs. No difference was found between MLIP and control groups in total pharmacy costs. 
 Many other states reported economic savings in internal MLIP evaluations. In 2012, Keast 
presented results of a pre-post MLIP enrollment analysis among 52 Oklahoma Medicaid beneficiaries 
who were locked in to a single pharmacy.119 This investigation found significant decreases in pharmacy- 
and emergency department-related costs. A 1995 audit of Utah’s MLIP found a decrease in total 
healthcare costs of 50% for their 22 enrollees. Kentucky MLIP administrators forecasted savings to the 
state of over $6,300 per lock-in enrollee.120 Iowa Medicaid’s lock-in program saved the state $2 million 
annually.121 Florida’s MLIP saved the state nearly $13 million over the programs first three years.122 
Similar economic findings are available for Connecticut123,124,  Illinois125, Massachusetts126, South 
Carolina127, and West Virginia128. 
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2.2.4.3 General MLIP Outcomes—Unpublished Utilization Findings 
 In addition to economic outcomes from MLIPs, much of the unpublished MLIP evidence centers 
on healthcare utilization measures. And similar to the unpublished economic findings, MLIPs generally 
resulted in significant decreases in utilization of Medicaid services.  
 In the 2005 report from the State of Washington, the average number of narcotic prescription 
claims per enrollee lowered from 3.1 to 1.6, the total dosage of opioid analgesics received by enrollees 
decreased over 40%, and the average number of prescribers per person reduced from 4.8 to 2.8 following 
lock-in.117 In 2012, the State of Washington found that, in the six months following an expansion of the 
MLIP, lock-in enrollees exhibited a 37%, 33%, and 24% decrease in outpatient care, emergency care, and 
prescription utilization, respectively.118 Best and colleagues also reported significant decreases in 
physician visits, emergency care visits, planned hospitalization costs, total narcotic prescription claims, 
and total narcotic tablets dispensed in the MLIP arm of their unpublished 2008 randomized controlled 
trial. No significant changes were found for total hospitalizations.  
 Utilization outcomes from the 2012 Oklahoma MLIP evaluation included significant decreases in 
total prescription claims, narcotic prescription claims, number of pharmacies used, number of prescribers 
used, and emergency department visits.119 Interrupted time series analysis showed that the MLIP 
enrollment not only caused a reduction in the level of average monthly narcotic prescription claims per 
enrollee, but it also caused the trend line to flip from an upward trend of 0.05 fills per month prior to lock-
in to a downward trend of -0.04 fills per month.  
  Lastly, an early internal Utah MLIP evaluation conducted in 1995 reported significant decreases 
in emergency room visits, multiple pharmacy use, and narcotic prescription claims in the magnitude of 
65-75%.129  
2.2.4.4 General MLIP Outcomes—Unpublished Clinical Findings 
 Only one unpublished source of MLIP outcomes evidence—the 2012 presentation materials from 
Best and colleagues in Washington State—investigated any type of clinical outcomes from MLIP 
enrollment. They reported that the 2008 randomized controlled trial, which investigated 12-month 
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outcomes among roughly 500 MLIP enrollees and 200 assigned to observation only, found no significant 
changes in all-cause mortality between the MLIP intervention and control groups.118 
2.2.5 Aim 1 MLIP Outcome—Engaging in Lock-in Circumvention 
 The potential for circumventing Medicaid and its MLIP restrictions remains one of the most 
notable limitations of the lock-in policy strategy.130 Circumvention occurs when Medicaid beneficiaries 
obtain controlled substances through cash purchases of these prescriptions, unbeknownst to the Medicaid 
program. In the context of MLIP enrollees, circumvention results in wasted MLIP resources. It represents 
a failure to prevent risky controlled substance utilization and to confer enhanced provider coordination of 
healthcare delivery. Very little attention has been paid to investigating the prevalence, patterns, and 
predictors of circumvention behaviors in MLIP programs. Only in the past two years have researchers 
begun to recognize the need to examine circumvention behaviors to assess its impact on the effectiveness 
of MLIPs as a policy tool in preventing controlled substance abuse and misuse.119 
 First, in Kachur et al.’s 2013 published abstract, the authors explicitly recommend researchers 
investigate the prevalence and predictors of circumvention in MLIP populations.112 In addition, the 2012 
presentation materials from Best and colleagues briefly mentions Washington Medicaid’s recent efforts to 
link their Medicaid claims database with data from the state’s prescription drug monitoring program.118 
This dataset allowed for identification of lock-in circumvention behaviors not observable in the Medicaid 
claims alone, similar to the dataset used in Aim 1 and 2 analyses. No peer-reviewed investigations into 
compliance with the MLIP restrictions have been published using Washington’s merged dataset, to date. 
However, their initial explorative analyses found over 2,000 clients in 2012—representing over half of 
their MLIP enrollees—had cash and Medicaid paid schedule prescriptions on the same day and have 
“identified 478 clients in 2012 where cash and Medicaid fills were <10 days apart and for the same drug 
and with a different prescriber.”  
 Despite Best’s presentation and Kachur’s abstract being the only known sources recognizing 
circumvention outcomes in MLIPs, it is possible that the existing literature reporting reductions in the 
number of controlled substance prescription fills due to MLIPs may have unknowingly captured 
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artifactual evidence of circumvention in MLIPs. For example, the unpublished evaluation of Oklahoma’s 
MLIP reported a reduction in monthly narcotic prescription fills among program enrollees.119 It is 
possible that this finding is partially attributable to Oklahoma MLIP enrollment inducing enrollees to 
engage in circumvention behaviors. Because narcotic prescriptions obtained through circumvention 
would not appear in the Oklahoma Medicaid claims data, highly prevalent circumvention behaviors 
would make it appear as though the lock-in program had an artificially exaggerated effect on reducing 
narcotic prescription use in the Medicaid data.  
 The lack of interest in circumvention behaviors in Medicaid lock-in programs shown in the 
published and unpublished literature prior to 2012 may be due to the recent momentum behind mitigating 
the public health epidemic of prescription drug abuse. States may have previously viewed MLIPs 
primarily as a tool for reducing expenditures, in which addressing circumvention behaviors was a low 
priority. After all, Medicaid agencies do not pay for circumvented controlled substance prescriptions. 
Now, the recent preliminary circumvention findings from Best and colleagues—in addition to a strong 
recommendation to examine MLIP circumvention behaviors by Kachur—may signal a shift in perception 
of MLIPs from strictly a cost savings and punitive measure to a tool for improving public health, in which 
preventing circumvention would be of high priority to ensure optimal program effects.112  
 This provides clear motivation for conducting the analyses in Aims 1 and 2 of this dissertation. 
Findings from Aim 1 will isolate the effect of enrollment in the NC MLIP on the likelihood of engaging 
in circumvention and identify patient-level predictors of obtaining controlled substances through 
circumvention within the NC MLIP population. Aim 2 will characterize the riskiness of opioid use 
occurring through circumvention by describing prescription-level opioid potency and dosage 
characteristics obtained across payment sources. Aim 2 will also examine the effect of MLIP enrollment 
and patient predictors on use patterns of these prescription-level characteristics. 
2.2.6 Aim 2 MLIP Outcomes—High-Risk Opioid Prescription Use 
 Aim 1 of this dissertation addresses the lack of knowledge regarding whether, and to what extent, 
MLIP enrollment causes people to circumvent Medicaid for controlled substance prescriptions. While it is 
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necessary to understand how often circumvention occurs in MLIPs, it is also crucial to understand which 
controlled substance prescriptions are being circumvented. Without knowledge the abuse/overdose 
potential of individual prescriptions obtained through circumvention, it is not possible to fully gauge the 
extent to which MLIP circumvention behavior counteracts the program’s intended reduction of high-risk 
utilization behavior. Aim 2 addresses this other key aspect of MLIP circumvention behavior by 
investigating prescription-level characteristics of circumvented opioid analgesic prescription fills in the 
NC MLIP. The specific prescription-level markers of interest were Schedule II classification, long-acting 
opioid formulation, and prescribed daily opioid dose. These three outcomes were selected for their 
representation of opioid potency and level of opioid exposure, which are key factors in the physiological 
process of developing dependence or experiencing overdose. They are also known markers of highly 
sought opioid prescriptions among abusers. 
 Schedule II opioid products are those deemed by the DEA to have the highest potential for 
abuse.30 Their high potential for abuse stems from pharmacological properties, namely high potency, that 
more readily lead to psychological dependence, physical dependence, and euphoric effects for the user.18 
Commonly used Schedule II opioid products during the dissertation study period included oxycodone, 
morphine, fentanyl, methadone, hydromorphone, oxymorphone, and tapentadol. Prior literature has 
shown receipt of Schedule II opioids as having strong association with abuse-motivated controlled 
substance use behavior. In 2013, Cepeda and colleagues conducted a retrospective cohort study of over 25 
million opioid users in the United States and found that most (nearly 70%) opioid users exhibiting doctor-
shopping behavior sought Schedule II products.131 A 2014 study of the California PDMP data reported 
that opioid doctor-shoppers received up to six-times higher cumulative amounts of Schedule II opioid 
products than opioid users who didn’t exhibit abuse-motivated behavior.132 Another large retrospective 
cohort study found 40% higher odds of abuse behaviors among Schedule II opioid users, controlling for 
numerous patient-level confounders.133 Schedule II opioid use was also a primary outcome of Blake’s 
study of the effect of Louisiana’s MLIP on high-risk controlled substance use behaviors.108,114 
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 Long-acting opioid products present an increased risk of opioid abuse and overdose outcomes for 
two primary reasons. First, long-acting opioid products typically contain high potency opioid agents. 
Second, long-acting opioid products contain high quantities of opioids within each dosage form, because 
they are designed to release medication for sustained periods of time. Commonly used long-acting opioid 
products at the time of the dissertation study period included transdermal preparations of fentanyl and 
buprenorphine and extended-release oral formulations of oxycodone, morphine, methadone, tapentadol, 
oxymorphone, and hydromorphone. Similar to the evidence for Schedule II products, prior literature has 
demonstrated significant concern for the role of long-acting opioid preparations in contributing to abuse 
and overdose. A 2012 study of a Washington State worker’s compensation system opioid overdose-
prevention policy was primarily focused on the policy’s effect on unsafe prescribing of long-acting opioid 
products.134 Long-acting opioid use was also a key predictor throughout the TROUP investigations of 
opioid abuse outcomes in a private payer and Medicaid sample.133,135-137 One of these studies found over 
2.5 times increased risk of an overdose event among long-acting opioid users compared to those only 
using short-acting opioids.135 A nearly identical result was found in a recent study of a large retrospective 
cohort of United States Veterans.138  
 The average prescribed daily dose of opioids—assessed as mean milligram morphine equivalents 
per day—has become a gold standard measure of prescription-level risk of opioid abuse and overdose. 
The average daily MME measures total opioid exposure by accounting for the potency of the opioid 
agent, prescribed drug strength, quantity, and dosing instructions within a single measure. A substantial 
body of evidence has developed over the last decade for the utility of the average MME in predicting a 
person’s risk for opioid abuse and overdose.139 Notably, the TROUP investigations and other landmark 
studies have demonstrated a clear trend of increased average daily prescribed MMEs being associated 
with significantly increased risk of opioid abuse and overdose events.131,133,135,137,140-144  Best also 
employed average MME/day as a key outcome in the investigation of Washington State’s MLIP in 
2012.118 
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 Taken as a whole, these three prescription-level opioid characteristics capture a prescription’s 
potential for contributing to adverse outcomes from high-risk opioid use behaviors. They also represent 
an opioid prescription’s attractiveness to MLIP enrollees intent on abusing or diverting these medications. 
Prescriptions for high potency opioids and high quantities of opioids are targeted by individuals engaged 
in high-risk behaviors, such as doctor and pharmacy shopping.37,131,145 In fact, prescription opioid abusers 
enrolled in a 2009 focus group study explicitly indicated that high potency opioid agents, high quantities 
of opioids, and long-acting opioid products were the most appealing for abuse and diversion.146 
 There are two primary motivations in Aim 2 for examining trends in these opioid prescription-
level characteristics in the context of NC MLIP circumvention. First, describing the types of opioid 
prescriptions that MLIP enrollees obtain through circumvention, when coupled with information about 
the extent of circumvention events from Aim 1, provides new evidence for the cumulative level of opioid 
exposure occurring beyond the reach of MLIP administrators. By extension, this allows assessment of the 
effect of MLIP enrollment on comprehensive exposure to opioids among NC MLIP enrollees from all 
payment sources. Second, Aim 2 provides evidence for the effect of NC MLIP enrollment, and patient 
predictors, on the likelihood of circumventing opioid prescriptions with high-risk attributes. It is widely 
regarded by Medicaid agencies that the controlled substance-seeking behaviors leading to MLIP 
eligibility often reflect intent to abuse these medications or divert them to third parties.130,147-149 Medicaid 
circumvention presents a viable route for MLIP enrollees to engage in abuse-motivated controlled 
substance use behaviors largely unchecked. Recent attention to the issue of MLIP circumvention112,118,130, 
coupled with MLIP enrollees’ heightened awareness of their Medicaid service use being monitored, raises 
concerns that MLIP enrollment may actually induce high-risk opioid use behaviors occurring outside the 
purview of Medicaid among enrollees highly motivated by abuse. Therefore, it is necessary to examine if 
MLIP enrollment results in increased circumvention of high-risk prescriptions and whether certain 
prescriptions have increased attractiveness for circumvention in order to inform improvements to the 
MLIP policy intervention. 
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2.2.7  MLIP Outcomes—Summary and Gaps 
 Section 2.2 describes findings from all available evidence for the effect of Medicaid lock-in 
programs on economic, utilization, and clinical outcomes. This review of the peer-reviewed and grey 
literature established our current understanding of MLIP effectiveness and provides motivation for the 
aims of this dissertation’s parent project—which involved a population-level policy analysis of controlled 
substance utilization and overdose outcomes—as well as Aims 1 and 2 of this dissertation, which 
investigated potential unintended consequences of MLIP enrollment in the form of lock-in circumvention 
behaviors. In general, minimal evidence exists to understand the public health benefit of MLIPs in 
reducing prescription drug abuse behaviors and outcomes. 
 Review of the literature identified six total peer-reviewed publications investigating Medicaid 
lock-in program-related outcomes. Two of these studies were published over 30 years ago.106,107 Two 
more publications from the previous decade provided evidence for state economic savings from MLIPs as 
well as positive impacts on use of Medicaid healthcare and prescription services.109,111 However, these 
articles were short, cursory programmatic evaluations with a narrow focus on the budgetary impact of 
MLIPs. The remaining peer-reviewed evidence consisted of conference poster presentations with a 
similar focus on economic and utilization outcomes.108,112 The breadth of evidence from these published 
presentation abstracts was limited, however.  
 Thorough review of the grey literature found that the vast majority of available MLIP evaluation 
data comes from publicly accessible, unpublished internal economic analyses either from state MLIP 
administrators. Ultimately, the current evidence for the effects of MLIPs exists almost entirely to 
demonstrate the financial viability of operating MLIPs and makes very little attempt to shed light on the 
ability of MLIPs to influence public health outcomes related to nonmedical controlled substance use.  
 Literature gap 1: There exists a lack of rigorous, peer-reviewed evidence for the effectiveness of 
MLIPs in preventing risky controlled substance use and diversion in Medicaid populations. 
Understanding the role of MLIPs in combating the epidemic of nonmedical controlled substance abuse 
will require researchers to conduct high quality examinations of MLIP effectiveness. Addressing the 
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dearth of MLIP literature available to researchers, policymakers, and MLIP administrators provides 
significant motivation for investigating all aims of this dissertation. Further, no one has conducted a peer-
reviewed examination of the North Carolina Medicaid Recipient Management Lock-In Program, 
specifically. While a peer-reviewed MLIP investigation from any state would provide broad lessons for 
the general landscape of controlled substance lock-in programs, the high variability across state MLIPs in 
program design means that one state’s MLIP evaluation may have limited generalizability to other state 
MLIPs. The findings of this dissertation will provide the first peer-reviewed, highly actionable evidence 
for MLIP administrators in North Carolina, who represent the most immediate audience of this 
dissertation research. 
 The available body of published and unpublished evidence overwhelmingly indicates that MLIPs 
have positive impacts on reducing Medicaid service utilization measures—prescription, controlled 
substance, emergency care, and inpatient care—as well as use of multiple prescribers and multiple 
pharmacies. MLIPs also provide states with significant economic savings stemming from reduced use of 
pharmacy and medical services.  
 Literature gap 2: Aside from Kachur’s investigation of all-cause mortality as a secondary 
outcome112, no peer-reviewed study has examined the link between MLIP enrollment and major clinical 
outcomes, such as overdose events or overdose-related mortality. The aims of the present dissertation 
project do not directly investigate the association between MLIP enrollment and major clinical outcomes. 
However, the parent project from which this dissertation was formed addresses this gap, allowing this 
dissertation to fill additional gaps pertaining to known, but previously unexamined, limitations of the 
MLIP policy approach. 
 A major limitation of the MLIP policy strategy is the possibility of enrollees circumventing lock-
in restrictions by purchasing controlled substance prescriptions completely out of pocket. This 
circumvention behavior wastes program resources and mitigates any intended effect of MLIP enrollment 
on regulating access to controlled substances for patients that abuse or divert these drugs. Circumvention 
also obviates the intended enhancements in care coordination for these high-risk patients. One 
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unpublished source provided initial estimates of a high prevalence of circumvention behavior in their 
MLIP population.118 Additionally, reported findings of reduced controlled substance utilization trends 
following MLIP enrollment—particularly those by Keast119—could feasibly reflect an artifact of MLIP 
enrollment inducing circumvention, which cannot be captured solely in Medicaid claims data.  
 Literature gap 3: There has been no effort in the peer-reviewed literature to understand the 
prevalence or predictors of circumvention behavior among MLIP enrollees. Prior MLIP-related research 
has identified the MLIP circumvention limitation as a priority for future investigation of the feasibility of 
this policy intervention in achieving a public health benefit in the fight against prescription drug 
abuse.106,112 Aim 1 of this dissertation directly addresses this gap by examining the prevalence and 
predictors of engaging in MLIP circumvention in North Carolina. More specifically, Aim 1 describes 
trends in circumvented opioid and benzodiazepine prescription fills in the NC MLIP program and 
attempts to isolate the effect of NC MLIP enrollment on the likelihood and extent of controlled substance 
circumvention. 
 Assessing the total threat of circumvention to the effectiveness of MLIPs in reducing prescription 
drug abuse behaviors and outcomes also requires an understanding of MLIP enrollees’ controlled 
substance use risk profile occurring through circumvention.  
 Literature gap 4: Building on the previously identified literature gap, there has been no effort in 
the peer-reviewed literature to describe controlled substance prescriptions obtained by MLIP enrollees 
through circumvention. There has also been no effort to investigate the potential effect of MLIP 
enrollment on prescription-level measures of high-risk controlled substance use through circumvention, 
which knowingly occurs outside Medicaid’s scope of influence. Aim 2 fills this gap in knowledge by 
describing trends in receipt of Schedule II opioids, long-acting opioids, and high-dose opioid 
prescriptions across payment sources before and after MLIP enrollment. Aim 2 also attempts to isolate the 
effect of NC MLIP enrollment on receipt of Schedule II and long-acting opioid prescriptions and on the 
average prescribed daily opioid dose. This information provides new evidence for any unintentional effect 
of MLIP enrollment on the degree of opioid use risk occurring through circumvention. Aim 2 also 
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elucidates whether certain opioid prescription characteristics have higher appeal for circumvention, which 
may inform targeted program optimizations to improve adherence to MLIP restrictions.   
 Additionally, to our knowledge, no one has utilized a dataset linking Medicaid claims data with 
the state’s PDMP data in any peer-reviewed investigation of Medicaid beneficiaries’ controlled substance 
utilization. The novel dataset linking Medicaid claims and PDMP data in Aim 1 to the peer-reviewed 
MLIP evidence base as a tool for monitoring MLIP enrollees’ utilization patterns. 
2.3 LITERATURE REVIEW—DEFINING HIGH-RISK OPIOID USE 
2.3.1 Section Overview 
 Enrollment criteria for state Medicaid lock-in programs are largely comprised of thresholds for 
the number of controlled substance prescription fills, number of prescribers writing controlled substances, 
and/or number of pharmacies dispensing controlled substances in a pre-defined time period. As indicated 
in Table 2.3 from Section 2.1.11, however, the specific criteria utilized by MLIP administrators vary 
widely from state to state.15 This lack of consistency in MLIP enrollment criteria suggests either a lack of 
evidence from which state MLIP administrators can base these decisions or a lack of consensus as to how 
best to apply the evidence.  
 In order to assess the evidence-base available to inform the design of MLIP enrollment criteria 
that are most likely to identify beneficiaries at the greatest risk of controlled substance-related adverse 
outcomes, this section presents relevant findings from a rigorous review of the peer-reviewed literature 
examining claims-based definitions for high-risk controlled substance utilization behaviors. A summary is 
provided at the end of Section 2.3, which also identifies gaps in the literature. Findings from this review 
of the literature provided a foundation for Aim 3 analyses. In this aim, we examined claims-based 
definitions of high-risk opioid analgesic use in North Carolina Medicaid that were most predictive of 
overdose-related events, signifying patients most likely to benefit from MLIP enrollment. To conduct this 
literature review we used PubMed, Google Scholar, Web of Science, and PsycINFO databases. We 
conducted free-text, as well as Boolean search strategies, to extract relevant studies published prior to 
May 2015 using key search terms such as, “controlled substance,” “opioid,” “benzodiazepine,” 
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“overdose,” “death,” “shopping,” “doctor shopping,” “pharmacy shopping,” “high risk,” “abuse,” 
“misuse,” and “nonmedical.” We performed secondary reviews of article bibliographies to obtain 
additional relevant pieces of evidence not identified in the initial literature search. 
2.3.2  Defining Risky Controlled Substance Use—Peer-Reviewed Literature  
 We first present findings from one study that explicitly investigated claims-based definitions of 
high-risk controlled substance use in the context of a Medicaid controlled substance lock-in program. We 
then organize the rest of the findings from our review of the published literature pertaining to claims-
based strategies for defining high-risk opioid use by type of measure utilized in Aim 3 analyses: opioid 
prescription count, opioid prescriber count, opioid pharmacy count, daily opioid dose, and daily 
acetaminophen dose. We also include an “Other measures” subsection that describes alternative 
approaches to defining high-risk opioid use that are not explicitly investigated in the proposed 
dissertation. However, touching on these high-risk opioid definitions not employed in Aim 3 analyses 
provides a comprehensive review of all prior work done in this field that can inform future MLIP 
eligibility criteria validation research. 
2.3.2.1 Wisconsin Medicaid Lock-In Program Eligibility Tool Study  
 Wisconsin Medicaid developed and tested a new automated decision tool for identifying 
beneficiaries for lock-in enrollment that would replace their manual review process.150 The authors used 
chi-squared automatic interaction detection analyses to determine which combinations of controlled 
substance utilization measures were most predictive of risky controlled substance use. Qualifying 
medication classes included opioids, benzodiazepines, sedative hypnotics, stimulants, skeletal muscle 
relaxants, and barbiturates. Their eight utilization measures included overlapping prescription days supply 
of same-class drugs (2 and 6-month measures), number of same-drug prescription refills overlapping by 
50% (2 and 6-month measures), number of same-day duplicate prescriptions using different providers, 
total number of controlled substance claims, number of total prescribers used, and number of total 
pharmacists used. The predictive ability of the decision tool was tested with 190 Wisconsin Medicaid 
beneficiaries that had been tapped for lock-in enrollment, receipt of a warning letter, or no further review 
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by through manual claims review performed by clinicians. The model correctly assigned lock-in 
enrollment 95% of the time, with a sensitivity and specificity of 87% and 96%, respectively. Table 2.4 
presents the controlled substance utilization criteria that the decision support tool analyses identified as 
having statistically significant success in identifying beneficiaries that expert manual review tapped for 
lock-in enrollment, presented roughly in order of increasing rigor. Ultimately, the number of pharmacies 
used in six months was most predictive, followed by the number of overlapping days of controlled 
substance supply. 
 
Table 2.4: Controlled Substance Overuse Criteria Identified as Significant by the Wisconsin 
Medicaid Decision Support Tool 
[4 to 7 pharmacies] 
[4 to 7 pharmacies] + [1-188 overlap days in 2 months] 
[4 to 7 pharmacies] + [1-188 overlap days in 2 months] + [≥8 prescribers] 
[4 to 7 pharmacies] + [≥189 overlap days in 2 months] 
[4 to 7 pharmacies] + [≥189 overlap days in 2 months] + [≥314 overlap days in 6 months] 
 
[≥8 pharmacies] 
[≥8 pharmacies] + [128-313 overlap days in 6 months] 
[≥8 pharmacies] + [≥314 overlap days in 6 months] 
Note: Measures assessed over a 6-month period. Measures denoted as 2-month measures were assessed over the 
most recent 60 days. 
Source: Mailloux AT, Cummings SW, Mugdh M. A decision support tool for identifying abuse of controlled 
substances by ForwardHealth Medicaid members. Journal of hosp marketing & public relations. 2010;20(1):34-55. 
 
2.3.2.2 Claims-Based High-Risk Opioid Use Measures—Opioid Prescription Counts 
 Table 2.5 summarizes key claims-based definitions of high-risk opioid use from relevant peer-
reviewed literature that were either developed through study analyses or defined by the researchers a 
priori. The table is organized by year published and lists the lead author, study population, the study 
outcome predicted by the measure (or if the measure was defined a priori), the observation period in 
which the opioid utilization measure was assessed, and threshold levels for the five key measures of high-
risk opioid use utilized in Aim 3 analyses—opioid prescription count, prescriber count, pharmacy count, 
daily dose, and daily acetaminophen dose. 
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Table 2.5: Summary of Key Claims-Based Measures of High-Risk Opioid Use in Peer-Reviewed Literature 
Study Patient population Outcome predicted 
Obs.  
period 
(mo.) 
Rx 
count 
Prescriber 
count 
Pharm. 
count 
Opioid dose 
(MME/day) 
APAP 
dose 
(mg/day) 
Parente, et al (2004) Privately insured Expert chart review Any  ≥6 ≥4  4000mg 
Buurma, et al (2008) Netherlands "Drug-seeking" behavior 12   ≥5   
Hall, et al (2008) West Virginia residents Overdose death 12  ≥5 (CS)   
Braker, et al (2009) Medicaid (MI) N/A (researcher-defined) 6 ≥3 ≥2    White, et al (2009) Privately insured (ME) Opioid abuse Dx 3 
12 
≥4 
≥12 
≥2 ≥2 
≥3 
  
Braden, et al (2010) Medicaid (AR), private Drug-related event 6    ≥120mg  
Dunn, et al (2010) HMO Overdose event 3    ≥50-100mg  
Katz, et al (2010) Massachusetts residents "Drug-seeking" behavior 12  ≥4 (CII) ≥4 (CII)   
Sullivan, et al (2010) Medicaid (AR) Novel risk score 6    ≥120mg  
Bohnert, et al (2011) US Veterans Overdose death Varied    ≥50mg  
Gomes, et al (2011) Ontario, Canada residents Overdose death 4    ≥200mg  
Wilsey, et al (2011) California residents "Drug-seeking" behavior 12  ≥5    
Cepeda, et al (2012, 13) Population-based "Drug-seeking" behavior 18      
Paulozzi, et al (2012) New Mexico residents Overdose death 6 ≥6 (CS)   ≥120mg  
Peirce, et al (2012) West Virginia residents Overdose death 6  ≥4 (CS)           ≥4 (CS)   
Rice, et al (2012) Privately insured Opioid abuse Dx 12 ≥6  ≥3   
Liu, et al (2013) Privately insured N/A (researcher-defined) 12    ≥100mg  
McDonald, et al (2013) Population-based "Drug-seeking" behavior 12  ≥10    
Weiner, et al (2013) Population-based N/A (researcher-defined) 12 ≥4 ≥4    
Baumblatt, et al (2014) Tennessee residents Overdose death 12  ≥4 ≥4 ≥100mg  
Han, et al (2014) California residents N/A (researcher-defined) 12  ≥5 (CII)    
Huffman, et al (2015) Substance use clinic Opioid addiction Dx Varied    ≥76mg  
Yang, et al (2015) Medicaid  Overdose event 3   ≥4   
Note: All findings reported in the table refer to opioid utilization unless otherwise specified. Rx=prescription; Pharm=Pharmacy; MME=Milligram morphine 
equivalent; mg=milligram; APAP=acetaminophen; CS=controlled substances; MI=Michigan; N/A=not applicable; ME=Maine; Dx=diagnosis; AR=Arkansas; 
HMO=health maintenance organization; CII=Schedule II; US=United States. 
  44 
 Five peer-reviewed articles offer an explicit threshold for the number of opioid prescriptions 
received by a patient indicating potential high-risk use behaviors. In a 2009 article in the American 
Journal of Managed Care, White, et. al., investigated predictors of opioid abuse diagnoses among 
116,382 privately insured Maine residents using opioids between the ages of 12 and 64.151 The authors 
used a stepwise multivariable logistic regression approach to evaluate the strength of association between 
various potential predictors and the presence of an opioid abuse diagnosis in claims data, controlling for 
age, sex, mental health diagnoses, and overall healthcare utilization. Their model containing measures for 
number of opioid prescriptions, number of pharmacies, number of early opioid fills, and opioid dose 
escalation variables was highly predictive of opioid abuse outcomes, with a Receiver Operating 
Characteristic c-statistic of 0.84. In terms of prescription quantity, White reports that having four or more 
opioid prescriptions in a three-month time period or 12 or more prescriptions in a 12-month time period 
were significantly associated with an opioid abuse diagnosis.  
 Paulozzi, et. al., conducted a retrospective case control study using a sample of 300 New Mexican 
residents over the age of 10 that died of drug overdose between 2006 and 2008, with 5,993 matched 
controls.144 Paulozzi found that filling six or more controlled substance prescriptions of any class during a 
six-month exposure period quadrupled the mortality risk. 
 Rice, et. al., published a study in 2012 investigating prescription utilization behaviors associated 
with diagnosed opioid abuse in a large, nation-wide administrative claims database of privately insured 
individuals with prior opioid use.152 In descriptive analyses, study subjects with diagnosed opioid abuse 
had an average of 13.3 opioid fills in the 12 months prior to the study index date, 2.4 pharmacies used, 3.2 
prescribers used, and nearly 10% of opioid refills filled early. Using logistic regression analyses, Rice and 
colleagues found receipt of six or more opioid prescriptions in a 12-month period to increase the odds of 
opioid abuse seven-fold. 
 In addition, two articles utilized pre-determined prescription count thresholds to develop 
measures of high-risk opioid use patterns. In 2009, Braker used a cutoff of three or more opioid 
prescriptions during a six month observation period to screen for potential opioid misuse among 
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Michigan Medicaid beneficiaries.153 In 2013, Weiner and colleagues defined high-risk opioid use as four 
or more opioid prescription fills in a 12-month span.154 
2.3.2.3 Claims-Based High-Risk Opioid Use Measures—Opioid Prescriber Counts 
 Nearly a dozen studies describe high-risk opioid use in terms of the number of prescribers used. 
One of the earliest, and most rigorous, efforts to do so came in 2004 from Parente, et al, in 2004 when 
they sought to develop and validate explicit claims-based criteria for controlled substance misuse.155 The 
authors created a multidisciplinary panel of experts who developed nearly 40 CS-PURE criteria, 
“controlled substance patterns of utilization requiring evaluation.” Each criterion was operationalized 
using two large administrative claims databases comprised of a total of nearly four million privately 
insured lives under the age of 65. The authors then validated each criterion in 150 randomly-selected 
patient cases by modeling the association between the criterion and a controlled substance misuse score 
assigned by expert review. The best predictor of high-risk opioid use was the use of six or more 
prescribers of the same opioid product in any time period.  
 A few of these studies provide estimates of the association between number of opioid prescribers 
and adverse opioid-related clinical outcomes. The previously described 2009 study from White, et al, 
found that a threshold of two or more opioid prescribers in a three-month period was a strong predictor of 
opioid abuse diagnosis.151 In a 2012 case control study among West Virginia opioid users, Peirce and 
colleagues found that use of four or more prescribers in a six-month time period was associated with 
double the odds of experiencing an opioid overdose-related death.156 A similar case control design was 
recently employed in the population of all opioid users in the State of Tennessee by Baumblatt, et al. They 
found that receiving opioids from four or more prescribers in one year significantly increased the odds of 
opioid-related death by over 600%.157 
 The remaining literature offers a precedent of prescriber-based measures of high-risk opioid use 
by providing examples of researcher-defined thresholds for risky doctor shopping behaviors. Braker153, 
Katz158, and Weiner154 all essentially used thresholds of 4 or more prescribers in a 12-month period to 
identify subjects with risky opioid use, while Hall60, Wilsey159, and Han132 employed a cut-off of five or 
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more unique controlled substance prescribers in a 12-month period. In 2013, McDonald and colleagues 
identified 10 or more opioid prescribers in a year as an appropriate definition of risky doctor shopping in 
their analyses of a large, nationally representative sample of pharmacy fill data.160 
2.3.2.4 Claims-Based High-Risk Opioid Use Measures—Opioid Pharmacy Counts 
 The majority of the articles describing opioid prescriber measures also investigated counts of 
pharmacies used by patients to obtain opioid prescriptions as a strategy for defining high-risk behaviors. 
The CS-PURE algorithm tool developed and validated by Parente and colleagues in 2004 found that use 
of four or more pharmacies to obtain the same opioid product within any time period was the second best 
indicator of high-risk use behind the number of prescriptions received.155 Similarly, White found that two 
or more pharmacies in a three-month period, as well as three or more pharmacies in a 12-month period, 
was significantly associated with an increased probability of receiving an opioid abuse diagnosis.151 
Rice’s previously described examination of the associations between opioid use patterns and the 
likelihood of being diagnosed with opioid abuse found that receiving opioids from three or more 
pharmacies in one year was significantly higher.152 Peirce used a more stringent definition of pharmacy 
shopping in her case control study—four or more pharmacies in a six-month period—and found that 
pharmacy shopping was associated with a three-fold risk of opioid-related death.156 The recent case 
control study from Baumblatt found a six-fold increase in the odds of opioid-related death in patients 
using four or more opioid pharmacies in one year.157 The pharmacy threshold used by Baumblatt was 
partially based on Katz’s prior success in defining pharmacy shopping as using four or more pharmacies 
for opioids in one year to identify high-risk patients.158 Most recently, Yang and colleagues employed a 
threshold of four or more opioid dispensing pharmacies in a 90-day period as a claims-based predictor of 
opioid use disorder among a national population of Medicaid managed care patients.161 
 Additionally, Buurma, et. al., used the following definitions of pharmacy shopping to investigate 
predictors of this behavior: “light (all patients who visited more than one pharmacy at least once in 2001, 
except for patients defined as heavy or moderate shoppers), moderate (visited 3 or 4 pharmacies and had 
proportion of prescriptions elsewhere >10% and number of prescriptions elsewhere >10) or heavy (visited 
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5 or more pharmacies and had proportion of prescriptions elsewhere >10% and number of prescriptions 
elsewhere >10).”162 
2.3.2.5 Claims-Based High-Risk Opioid Use Measures—Daily Opioid Dose 
 Multiple studies have used average daily opioid dose, measured in milligram morphine 
equivalents, to investigate the association between the amount of opioids received and adverse clinical 
outcomes like opioid overdose events and opioid-related deaths. In 2010, Braden and colleagues 
published one of the earliest studies attempting to identify a threshold level of MMEs associated with 
adverse opioid events. They conducted a retrospective cohort study in a database of private payer and 
Medicaid beneficiaries and ultimately found that an average opioid dose of 120mg/day over a six-month 
time period doubled the risk of a serious opioid event, when controlling for baseline demographic and 
clinical characteristics.135 
 Dunn and colleagues applied survival analysis methodologies to investigate the association 
between the average prescribed daily opioid dose and opioid overdose events in a sample of health 
maintenance organization beneficiaries with three or more opioid prescriptions in a 90-day period.141 An 
average daily dose of 21-50mg of morphine equivalents was associated with a 50% increase in overdose 
risk, while doses of 51-100mg daily were associated with nearly four times the overdose risk of those 
with averages doses of 20mg or less. The authors found that once average daily opioid doses exceed 
100mg morphine equivalents the risk for opioid overdose increased nine-fold. 
 Bohnert, et. al., conducted a case-cohort analysis in 2011 of 750 Veterans Health administration 
beneficiaries with unintentional opioid overdose-related deaths between 2004-2008, along with over 
150,000 control subjects with opioid use during the observation period.140  After adjusting for various 
clinical and demographic measures, they found daily doses of 50mg morphine equivalents or more to 
mark a significant increase in the risk of opioid-related mortality for patients with both chronic and acute 
indications for opioid therapy. 
 Gomes and colleagues employed a similar methodology in a Canadian sample of 498 opioid 
overdose decedents, with 1,714 matched controls.142 After substantial adjustment for various clinical and 
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demographic variables, an average daily dose of >200mg of morphine equivalents resulted in a substantial 
higher odds of death compared to those with <20mg of morphine equivalents per day (Odds ratio=2.88: 
95% CI 1.79-4.63). All other intermediate daily dosing categories were insignificant predictors. The 
authors suggested a threshold of 200mg/day in morphine equivalents for significant risk for opioid-related 
adverse outcomes. Gomes substantiated this finding in a subpopulation of economically disadvantaged 
patients that same year.163   
 In 2012, Paulozzi’s case control study of New Mexican opioid-related deaths found that having a 
daily average morphine equivalent dosage of 40mg or more increased the odds of opioid-related mortality 
by 1200%, and mortality risk increased as average daily MME increased until it plateaued at 200mg 
MED/day. In the discussion, the authors highlight a single opioid prescription equaling an average daily 
MED of 120mg/day or greater as a suggested cause for review. Additionally, this 120mg/day MME figure 
reflects a previously validated threshold133,135 and Centers for Medicare and Medicaid services have 
recently directed Medicare Part D plan administrators to utilize this threshold of 120 MME/day as a 
claims-based screening tool for risky opioid abuse.164 
 More recently, though, Liu and colleagues defined high-risk opioid use with a threshold of 
100mg/day MME143, and Baumblatt demonstrated in his case control study of Tennessean opioid-related 
decedents that an average daily opioid dose of 100 MME/day was associated with 11 times the risk of 
opioid-risk death compared to controls.157 Using logistic receiver operating characteristic modeling, 
Huffman, et al, identified 76.1 MME/day as the optimal threshold for predicting an opioid use disorder 
upon retrospective review of 199 patients of a pain rehabilitation program.165 
2.3.2.6 Claims-Based High-Risk Opioid Use Measures—Daily Acetaminophen Dose 
 Only one study in the published literature—the 2004 analysis of the CS-PURE criteria from 
Parente, et al—considered using APAP dosage from opioid-APAP combination products as a strategy for 
identifying patients at high risk for opioid-related adverse events. Through the use of multidisciplinary 
expert input and validation through retrospective claims analysis, an average daily APAP dose of 
4,000mg/day over any time period was one of the top-5 performing thresholds of high-risk opioid use.155 
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2.3.2.7 Claims-Based High-Risk Opioid Use Measures—Other Measures 
 Multiple alternative measures for defining high-risk opioid use in claims data were used in the 
peer-reviewed literature and are summarized in Table 2.6. These measures were not used in the proposed 
dissertation analyses, but they deserve mention here if only to guide potential future research regarding 
the development of standardized MLIP enrollment criteria. One study defined high-risk opioid use as 
receiving 210 days supply of opioids in one year.166 Multiple studies considered aberrant opioid 
utilization patterns in the form of inappropriately early opioid refills and receipt of multiple overlapping 
opioid prescriptions.131,143,151,152,161,167 White and colleagues measured notable opioid dose escalations over 
consecutive months as markers of inappropriate opioid utilization,151 Bohnert, et al, assessed whether or 
not patients received only “as needed” opioid prescriptions compared to schedule opioid dosing140, and 
Liu compared considered receipt of long-acting and extended release opioid preparations as a potential 
risk factor.143 Interestingly, Rice was able to measure household opioid use and found that six or more 
household opioid prescriptions or an opioid abuse diagnosis in 12 months significantly increases a 
patient’s likelihood of receiving an opioid abuse diagnosis.152 
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Table 2.6: Summary of Alternative Claims-Based Measures of High-Risk Opioid Use in Peer-Reviewed Literature 
Study Patient population Outcome predicted 
Observation 
period Alternative high-risk opioid definition  
Edlund, et al (2007) US Veterans Opioid abuse Dx 12 months ≥210 total days supplied 
Buurma, et al (2008) Netherlands "Drug-seeking" behavior 12 months >10% of all Rx filled elsewhere + >10 Rx filled 
elsewhere 
White, et al (2009) Privately insured (ME) Opioid abuse Dx 6 months ≥1 early refill; ≥2 consecutive dose escalations 
Sullivan, et al (2010) Medicaid (AR) Novel risk score 6 months Novel opioid misuse scoring algorithm 
Bohnert, et al (2011) US Veterans Overdose death Variable Receiving only Rx with "as needed" dosing schedule 
Cepeda, et al (2012, 13) Population-based "Drug-seeking" behavior 18 months ≥2 overlapping Rx from 2 prescribers at ≥3 pharmacies 
Peirce, et al (2012) WV residents Overdose death 6 months Concomitant opioid/benzodiazepine use 
Rice, et al (2012) Privately insured Opioid abuse Dx 12 months Early refills; ≥6 household Rx fills; household opioid 
abuse Dx 
Daubresse, et al (2013) Privately insured Novel risk score 3 months Novel opioid misuse scoring algorithm 
Liu, et al (2013) Privately insured N/A (researcher-defined) 12 months Overlapping opioid Rx; Overlapping 
opioid/benzodiazepine Rx; LA/ER opioid use;  
Yang, et al (2015) Medicaid Overdose event 90 days Overlapping opioid Rx 
Note: All findings reported in the table refer to opioid utilization unless otherwise specified. US=United States; Dx=diagnosis; Rx=prescription; 
ME=Maine; AR=Arkansas; WV=West Virginia; LA=long-acting; ER=extended release. 
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 Additionally, two large-scale efforts have also been made in the literature to develop claims-
based aggregate opioid risk scoring systems to identify high-risk patients. Researchers in 2010 built upon 
the work of Parente, et. al., to develop and validate an opioid misuse score in the context of the large-
scale TROUP (Trends and Risks of Opioid Use for Pain) study.133 The opioid misuse score was based on 
the assessment of days supply of short-acting opioids, days supply of long-acting opioids, number of 
pharmacies used, and number of prescribers used over a six-month period. Each of the four measures was 
scored on a scale of 0-2, and year-long opioid misuse scores were stratified into no misuse (0-1), possible 
misuse (2-4), and probable misuse (5-16). The authors validated the opioid misuse score in two insurance 
claims databases for years 2000-2005: one containing nearly 3.8 million privately insured beneficiaries 
and the other comprised of 128,000 Arkansas Medicaid beneficiaries.133 Sullivan and colleague’s opioid 
misuse score also had a strong, linear relationship with receipt of an opioid abuse diagnosis.  
 More recently, Daubresse and colleagues developed a different controlled substance misuse 
scoring algorithm for use in claims data.168 The controlled substance use score was based primarily on the 
volume of controlled substance prescriptions filled, number of pharmacies and physicians visited, and rate 
of utilization of controlled substances (Table 2.7). The authors assessed utilization of all Schedule II 
through Schedule V drug classes over a 90-day observation period. Although the authors did not 
explicitly validate these criteria by investigating associations between scores and controlled substance-
related overdose or mortality, they did express confidence in their controlled substance score’s specificity 
while still identifying a sample of high utilizers of sufficient size for analysis and intervention. 
Table 2.7: Controlled substance risk score component measures 
Source of information Weight 
Volume of controlled 
substance claims 
Assign half a point to the individual for each of their first 8 claims for a controlled 
substance; assign 1 point for each additional controlled substance claim thereafter 
Number of unique 
pharmacies and prescribers 
Based on the combined total of unique pharmacies and prescribers, assign 1 point for 
the first two unique entities; assign 1.5 points for each unique entity thereafter 
Rate of utilization of 
controlled substances 
Assign 1 point if the number of claims for controlled substances in the 3rd month of 
the 90-day pre-intervention is two or more than the number of claims in the 2nd 
month of the pre-intervention period 
Source: Daubresse M, Gleason PP, Peng Y, Shah ND, Ritter ST, Alexander GC. Impact of a drug utilization review 
program on high-risk use of prescription controlled substances. Pharmacoepidemiol Drug Saf. Jul 24 2013.  
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2.3.3 Defining Risky Controlled Substance Use—The “ADOPT” Report 
 In addition to the published literature, a 2012 CDC grant report detailed results from a recent 
initiative to develop a tool that predicts the effectiveness of Medicaid lock-in programs based on a state’s 
MLIP enrollment criteria and characteristics of their Medicaid population.169 The end result of this project 
was the “Approaches to Drug Overdose Prevention Analytic Tool” (ADOPT), an Excel-based simulation 
tool that produces predictions of clinical, utilization, and economic outcomes based on an MLIP’s design 
and beneficiary population. Although ADOPT is yet to be validated in the peer-reviewed literature, the 
authors conducted extensive analyses into the associations between overdose-related events and 
controlled substance dosing and utilization patterns, which informed the development of the ADOPT 
simulation method. Findings from these analyses, like the literature discussed previously, have direct 
implications for the development of actionable definitions of high-risk opioid use. 
 Melnikow, et. al., used a large, nationally-representative administrative claims database to create 
a cohort of nearly 430,000 Medicaid managed care beneficiaries ages 12 and older with any opioid use in 
years 2008-10 and 24 months of continuous enrollment. A total of 1,738 opioid overdose events were 
identified in the sample. In primary analyses, average opioid doses of 50-100mg/day and >100mg/day, 
measured in morphine equivalents over 90 day periods, were associated with a significant three-fold and 
five-fold increase in overdose risk compared to average doses of <20mg/day.  
 Secondary analyses looked at measures of overlapping prescriptions and pharmacy shopping. 
Overlapping prescriptions was defined as obtaining an opioid prescription fill with at least 25% of a 
previous opioid fill remaining. Comparative measures of pharmacy shopping were evaluated based on 
capture of overdose events among variations on use of three or four pharmacies assessed over observation 
periods of 90, 180, and 365 days (Table 2.8). The authors selected a threshold of four or more pharmacies 
in a 90-day period as an operational definition of pharmacy shopping. In descriptive analyses looking at 
varied combinations of the pharmacy shopping and overlapping prescription criteria, a definition of risky 
opioid-seeking behavior combining pharmacy shopping and overlap was most effective at identifying 
those ultimately experiencing overdose events, followed by an overlapping prescription-only definition. 
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Table 2.8. Comparison of Different Pharmacy Shopping Criteria in Medicaid MarketScan® Dataset  
 
Pharmacy 
shopping criteria 
Eligible 
recipients 
Overdose 
events 
% Overdose 
among eligible 
recipients 
% of total 
overdose DOR 
1-year setting, 
≥3 pharmacies 
44,266 825 1.86% 69.86% 2.38 
1-year setting, 
≥4 pharmacies 
29,175 620 2.13% 52.50% 2.3 
180-day setting, 
≥3 pharmacies 
38,157 818 2.14% 69.26% 3.05 
180-day setting, 
≥4 pharmacies 
21,351 599 2.81% 50.72% 2.73 
90-day setting, 
≥3 pharmacies 
28,730 788 2.74% 66.72% 4.28 
90-day setting, 
≥3 pharmacies 
13,083 555 4.24% 46.99% 5.23 
DOR= Diagnostic odds ratio 
Reproduced from: Melnikow J, Yang Z, Soulsby M, Ritley D, Kizer K. Approaches to Drug Overdose Prevention 
Analytical Tool (ADOPT): Evaluating Cost and Health Impacts of a Medicaid Patient Review & Restriction 
Program. University of California, Davis; December 2012. 
 
 The measures of pharmacy shopping and overlapping opioid prescriptions were then included in 
the previous analytic model predicting overdose risk based on opioid dosing strata. Dosing categories of 
50-100mg morphine equivalents per day and >100mg/day remained highly predictive of opioid overdose 
events. Pharmacy shopping and overlapping opioid prescriptions significantly increased the risk of 
overdose 80% and 200%, respectively. The authors recommend using thresholds of 100mg mean 
morphine equivalents per day, the presence of 25% overlap in similar opioid prescriptions, and use of four 
or more pharmacies in a 90-day period as criteria for identifying Medicaid beneficiaries at greatest risk of 
adverse opioid-related outcomes.  
2.3.4 Defining Risky Controlled Substance Use—Summary and Gaps 
 There is general consistency in the literature regarding measures of high-risk opioid use. The 
evidence overwhelmingly supports the use of number of pharmacies visited, number of prescribers used, 
number of controlled substance prescription fills, and average daily dose of opioid analgesics, measured 
in morphine equivalents. Additional measurement strategies have been used with some success: presence 
of overlapping controlled substance prescriptions131,150,152,155,167,169, accelerated opioid use151,168, total 
opioid days supplied166, daily APAP consumption (from opioid analgesic combination products)155, and 
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household opioid utilization patterns152. There is less consistency in the actual measurement thresholds 
used to delineate risky use, as well as observation periods over which these measures should be assessed. 
The most agreement seems to be found in recommendations to use high-risk thresholds of 2-5 
pharmacies, 2-5 prescribers, and average daily morphine equivalent doses of opioids of 50-120mg/day, 
assessed over 6 to 12-month periods.  
 Literature gaps: There is scant evidence in the peer-reviewed literature, to date, explicitly 
investigating the development of definitions of high-risk opioid use for the purpose of creating effective 
and standardized Medicaid lock-in program eligibility criteria.150 One peer-reviewed article detailed the 
development of an automated claims-based algorithm for the purpose of identifying MLIP-eligible 
beneficiaries.150 However, the authors only evaluated the ability of their algorithm to predict agreement 
with previous MLIP enrollment decisions based on retrospective manual case review and not actual 
adverse clinical outcomes that MLIPs are intended to prevent. Additionally, the results of this study have 
limited generalizability to state MLIPs outside of Wisconsin, including the NC MLIP. The ADOPT 
Report from Melnikow, et. al., also rigorously evaluated the association between opioid utilization 
behaviors and opioid overdose events in Medicaid beneficiaries for the purpose of informing MLIP 
design.169 However, its study sample did not included Medicaid fee-for-service beneficiaries, and it used a 
multi-state pooled sample of Medicaid patients (most of which likely lived in states with active MLIPs 
that may have biased results). Also, ADOPT analyses were conducted to inform the development of an 
MLIP outcomes simulation tool estimating the effects of an MLIP based on pre-determined eligibility 
criteria and not to inform the development of optimal MLIP enrollment criteria strategies for individual 
states. These gaps in knowledge motivated Aim 3 of this dissertation in which we sought to identify and 
validate measures of high-risk opioid use that are most predictive of downstream adverse clinical 
outcomes from opioid abuse. These findings would inform standardized MLIP eligibility criteria. 
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2.4 CONCEPTUAL MODEL 
 This dissertation research was designed based on Andersen’s Behavioral Model of Health Service 
Use, a theoretical framework illustrating the associations of individual and contextual factors with health 
behaviors and outcomes.170 In general, the Andersen model states that a patient’s health service utilization 
is a product of non-modifiable characteristics predisposing a patient to certain health behaviors and 
outcomes; enabling characteristics that facilitate or hinder healthcare use; and their need for health 
services.171 
2.4.1 Andersen’s Behavioral Model of Health Services Use 
 The Andersen Behavioral Model of Health Service Use was first introduced in the 1960s for the 
purpose of guiding the research and development of health policies to ensure equitable access to 
healthcare across patient populations.170 The model was intended to achieve these ends by helping 
establish standardized definitions and measures of myriad factors thought to influence access to care. 
Since its introduction in the literature, the Andersen model has been expanded and revised numerous 
times, with the fifth—and most recent—revision occurring in 2008. Figure 2.2 portrays the fifth phase of 
the Andersen model. The most notable change to the Andersen model seen in Phase 5 is the recognition 
that contextual determinants of healthcare use on the aggregate healthcare system-, community-, and 
provider-levels can also be conceptualized as predisposing, enabling, and need characteristics. 
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Figure 2.1: Andersen’s Behavioral Model of Health Services Use (Phase 5, 2008) 
  
Reproduced from: Andersen RM. National health surveys and the behavioral model of health services use. Med 
Care. Jul 2008;46(7):647-653. 
 
  
 Individual characteristics that predispose patients to use healthcare services include patient 
demographics (such as age and gender), social characteristics (such as race and education level), and 
personal beliefs and values concerning health and healthcare.170 Enabling characteristics of the individual, 
such as income and health insurance coverage, work to regulate accessibility of healthcare services. 
Lastly, individual need characteristics represent the evaluated clinical need for services as well as 
perceived need. All types of individual characteristics are influenced by contextual determinants of 
healthcare use. These include the predisposing factors like the age and social structure of the community; 
enabling factors like the supply of accessible healthcare facilities and providers in the area; and the 
community need for healthcare services based on the health status and comorbidities of the population. 
 Individual and contextual characteristics determine patient and provider health behaviors, 
including personal health practices, processes of medical care, and use of personal health services.170 
Personal health practices encapsulate individual behaviors that alter or maintain health such as dieting, 
exercising, and smoking. Processes of medical care represent provider behaviors with regard to diagnostic 
and therapeutic activities undertaken in the course of patient care. Use of health services refers to 
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patients’ use of the healthcare system, such as through pharmacy, outpatient, inpatient, and emergency 
care visits.  
 Health outcomes in the Andersen model include evaluated clinical benefits and harms from 
healthcare; patients’ perceived health; and patient satisfaction with care.170 Health outcomes are 
influenced by contextual characteristics, individual characteristics, and health behaviors. Health outcomes 
are also capable of impacting these factors in the pursuit of future healthcare services. 
2.4.2 Dissertation Conceptual Model 
 Figure 2.3 depicts the conceptual model informing the investigation of the dissertation aims, as 
well as the outcomes of the parent project. The conceptual model is a modified version of the Andersen 
Behavioral Model of Health Services Use. The individual and contextual characteristics were 
consolidated for ease of interpreting predisposing, enabling, and need characteristics. The NC MLIP 
policy intervention was also introduced to the conceptual model as a unique determinant of health 
behaviors in the NC Medicaid population.   
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Figure 2.2: Dissertation conceptual model based on Andersen’s Behavioral Model of Health Service Use  
 
Note: *unobservable; CS=Controlled substance; Rx=Prescription; NC=North Carolina 
 P=Parent project outcome of interest; 1=Aim 1 outcome of interest; 2=Aim 2 outcome of interest;  
 3=Aim 3 outcome of interest (overdose event health outcomes used for the purpose of validating high-risk CS utilization health behavior measures)
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2.4.2.1 Dissertation Conceptual Model—Predisposing Characteristics  
 Measurable predisposing characteristics in the conceptual model include age, sex, and 
race/ethnicity. Nonmedical use of controlled substances and its related consequences have been shown to 
be associated with each of these variables. The evidence overwhelmingly indicates that young and 
middle-aged adults, roughly ages 20-50, receive controlled substance prescriptions most 
frequently39,42,132,137,172,173 and are most likely to nonmedically use prescriptions1,52,53,133,174,175, engage in 
doctor/pharmacy shopping60,132,162, receive opioid abuse diagnoses54,137,166,176,177, and experience overdose 
events and overdose-related death.2-4,59,60,173 The age range of 45-54 years exhibits the greatest risk for 
opioid-related deaths in the US, according to the CDC.3  
 Conflicting evidence exists over the prevalence of controlled substance utilization between the 
sexes.39,42,178,179 However, the literature does indicate that male sex is associated with greater dose 
escalation of opioid analgesics172 and increased nonmedical use behaviors.1,52,175,179 In 2012, lifetime 
prevalence of nonmedical controlled substance use was 15.9% for men and 11.2% for women in the 
US.180 Non-medically used controlled substances were more likely to be received from a friend or family 
member for men180, while women were more likely to engage in doctor- and pharmacy-shopping 
behaviors.60,162 Male nonmedical users of controlled substances are at a much greater risk of receiving an 
opioid abuse diagnosis54,166,181 and experiencing overdose-related death compared to women. 2,3,60,173 
 Additionally, non-Hispanic White and Native American individuals report the most nonmedical 
use of prescription drugs52,182 and also have the greatest controlled substance-related mortality risk of all 
races and ethnicities.2,4,173 Patient health beliefs also serve as a key predisposing characteristic, but this 
factor was not measurable in the study data. 
2.4.2.2 Dissertation Conceptual Model—Enabling Characteristics 
 Enabling variables in the conceptual model include measurable characteristics thought to 
facilitate the accessibility of health services of interest in the dissertation. These primarily included 
county-level measures that capture rural residence. Rural residence has been theorized as a key driver in 
substance abuse183 and has previously been associated with an increased risk of nonmedical use51, 
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diagnosed opioid abuse73,184, and controlled substance overdose events.2,56 Multiple studies have shown 
that opioid abuse and overdose is heavily concentrated in the Appalachia region of the United States, 
which includes western parts of North Carolina.184,185 Increased local supply of physicians and 
pharmacies—a marker of metropolitan residence and increased accessibility of healthcare services—also 
results in higher levels of prescriber- and pharmacy-shopping.186  
 Additionally, provider-level characteristics of specialty training, location, and practice setting 
serve as enabling factors in the conceptual model. Previous research shows that prescriber specialty 
training is predictive of increased opioid prescribing compared to primary care providers.187 Inappropriate 
controlled substance shopping behaviors are associated with traveling increasing distances from a 
patient’s home to the controlled substance prescriber.188 The prescriber’s practice setting, namely the 
emergency department setting, is associated with increased likelihood of opioid prescribing.187 Pharmacy 
characteristics, such as chain vs. independent, may help predict controlled substance use patterns. 
However, the data sources used in this dissertation did not allow for reliable assessment of provider- and 
pharmacy-level characteristics, but this highlights a rich area for future MLIP research. 
 Although the study population consists entirely of North Carolina Medicaid beneficiaries, 
Medicaid coverage status was included in the conceptual model to recognize its role in enabling 
healthcare service use. Also, the conceptual model recognizes household controlled substance utilization 
and opioid abuse diagnoses as key predictors of nonmedical use181, despite the fact that this was not 
measurable in the study data.  
2.4.2.3 Dissertation Conceptual Model—Need Characteristics 
 The primary evaluated need characteristics in the conceptual model pertain to diagnosed 
conditions for which opioid analgesics and benzodiazepines are indicated. These include chronic non-
cancer pain diagnoses189 and anxiety disorder diagnoses, respectively. Additionally, an increased burden 
of comorbid conditions—primarily mental health and co-occurring substance abuse conditions—are 
known predictors of nonmedical prescription use and its subsequent outcomes.190 Mental illness, such as 
depression, anxiety disorders, and mood disorders, are all associated with increased utilization of 
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controlled substances191-195, nonmedical use behaviors196-199, and diagnosed opioid abuse.67,166,176,181,200 
Researchers estimate having one of these conditions results in a 2-3 times higher risk of nonmedical use 
and opioid abuse, compared to those without mental health conditions.181,198 Similarly, a history of co-
occurring substance abuse, including alcohol and illicit street drugs, also was associated with higher 
controlled substance utilization192-194, nonmedical use7,51,175,182,196,199, and opioid abuse66,67,166,176,181, in 
addition to opioid overdose-related death.140  
 Other physical comorbid burden, such as chronic diseases like hypertension, are also included in 
the conceptual model as need characteristics. The overall health status and comorbidity burden have been 
shown to be worse among patients receiving controlled substance medications.201-204 Physical comorbidity 
burden also helps to explain the extent to which patients interact with the healthcare system. Perceived 
need was recognized in the model as an important factor in patients’ healthcare seeking behaviors; 
however, perceived need was not measurable in the dissertation data. 
2.4.2.4 Dissertation Conceptual Model—NC Medicaid Lock-In Program Status 
 The main modification to the Andersen framework in the development of the dissertation 
conceptual model was the inclusion of an additional construct for NC MLIP enrollment status. As 
depicted, enrollment in the NC MLIP occurs as a function of individual and contextual predisposing, 
enabling, and need characteristics, as well as health behaviors around controlled substance use that 
contribute to eligibility for the program. Enrollment in the NC MLIP also modifies health behaviors by 
imposing provider access restrictions that are intended to influence patients’ controlled substance 
utilization patterns. MLIP enrollment status would also have an effect on contextual and individual need 
characteristics. Accounting for the role of the lock-in program in the conceptual model as a stand-alone 
construct recognizes that other factors in the model impact eligibility and enrollment in the program and 
can also be subsequently influenced by MLIP enrollment. The effect of NC MLIP enrollment status on 
controlled substance-related health behaviors motivates the investigations of Aims 1 and 2. 
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2.4.2.5 Dissertation Conceptual Model—Health Behaviors 
 Predisposing, enabling, and need characteristics, as well as NC MLIP enrollment status, 
determined key patient health behaviors in this dissertation. The specific health behaviors of interest were 
controlled substance use behaviors that determine the effectiveness of MLIPs in mitigating high-risk 
controlled substance use. These controlled substance use behaviors included the receipt of controlled 
substance prescriptions, patient decisions regarding source of payment for controlled substance 
prescriptions (circumvention versus Medicaid coverage), and the types and characteristics of controlled 
substance prescriptions obtained by patients.  
 Aim 1 investigates the effect of NC MLIP enrollment on engaging in Medicaid circumvention to 
obtain controlled substances. Aim 1 was founded on a conceptual relationship in which NC MLIP 
enrollment is believed to induce people to circumvent Medicaid to obtain controlled substances. 
Unpublished sources suggest that circumvention is common in MLIP programs118 and that further 
investigation of circumvention behavior is needed to improve the benefit of MLIPs through better lock-in 
adherence.112 Circumvention is problematic, because it results in failure to achieve care coordination 
between designated lock-in providers, and it signals a failure to regulate access to controlled substances 
for those intent on abusing or diverting these medications.  
 Evidence of MLIP-induced circumvention reveals concerns over lock-in restrictions inadvertently 
causing some Medicaid beneficiaries to engage in high-risk controlled substance use behaviors knowingly 
occurring outside the purview of the Medicaid program.112,118,130 High-risk controlled substance use, 
however, is not just a function of how frequently patients seek these medications. The characteristics of 
the controlled substance prescriptions themselves also contribute to high-risk use behaviors and 
outcomes. More specifically, high potency opioid agents and large dosages of opioids per prescription are 
associated with greatly increased risk of substance abuse disorders and overdose 
outcomes.135,137,140,142,145,205 And unsurprisingly, high potency and high dosage opioid prescriptions are 
specifically sought by opioid abusers due to their enhanced euphoric effects and increased street 
value.37,133,146,206-208 Therefore, Aim 2 examined the effect of NC MLIP enrollment on receipt of high 
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potency and high dosage opioid prescriptions through circumvention. This study was founded on the 
conceptual underpinning that NC MLIP restrictions may influence the use of these high-risk opioid 
products known to have greater appeal to opioid abusers, especially when purposely sought outside the 
purview of MLIP administrators.  
 In Aim 3, controlled substance utilization patterns comprised the independent variables predicting 
clinical outcomes from high-risk controlled substance use. Measures of controlled substance use in Aim 3 
centered around the extent of controlled substance prescriptions received and providers used. 
2.4.2.6 Dissertation Conceptual Model—Health Outcomes 
 Patient predisposing, enabling, and need variables; health behaviors; and NC MLIP enrollment 
status work in concert to determine key health outcomes in the conceptual model. These included the 
primary Aim 3 outcome of unintentional opioid analgesic overdose, as well as secondary Aim 3 clinical 
outcomes of unintentional APAP overdose due to opioid/APAP combination products, unintentional 
overdose of any drug product, diagnosed opioid use disorder, and diagnosed substance use disorder of any 
type. The secondary outcomes accounting for unintentional overdose and substance use disorder 
diagnoses from all drug products were assessed, because opioid analgesics readily contribute to these 
outcomes when in cocktail with other substances but may not be characterized in administrative claims 
data as the primary responsible agent.4,20,60,61,209 Perceived health status is also an important health 
outcome; however, it was not evaluated due to the absence of self-reported health information in the study 
data. 
2.5 CHAPTER SUMMARY 
 In Chapter II we provided background information detailing the recent epidemic of prescription 
drug abuse and misuse in the United States and major state-level policy strategies intended to prevent 
nonmedical use of controlled substances and its outcomes. We provided a comprehensive review of the 
peer-reviewed and grey literature for the effect of one specific and highly prevalent policy strategy, 
Medicaid controlled substance lock-in programs, on patient outcomes. Overall, we found a stark lack of 
rigorous evidence for the effect of MLIPs on patient outcomes and identified major gaps in the literature 
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motivating the research questions posed by the dissertation parent project and Aims 1 and 2 of this 
dissertation, which evaluate the North Carolina MLIP implemented in 2010. Specifically, the parent 
project addressed the lack of peer-reviewed literature around the effect of MLIPs on controlled substance 
Medicaid claims and the overdose outcomes. Aim 1 of this dissertation was designed to address the 
current lack of knowledge around the prevalence and predictors of lock-in circumvention, which is a 
notable limitation of the MLIP policy strategy. Aim 2 further addressed the limitation of MLIP 
circumvention by examining prescription-level characteristics of opioids obtained by MLIP enrollees 
through circumvention. 
 We also provided a rigorous review of the literature investigating claims-based definitions of 
high-risk opioid use to understand the evidence available to inform MLIP eligibility criteria, which varied 
significantly across states. Aim 3 of this dissertation was motivated by the lack of literature examining 
claims-based thresholds of high-risk opioid use in Medicaid claims data, specifically in the context of 
identifying beneficiaries most likely to benefit from MLIP enrollment with regard to overdose prevention.  
 We closed Chapter II by detailing a conceptual model based on the Andersen Behavioral Model 
of Health Service Use theoretical framework, which guided the investigations of each dissertation aim. 
This model conceptualized the relationship of subjects’ predisposing, enabling, and need characteristics 
with their medication use behaviors; the North Carolina MLIP; and subsequent clinical outcomes.  
  
  65 
 
 
 
 
 
 
CHAPTER III:  METHODS 
  
 This chapter outlines the methodologies that were used to investigate the aims of this dissertation. 
More specifically, Chapter III describes the dissertation data sources, overall study design and population, 
measures used, and analytic approach for each aim, including cohort selection and statistical analysis. The 
aims of this dissertation were:  
1) To examine the effect of the North Carolina Medicaid Recipient Management Lock-in Program, 
as well as patient-level characteristics, on controlled substance circumvention behaviors; 
2) To investigate prescription-level characteristics of opioid analgesics obtained by North Carolina 
Medicaid Recipient Management Lock-In Program enrollees through circumvention. 
3) To identify and validate the most effective measures of high-risk opioid analgesic use in the 
North Carolina Medicaid population. 
3.1 DATA SOURCES 
 This dissertation used two primary quantitative data sources to conduct study analyses. The first 
data source, which was used in all aims of the dissertation, came from the North Carolina Division of 
Medical Assistance’s (DMA) DRIVE database. DRIVE (Data Retrieval Information and Validation 
Engine) is a state-operated data warehouse that aggregates information about North Carolina Medicaid 
beneficiaries and their health service utilization.210 More specifically, DRIVE provides detailed 
demographic information for Medicaid beneficiaries; detailed periods of Medicaid enrollment for 
individual beneficiaries; administrative claims data for prescription, outpatient, inpatient, and emergency 
care services paid by NC Medicaid; provider-level information; and administrative records of enrollment 
in the North Carolina Medicaid lock-in program. We used DRIVE data from 10/1/2008 to 9/30/2012, 
encompassing two years prior to and two years following NC MLIP implementation. 
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 Data from North Carolina’s CSRS comprised the second major quantitative data source and was 
used in Aims 1 and 2 analyses. The CSRS database is managed by the North Carolina Division of Mental 
Health, Developmental Disabilities, and Substance Abuse Services.98 The CSRS provided records for 
each Schedule II, III, IV, and V medication dispensed by community and outpatient pharmacies in North 
Carolina. For each controlled substance prescription record, the CSRS data provided patient name, 
birthdate, address, and phone number; prescription written and filled dates; prescription number; 
indication of a new fill or refill; National Drug Code identifier of the prescribed medication, quantity 
dispensed, and days supply; pharmacy’s DEA number; and prescriber’s DEA number.98 North Carolina 
pharmacies are required to report this information for each controlled substance prescription filled within 
72 hours of its dispensation. Notably, the CSRS data do not contain information about payment source of 
controlled substance prescriptions. We used CSRS data from 10/1/2009 through 9/30/2012, which 
represented one year prior to and two years following NC MLIP implementation in October 2010. 
 The CSRS did not perfectly capture all Medicaid controlled substance prescription claims during 
the study period. A total of 6.6% of opioid and benzodiazepine Medicaid claims failed to produce a 
matching CSRS record among Medicaid prescription claims included in Aim 1 and 2 analyses. We 
examined these claims for evidence of systematic missingness that may have introduced bias into Aims 1 
and 2 analyses (Appendix Table 1). There was no obvious evidence of meaningful systematic differences 
in Medicaid prescription claims that were captured vs. not captured by the CSRS with regard to relevant 
study measures. There was no statistically significant difference between these subsets of Medicaid 
claims with regard to subject gender and clinical comorbidity burden. There were statistically significant, 
but very small differences with regard to subject age, rurality of county of residence, and each of the three 
prescription-level outcomes investigated in Aim 2. The distribution of CSRS captured and non-captured 
Medicaid prescription claims were analogous across the duration of the study period, as well (Appendix 
Figure 1). Based on these findings, we assumed the 6.6% of missing Medicaid prescription claims in the 
CSRS dataset only contributed to conservative estimates of the prevalence and rate of circumvention 
behavior and did not introduce bias. 
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3.1.1 North Carolina Medicaid and CSRS Data Linkage 
 Aim 1 and 2 analyses utilized a dataset that links North Carolina Medicaid and CSRS data. An 
external individual hired by the parent project research team performed the CSRS and Medicaid data 
linkage. Because the CSRS and Medicaid datasets lacked a shared crosswalk, such as Medicaid ID or 
Social Security Number, patient-level name, date of birth, and address identifiers were used by the data 
programmer to manually perform systematic linkages for Medicaid beneficiaries that were enrolled at any 
point in the MLIP. All patient identifiers were removed prior to delivery of the final merged dataset to the 
researchers with encrypted Medicaid IDs used to identify individual subjects. 
 Distinct advantages and disadvantages exist with the merged North Carolina Medicaid and CSRS 
dataset. To our knowledge, this was the first instance of a peer-reviewed MLIP investigation linking these 
two data sources. This allowed the investigators to assess controlled substance-seeking behavior for 
MLIP enrollees that paid for these medications completely out-of-pocket, which Medicaid claims data is 
unable to detect. However, due to the lack of a shared crosswalk between the two datasets and the 
administrative burden of linking these data sources means that CSRS data were only available for NC 
MLIP enrollees. Therefore, the analytic dataset was unable to observe controlled substance cash payments 
among the full NC Medicaid population. This prevented any comparison between the subset of MLIP 
enrollees and the general Medicaid beneficiary population of the rates of Medicaid circumvention for 
obtaining controlled substances. Additionally, the CSRS dataset only captured controlled substance 
utilization behaviors within the State of North Carolina. Therefore, the linked Medicaid–CSRS dataset 
was unable to detect circumvention behaviors that occurred across state lines among NC MLIP enrollees. 
3.2 OVERALL STUDY SAMPLE AND DESIGN 
 The dissertation evaluated the NC MLIP through a retrospective cohort design that included 
adults age 18-64 enrolled as a North Carolina Medicaid beneficiary at any point between 10/1/2008 and 
9/30/2012. Adults eligible for Medicaid coverage in North Carolina included those with annual income 
less than 46% of the Federal Poverty Limit (FPL) who are working parents of dependent children, adults 
making less than 36% FPL who are non-working parents of dependent children, pregnant women making 
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less than 196% FPL, and disabled working and non-working adults.211 Specific study population criteria 
differed by aim and are presented for each aim below in Section 3.5.  
3.3 POWER CALCULATIONS 
 Statistical power of dissertation analyses was examined a priori in SAS 9.3. It was determined 
sufficient power existed for Aims 1-3 under reasonable, conservative assumptions from prior literature 
and current understanding of the study population and data sources. For Aims 1 and 2, approximately 
4,500 individuals were enrolled in the NC MLIP during the first 18 months of the program, and based on 
prior literature of Medicaid enrollment it was expected 50% of these subjects would meet the continuous 
enrollment inclusion criteria.212 For the dichotomous circumvention outcome we ignored the contribution 
of repeated measures to be conservative and assumed a 50% prevalence of circumvention.118 We 
estimated having 80% power to detect a 19%, 16%, 13%, and 9% increase in odds of circumvention 
assuming possible within-subject correlations of 0.0, 0.25, 0.5, or 0.75, respectively. For the count 
outcome, we estimated over 90% power to detect a change in 0.5 circumvention events for the expected 
1,125 circumventers, based on an assumed standard deviation of 5.0 and correlation of 0.5. 
 For Aim 3, we used the parent project’s preliminary analyses of NC Medicaid claims data for the 
12 months prior to the MLIP implementation to estimate that 300,000 adults filled an opioid prescription 
during our study period and 1,500 experienced an overdose event. We conservatively expected 50% of 
subjects to meet continuous enrollment inclusion criteria.212 Therefore, after randomly dividing subjects 
into 50% subsamples, we anticipated an Aim 3 testing sample of 75,000 subjects with 375 overdose 
events. Assuming a null area under the curve (AUC) value of 0.70, this sample size would provide us 
with 95% power to determine whether the true AUC of our high-risk opioid measures in ROC analyses 
was 0.75 or greater at an alpha level of 0.05. And assuming that the true sensitivity of an opioid measure 
threshold was excellent at 90%, with 375 overdose cases in the validation sample we estimated having 
80% power to conclude that the sensitivity was 85% or greater using a two-sided test and alpha of 0.05.  
3.4 MEASURES 
 Measures used in dissertation analyses are defined in Table 3.1 and described below. 
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Table 3.1: Definitions and characteristics of dependent and independent variable measures used in dissertation analyses 
Aim Variable Type 
Time  
Variation Data Source Description 
 Dependent Variables     
1	       Circumvented fill Dichotomous Variant Medicaid/CSRS 1=Present; 0=Absent 
1 Circumvented fill Count Variant Medicaid/CSRS Number of circumvention events 
2 Long-acting opioid fill Dichotomous N/A Medicaid/CSRS 1=Long-acting opioid; 0=Short-acting opioid 
2 Schedule II opioid fill Dichotomous N/A Medicaid/CSRS 1=Schedule II opioid; 0=Schedule III-V opioid 
2 Prescribed daily opioid dose Continuous N/A Medicaid/CSRS Average daily milligram morphine equivalents prescribed 
3 Unintentional overdose, opioid Dichotomous N/A Medicaid 1=Present; 0=Absent 
3 Unintentional overdose, APAP Dichotomous N/A Medicaid 1=Present; 0=Absent 
3 Unintentional overdose, any drug Dichotomous N/A Medicaid 1=Present; 0=Absent 
3 Substance use disorder, opioid Dichotomous N/A Medicaid 1=Present; 0=Absent 
3 Substance use disorder, any drug Dichotomous N/A Medicaid 1=Present; 0=Absent 
      
 Independent Variables     
 Predisposing characteristics     1,2 Age Continuous Variant Medicaid Patient age in years 
1,2 Sex Dichotomous Invariant Medicaid 1=Female; 0=Male 
1,2 Race/ethnicity Categorical Invariant Medicaid White, Black, Other/unknown race 
 
Enabling characteristics     
1,2 Rural-Urban Continuum Code Categorical Variant Medicaid/USDA County rurality rating from 1=most metropolitan, 9=most rural 
1,2 Metropolitan county Dichotomous Variant Medicaid/USDA 1=RUCC of 1-3; 0=RUCC of 4-9 
1,2 Prescriber supply count Continuous Variant Medicaid/HPDS Number of unique prescribers in a county 
1,2 Pharmacy supply count Continuous Varian Medicaid/NPPES Number of unique community pharmacies in a county 
1,2     Border county Dichotomous Variant Medicaid 1=County of residence on NC border; 0=Not on border 
 
Need characteristics     
1,2     Any chronic non-cancer pain Dx Dichotomous Invariant Medicaid 1=Present; 0=Absent 
1,2     Any anxiety disorder Dx Dichotomous Invariant Medicaid 1=Present; 0=Absent 
1,2     Any substance abuse Dx Dichotomous Invariant Medicaid 1=Present; 0=Absent 
1,2     Any depression Dx Dichotomous Invariant Medicaid 1=Present; 0=Absent 
1,2     Any other MH Dx Dichotomous Invariant Medicaid 1=Present; 0=Absent 
1,2     Comorbid disease burden Continuous Invariant Medicaid Charlson Comorbidity Score, ranging from 0-37  
1,2 Prescription drug burden Continuous Invariant Medicaid Number of unique drug therapy products received 
Note: CSRS=Controlled Substances Reporting System; APAP=acetaminophen; NC=North Carolina; USDA=United States Department of Agriculture; 
RUCC=Rural-urban continuum code; HPDS=Health Professions Data System; NPPES=National Plan & Provider Enumeration System; Dx=Diagnosis  
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Table 3.1: Describing dependent and independent variable measures used in dissertation analyses (continued) 
Aim Variable Type 
Time  
Variation 
Data  
Source Description 
 Independent variables cont’d     
 Lock-in Policy Characteristics     
1,2 Month Continuous Variant Medicaid Month of study period 
1,2 Lock-in period Dichotomous Variant Medicaid 1=Lock-in policy period; 0=Pre-lock-in policy period 
1,2 Lock-in period * month Continuous Variant Medicaid Month of Lock-in policy period 
1,2 Lock-in eligible Dichotomous Variant Medicaid 1=Lock-in eligible; 0=Not eligible 
1,2 Lock-in enrolled (KEY IV) Dichotomous Variant Medicaid 1=Enrolled in lock-in program; 0=Not enrolled 
1,2 Lock-in enrolled * month Continuous Variant Medicaid Month of lock-in enrollment 
1,2 Lock-in enroll delay Dichotomous Variant Medicaid 1=Lock-in eligible/not enrolled; 0=Eligible/enrolled or ineligible/not enrolled 
1,2 Lock-in enroll delay * month Continuous Variant Medicaid Month of lock-in eligibility without enrollment 
1,2 Opioid-based eligibility Dichotomous Invariant Medicaid 1=Lock-in eligible due to opioid use; 0=Not opioid eligible 
1,2 Benzodiazepine-based eligibility Dichotomous Invariant Medicaid 1=Lock-in eligible due to benzodiazepine use; 0=Not benzodiazepine eligible 
1,2 Provider-based eligibility (proxy) Dichotomous Invariant Medicaid 1=Four or more unique pharmacies used; 0=Less than four unique pharmacies 
1,2 No eligibility Dichotomous Invariant Medicaid 1=No lock-in eligibility criteria met; 0=Any lock-in eligibility met 
 Opioid exposure measures     
3 Opioid prescription fills Continuous N/A Medicaid Number of opioid prescription claims 
3 Opioid pharmacies used Continuous N/A Medicaid Number of unique pharmacies dispensing opioid prescriptions 
3 Daily opioid dose Continuous N/A Medicaid Average daily milligram morphine equivalents received 
3 Daily acetaminophen dose Continuous N/A Medicaid Average daily milligrams of acetaminophen received from opioid 
combination products 
Note: IV=independent variable
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3.4.1 Dependent Variables 
 Aim 1 analyzed two distinct outcome measures that were assessed using the linked Medicaid—
Controlled Substances Reporting System dataset. These included: 
• A binary indicator of a circumvented fill, defined as the presence of any record for an opioid 
analgesic or benzodiazepine prescription fill in the CSRS dataset that lacked a corresponding 
claim in the Medicaid dataset for the same prescription fill. The presence of circumvention was 
assessed in calendar month intervals.  
• A count measure of number of circumvented fills for an individual in a given calendar month. 
 
 Aim 2 analyses involved three outcome variables that were measured using the linked Medicaid-
CSRS dataset (Table 3.2). Each Aim 2 outcome reflected the potency and abuse potential of 
prescription opioid products received by NC MLIP enrollees. These included: 
• A dichotomous prescription-level measure indicating whether an opioid prescription fill 
contained a long-acting preparation vs. an immediate-release preparation. Long-acting 
preparations included extended-release oral formulations and transdermal patch formulations. 
Immediate release opioid products do not have features that reduce the rate of absorption of 
opioid products. Classification of long-acting versus short-acting opioid products was performed 
using a drug information database and expert review.31 
• A binary prescription-level variable indicating whether an opioid fill was for a Schedule II 
product vs. a Schedule III-V product, as per DEA classifications. This measure reflected opioid 
scheduling in use during the study period. Therefore, hydrocodone combination products were 
assessed as Schedule III products in Aim 2 analyses despite having since been reclassified as 
Schedule II following the end of the dissertation study period. As of 2014, tramadol products 
were reclassified as Schedule IV. However, tramadol products were not included in Aim 2 
analyses as they were not a controlled substance during the dissertation study period and therefore 
not regulated under the NC MLIP. Classification of Schedule II opioid products was performed 
using a drug information database and expert review.31 
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• A continuous prescription-level variable of opioid dose measured as prescribed average daily 
milligram morphine equivalents (MMEs). MMEs represent the dose of an opioid product 
standardized to oral morphine, which facilitates direct comparison of dosage across opioid 
products. Total MMEs provided by a single opioid prescription were calculated by multiplying 
the prescription quantity dispensed by the drug strength and by the oral morphine equivalent 
conversion factor. The oral morphine equivalent conversion factor came from evidence-based 
recommendations from the CDC for calculating equivalent opioid doses.213,214 Average daily 
MME for an opioid prescription was calculated by dividing by the total MMEs provided by the 
prescription divided by prescribed days supply. This measure is the gold standard for assessing 
opioid exposure levels in the prescription drug abuse literature.135,140-142 Quantity and days supply 
values were taken from the adjudicated Medicaid claim for all Medicaid-covered prescriptions 
and taken from CSRS records for all circumvented fills. There were 0.6% of prescription fills 
included in Aim 2 analyses in which quantity value discrepancies existed between Medicaid and 
CSRS data. The Medicaid claim quantity value was used in these instances. Less than 2% of Aim 
2 prescription records for circumvented fills reported a days supply of zero in the CSRS record, 
which was assumed to be in error. For these circumvented fill records, we imputed days supply 
based on the average day-per-unit dispensed for that specific product, which we calculated from 
similar prescription fills in the data that had complete quantity and days supply information.   
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Table 3.2: Categorizations of Schedule II opioids, long-acting opioids, and MME conversion factors 
Aim 2 measure Opioid product 
Schedule II opioid agents Codeine (single agent), fentanyl, hydromorphone, meperidine, methadone,  
morphine, opium, oxycodone, oxymorphone tapentadol 
Long-acting opioid products Buprenorphine patch, fentanyl patch, hydromorphone ER tabs, methadone 
tabs/caps/liquid, morphine ER caps/tabs, oxycodone ER tabs, oxymorphone 
ER tabs, tapentadol ER tabs 
MME Conversion Factor 
 0.10 Meperidine 
0.125 Oral transmucosal fentanyl 
0.15 Codeine 
0.23 Propoxyphene 
0.25 Dihydrocodeine 
0.37 Pentazocine 
0.40 Tapentadol 
1.00 Hydrocodone, morphine 
1.50 Oxycodone 
3.00 Methadone, oxymorphone 
4.00 Hydromorphone 
7.00 Butorphanol  
7.20 Transdermal fentanyl1 
12.60 Transdermal buprenorphine2 
Note: ER=Extended release; Tabs=tablets; Caps=Capsules; MME=Milligram morphine equivalent 
1. Conversion factor of transdermal fentanyl was based on the assumption that 1mg parenteral fentanyl = 
100mg oral morphine, and one patch delivers dispensed micrograms/hour for a 24 hour period for 3 days. 
2. Conversion factor for transdermal buprenorphine assumed 1mg parenteral buprenorphine = 75mg oral 
morphine, and one patch delivers dispensed micrograms/hour for a 24 hour period for 7 days 
 Aim 3 examined five relevant substance use-related clinical outcomes defined using International 
Classification of Diseases, Ninth Revision, Clinical Modification215 (ICD-9-CM) case definitions in the 
NC Medicaid claims data to test and validate various measures of high-risk opioid use. These clinical 
outcomes included: 
• Unintentional opioid overdose event identified in the Medicaid claims data using modified ICD-
9-CM code definitions developed by Dunn, et. al and Yang, et. al and validated through chart 
review.141,161 A subject meeting at least one of two ICD-9-CM case definitions for an 
unintentional opioid overdose was considered to have experienced this outcome. The first 
definition characterized a definite unintentional opioid-related poisoning event, and involved the 
presence of at least one of the following diagnoses: 965.0X, E850.1, or E850.2. The second case 
definition captured a probable unintentional opioid overdose and included an ICD-9-CM 
diagnosis of E935.0, E935.1, or E935.2, indicating an opioid-related adverse effect, plus at least 
one additional diagnosis on the same date for a specific sign or symptom of an opioid overdose 
event, including mixed acid-balance disorder (276.4), drug-induced mental disorders (292.1, 
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292.8X), respiratory distress symptoms (486, 496, 518.81, 518.82, 786.03, 786.05, 786.09, 
786.52, 799.0X), and/or altered mental status (780.0X, 780.97). These case definitions for 
unintentional opioid overdose were modified to exclude ICD-9-CM codes indicating self-
injurious intent. 
• Acetaminophen overdose event was defined as the presence of one of the following ICD-9-CM 
codes in any diagnosis field in the Medicaid claims data: 965.4, E850.4, or E935.4. The original 
case definition (which also included E950.0 that was not used in this study due to lack of 
specificity to acetaminophen) was validated through medical chart abstraction (C-statistic=0.86) 
by Myers, et al.216  
• An unintentional overdose event involving any drug product, including alcohol, was identified 
using a claims-based definition employed by Miller, et al, as well as expert review.138 The 
presence of an ICD-9-CM code of 960-980 or E850-E860 was defined as an unintentional 
overdose event of any drug product, as well as any unintentional opioid or acetaminophen 
overdose as defined previously. 
• The presence of an opioid use disorder was assessed using ICD-9-CM case definitions informed 
by prior studies from White, et al in 2005 and 2009.151,217 A subject was considered to have 
received an opioid use disorder diagnosis if they recorded at least one of the following ICD-9-CM 
codes in the Medicaid claims data: 304.0X, 304.7X, or 305.5X. 
• The presence of any substance use disorder was adapted from White’s opioid use disorder case 
definition151,217 and included the presence of at least one of the following ICD-9-CM codes: 
303.X, 304.X, or 305.X.  
3.4.2 Independent Variables 
 Independent variable measures were categorized into their role as a predisposing, enabling, or 
need characteristic, as detailed previously in Section 2.4, which described this dissertation’s conceptual 
model based on the Andersen’s Behavioral Model of Health Services Use. Independent variables also 
included NC MLIP characteristics that captured overall policy implementation characteristics and 
subjects’ experience with the program. 
3.4.2.1 Predisposing Characteristics 
 Analyses in all three aims utilized select predisposing characteristics coded using Medicaid data 
as follows: 
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• Subject age was defined as a subject’s age, in years, on the 15th day of the observed month. In 
aim 3, age was defined as patient age, in years, at the index opioid fill. 
• Sex was coded as a binary indicator with 1 denoting female sex and 0 denoting male sex. 
• Race/ethnicity will be coded using mutually exclusive and exhaustive categories of race and 
ethnicity that were self-reported by subjects at the time of their Medicaid enrollment. The 
categories include White, Black, and other/unknown. White race serves as the referent group. 
3.4.2.2 Enabling Characteristics 
 Five county-level variables representing enabling characteristics were measured for use as 
covariates in Aim 1 and 2 analyses.  
• Rural/urban residence was assessed using the measure of Rural-Urban Continuum Code (RUCC) 
developed by the United States Department of Agriculture’s (USDA) Economic Research 
Service.218 RUCC is a county-level measure with a discrete range of 1-9, with 1 denoting the 
most metropolitan counties and 9 denoting the most rural counties. The 2013 RUCC measures 
were used, which were created based on county population and commuting flow data from the 
American Community Survey. These were linked to a subject’s county of residence from the 
Medicaid data. 
• The binary indicator of residence in a metropolitan vs. non-metropolitan county was created 
based on the USDA’s suggested delineation of RUCC codes. Metropolitan counties had a RUCC 
of 1-3, and a non-metropolitan county has a RUCC of 4-9. 
• Prescriber supply was defined as the total number of actively practicing medical professionals 
with Schedule II through Schedule V prescribing authority (physicians, physician assistants, and 
nurse practitioners) in a subject’s county of residence. This measure was created using North 
Carolina Health Professions Data System data from 2010.219 It was linked to study subjects’ 
county of residence in the Medicaid data. 
• Pharmacy supply was defined as the number of licensed community and outpatient pharmacies in 
a subject’s county of residence. This measure was derived using the Centers for Medicare and 
Medicaid Services 2012 master file of pharmacy National Provider Identifiers by identifying the 
number of pharmacies in each North Carolina county.220 The pharmacy supply measure was 
linked to study subjects’ county of residence in the Medicaid data.  
• The border county measure was a dichotomous indicator for whether a subject’s county of 
residence shared a border with neighboring states. This was assessed to control for potential 
CSRS data artifacts stemming from the fact that controlled substance fills occurring outside of 
North Carolina would not be captured in the CSRS. The border county variable accounted for 
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potential disproportionate missingness of controlled substance service use behavior occurring 
across state lines owing to closer proximity to state borders. 
 
3.4.2.3 Need Characteristics 
 Multiple variables were created using Medicaid claims data to indicate the presence of key 
diagnoses in which either opioids and benzodiazepines are indicated or for which the diagnosis is a 
known risk factor for nonmedical controlled substance use. These included chronic noncancer pain, 
anxiety disorder, substance use disorder, depression, and any other mental health disorder. Indicator 
variables for each condition reflected the presence of at least one ICD-9-CM diagnosis code in the 
Medicaid claims data during the 12-month baseline study periods of Aims 1 and 2 using coding groups 
detailed in Table 3.2. The chronic noncancer pain diagnosis codes were identified based on prior literature 
and expert review.221,222 Diagnosis codes for the anxiety, substance use, depression, and other mental 
health disorder were identified using the Agency for Healthcare Research & Quality’s Clinical 
Classification Software and expert review.223 
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Table 3.3: ICD-9-CM diagnosis code groups for need characteristic indicator variables 
Need variable ICD-9-CM diagnosis codes 
Chronic noncancer 
pain 
Chronic pain: 3382 33821 33822 33828 33829 3384; 
Back pain: 7213-7219 7222 72230 72270 72280 72290 72232 72272 72282 72292 72233 72273 72283 
72293 724 7371 7373 7384 7385 7392 7393 7394 75610 75611 75612 75613, 75619 8054 8058 8392 
83942 846 8460 8471 8473 8472 8479;  
Neck pain: 7210 7211 7220 72231 72271 72281 72291 723 8390 8391 8470;  
Arthritis: 710-719  725-739;  
Headache and migraine: 346 30781; 
HIV/AIDS: 042 07953 27910 27919 79571 V08  
Anxiety disorder 29384 30000 30001 30002 30009 30010 30020 30021 30022 30023 30029 3003 3005 30089 3009 3080 
3081 3082 3083 3084 3089 30981 3130 3131 31321 31322 3133 31382 31383 
Substance use 
disorder 
Alcohol: 2910 2911 2912 2913 2914 2915 2918 29181 29182 29189 2919 30300 30301 30302 30303 
30390 30391 30392 30393 30500 30501 30502 30503 3575 4255 53530 53531 5710 5711 5712 5713 
76071 9800 
Other substances: 2920 29211 29212 2922 29281 29282 29283 29284 29285 29289 2929 30400 30401 
30402 30403 30410 30411 30412 30413 30420 30421 30422 30423 30430 30431 30432 30433 30440 
30441 30442 30443 30450 30451 30452 30453 30460 30461 30462 30463 30470 30471 30472 30473 
30480 30481 30482 30483 30490 30491 30492 30493 30520 30521 30522 30523 30530 30531 30532 
30533 30540 30541 30542 30543 30550 30551 30552 30553 30560 30561 30562 30563 30570 30571 
30572 30573 30580 30581 30582 30583 30590 30591 30592 30593 64830 64831 64832 64833 64834 
65550 65551 65553 76072 76073 76075 7795 96500 96501 96502 96509 V6542 
Depression 29620 29621 29622 29623 29624 29625 29626 29630 29631 29632 29633 29634 29635 29636 3004 
3091 311  
Other mental health  Adjustment disorders: 3090 3091 30922 30923 30924 30928 30929 3093 3094 30982 30983 30989 3099 
ADHD-related disorders: 31200 31201 31202 31203 31210 31211 31212 31213 31220 31221 31222 
31223 3124 3128 31281 31282 31289 3129 31381 31400 31401 3141 3142 3148 3149 
Delirium/Dementia: 2900 29010 29011 29012 29013 29020 29021 2903 29040 29041 29042 29043 
2908 2909 2930 2931 2940 2941 29410 29411 29420 29421 2948 2949 3100 3102 3108 31081 31089 
3109 3310 3311 33111 33119 3312 33182 797 
Developmental disorders: 3070 3079 31531 31534 31535 31539 V401 31501 31502 31509 31532 3155 
3158 317 3180 3181 3182 319 31500 3151 3152 3159 V400 3154 29900 29901 29910 29911 29980 
29981 29990 29991 30720 30721 30722 30723  
Impulse control: 31230 31231 31232 31233 31234 31235 31239 
Bipolar disorders: 29600 29601 29602 29603 29604 29605 29606 29610 29611 29612 29613 29614 
29615 29616 29640 29641 29642 29643 29644 29645 29646 29650 29651 29652 29653 29654 29655 
29656 29660 29661 29662 29663 29664 29665 29666 2967 29680 29681 29682 29689 29690 29699 
Personality disorders: 3010 30110 30111 30112 30113 30120 30121 30122 3013 3014 30150 30151 
30159 3016 3017 30181 30182 30183 30184 30189 3019 
Schizophrenia/Psychosis: 29381 29382 29500 29501 29502 29503 29504 29505 29510 29511 29512 
29513 29514 29515 29520 29521 29522 29523 29524 29525 29530 29531 29532 29533 29534 29535 
29540 29541 29542 29543 29544 29545 29550 29551 29552 29553 29554 29555 29560 29561 29562 
29563 29564 29565 29570 29571 29572 29573 29574 29575 29580 29581 29582 29583 29584 29585 
29590 29591 29592 29593 29594 29595 2970 2971 2972 2973 2978 2979 2980 2981 2982 2983 2984 
2988 2989 
Sleep disorder: 30740 30741 30742 30743 30744 30745 30746 30747 30748 30749 
Other: 33392 V110 V111 V112 V114 V118 V119 V154 V1541 V1542 V1549 V1582 V6285 V663 
V701 V702 V7101 V7102 V7109 V790 V792 V793 V798 V799 30012 30013 30014 30015 3006 3071 
30750 30751 30752 30753 30754 30759 30016 30019 3060 3061 3062 3063 3064 30650 30652 30653 
30659 3066 3067 3068 3069 3021 3022 3023 3024 30250 30251 30252 30253 3026 30270 30271 30272 
30273 30274 30275 30276 30279 30281 30282 30283 30284 30285 30289 3029 30651 30011 3007 
30081 30082 30780 30781 30789 29389 2939 3101 316 64840 64841 64842 64843 64844 V402 V403 
V4031 V4039 V409 V673 
Note: ICD-9-CM=International Classification of Diseases, 9th revision, Clinical Modification; HIV=Human 
immunodeficiency virus; AIDS=Acquired immune deficiency syndrome; ADHD=Attention deficit hyperactivity 
disorder 
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In addition, we created two measures of overall comorbid disease burden using Medicaid claims data. 
• The Charlson Comorbidity Index score was calculated for each study subject in Aims 1 and 2 to 
capture overall comorbidity burden and baseline health status. The Charlson Comorbidity Index 
was originally developed to predict one-year mortality and involves identifying the presence of 
17 unique clinical conditions diagnoses in a patient.224 Each condition is assigned a point value 
weighted by severity, and scores can range from 0 to 37 with higher scores indicating greater 
comorbid burden. The Charlson score was measured using Medicaid claims over the 12-month 
baseline observation period in Aims 1 and 2 using ICD-9-CM coding schemes validated by Quan, 
et al in 2005.225 It is important to note that the pain, mental health, and substance abuse disorders 
captured in the binary variables described previously did not contribute to the Charlson 
Comorbidity Index score.  
• We also used Medicaid claims data to measure the number of unique prescription medications, at 
the drug product level, filled by a study subject over the 12-month baseline period in Aims 1 and 
2 analyses. This measure of prescription drug burden has been previously validated as a strong 
independent predictor of a patient’s comorbid burden and overall clinical complexity.226 
3.4.2.4 Lock-in Policy Variables 
 Multiple independent variables were also developed to capture characteristics of the North 
Carolina Medicaid lock-in program implementation and subjects’ eligibility and enrollment in the 
program. We used Medicaid data from North Carolina DMA to construct the following measures: 
• The month variable measured time across the entire study periods of Aims 1 and 2 in calendar 
month intervals, with Month 1 referring to October 2009—one year prior to MLIP 
implementation—through Month 36, representing September 2012. 
• Lock-in period was a binary indicator of NC MLIP operation, with 1 referring to the active lock-
in policy period starting October 2010 and 0 reflecting the pre-policy period before October 2010.  
• Lock-in period*month was an interaction variable that measured the discrete number of months 
into the lock-in policy period being observed, with 1=October 2010 through 24=September 2012. 
• Lock-in eligibility was assessed monthly with dichotomous variables indicating whether a subject 
had seven or more opioid prescriptions; seven or more benzodiazepine prescriptions; or four or 
more unique opioid and benzodiazepine dispensing pharmacies in a two calendar month period in 
Medicaid claims data (see provider-based MLIP eligibility measure definition below for further 
detail about the pharmacy use measure). October 2010 was the first month in which lock-in 
eligibility was possible, because this was when the program was implemented. The first two-
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month period in which lock-in eligibility was assessed was July/August 2010. A subject was 
considered perpetually eligible for the MLIP once they met at least one eligibility criterion, which 
reflected the program administrator’s consideration of MLIP eligibility, necessitated by the 
phased-in program implementation. 
• Lock-in enrollment represented the key independent variable in Aims 1 and 2 and was defined as 
a monthly binary indicator variable in which 1=enrolled in the MLIP at any point in the calendar 
month and 0=not enrolled in the MLIP. 
• The interaction term, lock-in enrollment*month, was a continuous measure of the number of 
months into a subject’s lock-in enrollment period, with 1=first month enrolled in the MLIP. 
• The lock-in enrollment delay variable was defined dichotomously as 1=eligible for the MLIP but 
not enrolled in a given month and 0=eligible for and enrolled in the MLIP or ineligible and not 
enrolled in the MLIP. This variable accounted for the fact that the NC MLIP implementation was 
phased in, and subjects with the highest controlled substance use based on retrospective 
claims/manual review were prioritized for enrollment. Therefore, many subjects were initially 
eligible for the MLIP but experienced a delay in enrollment. 
• The lock-in enrollment delay*month interaction variable was a monthly measure of the number 
of months in which an eligible subject’s MLIP enrollment was delayed. This variable had a value 
of 0 prior to meeting MLIP eligibility, had a consecutively discrete positive value during the 
delay period, and returned to 0 once enrolled in the MLIP. 
• Opioid-based eligibility was a fixed measure defined dichotomously as 1=eligible for the MLIP 
due to recording seven or more opioid claims in a two calendar month period and 0=not eligible 
based on opioid use. Eligible opioid prescriptions included all products assessed by NC MLIP 
administrators (First DataBank therapeutic class codes: H3A, H3H, H3J, H3M, H3N, H3U, and 
H3X, excluding tramadol products with generic code numbers of 07221, 26387, 50417, 50427, 
13909, and 99151).227 
• Benzodiazepine-based eligibility was a fixed measure defined dichotomously as 1=eligible for the 
MLIP due to having seven or more benzodiazepine claims in a two calendar month period and 
0=not eligible based on benzodiazepine use. 
• Provider-based MLIP eligibility was approximated using the dichotomous measure of 1=receipt 
of opioid and/or benzodiazepine paid Medicaid claims from four or more unique community and 
outpatient pharmacies in a two calendar month period and 0=less than four unique pharmacies 
used to obtain these medications. It must be noted that the measure of unique dispensing 
pharmacies was not used in practice to assess NC MLIP eligibility; NC MLIP administrators used 
an eligibility measure of four or more unique prescribers of these medications. The data provided 
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by program administrators did not allow for reliable assessment of the number of unique 
prescribers. Therefore, we constructed the measure of number of unique community and 
outpatient pharmacies used to obtain opioids and benzodiazepines in the Medicaid claims data as 
a proxy measure for prescriber use, because it similarly captured the extent of provider use. 
• No MLIP eligibility was defined as 1=enrolled in the MLIP despite never previously satisfying 
any of the three previous MLIP eligibility criteria and 0=meeting at least one MLIP eligibility 
criterion prior to MLIP enrollment. 
3.4.2.5 Opioid Utilization Measures  
 The final set of independent variables represented varied measures of opioid exposure used as key 
independent variables in Aim 3 to predict relevant prescription drug-abuse related clinical outcomes. All 
opioid utilization measures were constructed in Medicaid claims data and included: 
• The number of opioid prescription fills, defined as the number of paid Medicaid claims for opioid 
analgesic products for a single study subject in a 60-day observation period.  
• The measure of number of opioid-dispensing pharmacies was defined as the discrete number of 
community and outpatient pharmacies that dispensed a Medicaid-covered opioid analgesic 
prescription to a single study subject in a 60-day observation period. 
• Average daily opioid dosage was defined as the average MMEs of opioid products obtained 
through NC Medicaid for the 60-day observation period. MMEs were calculated by multiplying 
the prescription quantity by the drug strength in milligrams and then multiplying this total by the 
appropriate morphine equivalent conversion factor specific to that opioid agent.213,214 MMEs were 
then summed across a 60-day period and divided by 60 to obtain average daily opioid exposure in 
MMEs. 
• Cumulative acetaminophen dosage was defined as the average daily milligrams of acetaminophen 
received over a 60-day period by a study subject through Medicaid-covered prescriptions for 
combination opioid-APAP drug products. 
 
3.5 DATA ANALYSIS BY AIM 
3.5.1 Aim 1 
 To examine the effect of the North Carolina Medicaid Recipient Management Lock-in Program, 
as well as patient-level characteristics, on controlled substance circumvention behaviors. 
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3.5.1.1 Study Design—Aim 1 
 We employed a retrospective cohort study design with repeated monthly measures in a 
longitudinal cohort of continuously enrolled NC Medicaid beneficiaries to investigate the effect of 
enrollment in the MLIP and patient-level characteristics on controlled substance circumvention. The 
study period for analysis ranged from 10/1/2009 through 9/30/2012, representing one year before through 
two years following MLIP implementation on October 1, 2010. The Aim 1 study sample consisted of a 
single cohort of NC Medicaid beneficiaries enrolled in the Medicaid lock-in program within the first 18 
months of program implementation. Subjects were also continuously enrolled in NC Medicaid for twelve 
months prior to MLIP implementation through at least six months following their MLIP enrollment to 
allow for longitudinal analysis.  
 This retrospective cohort design facilitated observation of NC MLIP enrollees’ circumvention 
behaviors through up to four distinct phases of the MLIP policy (Figure 3.1). Each subject had a 
mandatory 12-month baseline period leading up to MLIP policy implementation in which to observe 
circumvention prior to the program’s existence and to assess baseline covariates. We required subjects to 
contribute data for at least six months of their 12-month MLIP enrollment period for observation of the 
effect of MLIP enrollment on circumvention. Subject A in Figure 3.1 represents an individual with a 12-
month pre-MLIP baseline period that was eligible and enrolled in the NC MLIP at the program’s start in 
October 2010 and contributed a full 12 months of data for their entire initial MLIP enrollment period. 
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Figure 3.1: Aim 1 retrospective cohort study design 
 
 There were two distinct observation periods in addition to the pre-MLIP implementation baseline 
period and MLIP enrollment period that reflected the potential for the MLIP to have had an indirect effect 
on controlled substance-seeking behaviors among those not yet enrolled in the program. Due to the 
phased-in implementation of the NC MLIP, many study subjects experienced a period of delayed 
enrollment after first becoming eligible. This enrollment delay period is demonstrated in Subject B in 
Figure 3.1 who was eligible for MLIP enrollment at program implementation in October 2010 but whose 
enrollment was delayed nine months. Lastly, subjects may not have become eligible for MLIP enrollment 
until after the program was implemented, creating a period of observation in which the MLIP was active 
but a subject was not yet eligible or enrolled. Subject C depicts an individual who first became eligible for 
the MLIP 12 months into the program’s existence and then had a four-month delay in enrollment. 
 In figure 3.1, excluded subjects D and E are shown to further demonstrate the Aim 1 study 
design, in which we required a 12-month pre-MLIP baseline observation period (Subject D) and at least 
six months of observation after they were enrolled in the MLIP (Subject E). 
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3.5.1.2 Study Cohort—Aim 1 
 The study cohort initially included all NC Medicaid beneficiaries enrolled in the MLIP during the 
entire study period of 10/1/2009 through 9/30/2012. We then reduced the sample to NC MLIP enrollees 
that first entered the program during the first 18 months of the NC MLIP policy period from 10/1/2010 to 
3/31/2012. The sample was further restricted to subjects with 12 months of continuous Medicaid coverage 
prior to NC MLIP implementation in October 2010 and continuing through at least six months following 
their lock-in date. Lastly, we excluded subjects who were less than 18 or greater than 65 years of age at 
any point in their observation period. 
 The continuous Medicaid enrollment inclusion requirements ensured we were able to observe 
baseline circumvention behaviors for a full year prior to the existence of the NC MLIP. It also allowed for 
baseline assessment of need characteristic variables. The post-MLIP enrollment continuous coverage 
requirement ensured we were able to observe subjects’ circumvention behaviors for at least six months 
following lock-in. Aim 1 subjects could have contributed up to 12 months of data following enrollment in 
the MLIP, which is the length of the initial lock-in period, provided their observation in the data wasn’t 
censored by a gap in Medicaid coverage or the end of the study period on 9/30/2012.  
 Continuous Medicaid enrollment was defined as having gaps in coverage of no greater than one 
calendar month. We examined coverage gaps in the final analytic cohort to assess the level of turbulence 
in NC Medicaid coverage. High levels of turbulence would likely bias study estimates through inclusion 
of monthly observations of controlled substance use behaviors that was assumed to occur in the context of 
Medicaid coverage that did not actually exist. However, 93% of the final sample had zero gap months of 
coverage, and the maximum number of gap months was two (Appendix Table 2). This level of Medicaid 
coverage turbulence was within the scope of commonly used definitions of continuous Medicaid coverage 
that allow one month of coverage gap for every 12 months of observation.228,229 A sensitivity analysis was 
performed in which Aim 1 models were ran excluding the 7% of subjects that had a gap in NC Medicaid 
coverage (Appendix Table 3). Differences in findings between the sensitivity and base analyses were 
negligible, so we reported findings for the base Aim 1 cohort.  
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3.5.1.3 Statistical Analyses—Aim 1 
 We used descriptive statistics to summarize the Aim 1 cohort. We reported means and 
frequencies of the predisposing, enabling, and need characteristics detailed previously in Section 3.4, both 
overall and by route of MLIP eligibility. We also described MLIP policy characteristics of the study 
sample, including frequencies of routes of MLIP eligibility and months of observation in various policy 
phases, such as MLIP enrollment delays. Bivariate analyses were performed to compare opioid and 
benzodiazepine utilization behaviors—both Medicaid-covered and circumvented—before and after MLIP 
enrollment. T-tests and chi-square tests were performed for continuous and binary measures, respectively, 
with statistical significance defined with an alpha level of 0.05.  
 We used generalized estimating equations (GEE) to model the effect of enrollment in the NC 
MLIP and patient predictors on circumvention behaviors. GEE is an extension of the generalized linear 
model and estimates a population average effect of independent variables on an outcome while 
accounting for correlation across repeated longitudinal measures.230 GEE requires specification of a 
distribution family of the outcome variable, a link function—which serves to linearize non-linear 
relationship between independent and dependent variables—, and a correlation structure across repeated 
measures.  
 The Aim 1 analytic dataset was structured to allow for GEE modeling by measuring time-varying 
variables in calendar month increments. The study observation period began with October 2009 identified 
as Month 1 and extended through two years following MLIP implementation with September 2012 
characterized as Month 36. Therefore, study subjects contributed a minimum of 18 data observations 
(monthly measures from October 2009 – March 2011) to a maximum of 36 observations (monthly 
measures from October 2009 – September 2012), depending on when they were enrolled in the program 
and continuity of Medicaid coverage. Limitations of the Medicaid-CSRS dataset did not allow for 
identification of a comparator group of controlled substance users never enrolled in the MLIP. However, 
the GEE repeated measures design allowed for the single MLIP enrollee cohort to, in a sense, serve as its 
own control. Most of the MLIP enrollees experienced a delay in enrollment due to a phasing in of the 
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policy, so observing these subjects’ circumvention behaviors while they qualified for MLIP enrollment 
for a period of time before they were actually enrolled served a pseudo-control group. Additionally, the 
within-individual control approach we used may be preferred, because potential control subjects not 
chosen for enrollment in the MLIP may not be an appropriate comparator to MLIP enrollees. 
 We performed two GEE models to estimate the effect of the dichotomous indicator of MLIP 
enrollment—the key independent variable—and patient-level characteristics on the likelihood of 
obtaining any circumvented fill and on the number of circumvented fills received in a person-month 
observation. Each GEE model provided distinct, but interesting information about circumvention 
behaviors in the NC MLIP; the first model examined predictors of engaging in controlled substance 
circumvention at all, while the second model examined predictors of the number of circumvention events 
in a month.  
 The first GEE model used a modified Poisson regression approach to estimate the effect of the 
MLIP on the likelihood of any circumvented fills in a month. The modified Poisson model allows 
estimation of relative risk for binary outcome variables through specification of a Poisson distribution 
family and a log link. Huber/White robust sandwich variance estimators are used to correct artificially 
wide confidence intervals that are initially produced when fitting a Poisson distribution to the binomially 
distributed outcome variable. Model estimates are exponentiated to report relative risk. Prior literature has 
demonstrated the modified Poisson approach is a reliable and efficient estimator of relative risk for binary 
outcomes in generalized linear models and GEE models with correlated data.231-233 It provided a number 
of distinct advantages over the standard logistic regression approach. First, odds ratios estimated with 
logistic regression always overestimate the association of the independent and dependent variables away 
from the null, especially when the outcome is common (>10%). Relative risks are a more accurate and 
conservative estimator. Second, the interpretation of relative risk is naturally much more intuitive than 
interpretation of the odds ratio. Lastly, the modified Poisson approach is more robust to omitted variable 
bias than logistic regression. Omitted variable bias affects the actual point estimates in logistic regression 
as opposed to simply increasing the error term in the model. A sensitivity analysis was performed in 
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which the dichotomous circumvention outcome measure was modeled with a logistic regression approach 
to demonstrate odds ratio inflation (Appendix Table 4). The odds ratio on the key MLIP enrollment 
variable suffered from a relative inflation of 68% over the reported relative risk measure. 
 The second model used a Poisson count model approach to predict the number of circumvention 
events in a month. In this GEE model, we specified a Poisson distribution and a log link, and we 
exponentiated model estimates to report incidence rate ratios. In both GEE models, we specified an 
autoregressive correlation structure with a lag of one month. Selection of the one month autoregressive 
correlation structure was guided by the quasi-likelihood information criteria (QIC) method, which 
indicated this correlation structure provided a better model fit over autoregressive correlations with 
independent, exchangeable, and unstructured correlations.234 Robust standard errors—also known as 
Huber-White sandwich estimators—were used in both GEE models. Robust standard errors in GEE serve 
two primary purposes in addition to their necessity in the modified Poisson for binary outcomes. First, 
they produce valid standard errors even in the presence of a misspecified correlation structure.235 They 
also account for within-person correlation in GEE by effectively clustering by subject. This prevents 
artificially small standard errors that would overstate covariate statistical significance. 
 In addition to the key independent variable of MLIP enrollment, both GEE models controlled for 
lock-in policy characteristic covariates defined in Section 3.4.2. These measures adjusted for the overall 
effect of the policy period, delays in MLIP enrollment, and the effects of time spent in various phases of 
the MLIP policy period. The models also included patient predisposing, enabling, and need characteristic 
variables as defined previously. The evidence-based conceptual model detailed in Section 2.4.2 guided 
selection of patient-level variables. The final GEE analytic models are depicted in Figure 3.2. 
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Figure 3.2. Specification of the Aim 1 generalized estimating equation models 
 
 The final GEE models reflected a few key modifications to the initial patient-level variable 
specifications. Specifically, county-level prescriber supply was excluded in final analysis due to high 
correlation with the measure of county-level pharmacy supply upon examination of Pearson’s Correlation 
Coefficients within enabling and need variable groups (r2=0.92) (Appendix Tables 5 and 6). We also 
opted to control for residence in a rural county with the dichotomous metropolitan vs. non-metropolitan 
county indicator as opposed to the ordinal measure of county-level RUCC score to enhance 
interpretability. Continuous measures of county-level pharmacy supply and Charlson Comorbidity Index 
score were transformed into categorical variables in the final model to allow for more meaningful 
interpretation of model output. County pharmacy supply was categorized into 0-10, 11-25, 26-50, 51-100, 
and >100 pharmacies (Appendix Table 7). Charlson scores were grouped into 0, 1, and ≥2 based on prior 
literature to reflect no, low, or high comorbidity burden.236,237 Sensitivity analyses in which these three 
variables were entered into the GEE models in their original continuous form confirmed that our final 
analytic models were robust to these categorical transformations (Appendix Table 8). 
3.5.2 Aim 2 
 To investigate prescription-level characteristics of opioid analgesics obtained by North Carolina 
Medicaid Recipient Management Lock-In Program enrollees through circumvention. 
3.5.2.1 Study Design—Aim 2 
 A retrospective cohort study was used to investigate the effect of NC MLIP enrollment, as well as 
patient-level predictors, on three prescription-level opioid utilization characteristics associated with 
Model 1 (Binary circumvention): Distribution=Poisson, link=log, corr=autoregressive (1 month) 
Model 2 (Count circumvention): Distribution=Poisson, link=log, corr=autoregressive (1 month) 
 
Circumvention outcome = β0 + β1XMLIP enrollment + β2XMLIP enrollment*month + β3XMLIP delay + β4XMLIP delay*month + 
β5Xmonth + β6XMLIP period + β7XMLIP period*month + β8XMLIP eligibility:opioid +  β9XMLIP eligibility:benzo +                   
β10XMLIP eligibility:provider + β11XMLIP eligibility:none + β12XAge + β13XFemale + β14XBlack + β15XOther/unknown race + 
β16XMetropolitan county + β17XPharmacy supply:11-25 + β18XPharmacy supply:26-50 + β19XPharmacy supply 51-100 +              
β20XPharmacy supply:>100 + β21XBorder county + β22XChronic pain + β23XAnxiety + β24XSubstance use + β25XDepression +             
β26XOther mental illness + β27XCharlson:1 + β28XCharlson:≥2 + β29XNeed + β30XPrescription burden + ε 
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increased potential to contribute to abuse and overdose events. The study period for Aim 2 was 10/1/2009 
through 9/30/2012, representing one year prior and two years following the start of the NC MLIP. Aim 2 
utilized the same study cohort as Aim 1. These subjects represented adult NC Medicaid beneficiaries 
enrolled in the NC MLIP during its first 18 months of operation. They had continuous NC Medicaid 
coverage from 10/1/2009 through at least six months following their MLIP enrollment date. Because Aim 
2 analyses only investigated opioid use, we further excluded subjects who solely used benzodiazepines 
during the study period.  
 The three key prescription-level dependent variables of interest in Aim 2 were a binary indicator 
of a long-acting versus short-acting opioid prescription fill, a binary indicator of a Schedule II versus 
Schedule III-V opioid prescription fill, and a continuous measure of average daily prescribed opioid dose 
in a given prescription, measured in MMEs. We employed a pre-post design to examine changes in these 
prescription-level characteristics of opioids obtained by NC MLIP enrollees (Figure 3.3). A subject’s 
MLIP enrollment date served as the index date delineating the pre-MLIP enrollment and post-MLIP 
enrollment periods. The unit of analysis for assessing these outcomes was the prescription fill.  
 We were primarily interested in observing changes in prescription-level measures of opioid abuse 
potential for prescriptions obtained through circumvention. This provided valuable information regarding 
the potential attractiveness of certain opioid prescriptions to circumvention among MLIP enrollees. 
Additionally, it allowed us to gauge the level of high-risk opioid use that occurred through circumvention, 
which was previously unobservable for NC MLIP administrators. This knowledge, coupled with 
observable trends in Medicaid-paid opioid prescriptions provided a previously unseen comprehensive 
view of changes in prescription-level opioid use behaviors that occurred among MLIP enrollees. 
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Figure 3.3: Aim 2 pre-post retrospective cohort design for prescription-level outcomes  
 
 
 
 Retaining the longitudinal cohort from Aim 1 allowed us to assess if a given observation occurred 
during one of four potential policy phases described in more detail previously (Section 3.5.1.1): pre-MLIP 
baseline period prior to 10/1/2010; post-MLIP implementation but not yet MLIP eligible; MLIP eligible 
but not yet enrolled; and enrolled in MLIP. Hypothetical subject B in Figure 3.3 depicts the varying 
policy phases in which observations could have been made. This enabled us to control for the phased-in 
policy implementation that resulted in numerous subjects experiencing a delay in MLIP enrollment after 
meeting the state’s definition of high-risk controlled substance use behavior. The Aim 1 cohort, which 
had continuous NC Medicaid coverage, also ensured a standard baseline observation period in which to 
construct patient-level clinical need variables known to predict prescription drug abuse behaviors.  
3.5.2.2 Study Cohort—Aim 2  
 Aim 2 analyses used a longitudinal cohort of NC MLIP enrollees stemming from the cohort 
created in Aim 1 (see Section 3.5.1.2). This cohort included all NC Medicaid beneficiaries that were 
enrolled the NC MLIP at some point between 10/1/2010 and 3/31/2012. Subjects were continuously 
enrolled as NC Medicaid beneficiaries from 10/1/2009 through at least six months following their NC 
MLIP enrollment date. Subjects were excluded if they were less than 18 years or greater than 64 years of 
age at any point in their observation period. In addition to the exclusion criteria applied to the cohort for 
Aim 1 analyses, subjects lacking any opioid use during the study period were excluded from Aim 2 
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analyses. Subjects contributed data until censored either by the end of the study period on 9/30/2012, a 
lapse in NC Medicaid coverage, or the end of the 12-month NC MLIP enrollment period. 
 Application of the continuous NC Medicaid coverage inclusion criteria was described previously 
in Aim 1 (Section 3.5.1.2). Similar concerns persisted in Aim 2 regarding the potential biasing effect of 
including subjects with one or more gaps in coverage of one month. Roughly 93% of subjects had no 
lapses in Medicaid coverage. Sensitivity analyses were performed for Aim 2 models among circumvented 
opioid prescriptions excluding 117 subjects who had one or two month-long gaps in coverage to assess 
robustness of Aim 2 findings with regard to NC Medicaid coverage turbulence (Appendix Table 9). These 
sensitivity analyses showed a negligible impact in observed relative risk estimates for the binary schedule 
II opioid and long acting opioid outcomes, as well as negligible changes in marginal effect estimates for 
the continuous mean prescribed MME/day outcome. Therefore, no further concern persisted over a 
biasing effect of NC Medicaid coverage turbulence in the Aim 2 cohort, and primary analysis findings in 
the full Aim 2 cohort are presented. 
 
3.5.2.3 Statistical Analyses—Aim 2 
 Descriptive statistics for patient-level characteristics of the study cohort, including predisposing, 
enabling, and need variables, were conducted in Aim 1. In Aim 2, we examined prescription-level 
descriptive characteristics of opioid prescriptions received by study subjects. These include frequencies of 
the primary outcome variables of long-acting opioid and Schedule II opioid fills, and mean values for 
average daily MMEs. Additionally, we further described opioid prescription characteristics, including the 
frequencies of individual opioid agents received (hydrocodone product, oxycodone product, etc.) and 
specific opioid product formulations received (hydrocodone/acetaminophen 5mg/325mg tablets, 
Duragesic 50mcg/hour patches, etc.). All opioid prescription-level descriptive statistics were reported for 
the circumvented opioid prescription fills, Medicaid-covered opioid fills, and the entire sample of opioid 
prescriptions from both payment sources.  
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 Bivariate analyses were performed to compare differences in opioid prescription-level 
characteristics before and after subject enrollment in the NC MLIP. Bivariate comparisons were reported 
for circumvented opioid prescription fills, as well as for the Medicaid-covered subset of opioid 
prescriptions and total opioid prescription fills. Chi-squared tests examined differences between 
dichotomous measures before and after MLIP enrollment. Paired T-tests were performed to compare 
means of continuous measures. Statistical significance was defined at an alpha level of 0.05. 
 Generalized linear models (GLM) were used to estimate the effect of the key independent 
variable—a binary indicator of NC MLIP enrollment—and patient characteristics on the three key 
outcome measures: the likelihood of a long-acting opioid prescription fill, the likelihood of a Schedule II 
opioid prescription fill, and the average daily MME prescribed. The unit of analysis was at the opioid 
prescription-level. GLM is a highly flexible class of models that allows researchers to specify the variance 
distribution and a link function that linearizes non-linear relationships between independent and 
dependent variables.238,239 The GLM models investigating binary outcomes employed a modified Poisson 
regression approach to estimate relative risks. The modified Poisson regression approach involved 
specification of a Poisson distribution family and log link. Huber/White sandwich variance estimators 
were necessary in the modified Poisson model to correct inappropriately wide confidence intervals 
initially produced when fitting a Poisson distribution to the binary outcome. Specifically, we used cluster-
robust sandwich estimators to account for within-subject correlation. Model estimates were exponentiated 
to report relative risks. The modified Poisson approach is a reliable and efficient estimator of relative risk 
for dichotomous outcomes.231,232 It is often preferred over the logistic regression model due to the relative 
risk’s improved accuracy when estimating common outcomes, more intuitive interpretation compared to 
the odds ratio, and enhanced robustness to omitted variable bias over logistic regression.  
 GLM models predicting the continuous average daily MME outcome used an inverse Gaussian 
distribution and a log link. This distribution and link function were selected based on examination of the 
outcome distribution and relevant specification tests for the key model of circumvented opioid fills. The 
average MME/day outcome variable responses, as well as residuals from ordinary least squares modeling 
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of the level outcome, exhibited a strong right skew (Appendix Figure 2), suggesting the appropriateness 
of the logged form of the dependent variable. A Modified Park Test found that an inverse Gaussian 
distribution family with a log link provided the best model fit.240 This was verified through a Pregibon’s 
link test, which indicated appropriate model specification241,242, and a normal distribution of plotted 
residuals from the GLM model with inverse Gaussian distribution and log link (Appendix Figure 3). 
Cluster-robust standard errors were used to account for within-subject correlation and enhance robustness 
of the model output in the face of possible misspecification. We reported the average differential/marginal 
effects of independent variables on average daily MME dose per prescription. Prescription opioid fills for 
injectable solutions, powder, and suppository formulations were excluded from the GLM analysis of 
average daily MMEs. This was necessary due to an inability to reliably calculate MME values for these 
dosage forms. Excluding these products from MME analysis is common practice135,142,213, and it resulted 
in dropping only 0.13% of opioid prescription fills. 
 Aim 2 GLM models controlled for the patient-level and policy-level covariates included in Aim 1 
analyses of circumvention behavior (Figure 3.4). Selection of patient predisposing, enabling, and need 
characteristic variables was driven by the evidence-based conceptual model described in Section 2.4.2. 
The policy covariates controlled for time trends, the various phases of policy implementation, and route 
of NC MLIP eligibility. Variable specifications in Aim 2 base analyses reflected those employed in Aim 1 
models. Each of the GLM models were performed in the sample of circumvented opioid prescription fills, 
as well as in the sample of Medicaid-covered opioid prescription fills and combined sample of all opioid 
fills. This allowed observation of changes in the opioid characteristic outcomes attributable to 
circumvention behavior, while placing these changes in the overall context of opioid utilization from all 
payment sources.  
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Figure 3.4: Specification of Aim 2 generalized linear models 
 
3.5.3 Aim 3  
 To identify and validate the most effective measures of high-risk opioid analgesic use in the 
North Carolina Medicaid population. 
3.5.3.1 Study Design—Aim 3 
 We used a retrospective cohort design to examine claims-based opioid exposure measures in the 
North Carolina Medicaid population that were most predictive of adverse clinical outcomes of high-risk 
opioid use (Figure 3.5). The purpose of this Aim was to inform optimal NC Medicaid lock-in program 
eligibility criteria. Aim 3 analyses used North Carolina Medicaid pharmacy and medical claims data and 
encompassed a study period of 10/1/2008 through 9/30/2010, representing the two years immediately 
preceding NC MLIP implementation. This study period allowed for investigation of optimal high-risk 
opioid use measures in the absence of any co-occurring effects of the NC MLIP policy on opioid 
utilization in the study cohort. A retrospective cohort was used consisting of adult NC Medicaid 
beneficiaries who received an opioid prescription during the first 10 months of the study period and did 
not have any administrative or clinical characteristics that would preclude them from being enrolled in the 
NC MLIP if MLIP eligibility criteria were met.   
  
GLM (Long-acting opioid fill): Distribution=Poisson, link=log, cluster-robust standard errors 
GLM (Schedule II opioid fill): Distribution=Poisson, link=log, cluster-robust standard errors 
GLM (Average daily MME received): Distribution=Inverse Gaussian, link=log, cluster-robust  
            standard errors 
 
Model covariate specifications = β0 + β1XMLIP enrollment + β2XMLIP enrollment*month + β3XMLIP delay + β4XMLIP 
delay*month + β5Xmonth + β6XMLIP period + β7XMLIP period*month + β8XMLIP eligibility:opioid +  β9XMLIP eligibility:benzo + 
β10XMLIP eligibility:provider + β11XMLIP eligibility:none + β12XAge + β13XFemale + β14XBlack + β15XOther/unknown race + 
β16XMetropolitan county + β17XPharmacy supply:11-25 + β18XPharmacy supply:26-50 + β19XPharmacy supply 51-100 + β20XPharmacy 
supply:>100 + β21XBorder county + β22XChronic pain + β23XAnxiety + β24XSubstance use + β25XDepression + β26XOther mental illness + 
β27XCharlson:1 + β28XCharlson:≥2 + β29XNeed + β30XPrescription burden + ε 
  94 
 In order to identify and then validate optimal claims-based opioid exposure measures, we 
randomly assigned 50% of the study cohort to testing and validation samples.243 This cross-validation 
method allowed evaluation of selected optimal opioid exposure measure performance in predicting 
primary and secondary outcomes in a sample of subjects entirely separate from those that contributed to 
the selection of these measures and measure thresholds.   
 In the testing phase of Aim 3, we examined the performance of four opioid exposure measures in 
predicting Aim 3 outcomes. The opioid exposure measures included number of opioid prescription claims 
received, number of unique community and outpatient pharmacies used to obtain opioid prescriptions, 
average daily opioid dose (in mean MME/day), and average daily APAP dose from opioid/APAP 
combination products. Number of unique opioid prescribers was not measureable due to limitations in the 
study data provided to the researchers. All opioid exposure measures were assessed over a 60-day period 
beginning on the date of the index opioid prescription fill, which must have occurred between 10/1/08 
through 8/2/09. A 60-day exposure assessment period was chosen to simulate current NC MLIP eligibility 
assessment practices. The primary clinical outcome of interest was an unintentional opioid overdose 
event, as defined in Section 3.4.1. This was considered the primary outcome, because accidental opioid 
overdose represented the most immediate and preventable outcome from high-risk opioid use behaviors. 
Secondary clinical outcomes included an unintentional APAP overdose event, an unintentional overdose 
event involving any drug product, an opioid use disorder diagnosis, and a substance use disorder 
diagnosis of any type. Subjects were observed for up to 365 days following the end of their 60-day 
exposure assessment period for the presence of an outcome event. A 365-day follow-up period was 
selected for generalizability to the 12-month MLIP enrollment period. For each opioid exposure/outcome 
pairing, the length of follow-up was determined either by the end of the study period, a lapse in NC 
Medicaid coverage, or the outcome event.  
 In the validation phase of Aim 3, we used the remaining 50% of subjects randomly assigned to 
the validation cohort to evaluate the performance of the best performing opioid exposure measures and 
thresholds from the testing phase. The same study design as the testing phase was used. Validation cohort 
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subjects’ index opioid claim was identified between 10/1/08 through 8/2/09, at which point their opioid 
exposure was assessed for the following 60 days. However, opioid exposure assessment in the validation 
phase included dichotomous indicators for whether the subject met an opioid use criterion identified as 
optimal from testing phase analyses. Follow-up observation for an outcome event was also time 
dependent—as it was in the testing phase—and was right-censored either by the end of the 365-day 
maximum follow-up period, a lapse in NC Medicaid coverage, or the outcome event.  
 Figure 3.5 depicts the study design used in Aim 3 testing and validation phases. (This figure is 
dynamic with regard to each unique opioid exposure measure and clinical outcome pairing). Notable 
events include identification of the index opioid claim, 60-day opioid use assessment period, follow-up 
observation period after opioid use assessment, and end of subject observation. Subject A represents an 
individual who contributed the full 365 days of follow-up time without experiencing the given outcome. 
Subjects B and C contributed less than 365 days of follow-up due to experiencing the given outcome and 
having a lapse in continuous NC Medicaid coverage, respectively. 
Figure 3.5: Aim 3 retrospective cohort study design for testing and validation phases 
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3.5.3.2 Study Cohort—Aim 3  
 The Aim 3 study cohort was selected from the initial population of all adults enrolled in NC 
Medicaid at any point during the study period of 10/1/08 through 9/30/10. The sample was then reduced 
to include all opioid users, defined as individuals who had a Medicaid prescription claim for an opioid 
analgesic between 10/1/08 through 8/2/09. Subjects were then excluded if they lacked 60 days of 
continuous NC Medicaid coverage following their index opioid fill date. For Aim 3, continuous NC 
Medicaid enrollment was defined as having no gaps in coverage greater than 15 days. In order to create a 
study cohort that closely mirrored the population of NC Medicaid beneficiaries that would be considered 
for MLIP enrollment if eligible, subjects were excluded who had dependent-living status (NC Medicaid 
living arrangement codes not equal to 10 or 11), dual Medicare coverage (Medicaid class codes B, E and 
Q), and a concomitant cancer diagnosis (ICD-9-CM 140-239 at any point during study observation). 
Subjects were excluded if they were less than 18 years of age or greater than 64 years of age at any point 
during their Aim 3 observation. Lastly, 50% random subsets of the final analytic cohort were created for 
distinct testing and validation samples (performed using STATA “cut” function for random uniform 
variable; seed=626; sorted on subject dummy ID).243 Final Aim 3 cohort selection algorithm is presented 
below in Figure 4.8 in Section 4.3.1. 
 It should be noted that continuous NC Medicaid coverage following the 60-day opioid exposure 
assessment period was not applied as an inclusion criteria in testing and validation phases. Subjects were 
allowed to contribute varied follow-up observation time, up to a maximum of 365 days, for three primary 
reasons. First, including subjects with variable durations of continuous NC Medicaid coverage during 
follow-up allowed for enhanced sample size and capture of potentially rare overdose outcomes. Second, 
this allowed for use of time-to-event analyses, which only concerned the first instance of the outcome and 
were able to account for the timing of the outcome in relation to the opioid exposure assessment period. 
Third, requiring one year of continuous NC Medicaid coverage after the 60-day exposure period would 
have greatly reduced the generalizability of findings. Applying this requirement to the cohort would have 
resulted in a sample of subjects that, for each outcome event they experienced, would have had to have 
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received treatment for the event and survived (with NC Medicaid coverage) for the remainder of the 12-
month follow-up period. Not requiring 365 days of continuous coverage allowed us to include subjects 
that received treatment for a study outcome during follow-up but died while receiving care or died at 
some point following discharge but prior to the end of the 365-day follow-up. (Study data limitations 
precluded capture of fatal overdose events that did not result in contact with the healthcare system). 
3.5.3.3 Statistical Analyses—Aim 3 
 Univariate statistics were performed to describe the full sample, testing subset, and validation 
subset, while bivariate statistics were conducted to ensure successful random assignment of subjects to 
testing and validation samples with regard to key measures. Measures reported in these analyses included 
subject demographic characteristics of age, sex, and race; mean follow-up observation time; opioid 
exposure measure means; frequencies of outcome events; and mean time to outcome events. Chi-squared 
tests and independent sample t-tests were performed for bivariate analyses at an alpha level of 0.05. 
Analyses specific to the testing and validation phases are presented in distinct subsections below. Of note, 
all Aim 3 modeling that occurred in testing and validation phases were not adjusted for any covariates. 
This approach mirrored the real-world application of NC MLIP eligibility criteria for which patient-level 
characteristics outside of a given controlled substance use measure, such as age and sex, do not contribute 
to MLIP eligibility assessment. 
3.5.3.3.1 Statistical Analyses—Aim 3 Testing Phase  
 In the testing phase of Aim 3, survival receiver operating characteristic (ROC) models were 
performed for each individual pairing of opioid exposure measure and outcome measure. Survival ROC 
employs a Kaplan-Meier time-to-event modeling approach to calculate time-dependent sensitivities and 
specificities of unique opioid exposure measure cutpoint values in discriminating between subjects that 
experienced and did not experience the outcome.244-247 The survival ROC-produced sensitivities and (1-
sensitivities) for each opioid exposure/outcome pairing were then plotted to determine the overall area 
under the curve (AUC), or c-index statistic. The AUC is a measure of discriminatory capability of the 
exposure measure in predicting the outcome. The AUC is bounded by 0.50 and 1.00 with 0.50 equaling 
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zero association between the exposure and outcome and 1.00 equaling perfect discrimination. AUC 
values were categorized as follows in terms of discriminatory capability: Excellent=0.90-1.00; 
good=0.80-0.89; fair=0.70-0.79; poor=0.60-0.69; and failure=0.50-0.59.248 Optimal opioid exposure 
measure thresholds were derived from survival ROC modeling output using the measure of survival ROC 
plot Euclidean distance. Euclidean distance refers to the point on the survival ROC plot with the shortest 
distance to the (0,1) point on the figure, which represents 100% sensitivity and 100% specificity. 
Therefore the survival ROC-derived optimal threshold was defined as the value of the opioid exposure 
measure with the shortest Euclidean distance. This can also be characterized as the opioid exposure 
measure value with the highest joint sensitivity and specificity, calculated as:              
1-√[(1-sensitivity)2 + (1-specificity)2]. We reported survival ROC findings at a time point of 365 days, 
which results in a per-person-year interpretation of time-dependent AUCs, sensitivities, and specificities. 
This reflected analysis of key public health outcomes for the duration of a 12-month MLIP enrollment 
period. 
 Because the survival ROC statistical package in R (v3.1.3) did not allow for including multiple 
predictors in the survival ROC models, logistic regression ROC was performed to examine the 
discriminatory capability of combined opioid exposure measures. Logistic ROC models could not account 
for time dependent characteristics of the analytic dataset, so these models were performed in the full 
testing sample and among testing sample subjects who had a full year of continuous Medicaid coverage 
after their opioid exposure period. 
 After examining findings from the survival ROC models, it was determined that additional 
analysis was required to identify optimal thresholds of opioid exposure measures with alternative 
methods. Concerns existed over survival ROC-derived thresholds flagging more subjects as high-risk than 
would be feasible for MLIP enrollment based on real-world capacity of currently operating MLIPs. 
Therefore, time-to-event model log likelihood plots were used to identify the cutpoint(s) of an opioid 
exposure measure that maximized predictive fit with a given outcome.249,250 For each exposure/outcome 
pairing, a series of bivariate Cox proportional hazard models predicting the time to Aim 3 outcome event 
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for each unique cutpoint of the exposure measure was performed. Each model produced a log likelihood 
value—a numerical representation of model fit—and the cutpoint value of the exposure measure 
maximizing the log likelihood was considered the optimal cutpoint for predicting that outcome. 
 Selection of optimal opioid exposure measures for further validation was informed by findings 
from survival ROC results. Selection of optimal opioid exposure measure thresholds was guided by 
results from the Cox model log likelihood plots. For both decisions, findings from models predicting the 
primary outcome of unintentional opioid overdose were weighed more heavily than those predicting 
secondary outcomes.  
3.5.3.3.2 Statistical Analyses—Aim 3 Validation Phase  
 The performance of opioid exposure measures and their optimal thresholds selected in the testing 
phase was evaluated in the remaining 50% random sample of the Aim 3 cohort. For each opioid exposure 
criterion/outcome pair, we described frequencies of subjects meeting each criterion, frequencies of 
subjects experiencing outcomes, and the time-dependent sensitivities and specificities of each opioid 
exposure criterion at 365 days of follow-up. Bivariate Cox proportional hazard models estimating the 
effect of an opioid exposure criterion on an outcome was performed for each exposure/outcome 
pairing.251 Hazard ratios and 95% confidence intervals were reported, as well as log likelihood values, 
which allowed comparison of exposure measure criterion performance in predicting a given outcome. 
Lastly, Kaplan-Meier survival function estimates were obtained to evaluate the performance of an opioid 
exposure measure threshold in predicting an outcome.252 Kaplan-Meier survival functions were plotted for 
subjects at or above the opioid use measure threshold and subjects below the threshold. Using Kaplan-
Meier estimates, absolute risk differences (ARD) for an outcome between those not flagged as high-risk 
by a criterion and those flagged as high-risk were reported for time periods of 30, 90, 180, and 365 days 
after opioid exposure assessment. Using the absolute risk differences at each time point, the number 
needed to enroll (NNE) figure was calculated as (1 / ARD). NNE was interpreted as the number of opioid 
users needed to enroll in an MLIP using a given opioid exposure criterion in order to have the opportunity 
to prevent one outcome event. 
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 All validation phase analyses were performed for each individual opioid exposure criterion, the 
current NC MLIP criteria of ≥7 opioid fills, and all combinations of these opioid exposure criteria. 
Unconditional and conditional combinations of opioid exposure criteria were examined. For example, 
consider two unique opioid exposure measures: measure A and measure B. An unconditional combination 
required a subject to meet a threshold for high-risk opioid use for either measure A or measure B. This 
represented the current application of NC MLIP eligibility criteria, in which meeting at least one of three 
criteria qualifies someone for enrollment. Conditional combinations of opioid exposure criteria were also 
investigated, in which subjects were required to meet thresholds for both criterion A and criterion B. 
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CHAPTER IV: RESULTS 
 
4.1 AIM 1 RESULTS 
4.1.1 Aim 1 Descriptive Analysis Findings 
 The Aim 1 analytic cohort included 1,647 study subjects. Figure 4.1 details the application of the 
inclusion criteria that led to subject selection. A total of 4,402 North Carolina Medicaid beneficiaries 
were enrolled in the Medicaid lock-in program during the study period. We excluded 1,232 subjects who 
were first enrolled in the MLIP after 3/31/12, which was beyond the first 18 months of program 
operation. An additional 1,483 subjects were excluded due to a lack of continuous enrollment in NC 
Medicaid beginning 10/1/2009 through at least six months following their MLIP enrollment. Lastly, 40 
subjects were excluded who were less than 18 or greater than 65 years of age at any point during their 
observation. 
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Figure 4.1: Aim 1 analytic cohort selection  
 
 
  
 Prior to being locked in, 88%, 4%, and 69% of the Aim 1 cohort met the opioid use, 
benzodiazepine use, and pharmacy use criteria for MLIP enrollment, respectively (Table 4.1). Nearly 
two-thirds of subjects met exactly two MLIP eligibility criteria, while 31% satisfied a single criterion, and 
1% met all three MLIP criteria prior to their lock-in. Roughly 5% of the sample was enrolled in the MLIP 
without previously meeting an MLIP eligibility criterion. This was possible due to an enrollment 
mechanism allowing providers to identify and recommend NC Medicaid beneficiaries for lock-in. The 
most common MLIP eligibility route in the sample (62%) was recording ≥7 opioid Medicaid claims in 
two calendar months, as well as using ≥4 opioid or benzodiazepine dispensing pharmacies in two calendar 
months. 
  
North Carolina Medicaid beneficiaries enrolled in the lock-
in program during the dissertation study period of 
10/1/2008 through 9/30/2012 
n= 4,402 
North Carolina Medicaid beneficiaries enrolled in the lock-
in program during the first 18 months of its operation from 
10/1/2010 through 3/31/2012, as per Aim 1 study design. 
n= 3,170 
Lock-in enrollees with continuous NC Medicaid coverage 
from 10/1/2009 through at least six months following their 
lock-in date. 
n= 1,687 
Lock-in enrollees meeting continuous NC Medicaid 
coverage requirements who were ≥18 years old and <65 
years old during their entire Aim 1 observation period. 
n= 1,647 
Excluded n=1,483 
Excluded n= 1,232 
Excluded n= 40 
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Table 4.1: Aim 1 cohort MLIP eligibility, enrollment delay, and observation characteristics 
MLIP characteristics 
Total  
(n=1647) 
Total subjects meeting MLIP criteria, n (%) 
 Opioid use criterion met 1446 (87.8%) 
Benzodiazepine use criterion met 58 (3.5%) 
Pharmacy use measure met 1141 (69.3%) 
Specific routes of MLIP eligibility, n(%) 
 Single MLIP criterion met 511 (31.0%) 
Opioid use only 411 (25.0%) 
Benzodiazepine use only 14 (0.9%) 
Pharmacies used only 86 (5.2%) 
Two MLIP criteria met 1043 (63.3%) 
Opioid use & benzodiazepine use 4 (0.2%) 
Opioid use & pharmacy use 1015 (61.6%) 
Benzodiazepine use & pharmacy use 24 (1.5%) 
All three MLIP criteria met 16 (1.0%) 
No MLIP criteria met 77 (4.7%) 
  Observation months, mean (SD) 
 Total pre- and post-lock-in enrollment 31.4 (4.3) 
Pre-lock-in enrollment 20.6 (5.0) 
Post-lock-in enrollment 10.9 (1.8) 
MLIP enrollment delay 
 MLIP enrollment delayed, n (%) 1547 (93.9%) 
Months enrollment delayed, mean (SD) 5.6 (3.9) 
Note: MLIP= Medicaid lock-in program; SD=Standard deviation; Opioid eligibility = ≥7 opioid Medicaid claims in 
a two calendar month period; Benzodiazepine eligibility = ≥7 benzodiazepine Medicaid claims in a two calendar 
month period; Pharmacy use measure = opioid and/or benzodiazepine Medicaid claims from ≥4  unique pharmacies 
in a two calendar month period (proxy for the NC MLIP eligibility criterion of ≥4 unique prescribers). 
  
 On average, the total observation period for study subjects was 31 months, with 20 months 
coming prior to MLIP enrollment and 11 months of observation after enrollment in the MLIP (Table 4.2). 
Very few subjects were enrolled in the MLIP immediately after becoming eligible for lock-in. 
Specifically, 94% of subjects experienced a delay in MLIP enrollment of at least one calendar month. 
Enrollment delays were nearly six months, on average, and resulted from the phased-in implementation of 
the NC MLIP in which enrollment capacity increased monthly beginning in October 2010. This meant 
that nearly all subjects contributed data for the unique observation period in which they had demonstrated 
high-risk controlled substance use behaviors but had not yet experienced the MLIP policy intervention. 
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 Figure 4.2 visualizes the temporal trends in total Aim 1 subjects eligible for and enrolled in the 
NC MLIP. This figure demonstrates how the phased-in MLIP implementation affected the rate of lock-in 
enrollment and contributed to enrollment delays. Roughly half of the 1,647 subjects included in Aim 1 
first satisfied NC MLIP eligibility during the initial eligibility assessment period of August through 
October 2010. The total number of Aim 1 subjects eligible for the MLIP steadily increased across the 
study period. The high prevalence of MLIP enrollment delays is evident by the large gap between total 
MLIP enrollment numbers (red line) and total MLIP eligibility numbers (blue line). Only about 30 
subjects were enrolled in the first month of operation in October 2010 despite roughly 800 being eligible. 
MLIP enrollment totals increased over the study period, reaching full capacity just two months prior to 
the end of the period of assessment for MLIP enrollment. The height of the cumulative MLIP enrollment 
line exceeded the height of the cumulative MLIP eligibility line in the final month due to the 70 subjects 
enrolled in the MLIP despite not meeting NC MLIP eligibility criteria in retrospective claims review. 
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Figure 4.2: Cumulative MLIP eligibility and enrollment totals for Aim 1 subjects across the study period  
 
 
 Table 4.2 presents summary statistics for the analytic cohort, including predisposing, enabling, 
and need variables for the entire sample and by route of MLIP eligibility. Overall, the study cohort had a 
mean age of 39.7 years and was predominantly female (73.5%) and White (75.8%). Predisposing 
characteristics were similar across sample subsets of MLIP enrollment eligibility based on opioid use, 
benzodiazepine use, and/or prescriber use. The 77 subjects that failed to meet any MLIP eligibility criteria 
prior to lock-in were more often White (81.8%) than the total sample and other eligibility criterion 
subsets. 
 The Aim 1 sample primarily resided in metropolitan areas, with 72.7% of subjects residing in a 
metropolitan county (RUCC score of 1-3). On average, a subject’s county of residence at the time of 
MLIP enrollment had 50 community pharmacies and over 700 prescribers. However, pharmacy and 
prescriber supply varied widely across the sample. Over one-third of the sample reported living in a North 
Carolina county that bordered another state. County-level enabling characteristics were comparable across 
MLIP eligibility route subsets. The 58 people that were eligible due to high benzodiazepine use resided in 
metropolitan and border counties less often than subjects meeting any other eligibility criteria. Those who 
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were enrolled in the MLIP despite not meeting any eligibility criteria lived in metropolitan counties more 
often than subjects that met an eligibility criterion.  
 Need variable summary statistics indicated high prevalence of key comorbidities in the Aim 1 
cohort. Nearly all subjects had a chronic noncancer pain diagnosis during the 12-month baseline period, 
and nearly 60% had an anxiety disorder. Forty-five to 55% of subjects recorded a diagnosis in the 
baseline period for a substance use disorder, depression, or any other mental health condition. The mean 
Charlson Comorbidity Index score was 1.4, which reflects a weighted aggregate score of the burden of 
physical comorbidities, excluding pain and mental health conditions. Subjects’ physical comorbid burden 
were distributed relatively evenly when grouped into Charlson index scores of 0, 1, and ≥2. The Aim 1 
cohort also received a high number of unique prescription drug products—controlled and non-controlled 
medications—during the 12-month baseline period, with a mean of 19.3 medications. Subjects eligible for 
the MLIP due to high benzodiazepine use had higher comorbidity burden compared to the total cohort.
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Table 4.2: Summary statistics for predisposing, enabling, and need characteristics of the Aim 1 cohort, overall and by route of Medicaid 
lock-in program eligibility 
Patient characteristic 
Total  
(n=1647) 
Opioid 
eligibility 
(n=1446) 
Benzodiazepine 
eligibility 
(n=58) 
Pharmacy 
eligibility 
(n=1141) 
No eligibility 
(n=77) 
Predisposing characteristics      
Age1, mean (SD) 39.7 (10.5) 39.8 (10.6) 40.0 (10.7) 38.3 (10.4) 39.4 (10.3) 
Female, n (%) 1211 (73.5%) 1069 (73.9%) 43 (74.1%) 823 (72.1%) 56 (72.7%) 
Race, n (%)      
White 1248 (75.8%) 1076 (74.4%) 44 (75.9%) 859 (75.3%) 63 (81.8%) 
Black 291 (17.7%) 268 (18.5%) 10 (17.2%) 206 (18.1%) 11 (14.3%) 
Other/unknown 108 (6.6%) 102 (7.1%) 4 (6.9%) 76 (6.7%) 3 (3.9%) 
Enabling characteristics1,2      
Metropolitan residency3, n (%) 1197 (72.7%) 1060 (73.3%) 37 (63.8%) 831 (72.8%) 65 (84.4%) 
Pharmacy supply, mean (SD) 49.3 (58.6) 50.3 (59.4) 42.0 (50.2) 52.3 (62.3) 37.9 (41.2) 
Prescriber supply, mean (SD) 711.2 (942.7) 725.0 (950.4) 592.7 (815.8) 735.3 (975.4) 606.1 (834.7) 
Border county, n (%) 600 (36.4%) 528 (36.5%) 10 (17.2%) 437 (38.4%) 24 (31.2) 
Need characteristics4 	       
Charlson Comorbidity Index score, mean (SD) 1.4 (2.0) 1.4 (2.0) 1.6 (1.8) 1.2 (1.8) 1.2 (2.1) 
     Charlson score = 0, n (%) 676 (41.0%) 579 (40.0%) 20 (34.5%) 514 (45.1%) 38 (49.4%) 
     Charlson score = 1, n (%) 465 (28.2%) 411 (28.4%) 13 (22.4%) 322 (28.2%) 21 (27.3%) 
     Charlson score ≥ 2, n (%) 506 (30.7%) 456 (31.5%) 25 (43.1%) 305 (26.7%) 18 (23.4%) 
Prescription drug burden, mean (SD) 19.3 (9.9) 19.5 (9.7) 17.0 (10.9) 17.7 (8.6) 18.8 (12.6) 
Chronic non-cancer pain, n (%) 1583 (96.1%) 1396 (96.5%) 54 (93.1%) 1101 (96.5%) 68 (88.3%) 
Anxiety disorder, n (%) 959 (58.2%) 817 (56.5%) 49 (84.5%) 660 (57.8%) 51 (66.2%) 
Substance use disorder, n (%) 743 (45.1%) 614 (42.5%) 33 (56.9%) 516 (45.2%) 57 (74.0%) 
Depression, n (%) 905 (55.0%) 774 (53.5%) 39 (67.2%) 592 (51.9%) 53 (68.8%) 
Other mental illness, n (%) 836 (50.8%) 701 (48.5%) 40 (69.0%) 562 (49.3%) 50 (64.9%) 
Note: Opioid eligibility = ≥7 opioid Medicaid claims in a two calendar month period; Benzodiazepine eligibility = ≥7 benzodiazepine Medicaid claims 
in a two calendar month period; Pharmacy eligibility = opioid and/or benzodiazepine Medicaid claims from ≥4 unique pharmacies in a two month 
period (proxy for unique prescriber measure used in practice); Study subjects could be included in multiple MLIP eligibility groups; SD=Standard 
deviation. 
1. Age and county of residence measures reflect values of the measures at the time of a subject's enrollment in the lock-in program 
2. All enabling characteristics were assessed at the county-level and reflect a subject's county of residence at time of lock-in enrollment.  
3. Rural-urban continuum codes reflect 2013 version from the US Department of Agriculture, which ranges 1 to 9 with 1 being the most metropolitan 
counties and 9 being the most rural counties. Metropolitan counties have RUCC=1-3 and non-metropolitan counties=4-9  
4. Clinical characteristics were assessed for all subjects during the 12-month baseline period from 10/1/2009 to 9/30/2010 
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4.1.2 Aim 1 Bivariate Analysis Findings  
 The longitudinal Aim 1 cohort obtained an average of 2.56 combined opioid and benzodiazepine 
prescription fills per-person-per-month across the entire study period. This figure includes Medicaid-
covered fills and circumvented fills (Table 4.3). Three-fourths of these fills were for opioid analgesics. 
When comparing before and after MLIP enrollment in bivariate analysis, total overall fills of these 
medications from any payment source decreased 17% (p<0.001).  
Table 4.3: Bivariate trends in opioid and benzodiazepine prescription fills and prescribers, before and 
after enrollment in the lock-in program 
  
Total 
(n=1647) 
Before MLIP  
enrollment 
(n=1647) 
After MLIP  
enrollment 
(n=1647) 
Percent  
change 
P-
value 
Monthly total prescription fills per 
person (Medicaid + circumvented), 
mean (SD) 
        Opioid + benzodiazepine 2.56  (2.06) 2.72  (2.13) 2.26  (1.89) -17% <0.001 
Opioid 1.90  (1.79) 2.04  (1.87) 1.62  (1.58) -21% <0.001 
Benzodiazepine 0.67  (0.84) 0.68  (0.85) 0.65  (0.82) -5% <0.001 
Monthly Medicaid claims per person, 
mean (SD) 
        Opioid + benzodiazepine 2.07  (1.86) 2.43  (1.94) 1.39  (1.50) -43% <0.001 
Opioid 1.52  (1.59) 1.82  (1.70) 0.95  (1.19) -48% <0.001 
Benzodiazepine 0.55  (0.74) 0.61  (0.77) 0.44  (0.66) -28% <0.001 
Monthly unique opioid and 
benzodiazepine Medicaid prescribers 
per person, mean (SD) 
0.99  (0.81) 1.18  (0.87) 0.64  (0.52) -46% <0.001 
Number of subjects with any 
circumvented prescriptions, n (%) 
        Opioid + benzodiazepine 1566 (95%) 1337 (81%) 1436 (87%) 7% <0.001 
Opioid 1527 (93%) 1254 (76%) 1354 (82%) 8% <0.001 
Benzodiazepine 989 (60%) 577 (35%) 800 (49%) 39% <0.001 
Percent of person-months with any 
circumvented prescriptions, (%)         
    Opioid + benzodiazepine 26.1% 
21.5% 
8.8% 
17.6% 
14.5% 
5.2% 
42.3% 
34.9% 
15.6% 
140% <0.001 
    Opioid 141% <0.001 
    Benzodiazepine 200% <0.001 
Total monthly circumvented 
prescriptions per person, mean (SD) 
        Opioid + benzodiazepine 0.50  (1.13) 0.30  (0.85) 0.87  (1.45) 195% <0.001 
Opioid 0.38  (0.96) 0.23  (0.72) 0.67  (1.24) 193% <0.001 
Benzodiazepine 0.11  (0.42) 0.07  (0.32) 0.20  (0.55) 204% <0.001 
Note: MLIP=Medicaid lock-in program; SD=Standard deviation. The pre-MLIP enrollment period consisted of 
33,882 person-months, while the post-MLIP enrollment period consisted of 17,916 person-months 
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 When looking only at Medicaid-covered opioid and benzodiazepine fills—which reflects the 
perspective of NC MLIP administrators who were not able to observe circumvention—the average 
monthly Medicaid claims for these drugs decreased 43% from 2.43 to 1.39 fills per-person-per-month 
after MLIP enrollment (p<0.001). Most of this reduction in Medicaid controlled substance claims was 
attributable to fewer opioid Medicaid claims. A similar trend was observed in the mean number of unique 
opioid and benzodiazepine prescribers of Medicaid-paid fills. Aim 1 subjects used an average of 1.18 
unique Medicaid prescribers per-person-per-month before MLIP enrollment compared to 0.64 unique 
prescribers prior to being locked in (p<0.001). These findings indicate that, from an NC Medicaid 
administrator’s perspective, the MLIP appeared to result in an over 40% decrease in the utilization of 
opioids, benzodiazepines, and controlled substance prescribers in bivariate analysis. 
 However, circumvention of opioids and benzodiazepines was highly prevalent in the Aim 1 
cohort. It also increased significantly after enrollment in the NC MLIP in bivariate analysis. Roughly 95% 
of subjects circumvented their Medicaid coverage to obtain an opioid or benzodiazepine prescription fill 
at any point in the entire study period. The proportion of subjects engaging in any circumvention 
increased slightly from 81% in the pre-MLIP enrollment observation period to 87% in the post-MLIP 
enrollment period (p<0.001). The proportion of person-months in which a circumvented opioid or 
benzodiazepine fill occurred was nearly 2.5 times higher in the post-MLIP enrollment period compared to 
the pre-MLIP enrollment period (42.3% vs. 17.6%, p<0.001). In all, the mean number of circumvented 
opioid and benzodiazepine fills per-person-per-month nearly tripled from 0.30 to 0.87 circumvented fills 
before and after MLIP enrollment, respectively (p<0.001).  
 Figures 4.3 and 4.4 visualize trends in circumvented and Medicaid-paid controlled substance 
prescription fills for the Aim 1 cohort across the entire study period. There was a gradual increase in the 
proportion of subjects engaging in circumvention after implementation of the NC MLIP in October 2010 
(Figure 4.3). In each of the 12 months leading up to the start of the NC MLIP, roughly 17% of subjects 
received as least one opioid or benzodiazepine prescription through circumvention. After the NC MLIP 
was introduced, the proportion of subjects engaging in circumvention rose steadily to 40% 24 months into 
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program operation. This was coupled by a corresponding decrease in the proportion of subjects obtaining 
an opioid or benzodiazepine prescription through the NC Medicaid benefit during the same time period.   
 
Figure 4.3: Trends in the proportion of Aim 1 subjects recording any opioid or benzodiazepine fill in an 
observation month, by source of payment 
 
Note: Red dotted line delineates North Carolina Medicaid lock-in program implementation 
 
 Figure 4.4 depicts the mean opioid plus benzodiazepine prescription fill totals per person per 
month across the Aim 1 study period. The height of the column represents the mean total opioid and 
benzodiazepine fills obtained by a subject regardless of payment source. Each column is divided into the 
proportion of mean total controlled substance fills attributable to circumvention and use of the Medicaid 
benefit. Circumvention was stable prior to MLIP implementation in October 2010 at around 0.3 
circumvented fills per-person-per-month. After October 2010, circumvention events increased steadily to 
around 0.8 circumvented fills per-person-per-month after 24 months of NC MLIP operation. Subjects 
filled an average of 2.6 Medicaid-covered opioid and benzodiazepines prescriptions at the start of the NC 
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MLIP. There was a corresponding decrease in Medicaid controlled substance fills to 1.6 fills per person 
per month over the 24 months of NC MLIP operation observed in the study. Total receipt of these 
medications—through Medicaid and circumvention—also experienced a decline from October 2010 
through September 2012. 
Figure 4.4: Trends in mean opioid plus benzodiazepine prescription fill totals per-person-per-month for 
the Aim 1 cohort, by payment source   
 
Note: Red dotted line delineates North Carolina Medicaid lock-in program implementation 
 
4.1.3 Aim 1 Generalized Estimating Equation Analysis Findings  
 Table 4.4 presents findings from primary analyses in which generalized estimating equations 
modeled the effect of MLIP enrollment and patient-level predictors on the likelihood of receiving a 
circumvented opioid or benzodiazepine fill and the rate of circumvention. The left columns present risk 
ratio estimates for the likelihood of receiving a circumvented opioid or benzodiazepine prescription fill in 
a person-month. The right columns present incidence rate ratio estimates for the rate of circumvented 
prescription fills in a person-month.  
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 MLIP enrollment was associated with 3.6 times higher likelihood of controlled substance 
circumvention (RR=3.55; 95% CI: 3.13, 4.03) compared to months in which subjects were not enrolled in 
the MLIP, controlling for time, the overall policy period, and patient-level covariates. The probability of 
circumvention was 28% higher when subjects were in a period of delayed enrollment after first meeting 
eligibility for the lock-in program (RR=1.28; 95% CI: 1.13, 1.46). As time spent in an MLIP enrollment 
delay increased, the probability of circumvention increased slightly, but significantly (RR=1.02; 95% CI; 
1.00, 1.03). MLIP eligibility stemming from high utilization of benzodiazepines and controlled substance 
providers (using the proxy measure of unique dispensing pharmacies) was associated with a 52% 
(RR=1.52, 95% CI: 1.29, 1.79) and 10% (RR=1.16; 95% CI: 1.01, 1.21) higher likelihood of engaging in 
circumvention, respectively. It is worth noting the binary indicator for the overall MLIP policy period had 
a significantly negative relationship with the likelihood of circumvention. However, this finding has 
limited interpretability when controlling for variation in the outcome due to the key independent variable 
of MLIP enrollment. The MLIP policy indicator was included in the final models to control for any 
ambient effect of the MLIP’s existence on patient behavior whether or not they were enrolled in the 
MLIP. 
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Table 4.4: Generalized estimating equation results for the estimation of any circumvention fill and 
number of circumvented fills 
 
Any circumvented fill Number of circumvented fills	  
Variable RR (95% CI) P-value IRR (95% CI) P-value 
Key independent variable 
       	  MLIP enrollment (Key IV) 3.55 (3.13, 4.03) <0.001 4.40 (3.76, 5.15) <0.001 
MLIP policy variables       
MLIP enrollment * month 1.00 (0.99 , 1.01) 0.675 1.01 (0.99 , 1.02) 0.274 
MLIP enrollment delay 1.28 (1.13 , 1.46) <0.001 1.25 (1.06 , 1.47) 0.008 
MLIP enrollment delay * month 1.02 (1.00 , 1.03) 0.031 1.02 (1.00 , 1.05) 0.036 
Month 1.00 (0.99 , 1.01) 0.766 0.98 (0.97 , 1.00) 0.025 
MLIP policy period 0.81 (0.73 , 0.91) <0.001 0.88 (0.77 , 1.01) 0.074 
MLIP policy period * month 0.99 (0.98 , 1.00) 0.099 1.00 (0.98 , 1.01) 0.645 
MLIP eligibility route 
       Opioid use 1.01 (0.87, 1.16) 0.928 1.10 (0.92, 1.31) 0.283 
Benzodiazepine use 1.52 (1.29 , 1.79) <0.001 1.78 (1.47 , 2.16) <0.001 
Pharmacy use 1.10 (1.01 , 1.21) 0.028 1.18 (1.03 , 1.35) 0.018 
No eligibility criteria met 0.94 (0.72 , 1.22) 0.628 0.96 (0.68 , 1.36) 0.834 
Predisposing characteristics 
       Age 0.994 (0.99, 1.00) 0.001 0.99 (0.99, 1.00) 0.017 
Female 0.94 (0.86 , 1.02) 0.144 0.88 (0.78 , 1.00) 0.053 
Race (White referent) 
       Black 0.99 (0.90, 1.10) 0.892 0.97 (0.83, 1.13) 0.658 
Other 0.96 (0.82 , 1.11) 0.551 0.91 (0.74 , 1.12) 0.368 
Enabling characteristics 
       Metropolitan residence 1.01 (0.93, 1.10) 0.806 1.03 (0.91, 1.17) 0.602 
County pharmacy supply (<10 referent) 
       11-25 1.05 (0.95, 1.17) 0.343 1.03 (0.89, 1.19) 0.673 
26-50 1.10 (0.99 , 1.22) 0.071 1.06 (0.92 , 1.23) 0.414 
51-100 1.07 (0.96 , 1.20) 0.220 1.04 (0.89 , 1.22) 0.623 
>100 1.22 (1.07 , 1.39) 0.004 1.33 (1.08 , 1.65) 0.008 
Border county 1.00 (0.93 , 1.07) 0.925 1.01 (0.90 , 1.14) 0.817 
Need characteristics 
       Chronic non-cancer pain 1.33 (1.06, 1.68) 0.013 1.48 (1.11, 1.96) 0.008 
Anxiety disorder 1.12 (1.04 , 1.22) 0.003 1.11 (0.98 , 1.25) 0.100 
Substance abuse disorder 1.01 (0.94 , 1.08) 0.874 1.03 (0.93 , 1.15) 0.573 
Depression 1.07 (0.99 , 1.16) 0.071 1.11 (0.99 , 1.24) 0.070 
Other mental illness 1.05 (0.98 , 1.13) 0.195 1.03 (0.93 , 1.15) 0.542 
Charlson Comorbidity Index score 
       0 (referent) 
       1 1.00 (0.92, 1.09) 0.979 0.98 (0.87, 1.11) 0.753 
≥2 1.14 (1.03 , 1.25) 0.010 1.15 (0.99 , 1.34) 0.074 
Prescription drug burden 1.00 (0.99 , 1.00) 0.473 1.00 (0.99 , 1.01) 0.417 
Note: RR=relative risk; CI=confidence interval; IRR=incidence rate ratio; MLIP=Medicaid lock-in program. RR 
were obtained through generalized estimating equation (GEE) modeling with monthly measures using Poisson 
distribution, log link, and autoregressive (1 month) correlation structure with robust standard errors. IRR were 
obtained through GEE using Poisson distribution, log link, and autoregressive correlation structure with robust 
standard errors. 
 
 Patient age was the only statistically significant predisposing predictor of engaging in any 
circumvention. Each increase in age of one year was associated with a small, but significant, reduction in 
the likelihood of circumvention (RR=0.994; 95% CI: 0.99, 1.00). Sex and race were not predictive of 
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circumvention in this MLIP enrollee cohort. With regard to patient predisposing characteristics, living in 
a metropolitan county or a border county were not associated with circumvention. However, patients that 
resided in counties with a supply of more than 100 community pharmacies had a 22% higher likelihood of 
circumvention compared to those that lived in counties with 10 or fewer pharmacies (RR=1.22; 95% CI: 
1.07, 1.39). Receipt of a prior diagnosis of chronic noncancer pain (RR=1.33; 95% CI: 1.06, 1.68) or an 
anxiety disorder (RR=1.12; 95% CI: 1.04, 1.22) was associated with significantly higher probability of 
receiving a circumvented fill compared to subjects without these conditions. Subjects with a depression 
diagnosis had 7% higher likelihood of circumvention, but this finding fell slightly short of statistical 
significance based on an alpha level of ≤0.05. Patients with the highest burden of physical comorbidities, 
defined as a Charlson score of 2 or more, were significantly more likely to circumvent compared to those 
with a Charlson score of 0 (RR=1.14; 95% CI: 1.03, 1.25). 
 Similar findings were reported in the GEE model that used a Poisson count model approach to 
estimate the number, or extent, of circumvention events (as seen in the right column set in Table 4.4 
denoted as incidence rate ratios). The rate of circumvention events was 4.4 times higher when subjects 
were enrolled in the MLIP (IRR=4.40; 95% CI: 3.76, 5.15), compared to when they were not enrolled in 
the MLIP, controlling for policy and patient-level covariates. Periods of delayed MLIP enrollment were 
also associated with a significantly higher rate of circumvention events (IRR=1.25; 95% CI: 1.06, 1.47). 
When looking at patient-level characteristics, patient age, living in a county with >100 community 
pharmacies, and having a baseline diagnosis of chronic noncancer pain were significant predictors of 
higher numbers of circumvention events. Female sex had a strong, but not statistically significant, 
association with reduced rate of circumvention (IRR=0.88; 95% CI: 0.78, 1.00). Anxiety diagnosis, 
depression diagnosis, and a Charlson score of 2 or more were all strongly positive, but not statistically 
significant, predictors of the extent of circumvention in a given month. 
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4.2 AIM 2 RESULTS 
4.2.1 Aim 2 Descriptive and Bivariate Analysis Findings 
 
 The Aim 2 analytic cohort included 1,646 NC MLIP enrollees with opioid use during the study 
period of 10/1/2009 through 9/30/2012. This was the same study cohort used in Aim 1 analyses. 
However, one additional subject was excluded due to having only benzodiazepine use. The selection 
algorithm was presented previously in Figure 4.1. Aim 2 subjects were enrolled in the NC MLIP between 
10/1/2010 and 3/31/2012, had continuous NC Medicaid coverage from 10/1/2009 through at least six 
months following their MLIP enrollment date, and were ages 18-64.  
 Patient-level predisposing, enabling, need, and MLIP enrollment characteristics of the study 
cohort were described previously in Aim 1, Section 4.1.1. Therefore, we focus on reporting descriptive 
and bivariate analysis findings of prescription-level opioid use characteristics of the cohort. The three 
Aim 2 prescription-level outcomes of Schedule II opioid use, long-acting opioid use, and average daily 
prescribed opioid dose in mean MME/day are emphasized.  
 Tables 4.5a-c report frequencies of total opioid prescription fills, Schedule II opioid fills, long-
acting opioid fills, and mean prescribed MME/day. Bivariate comparisons of these measures across MLIP 
enrollment status are also reported. These data presented are grouped by payment source—circumvented, 
Medicaid paid, and all payers—for comprehension but will be detailed here in aggregate.  
 The Aim 2 cohort received a total of 98,243 opioid prescriptions during the study period. Of 
these, 19,778 were obtained through circumvention, while the remaining 78,465 opioid prescriptions were 
paid for using the Medicaid benefit. 
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Table 4.5a: Circumvented opioid prescription frequencies in the Aim 2 cohort by prescription-level 
characteristic and MLIP enrollment status  
  
Total 
(n=19,778)	  
Pre-MLIP  
enrollment 
(n=7,781)	  
Post-MLIP  
enrollment 
(n=11,997)	  
% 
Change p-value 
Schedule II (vs. Schedule III-V) 
opioid fills, n (%)	  
10869 (55.0%) 4314 (55.4%) 6555 (54.6%) -1% 0.270 
Long-acting (vs. short-acting) 
opioid fills, n (%)	  
2097 (10.6%) 968 (12.4%) 1129 (9.4%) -24% <0.001 
Prescribed MME/day per  
opioid Rx, mean (SD)	  
63.8 (86) 68.4 (101) 60.8 (75) -11% <0.001 
 
Table 4.5b: Medicaid paid opioid prescription frequencies in the Aim 2 cohort by prescription-level 
characteristic and MLIP enrollment status  
  
Total 
(n=78,465)	  
Pre-MLIP  
enrollment 
(n=61,517)	  
Post-MLIP  
enrollment 
(n=16,948)	  
% 
Change	   p-value 
Schedule II (vs. Schedule III-V) 
opioid fills, n (%)	   48551 (61.9%) 35726 (58.1%) 12825 (75.7%) 30% <0.001 
Long-acting (vs. short-acting) 
opioid fills, n (%)	  
15271 (19.5%) 9888 (16.1%) 5383 (31.8%) 98% <0.001 
Prescribed MME/day per  
opioid Rx, mean (SD)	  
83.4 (140) 75.7 (120) 111 (194) 47% <0.001 
 
Table 4.5c: All-payer opioid prescription frequencies in the Aim 2 cohort by prescription-level 
characteristic and MLIP enrollment status  
  
Total 
(n=98,243)	  
Pre-MLIP  
enrollment 
(n=69,298)	  
Post-MLIP  
enrollment 
(n=28,945)	  
% 
Change p-value 
Schedule II (vs. Schedule III-V) 
opioid fills, n (%)	   59420 (60.5%) 40040 (57.8%) 19380 (67.0%) 16% <0.001 
Long-acting (vs. short-acting) 
opioid fills, n (%)	  
17368 (17.7%) 10856 (15.7%) 6512 (22.5%) 43% <0.001 
Prescribed MME/day per  
opioid Rx, mean (SD)	  
79.4 (131) 74.8 (118) 90.5 (158) 21% <0.001 
Note: MLIP=Medicaid lock-in program; MME=Milligram morphine equivalent; Rx=Prescription; SD=Standard 
deviation 
  
 Sixty-two percent of all opioid prescriptions paid for with the Medicaid benefit were written for 
Schedule II products, while 55.0% of all circumvented opioid prescriptions contained Schedule II opioids. 
There was no change in the proportion of circumvented opioid prescriptions written for Schedule II 
opioids after subjects were enrolled in the NC MLIP (p=0.270). However, a significantly larger 
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proportion of Medicaid covered opioid prescriptions contained Schedule II products after MLIP 
enrollment (58.1% pre-MLIP enrollment vs. 75.7% post-MLIP enrollment; p<0.001).  
 Long-acting opioid prescription fills were less prevalent than Schedule II opioid fills, with 19.5% 
of all Medicaid covered opioid prescriptions and 10.6% of all circumvented opioid fills written for long-
acting opioid products. After NC MLIP enrollment, the proportion of circumvented opioid fills written for 
long-acting opioid formulations experienced a relative decrease of 24% (12.4% pre-MLIP enrollment vs. 
9.4% post-MLIP enrollment; p<0.001). However, the proportion of opioid prescriptions obtained by 
subjects through NC Medicaid nearly doubled after MLIP enrollment (16.1% pre-MLIP enrollment vs. 
31.8% post-MLIP enrollment; p<0.001).  
 Similar trends were observed for the average prescribed MME/day per prescription for the Aim 2 
cohort. On average, opioid prescriptions obtained through the NC Medicaid benefit had a mean MME/day 
of 83.4 for the entire study period. Circumvented opioid prescriptions had a lower mean daily opioid dose 
of 63.8 MME/day. The mean MME/day of opioid prescriptions that subjects obtained through 
circumvention decreased significantly from 68.4 to 60.8 MME/day (p<0.001) after enrollment in the NC 
MLIP. However, opioid fills obtained through the NC Medicaid benefit experienced a nearly 50% 
increase in average daily opioid dose per prescription after subjects were enrolled in the MLIP (75.7 
MME/day pre-MLIP enrollment vs. 111.0 MME/day post-MLIP enrollment; p<0.001). 
 Figure 4.5 depicts of the frequency of opioid products obtained by the study cohort across the 
entire study period. Three-fourths of all opioid prescriptions contained short acting oxycodone 
tablets/capsules or short acting hydrocodone tablets/capsules. The next five most commonly prescribed 
opioid products were all long acting opioid preparations, making up 2.5% to 4.3% of total opioid use 
individually. These included fentanyl transdermal patches, long acting oxycodone tablets, long acting 
morphine tablets/capsules, long acting oxymorphone tablets, and methadone tablets/capsules. The 
remaining 8.4% of all opioid prescription fills received by study subjects were comprised of 22 different 
opioid products.  
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Figure 4.5: Ranked frequency of opioid products obtained by the Aim 2 cohort  
 
Note: IR=Immediate release; LA=Long acting 
 
 The next series of tables (4.6a-b; 4.7a-b; 4.8a-b; and 4.9a-b) describes the ranked frequency of the 
most commonly received Schedule II, Schedule III-V, long acting, and short acting opioid products 
broken down by payment source and MLIP enrollment status. Short acting oxycodone tablets/capsules 
was by far the most commonly circumvented Schedule II opioid product before (69.5%) and after 
(75.2%) subjects were enrolled in the MLIP (Table 4.6a). Long acting oxycodone tablets and fentanyl 
transdermal patches were less commonly circumvented after MLIP enrollment. Among non-Schedule II 
products obtained through circumvention, prescriptions for short acting hydrocodone tablets comprised 
over 90% of all circumvented Schedule III-V opioids (Table 4.6b). 
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Table 4.6a: Circumvented Schedule II opioid product frequency, by MLIP enrollment status 
Pre-MLIP enrollment Post-MLIP enrollment 
Rank Freq. % Product Rank Freq. % Product 
1 2,996 69.5 Oxycodone IR, oral 1 4,931 75.2 Oxycodone IR, oral 
2 328 7.6 Oxycodone LA, oral 3 327 5.0 Methadone LA, oral 
3 293 6.8 Methadone LA, oral 6 241 3.7 Morphine LA, oral 
4 165 3.8 Hydromorphone IR, oral 4 227 3.5 Hydromorphone IR, oral 
5 161 3.7 Fentanyl LA, transdermal 2 201 3.1 Oxycodone LA, oral 
 
Table 4.6b: Circumvented Schedule III-V opioid product frequency, by MLIP enrollment status 
Pre-MLIP enrollment Post-MLIP enrollment 
Rank Freq. % Product Rank Freq. % Product 
1 3,122 90.1 Hydrocodone IR, oral 1 5,022 92.3 Hydrocodone IR, oral 
2 150 4.3 Propoxyphene IR, oral 3 325 6.0 Codeine IR, oral 
3 103 3.0 Codeine IR, oral 5 37 0.7 Butorphanol IR, spray 
4 58 1.7 Pentazocine IR, oral 6 27 0.5 Hydrocodone IR, liquid 
5 15 0.4 Butorphanol IR, spray 7 11 0.2 Buprenorphine LA, transdermal 
Note: MLIP=Medicaid lock-in program; Freq=Frequency; IR=Immediate release; LA=Long acting. Post-MLIP 
enrollment period ranks reflect that specific product’s frequency rank in the pre-MLIP enrollment period. 
 
 Schedule II opioid products paid for with the Medicaid benefit prior to MLIP enrollment had a 
similar profile to circumvented Schedule II opioid prescriptions in this period (Table 4.7a). Short acting 
oxycodone tablets/capsules made up about two-thirds of these prescriptions, with long acting oxycodone 
tablets comprising over 7%. After MLIP enrollment, short acting oxycodone tablets/capsules were still 
the most common Schedule II opioid obtained through Medicaid but it represented a smaller share 
(51.0%). Long acting oxymorphone, oxycodone, and morphine products comprised a larger proportion of 
Medicaid paid opioid fills after MLIP enrollment. Short acting hydrocodone tablets again represented the 
vast majority of Medicaid paid Schedule III-V opioid fills obtained by subjects before and after MLIP 
enrollment (Table 4.7b). 
 
Table 4.7a: Medicaid paid Schedule II opioid product frequency, by MLIP enrollment status 
Pre-MLIP enrollment Post-MLIP enrollment 
Rank Freq. % Product Rank Freq. % Product 
1 23,312 65.3 Oxycodone IR, oral 1 6,540 51.0 Oxycodone IR, oral 
2 2,543 7.1 Oxycodone LA, oral 5 1,388 10.8 Oxymorphone LA, oral 
3 2,452 6.9 Fentanyl LA, transdermal 3 1,379 10.8 Fentanyl LA, transdermal 
4 2,069 5.8 Morphine LA, oral 2 957 7.5 Oxycodone LA, oral 
5 1,387 3.9 Oxymorphone LA, oral 4 931 7.3 Morphine LA, oral 
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Table 4.7b: Medicaid paid Schedule III-V opioid product frequency, by MLIP enrollment status 
Pre-MLIP enrollment Post-MLIP enrollment 
Rank Freq. % Product Rank Freq. % Product 
1 23,293 90.3 Hydrocodone IR, oral 1 3,775 91.6 Hydrocodone IR, oral 
2 984 3.8 Codeine IR, oral 4 119 2.9 Butorphanol IR, spray 
3 900 3.5 Propoxyphene IR, oral 2 118 2.9 Codeine IR, oral 
4 375 1.5 Butorphanol IR, spray 7 91 2.2 Buprenorphine LA, transdermal 
5 96 0.4 Pentazocine IR, oral 5 6 0.2 Pentazocine IR, oral 
Note: MLIP=Medicaid lock-in program; Freq=Frequency; IR=Immediate release; LA=Long acting. Post-MLIP 
enrollment period ranks reflect that specific product’s frequency rank in the pre-MLIP enrollment period. 
 
 Table 4.8a and 4.8b describe the frequency of long acting and short acting opioid products, 
respectively, obtained by subjects through circumvention. Long acting oxycodone and methadone 
products comprised nearly two-thirds of all circumvented long acting opioid prescriptions prior to MLIP 
enrollment (Table 4.8a). Fentanyl transdermal patches and long acting morphine tablets/capsules 
contributed another 30% of pre-MLIP enrollment circumvention behavior. After MLIP enrollment, 
though, the prevalence of circumvented long acting oxycodone was reduced by half, and the prevalence 
of circumvented long acting morphine prescriptions increased from 12.6% to 21.4%. Short acting 
hydrocodone and oxycodone tablets/capsules comprised roughly 90% of all short acting opioid products 
obtained through circumvention before and after MLIP enrollment (Table 4.8b). 
 
Table 4.8a: Circumvented long acting opioid product frequency, by MLIP enrollment status 
Pre-MLIP enrollment Post-MLIP enrollment 
Rank Freq. % Product Rank Freq. % Product 
1 328 33.9 Oxycodone LA, oral 2 327 29.0 Methadone LA, oral 
2 293 30.3 Methadone LA, oral 4 241 21.4 Morphine LA, oral 
3 161 16.6 Fentanyl LA, transdermal 1 201 17.8 Oxycodone LA, oral 
4 122 12.6 Morphine LA, oral 3 196 17.4 Fentanyl LA, transdermal 
5 56 5.8 Oxymorphone LA, oral 5 149 13.2 Oxymorphone LA, oral 
 
Table 4.8b: Circumvented short acting opioid product frequency, by MLIP enrollment status 
Pre-MLIP enrollment Post-MLIP enrollment 
Rank Freq. % Product Rank Freq. % Product 
1 3,122 45.8 Hydrocodone IR, oral 1 5,022 46.2 Hydrocodone IR, oral 
2 2,996 44.0 Oxycodone IR, oral 2 4,931 45.4 Oxycodone IR, oral 
3 165 2.4 Hydromorphone IR, oral 5 325 3.0 Codeine IR, oral 
4 150 2.2 Propoxyphene IR, oral 3 227 2.1 Hydromorphone IR, oral 
5 103 1.5 Codeine IR, oral 9 92 0.9 Morphine IR, oral 
Note: MLIP=Medicaid lock-in program; Freq=Frequency; IR=Immediate release; LA=Long acting. Post-MLIP 
enrollment period ranks reflect that specific product’s frequency rank in the pre-MLIP enrollment period. 
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 Long acting oxycodone tablets/capsules and fentanyl transdermal patches each represented a 
quarter of all Medicaid paid long acting opioid prescriptions before MLIP enrollment (Table 4.9a). After 
MLIP enrollment, long acting oxymorphone products replaced long acting oxycodone as the most 
common long acting opioid product obtained through Medicaid. Although methadone prescriptions were 
among the most commonly circumvented long acting product, methadone products were only the fifth-
most common prescriptions among Medicaid paid Schedule II opioid fills. Similarly to previous findings, 
short acting oxycodone and hydrocodone prescriptions represented the vast majority of short acting 
opioid prescriptions obtained through the Medicaid benefit (Table 4.9b). 
 
Table 4.9a: Medicaid paid long acting opioid product frequency, by MLIP enrollment status 
Pre-MLIP enrollment Post-MLIP enrollment 
Rank Freq. % Product Rank Freq. % Product 
1 2,543 25.7 Oxycodone LA, oral 4 1,388 25.8 Oxymorphone LA, oral 
2 2,452 24.8 Fentanyl LA, transdermal 2 1,379 25.6 Fentanyl LA, transdermal 
3 2,069 20.9 Morphine LA, oral 1 957 17.8 Oxycodone LA, oral 
4 1,387 14.0 Oxymorphone LA, oral 3 931 17.3 Morphine LA, oral 
5 1,290 13.1 Methadone LA, oral 5 532 9.9 Methadone LA, oral 
 
Table 4.9b: Medicaid paid short acting opioid product frequency, by MLIP enrollment status 
Pre-MLIP enrollment Post-MLIP enrollment 
Rank Freq. % Product Rank Freq. % Product 
1 23,312 45.2 Oxycodone IR, oral 1 6,540 56.6 Oxycodone IR, oral 
2 23,293 45.1 Hydrocodone IR, oral 2 3,775 32.6 Hydrocodone IR, oral 
3 1,036 2.0 Hydromorphone IR, oral 3 319 2.8 Hydromorphone IR, oral 
4 995 1.9 Codeine IR, oral 9 192 1.7 Oxymorphone IR, oral 
5 900 1.7 Propoxyphene IR, oral 10 171 1.5 Tapentadol IR, oral 
Note: MLIP=Medicaid lock-in program; Freq=Frequency; IR=Immediate release; LA=Long acting. Post-MLIP 
enrollment period ranks reflect that specific product’s frequency rank in the pre-MLIP enrollment period. 
 
 Bivariate analyses of prescription-level opioid dosage showed that the average prescribed 
MME/day per prescription obtained through circumvention either significantly decreased or did not 
change after subjects were enrolled in the NC MLIP (Figure 4.6). Among all circumvented opioid fills, 
the mean MME/day decreased 10% from 68 to 61 MME/day (p<0.001) from the pre- to post-MLIP 
enrollment periods. Similar findings were reported for subsets of circumvented Schedule II, Schedule III-
V, and short acting opioid prescriptions. Circumvented long acting opioid products had the highest initial 
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average MME/day at around 175 MME/day, on average, which did not differ based on MLIP enrollment 
status. 
Figure 4.6: Bivariate comparisons of mean prescribed MME/day for circumvented opioid prescriptions, 
by MLIP enrollment status 
 
Note: MME=Milligram morphine equivalents; MLIP=Medicaid lock-in program; Rx=Prescription.***p<0.001; 
**p<0.01; *p<0.05 
 
 In contrast to the observed bivariate circumvented opioid prescriptions trends, Medicaid paid 
opioid prescriptions generally experienced a significant increase in mean MME/day per prescription after 
MLIP enrollment. Among all Medicaid paid opioid prescriptions, mean prescription-level MME/day 
increased by nearly 50% from 76 to 111 MME/day (p<0.001). A similar increase in post-MLIP MME/day 
was observed for subsets of Medicaid paid Schedule II and short acting opioid prescriptions. Long acting 
opioid prescriptions obtained through Medicaid experienced a small but significant increase in mean 
prescribed MME/day. Only Schedule III-V Medicaid paid opioid prescriptions experienced a decrease in 
daily opioid dose per prescription. It should be noted that MME/day values were comparable between 
circumvented and Medicaid paid opioid prescriptions in the pre-MLIP enrollment period. 
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Figure 4.7: Bivariate comparisons of mean prescribed MME/day for Medicaid paid opioid prescriptions, 
by MLIP enrollment status 
 
Note: MME=Milligram morphine equivalents; MLIP=Medicaid lock-in program; Rx=Prescription. 
***p<0.001; **p<0.01; *p<0.05 
 
4.2.2 Aim 2 Generalized Linear Modeling Findings  
4.2.2.1 Aim 2 Generalized Linear Modeling Findings—Schedule II opioid outcome 
 There was no association between NC MLIP enrollment and the likelihood of a circumvented 
opioid prescription fill containing a Schedule II opioid (RR=0.96; 95% CI: 0.84, 1.09) compared to a 
Schedule III-V opioid, controlling for patient- and policy-level covariates (Table 4.10). Among opioid 
prescriptions obtained by study subjects through the Medicaid benefit, NC MLIP enrollment was 
associated with a 32% increase in the likelihood of an opioid prescription containing a Schedule II 
product (95% CI: 1.23, 1.41). The effect of NC MLIP enrollment on opioid prescriptions from all 
payment sources expectedly fell between these two point estimates. Overall, opioid prescriptions were 
1.19 times more likely to be written for a Schedule II product after MLIP enrollment, controlling for 
covariates (95% CI: 1.12, 1.27). 
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Table 4.10: Generalized linear modeling estimates for the likelihood of an opioid Rx containing a Schedule II opioid product 
versus a Schedule III-V product 
 
Circumvented Opioid Fills Medicaid-Paid Opioid Fills Total Opioid Fills 
Variable RR (95% CI) P-value RR (95% CI) P-value RR (95% CI) P-value 
Key independent variable 
        	      MLIP enrollment 0.96 (0.84, 1.09) 0.521 1.32 (1.23, 1.41) <0.001 1.19 (1.12, 1.27) <0.001 
MLIP policy variables 
            MLIP enrollment * month 1.00 (0.99, 1.01) 0.618 1.01 (1.00, 1.02) 0.001 1.01 (1.00, 1.01) 0.043 
MLIP enrollment delay 1.00 (0.88 , 1.12) 0.940 1.07 (1.02 , 1.12) 0.010 1.06 (1.01 , 1.11) 0.014 
MLIP enrollment delay * month 1.01 (0.99 , 1.02) 0.353 1.01 (1.00 , 1.02) 0.004 1.01 (1.00 , 1.02) 0.006 
Month 1.01 (1.00 , 1.03) 0.023 1.01 (1.00 , 1.01) 0.012 1.01 (1.00 , 1.01) 0.001 
MLIP policy period 1.03 (0.91 , 1.17) 0.597 0.92 (0.88 , 0.97) 0.001 0.93 (0.89 , 0.97) 0.002 
MLIP policy period * month 0.98 (0.97 , 1.00) 0.036 0.99 (0.99 , 1.00) 0.031 0.99 (0.99 , 1.00) 0.019 
MLIP eligibility route 
            Opioid use 0.93 (0.76, 1.13) 0.442 0.93 (0.83, 1.05) 0.237 0.93 (0.83, 1.05) 0.227 
Benzodiazepine use 0.89 (0.69 , 1.15) 0.369 0.84 (0.67 , 1.06) 0.144 0.85 (0.69 , 1.04) 0.122 
Pharmacy use 1.02 (0.91 , 1.13) 0.775 0.90 (0.85 , 0.95) <0.001 0.90 (0.85 , 0.96) 0.001 
No eligibility criteria met 1.00 (0.76 , 1.31) 0.995 0.95 (0.81 , 1.12) 0.563 0.95 (0.81 , 1.12) 0.537 
Predisposing characteristics 
            Age 1.002 (1.00, 1.01) 0.353 1.006 (1.00, 1.01) <0.001 1.006 (1.00, 1.01) <0.001 
Female 0.81 (0.74 , 0.89) <0.001 0.86 (0.82 , 0.91) <0.001 0.86 (0.81 , 0.91) <0.001 
Race (White referent) 
            Black 1.12 (1.00, 1.26) 0.051 1.09 (1.02, 1.16) 0.008 1.09 (1.02, 1.17) 0.010 
Other 1.12 (0.95 , 1.32) 0.166 1.03 (0.94 , 1.14) 0.494 1.05 (0.95 , 1.16) 0.380 
Enabling characteristics 
            Metropolitan residence 0.91 (0.82, 1.01) 0.081 0.92 (0.86, 0.98) 0.015 0.92 (0.86, 0.98) 0.014 
County pharmacy supply (<10 referent) 
            11-25 0.96 (0.85, 1.10) 0.571 0.98 (0.90, 1.06) 0.566 0.97 (0.90, 1.05) 0.513 
26-50 0.97 (0.85 , 1.09) 0.586 0.95 (0.88 , 1.03) 0.210 0.95 (0.88 , 1.03) 0.200 
51-100 1.10 (0.96 , 1.26) 0.183 1.05 (0.96 , 1.14) 0.321 1.05 (0.96 , 1.15) 0.273 
>100 0.90 (0.74 , 1.08) 0.254 0.94 (0.85 , 1.05) 0.255 0.92 (0.83 , 1.03) 0.161 
Border county 0.90 (0.81 , 0.99) 0.031 0.93 (0.88 , 0.99) 0.022 0.93 (0.87 , 0.98) 0.010 
Need characteristics 
            Chronic non-cancer pain 1.26 (0.97, 1.63) 0.087 1.17 (1.00, 1.37) 0.045 1.18 (1.02, 1.38) 0.031 
Anxiety disorder 1.00 (0.90 , 1.10) 0.960 0.96 (0.91 , 1.02) 0.163 0.97 (0.91 , 1.02) 0.228 
Substance abuse disorder 1.03 (0.94 , 1.12) 0.558 1.09 (1.04 , 1.15) 0.001 1.07 (1.02 , 1.13) 0.009 
Depression 1.11 (1.01 , 1.22) 0.032 1.03 (0.97 , 1.09) 0.288 1.04 (0.98 , 1.10) 0.180 
Other mental illness 0.97 (0.88 , 1.07) 0.527 0.95 (0.90 , 1.00) 0.062 0.95 (0.90 , 1.00) 0.070 
Charlson Comorbidity Index (0 referent) 
            1 1.04 (0.93, 1.16) 0.492 0.98 (0.91, 1.04) 0.491 0.99 (0.92, 1.06) 0.711 
≥2 1.15 (1.02 , 1.30) 0.026 1.03 (0.96 , 1.10) 0.395 1.05 (0.98 , 1.13) 0.158 
Prescription drug burden 1.00 (0.99 , 1.00) 0.413 1.00 (1.00 , 1.00) 0.592 1.00 (1.00 , 1.00) 0.552 
Note: Rx=Prescription; RR=Relative risk; CI=Confidence interval; MLIP=Medicaid lock-in program. All GLM models used a Poisson distribution, log link, and cluster-robust 
standard errors. The circumvented model included 19,778 fills (1,527 subjects); Medicaid paid included 78,465 fills (1,634 subjects); total included 98,243 fills (1,646 subjects). 
  125 
 Few patient characteristics were predictive of the likelihood of Schedule II opioid receipt in the 
context of circumvention behavior. Female subjects were 19% less likely for a circumvented opioid fill to 
be written for a Schedule II product compared to males, all else being equal (95% CI: 0.74, 0.89). Black 
subjects had a strong, but not statistically significant, positive association with the probability of a 
circumvented opioid prescription containing a Schedule II product  (RR=1.12; 95% CI: 1.00, 1.26). 
Subjects residing in a border county in North Carolina were significantly less likely for a circumvented 
fill to contain a Schedule II product compared to those living in the interior of the state (RR=0.90; 95% 
CI: 0.81, 0.99). Finally, subjects with a baseline diagnosis of depression and high physical comorbidity 
burden had a significantly positive association with the dichotomous prescription-level Schedule II opioid 
outcome. 
 Many patient- and policy-level covariates were associated with Schedule II opioid prescribing in 
the context of Medicaid covered opioid use behavior. Compared to males, female sex was again 
associated with lower likelihood of a Medicaid paid opioid prescription being written for a Schedule II 
product (RR=0.86; 95% CI: 0.82, 0.91). Residence in a rural county and border county were significantly 
associated with an 8% (95% CI: 0.86, 0.98) and 7% (95% CI: 0.88, 0.99) decrease in the likelihood of a 
Medicaid paid opioid prescription containing a Schedule II product, respectively. Increased age 
(RR=1.006; 95% CI: 1.00, 1.01) and Black race (RR=1.09; 95% CI: 1.02, 1.16) were predictive of a 
higher likelihood of Schedule II opioid prescribing among the Medicaid paid opioid prescription subset. 
Among opioid use occurring within the NC Medicaid benefit, subjects with a chronic noncancer pain 
diagnosis (RR=1.17; 95% CI: 1.00, 1.37) and substance abuse disorder (RR=1.09; 95% CI: 1.04, 1.15) 
were significantly more likely to fill a Schedule II opioid compared to those without such baseline 
diagnoses. With regard to policy covariates, a Medicaid paid opioid fill occurring within a period of 
delayed MLIP enrollment was 7% more likely to be written for a Schedule II product, while MLIP 
eligibility due to high unique pharmacy user was predictive of lower likelihood of a Medicaid paid opioid 
prescription being written for a Schedule II product. 
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4.2.2.2 Aim 2 Generalized Linear Modeling Findings—Long-acting opioid outcome 
 Opioid prescriptions obtained by subjects through circumvention were more than 40% less likely 
to contain a long acting opioid product after they were enrolled in the NC MLIP (RR=0.58; 95% CI: 0.40, 
0.85), controlling for covariates (Table 4.11). However, opioid prescriptions that subjects paid for using 
the NC Medicaid benefit were 2.15 times more likely to be written for long acting opioid products after 
NC MLIP (RR=2.15; 95% CI: 1.86, 2.48). Overall, NC MLIP enrollment was associated with a 55% 
increase in the probability of receiving a long acting opioid when examining all opioid prescriptions from 
all payment sources (RR=1.55; 95% CI: 1.35, 1.79).
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Table 4.11: Generalized linear modeling estimates for the likelihood of an opioid Rx containing a long-acting opioid product 
versus a short-acting opioid product 
 
Circumvented Opioid Fills Medicaid-Paid Opioid Fills Total Opioid Fills 
Variable RR (95% CI) P-value RR (95% CI) P-value RR (95% CI) P-value 
Key independent variable 
        	      MLIP enrollment  0.58 (0.40, 0.85) 0.005 2.15 (1.86, 2.48) <0.001 1.55 (1.35, 1.79) <0.001 
MLIP policy variables             
MLIP enrollment * month 1.02 (0.99 , 1.06) 0.207 1.03 (1.01 , 1.04) <0.001 1.02 (1.01 , 1.04) 0.001 
MLIP enrollment delay 0.84 (0.61 , 1.18) 0.316 0.99 (0.89 , 1.11) 0.903 0.99 (0.89 , 1.11) 0.856 
MLIP enrollment delay * month 1.02 (0.97 , 1.07) 0.485 1.04 (1.02 , 1.06) <0.001 1.03 (1.01 , 1.05) 0.001 
Month 1.00 (0.96 , 1.04) 0.997 1.00 (0.99 , 1.01) 0.936 1.00 (0.99 , 1.01) 0.603 
MLIP policy period 1.35 (0.98 , 1.86) 0.069 0.88 (0.79 , 0.99) 0.029 0.90 (0.81 , 1.00) 0.046 
MLIP policy period * month 1.00 (0.95 , 1.04) 0.913 0.98 (0.97 , 1.00) 0.012 0.98 (0.97 , 1.00) 0.039 
MLIP eligibility route             
Opioid use 0.73 (0.45 , 1.19) 0.212 0.91 (0.68 , 1.22) 0.523 0.88 (0.66 , 1.17) 0.365 
Benzodiazepine use 0.76 (0.37 , 1.55) 0.447 0.65 (0.42 , 1.00) 0.052 0.65 (0.42 , 0.99) 0.044 
Pharmacy use 0.88 (0.66 , 1.18) 0.401 0.70 (0.62 , 0.80) <0.001 0.69 (0.60 , 0.79) <0.001 
No eligibility criteria met 0.65 (0.24 , 1.80) 0.409 0.91 (0.60 , 1.37) 0.651 0.85 (0.55 , 1.30) 0.443 
Predisposing characteristics             
Age 1.007 (0.99 , 1.02) 0.322 1.015 (1.01 , 1.02) <0.001 1.017 (1.01 , 1.02) <0.001 
Female 0.83 (0.61 , 1.13) 0.231 0.86 (0.76 , 0.98) 0.021 0.87 (0.76 , 1.00) 0.048 
Race (White referent)             
Black 0.98 (0.68 , 1.42) 0.913 0.97 (0.81 , 1.15) 0.689 0.95 (0.79 , 1.15) 0.619 
Other 0.95 (0.53 , 1.70) 0.874 1.08 (0.86 , 1.36) 0.486 1.06 (0.82 , 1.36) 0.667 
Enabling characteristics             
Metropolitan residence 0.86 (0.60 , 1.23) 0.411 0.86 (0.74 , 1.00) 0.051 0.86 (0.73 , 1.01) 0.071 
County pharmacy supply (<10 referent)             
11-25 0.90 (0.58 , 1.38) 0.619 0.98 (0.83 , 1.17) 0.851 0.97 (0.81 , 1.17) 0.757 
26-50 0.99 (0.65 , 1.50) 0.949 1.09 (0.90 , 1.31) 0.376 1.06 (0.87 , 1.29) 0.571 
51-100 1.14 (0.73 , 1.78) 0.563 1.12 (0.91 , 1.38) 0.299 1.11 (0.89 , 1.38) 0.346 
>100 0.81 (0.48 , 1.38) 0.435 1.15 (0.92 , 1.44) 0.210 1.08 (0.85 , 1.37) 0.519 
Border county 1.07 (0.80 , 1.44) 0.633 0.90 (0.79 , 1.02) 0.109 0.91 (0.80 , 1.04) 0.179 
Need characteristics             
Chronic non-cancer pain 5.08 (1.70 , 15.17) 0.004 2.35 (1.39 , 3.95) 0.001 2.47 (1.42 , 4.28) 0.001 
Anxiety disorder 0.86 (0.62 , 1.18) 0.343 0.83 (0.74 , 0.94) 0.003 0.83 (0.73 , 0.95) 0.006 
Substance abuse disorder 1.24 (0.93 , 1.66) 0.136 1.18 (1.05 , 1.33) 0.007 1.16 (1.02 , 1.32) 0.020 
Depression 1.21 (0.91 , 1.62) 0.193 1.07 (0.94 , 1.22) 0.283 1.08 (0.94 , 1.23) 0.295 
Other mental illness 0.92 (0.70 , 1.22) 0.562 0.94 (0.83 , 1.06) 0.289 0.93 (0.81 , 1.06) 0.263 
Charlson Comorbidity Index (0 referent)             
1 0.83 (0.57 , 1.22) 0.337 0.93 (0.80 , 1.08) 0.332 0.91 (0.78 , 1.07) 0.272 
≥2 1.20 (0.83 , 1.73) 0.338 0.99 (0.85 , 1.16) 0.926 1.02 (0.86 , 1.21) 0.817 
Prescription drug burden 0.99 (0.98 , 1.01) 0.281 1.00 (0.99 , 1.01) 0.928 1.00 (0.99 , 1.01) 0.779 
Note: Rx=Prescription; RR=Relative risk; CI=Confidence interval; MLIP=Medicaid lock-in program. All GLM models used a Poisson distribution, log link, and cluster-robust 
standard errors. The circumvented model included 19,778 fills (1,527 subjects); Medicaid paid included 78,465 fills (1,634 subjects); total included 98,243 fills (1,646 subjects). 
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 Among circumvented opioid prescription fills, only one patient-level characteristic was predictive 
of receiving a long acting opioid product. Circumvented opioid prescriptions obtained by subjects with a 
baseline diagnosis of chronic noncancer pain were over five times more likely to contain a long acting 
opioid compared to subjects with no history of chronic pain (RR=5.08; 95% CI: 1.70, 15.17).  
 In the context of Medicaid paid opioid prescriptions, multiple covariates were significantly 
associated with an opioid prescription written for a long acting product. Similarly to the Schedule II 
outcome discussed previously, female subjects were 14% less likely to fill a long acting opioid product in 
the context of Medicaid covered opioid use (RR=0.86; 95% CI: 0.76, 0.98) compared to males. Subjects 
residing in a metropolitan county showed a strong negative association with the outcome, but this was not 
statistically significant. Medicaid paid opioid prescriptions received by subjects who met MLIP eligibility 
due to high pharmacy use were 30% less likely to contain a long acting opioid product (RR=0.70; 95% 
CI: 0.62, 0.82). As patient age increased, the likelihood of a Medicaid paid opioid prescription being 
written for a long acting product also increased (RR=1.015; 95% CI: 1.01, 1.02). Both a baseline chronic 
noncancer pain diagnosis (RR=2.35; 95% CI: 1.39, 3.95) and substance abuse disorder (RR=1.18; 95% 
CI: 1.05, 1.33) were associated with an increased probability of a Medicaid paid opioid prescription 
containing a long acting preparation, while an anxiety disorder diagnosis had an opposite effect 
(RR=0.83; 95% CI: 0.74, 0.84). Notably, a subject’s MLIP enrollment delay was not associated with the 
probability of receiving a long acting opioid within the NC Medicaid benefit. 
4.2.2.3 Aim 2 Generalized Linear Modeling Findings—Mean MME/day outcome  
 Finally, Table 4.12 reports GLM estimates of average marginal effect of MLIP enrollment and 
covariates on average prescribed daily opioid dose, measured as mean prescribed MME/day. In the 
context of circumvented opioid use, NC MLIP enrollment was not associated with a prescription’s mean 
daily opioid dose (Marginal effect=2.11 MME/day; 95% CI: -6.82, 11.05), when controlling for patient 
and policy covariates. However, opioid prescriptions obtained through NC Medicaid had an increased 
prescribed daily opioid dose of 55.87 MME/day after NC MLIP enrollment compared to Medicaid paid 
opioid prescriptions filled prior to MLIP enrollment (95% CI: 38.33, 73.41).
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Table 4.12: Generalized linear modeling estimates of average prescribed MME/day per opioid prescription 
 
Circumvented Opioid Fills Medicaid-Paid Opioid Fills Total Opioid Fills 
Variable ME (95% CI) P-value ME (95% CI) P-value ME (95% CI) P-value 
Key independent variable 
        	      MLIP enrollment  2.11 (-6.82, 11.05) 0.643 55.87 (38.33, 73.41) <0.001 33.12 (21.03, 45.22) <0.001 
MLIP policy variables             
MLIP enrollment * month 0.43 (-0.35 , 1.21) 0.283 2.60 (1.48 , 3.72) <0.001 1.85 (0.91 , 2.79) <0.001 
MLIP enrollment delay 3.54 (-5.29 , 12.37) 0.432 6.98 (1.39 , 12.57) 0.014 6.95 (1.75 , 12.16) 0.009 
MLIP enrollment delay * month 0.94 (-0.54 , 2.42) 0.213 3.19 (1.93 , 4.46) <0.001 2.61 (1.49 , 3.73) <0.001 
Month -0.68 (-1.68 , 0.33) 0.188 0.32 (-0.17 , 0.81) 0.199 0.20 (-0.27 , 0.67) 0.400 
MLIP policy period -2.12 (-11.41 , 7.18) 0.655 -12.18 (-18.75 , -5.61) <0.001 -11.77 (-17.99 , -5.55) <0.001 
MLIP policy period * month 0.25 (-0.95 , 1.45) 0.684 -2.23 (-3.40 , -1.06) <0.001 -1.64 (-2.72 , -0.57) 0.003 
MLIP eligibility route             
Opioid use -3.04 (-19.21 , 13.13) 0.712 4.11 (-11.48 , 19.71) 0.605 2.45 (-12.25 , 17.15) 0.744 
Benzodiazepine use -4.02 (-22.85 , 14.81) 0.676 0.99 (-23.98 , 25.96) 0.938 -1.85 (-23.49 , 19.78) 0.867 
Pharmacy use -2.33 (-9.43 , 4.77) 0.520 -23.54 (-36.58 , -10.50) <0.001 -21.40 (-33.40 , -9.39) <0.001 
No eligibility criteria met -8.08 (-26.26 , 10.09) 0.383 -4.38 (-31.52 , 22.75) 0.752 -6.15 (-30.08 , 17.77) 0.614 
Predisposing characteristics             
Age 0.39 (0.08 , 0.70) 0.012 1.03 (0.67 , 1.40) <0.001 0.96 (0.63 , 1.30) <0.001 
Female -10.13 (-19.43 , -0.82) 0.033 -10.21 (-18.63 , -1.79) 0.018 -9.72 (-17.83 , -1.61) 0.019 
Race (White referent)             
Black -0.73 (-7.97 , 6.51) 0.843 -7.32 (-15.50 , 0.86) 0.079 -6.70 (-14.29 , 0.90) 0.084 
Other -3.10 (-14.86 , 8.67) 0.606 -0.31 (-16.37 , 15.74) 0.970 -0.14 (-14.58 , 14.30) 0.985 
Enabling characteristics             
Metropolitan residence -4.50 (-12.94 , 3.94) 0.296 -0.78 (-10.75 , 9.20) 0.879 -0.95 (-10.19 , 8.29) 0.840 
County pharmacy supply (<10 referent)             
11-25 -1.24 (-10.88 , 8.39) 0.800 -10.10 (-21.57 , 1.37) 0.084 -8.52 (-19.16 , 2.12) 0.117 
26-50 0.91 (-9.40 , 11.21) 0.863 -1.88 (-16.49 , 12.73) 0.801 -1.79 (-15.13 , 11.56) 0.793 
51-100 -0.08 (-10.48 , 10.31) 0.988 -6.51 (-19.53 , 6.50) 0.327 -5.48 (-17.55 , 6.59) 0.373 
>100 -7.84 (-16.61 , 0.94) 0.080 -12.06 (-26.11 , 1.99) 0.092 -12.59 (-24.86 , -0.31) 0.044 
Border county 2.56 (-5.52 , 10.64) 0.535 -1.14 (-9.64 , 7.37) 0.793 -0.78 (-8.64 , 7.07) 0.845 
Need characteristics             
Chronic non-cancer pain 13.52 (5.70 , 21.34) 0.001 12.29 (1.37 , 23.21) 0.027 13.76 (4.40 , 23.12) 0.004 
Anxiety disorder -3.32 (-10.47 , 3.83) 0.363 0.07 (-8.97 , 9.12) 0.987 -0.60 (-8.82 , 7.62) 0.886 
Substance abuse disorder 2.81 (-3.33 , 8.95) 0.370 7.24 (-1.76 , 16.25) 0.115 5.89 (-2.26 , 14.03) 0.157 
Depression 1.76 (-4.95 , 8.46) 0.608 3.26 (-4.64 , 11.16) 0.419 2.82 (-4.47 , 10.11) 0.448 
Other mental illness -0.66 (-7.16 , 5.84) 0.842 -3.14 (-11.76 , 5.49) 0.476 -2.99 (-10.92 , 4.94) 0.460 
Charlson Comorbidity Index (0 referent)             
1 5.26 (-2.60 , 13.12) 0.190 3.32 (-6.75 , 13.39) 0.518 4.50 (-5.02 , 14.02) 0.354 
≥2 15.72 (6.64 , 24.80) 0.001 6.36 (-3.49 , 16.20) 0.206 8.63 (-0.33 , 17.60) 0.059 
Prescription drug burden -0.48 (-0.82 , -0.15) 0.005 -0.43 (-0.94 , 0.07) 0.090 -0.45 (-0.90 , 0.00) 0.051 
Note: Rx=Prescription; ME=Marginal effect; CI=Confidence interval; MLIP=Medicaid lock-in program. All three GLM models specified an inverse Gaussian distribution, log 
link, and cluster-robust standard errors. The circumvented model included 19,691 fills (1,526 subjects), the Medicaid paid model included 78,429 fills (1,634 subjects), the total 
model included 98,120 fills (1,646 subjects). A total of 123 opioid fills were excluded from analysis due to parenteral or rectal route not amenable to MME measure assessment. 
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 Among circumvented opioid prescription fills, average MME/day per prescription increased 
significantly as age increased (ME: 0.39 MME/day; 95% CI: 0.08, 0.70). Circumvented opioid 
prescriptions filled by female subjects had 10.13 fewer mean MME/day compared to those circumvented 
by male subjects (95% CI: -19.43, -0.82). Similar to findings for the binary Schedule II and long acting 
product prescription-level outcomes, a baseline diagnosis of chronic noncancer pain was associated with 
an increase in mean prescribed MME/day per circumvented prescription of 13.52 (95% CI: 5.70, 21.34). 
Subjects with high physical comorbidity burden received circumvented opioid prescriptions with 
significantly higher average MME/day (ME=15.72 MME/day; 95% CI: 6.64, 24.80). However, 
prescription drug burden—another marker of comorbidity burden—exhibited a small, but significant, 
negative association with mean MME/day per circumvented prescription (ME=-0.48; 95% CI: -0.82, -
0.15). MLIP enrollees who were eligible 
 Increasing subject age (ME=1.03 MME/day; 95% CI: 0.67, 1.40), female sex (ME=-10.21 
MME/day; 95% CI: -18.63, -1.79), and baseline chronic pain diagnosis (ME=12.29 MME/day; 95% CI: 
1.37, 23.21) were associated with prescribed daily opioid dosage per opioid Medicaid paid prescription 
similarly to the effects observed in the subset of circumvented prescriptions. Medicaid paid opioid 
prescriptions obtained during a period of delayed MLIP enrollment provided 6.98 MME/day more than 
prescriptions filled outside of an enrollment delay (95% CI: 1.39, 12.57). Subjects eligible for the MLIP 
due to high use of pharmacies obtained Medicaid covered opioid prescriptions with significantly smaller 
prescribed daily opioid doses (ME=-23.54 MME/day; 95% CI: -36.58, -10.50). 
4.3 AIM 3 RESULTS 
4.3.1 Aim 3 Descriptive Analysis Findings 
 The Aim 3 analytic cohort included 139,355 NC Medicaid beneficiaries, which were randomly 
assigned into testing and validation samples comprised of 69,668 and 69,667 subjects, respectively 
(Figure 4.8). Subjects were selected from an initial pool of 895,212 adults with NC Medicaid coverage at 
some point during the study period of 10/1/08 to 9/30/10. Nearly 242,000 of these subjects recorded a 
Medicaid claim for an opioid analgesic prescription during the observation period for index opioid use 
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from 10/1/08 to 8/2/09. Over 17,000 subjects were excluded due to a lack of continuous Medicaid 
coverage for the entire 60-day exposure assessment period following the index opioid fill. An additional 
4,430 and 470 subjects were excluded due to non-private living status and dual Medicare coverage, 
respectively. Over 26,000 subjects recorded a cancer diagnosis during their study observation and were 
excluded from analysis. Lastly, 53,895 subjects were dropped from the study for being less than 18 or 
greater than 64 years of age at some point during their observation. 
Figure 4.8: Aim 3 analytic cohort selection 
 
Any paid Medicaid prescription claim for an 
opioid analgesic between 10/1/2008 and 
8/2/2009. 
n= 241,921 
Remaining random 50% sample. 
n= 69,667 
Random 50% sample. 
n= 69,668 
All adults age 18-64 enrolled in North Carolina 
Medicaid at any point from 10/1/08 to 9/30/10. 
n= 895,212 
TESTING SAMPLE 
Excluded n= 653,291 
VALIDATION SAMPLE 
Private living status. 
n= 220,184 
Excluded n= 4,430 
Continuous NC Medicaid coverage from date of 
first opioid claim through the 60-day exposure 
period. 
n= 224,614 
Excluded n= 17,307 
No concomitant cancer diagnosis, defined as an 
ICD-9 code for cancer (140–239) at any point in a 
subject’s observation period. 
n= 193,230 
Excluded n= 26,484 
No dual Medicare coverage. 
N= 219,714 
Excluded n= 470 
Excluded n= 53,895 
Age >18 or <65 during entire observation period. 
N= 139,335 
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 The mean age of the Aim 3 cohort was 34.3 years (Table 4.13). Seventy-seven percent of subjects 
were female, 55.6% were White race, and 37% were of Black race. On average, subjects contributed 275 
days of follow-up observation out of a maximum of 365 days of follow-up time. Overall, Aim 3 subjects 
received an average of 2.1 opioid prescriptions and used 1.2 unique dispensing pharmacies during the 60-
day exposure period following their index opioid fill. The mean MME/day for the 60-day exposure period 
was 22.3 MME/day, while the average daily APAP exposure from opioid/APAP combination products 
was 569mg APAP/day. A total of 376 subjects, which represented 0.3% of the full Aim 3 cohort, 
experienced the primary outcome of an unintentional opioid overdose during follow-up, with an average 
time to event of 170 days. For the secondary outcome measures, 172 subjects experienced an 
acetaminophen overdose. A total of 2,161 (1.6%) subjects experienced an unintentional overdose event 
from any drug substance. Both secondary overdose outcome measures had a mean time to event of 155-
160 days. Over 4,500 subjects (3.2%) received a diagnosis of an opioid use disorder during their follow-
up, while 39,533 (28.4%) recorded a substance use disorder diagnosis of any nature. Average time to 
diagnosis of substance use disorder secondary outcomes was around 120 days. Random assignment to the 
testing and validation samples resulted in no statistically significant differences between these groups 
with regard to any demographic, exposure, or outcome measure. 
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Table 4.13: Summary statistics for the Aim 3 cohort, by testing and validation sample subsets 
 
Overall 
(n=139,335) 
Testing 
sample 
(n=69,668) 
Validation 
sample 
(n=69,667) 
p-
value 
Demographic characteristics 
    Age, mean (SD) 34.3 (12.2) 34.3 (12.1) 34.3 (12.2) 0.984 
Female, n (%) 107172 (76.9%) 53499 (76.8%) 53673 (77.0%) 0.267 
Race, n (%) 
    White 77414 (55.6%) 38627 (55.4%) 38787 (55.7%) 0.387 
Black 51364 (36.9%) 25721(36.9%) 25643 (36.8%) 0.667 
Other/unknown 10557 (7.6%) 5320 (7.6%) 5237 (7.5%) 0.401 
Days of follow-up, mean (SD) 275 (129) 275 (129) 276 (129) 0.780 
Opioid exposures, mean (SD) 
    Opioid prescription count 2.1 (1.6) 2.1 (1.6) 2.1 (1.6) 0.255 
Pharmacy count 1.2 (0.5) 1.2 (0.5) 1.2 (0.5) 0.305 
Average MME/day 22.3 (70.1) 22.5 (69.5) 22.0 (70.7) 0.222 
Average APAP mg/day 569 (780) 571 (783) 567 (777) 0.256 
Primary outcome event, n (%) 
    Unintentional overdose, opioid 376 (0.3%) 202 (0.3%) 174 (0.3%) 0.148 
     Days to event, mean (SD) 170 (100) 164 (101) 176 (99) 0.246 
Secondary outcome events, n (%)     
Unintentional overdose, APAP 172 (0.1%) 82 (0.1%) 90 (0.1%) 0.542 
     Days to event, mean (SD) 155 (100) 147 (103) 162 (98) 0.325 
Unintentional overdose, any drug 2161 (1.6%) 1040 (1.5%) 1121 (1.6%) 0.079 
     Days to event, mean (SD) 159 (102) 156 (103) 162 (101) 0.181 
Opioid use disorder 4525 (3.2%) 2284 (3.3%) 2241 (3.2%) 0.516 
     Days to event, mean (SD) 121 (111) 119 (110) 124 (112) 0.098 
Any substance use disorder 39533 (28.4%) 19713 (28.3%) 19820 (28.4%) 0.524 
     Days to event, mean (SD) 118 (101) 118 (101 119 (101) 0.153 
Note: SD=Standard deviation; MME=Milligram morphine equivalent; APAP=Acetaminophen; mg=Milligrams. 
Reported percentages refer to the proportion of the total n represented within that column. 
 
4.3.2 Aim 3 Testing Phase Findings 
 AUCs from survival ROC models are presented first for each individual opioid exposure and 
outcome pairing to determine the overall discriminatory capability of each measure in predicting primary 
and secondary outcome events. After discussing opioid exposure measure AUCs, we then report optimal 
cutpoints for these measure based on survival ROC findings.  
 Each opioid exposure and outcome measure pairing demonstrated poor or failed ability to 
discriminate between subjects who experienced and did not experience the primary and secondary 
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outcomes during follow-up (Figures 4.9 – 4.12). The number of opioid prescriptions received in the 60-
day exposure period produced an AUC of 0.67 for the primary outcome of an unintentional opioid 
overdose event (Figure 4.9). The opioid prescription count measure resulted in AUCs of 0.60-0.67 for the 
secondary outcomes. Based on pre-determined AUC performance ranges described in the methods 
chapter (Excellent=0.90-1.00, Good=0.80-0.89, Fair=0.70-0.79, Poor=0.60-0.69, Failed=0.50-0.59), 
opioid fill count was a poor individual discriminator of relevant clinical outcomes from high-risk opioid 
use. 
 The number of unique community and outpatient pharmacies used to obtain an opioid 
prescription failed to discriminate between subjects at risk of an unintentional opioid overdose, with an 
AUC of 0.57 (Figure 4.10). The pharmacy count measure also failed to predict the secondary outcomes, 
with the exception of the opioid use disorder outcome, for which it had poor discriminatory capability 
(AUC=0.61).  
 Average MME/day over the 60-day opioid exposure assessment period had similar performance 
to the opioid fill count measure with regard to the primary outcome (Figure 4.11). Mean MME/day 
produced an AUC of 0.68 for the unintentional opioid overdose outcome. This exposure measure 
performed worse for the secondary outcomes, with AUCs ranging from 0.54 for the APAP overdose 
outcome to 0.64 for the opioid use disorder diagnosis outcome. 
 The measure of average APAP dose/day from opioid/APAP combination products nearly failed to 
discriminate between subjects who had an unintentional opioid overdose during following with an AUC 
of 0.60 (Figure 4.12). APAP mg/day did fail in its ability to discriminate between patients experiencing 
each secondary outcome as evidenced by AUCs all less than 0.60. 
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Figure 4.9: Survival ROC models of the prescription fill count opioid exposure measure 
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Figure 4.10: Survival ROC models of the unique pharmacy count opioid exposure measure 
 
Note: ROC=Receiver operative characteristic; AUC=Area under the curve  
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Figure 4.11: Survival ROC models of the average MME/day opioid exposure measure 
 
Note: ROC=Receiver operative characteristic; MME=Milligram morphine equivalent; AUC=Area under the curve 
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Figure 4.12: Survival ROC models of the average APAP mg/day opioid exposure measure 
 
Note: ROC=Receiver operative characteristic; APAP=Acetaminophen; mg=Milligrams; AUC=Area under the curve 
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 The discriminatory performance of opioid exposure measures when modeled together did not 
improve over the best performing individual measures (Table 4.14). Logistic regression ROC models—
which was used for this analysis due to limitations in the survival ROC modeling package disallowing 
multiple right-hand side variables—found an AUC of 0.70 when modeling opioid fill count and average 
MME/day simultaneously in the full testing sample. These two measures were combined because they 
were most predictive of the primary outcome individually. And when restricting to the 42,459 subjects 
with continuous NC Medicaid coverage for the full 365 days of follow-up, which was done to account for 
the inability of the logistic models to account for varied observation periods, the combined opioid fill 
count and average MME/day model achieved an AUC of 0.68 for the primary outcome. These were 
identical to logistic ROC estimation of the single mean MME/day measure. Adding the pharmacy count 
and mean APAP mg/day measures to the logistic ROC models for both the full and continuously enrolled 
testing samples did not contribute any additional discriminatory capability to the model. 
Table 4.14: Logistic ROC analysis findings for each individual and combinations of opioid exposure 
measures in predicting the primary Aim 3 outcome of unintentional opioid overdose 
 
Area under the curve 
  
Survival 
ROC 
method 
(n=69,668) 
Logistic ROC 
method- 
Full sample 
(n=69,668) 
Logistic ROC 
method- 
Cont. enrolled2 
(n=42,459) 
Individual measures1 
   Opioid fill count 0.67 0.69 0.67 
Pharmacy count 0.57 0.57 0.56 
Mean MME/day 0.68 0.70 0.68 
Mean APAP mg/day 0.60 0.62 0.59 
    Combinations 
   All four exposure measures 
 
0.70 0.68 
Opioid fill count + mean MME/day3   0.70 0.68 
Note: ROC=Receiver operating characteristic; Cont.=Continuously; MME=Milligram morphine equivalent; 
APAP=Acetaminophen; mg=Milligram. 
1. Individual opioid exposure measures were examined to compare similarity, and thus reliability, of the survival 
ROC method used in primary analysis with the logistic ROC method required to model multiple opioid exposure 
measures simultaneously. 
2. Continuously enrolled referred to the subset of subjects with a full 365 days of follow-up after the 60-day 
exposure assessment period. 
3. Opioid fill count and mean MME/day were selected because they were best performing in survival ROC models 
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 Based on survival ROC model results, the opioid exposure measures of unique pharmacy count 
and average APAP mg/day failed to predict the primary and secondary outcomes. Additionally, pharmacy 
counts and mean APAP mg/day measures failed to improve upon the discriminatory capability of the 
individual and combined opioid prescription counts and mean MME/day measures in ROC models and 
were disregarded from further examination. For the opioid prescription count and mean MME/day opioid 
exposure measures, survival ROC model results were analyzed to determine their optimal cutpoints. 
Survival ROC-derived optimal cutpoints were defined as the value of the exposure measure with jointly 
maximized sensitivity and specificity in predicting the primary outcome of unintentional opioid overdose 
event (Table 4.15). Receiving three or more opioid prescription fills and having an average of ≥10 
MME/day over the 60-day exposure assessment period were each identified as optimal cutpoints from the 
ROC output. Appendix Tables 10-29 report comprehensive findings for the number of subjects flagged 
and the discriminatory performance at varied cutpoints for all four opioid exposure measures. Optimal 
ROC-derived cutpoints were consistent for each opioid exposure measure across all outcomes.)  
Table 4.15: Optimal opioid exposure measure cutpoints from survival ROC models predicting primary 
outcome of unintentional opioid overdose  
 
Opioid Rx 
count 
Mean  
MME/day 
Optimal ROC cutpoint1 ≥3 fills ≥10 MME/day 
Subjects meeting cutpoint, 
n (% of total testing sample) 19,166 (27.5%) 23,122 (33.2%) 
Primary outcome events,  
n (% within cutpoint group) 117 (0.6%) 132 (0.6%) 
Cutpoint sensitivity 0.55 0.60 
Cutpoint specificity 0.73 0.67 
Cutpoint joint  
sensitivity/specificity1 
0.47 0.48 
Note: ROC=Receiver operating characteristic; Rx=Prescription; MME=Milligram morphine equivalent; 
APAP=Acetaminophen; mg=Milligram. 
1. The optimal ROC cutpoint was defined as the value of an opioid exposure measure with jointly maximized 
sensitivity and specificity. This was determined by identifying the opioid measure value on the ROC curve with the 
shortest Euclidean distance to the upper-left corner of the ROC plot, representing the value closest to perfect 
discriminatory capability of 100% sensitivity and 100% specificity  
 
 These thresholds for the opioid prescription count and mean MME/day measures resulted in 
19,166 and 23,122 subjects being flagged as high risk for an unintentional opioid overdose, respectively. 
  141 
This represented roughly one-third of Aim 3 testing cohort subjects. The high number of people meeting 
these ROC model-derived thresholds presented a concern over excessive inclusiveness of these cutpoints 
in light of the fact that the NC MLIP was operating at administrative capacity two years into the program 
having enrolled a cumulative total of 4,400 beneficiaries. For this reason, alternative analyses of optimal 
opioid exposure measure cutpoints were performed by comparing log-likelihood values from a series of 
Cox proportional hazard models utilizing dichotomous opioid exposure indicator variables at varied 
cutpoints. (Despite not being further considered for validation, Cox model log likelihood plots for the 
pharmacy count and mean APAP mg/day measures are presented in Appendix Figures 4 and 5 for 
reference). 
 Five or more opioid prescription fills in a 60-day period was the optimal Cox model-derived 
cutpoint for predicting the primary outcome of an unintentional opioid overdose. This was determined 
because a cutpoint of five or more fills provided the best model fit based on its maximized log likelihood 
value (Figure 4.13). A cutpoint of three or more opioid fills performed best for all secondary outcomes, 
except for the unintentional acetaminophen overdose outcome, which had an optimal cutpoint of seven or 
more fills.  
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Figure 4.13: Distribution of log likelihood values from Cox proportional hazard models predicting Aim 3 
outcomes at varied cutpoints of the opioid prescription fill count measure 
 
 The best performing Cox proportional hazard model for the exposure/outcome pairing of average 
MME/day and unintentional opioid overdose used a cutpoint of ≥12 MME/day (Figure 4.14). However, 
alternative cutpoints were identified at higher values of mean MME/day where additional peak log 
likelihood values were noted. Examination of log likelihood values at these higher MME/day values 
identified further cutpoints at ≥45 MME/day and ≥140 MME/day. These additional cutpoints were 
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obtained to provide high-performing, but less inclusive, MME/day threshold alternatives, because the 
optimal cutpoint of ≥12 MME/day flagged a high number of testing sample subjects (nearly one-third). 
Similar trends in optimal average MME/day cutpoints were observed in the Cox model series predicting 
secondary outcome events.  
Figure 4.14: Distribution of log likelihood values from Cox proportional hazard models predicting Aim 3 
outcomes at varied cutpoints of the mean MME/day measure 
 
Note: MME=Milligram morphine equivalent 
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 Results of the Aim 3 testing phase informed selection of opioid exposure measures and thresholds 
for performance evaluation in the validation sample. Based on findings from the survival ROC analyses, 
the opioid prescription fill count and average MME/day measures were selected for further examination 
as predictors of primary and secondary endpoints in the validation phase. Unique pharmacy counts and 
average APAP mg/day were deemed failures as discriminators of key clinical outcomes both individually 
and in combination with other opioid exposure measures. They were excluded from the validation phase. 
Optimal opioid fill count and mean MME/day cutpoints were informed by the results of the Cox model 
log likelihood distributions for each measure. The optimal threshold of opioid fill counts evaluated in the 
validation phase was ≥5 opioid fills in a 60-day period. The optimal threshold of mean MME/day 
evaluated in the validation phase was ≥12 MME/day in a 60-day period. Alternative MME/day cutpoints 
at ≥45 MME/day and ≥140 MME/day were also examined due to concerns over the ≥12 MME/day 
threshold’s inclusiveness having limited utility in real-world MLIP applications.  
4.3.3 Aim 3 Validation Phase Findings 
 
 For conciseness, validation phase results reported here focus on the performance of the selected 
opioid exposure measures and thresholds with regard to the primary outcome of unintentional opioid 
overdose. All analyses were performed for secondary clinical outcomes and are presented in full in 
relevant tables and figures in the Appendix, with in-text references to the Appendix provided.  
 Out of 69,667 validation sample subjects, 5,525 (7.9%) individuals received ≥5 opioid 
prescriptions in a 60-day period (Table 4.16). A total of 19,926 (28.6%); 7,541 (10.8%); and 1,980 (2.8%) 
subjects met the 60-day average daily opioid dose thresholds of ≥12 MME/day, ≥45 MME/day, and ≥140 
MME/day, respectively. Unsurprisingly, the sensitivity of the measures in capturing unintentional opioid 
overdose events increased as the percentage of the cohort flagged by a criterion increased. The most 
inclusive measure—≥12 MME/day—resulted in the highest sensitivity, at 59%. In other words, 59% of 
subjects who had an accidental opioid overdose (in one person-year of time) were flagged as high-risk 
opioid users based on having ≥12 MME/day on average over a 60-day period.  The least inclusive 
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individual criterion ≥140 MME/day, despite having the highest concentration of opioid overdose events 
for the number of people it flagged, was only 16% sensitive. Individual criterion selected from the testing 
phase generally exhibited high specificity of around 90% or greater. For example, with regard to the ≥5 
opioid fill criterion, 92% of subjects who did not experience an unintentional opioid overdose event were 
correctly classified as not high risk. The ≥12 MME/day criterion exhibited the lowest specificity at 72%. 
By point of comparison, the currently employed NC MLIP criteria of ≥7 opioid fills in a two-month 
period flagged the fewest subjects as high risk (2.4%), had the lowest sensitivity for accidental opioid 
overdose (9%), and had the highest specificity (98%). 
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Table 4.16: Describing application of selected opioid use criteria in Aim 3 validation sample for primary 
unintentional opioid overdose outcome 
 
Criterion met 
(N=69,667) 
Experienced  
outcome event* 
(N=174)    
n 
(% of total 
cohort) n 
(% within 
criterion) Sens.Ŧ Spec. Ŧ 
Individual measures       
     ≥5 opioid fills 5525 (7.9%) 47 (0.9%) 0.255 0.921 
     ≥12 MME/day 19926 (28.6%) 112 (0.6%) 0.592 0.715 
     ≥45 MME/day 7541 (10.8%) 66 (0.9%) 0.329 0.892 
     ≥140 MME/day 1980 (2.8%) 33 (1.7%) 0.159 0.972 
     NC MLIP standard: 
     ≥7 opioid fills  
1703 (2.4%) 16 (0.9%) 0.087 0.976 
Combined criteria  
(unconditional) 
  
≥5 opioid fills or 
    ≥12 MME/day 
20404 (29.3%) 115 (0.6%) 0.608 0.708 
≥5 opioid fills or 
    ≥45 MME/day 
10545 (15.1%) 80 (0.8%) 0.415 0.850 
≥5 opioid fills or 
    ≥140 MME/day 
6336 (9.1%) 62 (1.0%) 0.330 0.910 
≥7 opioid fills or 
    ≥12 MME/day 
19970 (28.7%) 112 (0.6%) 0.592 0.714 
≥7 opioid fills or 
    ≥45 MME/day 
8370 (12.0%) 68 (0.8%) 0.343 0.881 
≥7 opioid fills or 
    ≥140 MME/day 
3336 (4.8%) 42 (1.3%) 0.214 0.953 
Combined measures  
(conditional) 
      ≥5 opioid fills and 
    ≥12 MME/day 
5047 (7.2%) 44 (0.9%) 0.238 0.928 
≥5 opioid fills and 
    ≥45 MME/day 
2521 (3.6%) 33 (1.3%) 0.166 0.964 
≥5 opioid fills and 
    ≥140 MME/day 
1169 (1.7%) 18 (1.5%) 0.087 0.983 
≥7 opioid fills and 
    ≥12 MME/day 
1659 (2.4%) 16 (1.0%) 0.087 0.976 
≥7 opioid fills and 
    ≥45 MME/day 
874 (1.3%) 14 (1.6%) 0.072 0.988 
≥7 opioid fills and 
    ≥140 MME/day 
347 (0.5%) 7 (2.0%) 0.034 0.995 
Note: Sens=Sensitivity; Spec=Specificity; MME=Milligram morphine equivalent; NC MLIP=North Carolina 
Medicaid lock-in program. 
*Reported percentages in the “Experienced outcome event” column refer to the proportion of subjects flagged as 
high risk for that given opioid use criterion in that row. 
Ŧ Reported sensitivities and specificities are time-dependent measures calculated at 365 days of follow-up using 
survival ROC models accounting for time to event. Interpretation of these figures should be per-person-year. 
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 Unconditional combinations of the ≥5 opioid fill criteria with each of the three MME/day criteria 
resulted in marginal increases in sensitivity and decreases in specificity in comparison to individual 
measure performance. However, conditional combinations of these measures—in which subjects were 
required to satisfy both opioid thresholds in the combination—greatly reduced the number of subjects 
flagged as high risk, decreased criteria sensitivity, and increased its specificity. For example, 2,521 
subjects received ≥5 opioid fills and had an average daily opioid dose of ≥45 MME/day, while these 
measures would have individually flagged 5,525 and 7,541 subjects as high risk, respectively. The 
conditional combination of these criteria also resulted in a similar decrease in sensitivity for capturing the 
unintentional opioid overdose outcome, from 26-33% sensitivity individually to 17% sensitivity when 
combined in this way. However, the criteria of ≥5 opioid fills and ≥45 MME/day resulted in 96% 
specificity. Descriptive statistics for combinations of the NC MLIP current criterion of ≥7 fills with the 
mean MME/day measures, as expected, was more restrictive than the ≥5 fill, less sensitive, and more 
specific than the ≥5 opioid fill combinations. 
 The optimal thresholds of the opioid fill count measure and average daily opioid dose measures 
were less sensitive in capturing secondary outcome measures than they were for the primary unintentional 
opioid overdose outcome (Appendix Tables 30-33). For example, the ≥45 MME/day criterion was 33% 
sensitive for the primary outcome, but it was only 18%, 20%, 25%, and 15% sensitive for the 
unintentional APAP overdose, any overdose event, opioid use disorder, and any substance use disorder 
secondary outcomes, respectively. 
 Each opioid use measure criterion, both individually and in combination, were highly predictive 
of the primary outcome of unintentional opioid overdose in Cox proportional hazard modeling (Table 
4.17). In general, the hazard of an accidental opioid overdose was 4 to 7 times higher for subjects meeting 
a criterion for high risk opioid use, compared to subjects whose opioid use was below that threshold. Log 
likelihood values from each Cox model, which indicate model fit, show that a criterion’s performance in 
predicting an unintentional opioid overdose increased as the criterion’s inclusiveness increased. However, 
all three mean MME/day criteria had higher log likelihood values than the opioid prescription count 
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measures. This held true even for the ≥140 MME/day criterion, which flagged roughly one-third the 
number of subjects identified by the ≥5 opioid fill criterion as high risk. 
Table 4.17: Bivariate Cox proportional hazard model results estimating the hazard of an unintentional 
opioid overdose for each opioid use criterion 
 Criterion met 
(N=69,667) 
  
  
n (%) Hazard ratio 95% CI LL 
Individual measures       
     ≥5 opioid fills 5525 (7.9%) 4.09 (2.93 , 5.72) -1864.2 
     ≥12 MME/day 19926 (28.6%) 3.99 (2.93 , 5.44) -1850.3 
     ≥45 MME/day 7541 (10.8%) 4.36 (3.21 , 5.92) -1853.8 
     ≥140 MME/day 1980 (2.8%) 6.88 (4.71 , 10.05) -1857.9 
     NC MLIP standard: 
     ≥7 opioid fills  
1703 (2.4%) 3.82 (2.28 , 6.39) -1881.5 
Combined criteria  
(unconditional) 
  
≥5 opioid fills or 
    ≥12 MME/day 
20404 (29.3%) 4.18 (3.05 , 5.72) -1847.9 
≥5 opioid fills or 
    ≥45 MME/day 
10545 (15.1%) 4.29 (3.19 , 5.78) -1849.9 
≥5 opioid fills or 
    ≥140 MME/day 
6336 (9.1%) 5.19 (3.80 , 7.07) -1847.7 
≥7 opioid fills or 
    ≥12 MME/day 
19970 (28.7%) 3.98 (2.92 , 5.43) -1850.5 
≥7 opioid fills or 
    ≥45 MME/day 
8370 (12.0%) 4.12 (3.04 , 5.58) -1855.5 
≥7 opioid fills or 
    ≥140 MME/day 
3336 (4.8%) 5.69 (4.02 , 8.06) -1856.3 
Combined measures  
(conditional)       
≥5 opioid fills and 
    ≥12 MME/day 
5047 (7.2%) 4.09 (2.91 , 5.76) -1865.6 
≥5 opioid fills and 
    ≥45 MME/day 
2521 (3.6%) 5.55 (3.80 , 8.11) -1863.6 
≥5 opioid fills and 
    ≥140 MME/day 
1169 (1.7%) 5.85 (3.59 , 9.52) -1874.5 
≥7 opioid fills and 
    ≥12 MME/day 
1659 (2.4%) 3.91 (2.34 , 6.54) -1881.2 
≥7 opioid fills and 
    ≥45 MME/day 
874 (1.3%) 6.14 (3.56 , 10.60) -1877.4 
≥7 opioid fills and 
    ≥140 MME/day 
347 (0.5%) 7.17 (3.37 , 15.28) -1883.1 
Note: CI=Confidence interval; LL=Log likelihood; MME=Milligram morphine equivalent; NC MLIP=North 
Carolina Medicaid lock-in program. All hazard ratio estimates reported in this table were statistically significant at 
p<0.001. 
 
 All unconditional combinations of ≥5 opioid fills and the MME/day thresholds performed 
similarly and were better predictors of unintentional opioid overdose than any of the individual criteria. 
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The conditional combinations of opioid use criteria, which were more restrictive, had lower log likelihood 
values than the unconditional combinations and the individual mean MME/day measures but performed 
similarly to the ≥5 opioid fill individual criterion. The NC MLIP standard eligibility measure of ≥7 opioid 
fills, both alone and in combination, was significantly predictive of the primary outcome but did not 
outperform the other measures, in terms of Cox model log likelihood. 
 Aside from the unintentional APAP overdose, each opioid use criterion measure was also highly 
predictive of the secondary outcomes (Appendix Tables 34-37). However, the magnitude of the hazard 
ratio point estimates for secondary outcomes were roughly half those observed when estimating the 
primary outcome. The secondary outcome model performance trends across opioid use measures were 
similar to those observed in models estimating the primary outcome. In general, the average MME/day 
criteria were more predictive of the secondary outcomes—particularly the ≥12 MME/day and ≥45 
MME/day cutpoints—compared to the opioid fill count measures. 
 Kaplan-Meier survival function analyses were the final method employed to assess the 
performance of opioid use measures and thresholds identified from the testing phase in predicting relevant 
public health outcomes from high risk opioid use. All Kaplan-Meier survival function models showed a 
statistically significant decrease in likelihood of not experiencing an unintentional opioid overdose over 
time (p<0.001 for all) (Figures 4.15-4.17). In other words, the probability of experiencing the primary 
outcome was significantly higher over time among subjects who met each criterion for high-risk opioid 
use. Visual inspection of the Kaplan-Meier plots showed that the criterion of ≥140 MME/day, alone and 
in combination, consistently produced the greatest disparity in risk of an unintentional opioid overdose 
between those meeting and those not meeting the criterion. Similar findings were observed for the 
secondary outcomes (Appendix Figures 6-17), except for the unintentional APAP overdose outcome for 
which the predictive performance of the opioid use measures was much less pronounced or nonexistent. 
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Figure 4.15: Kaplan-Meier survival function plots of time to an unintentional opioid overdose event, by 
individual high risk opioid use measure criteria  
 
Note: p-values refer to the statistical test for the hypothesis that the survivor functions are equal  
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Figure 4.16: Kaplan-Meier survival function plots of time to an unintentional opioid overdose event, by 
unconditional combination of high risk opioid use measure criteria  
 
Note: p-values refer to a statistical test for the hypothesis that the survivor functions are equal   
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Figure 4.17: Kaplan-Meier survival function plots of time to an unintentional opioid overdose event, by 
conditional combination of high risk opioid use measure criteria  
 
Note: p-values refer to a statistical test for the hypothesis that the survivor functions are equal 
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the absolute risk difference was small (typically <1%). This is largely due to the primary outcome being 
uncommon in the sample, occurring in 0.25% of the validation sample subjects. However, using the 
absolute risk difference to calculate the number needed to enroll (NNE) provided a more intuitive 
interpretation of how these opioid use criteria performed in practice.  
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Table 4.18: Kaplan-Meier estimates of unintentional opioid overdose event, by opioid use criterion, 
represented as absolute risk differences and numbers needed to enroll 
   Follow-up time 
Criterion met 
(N=69,667) 30 days 90 days 180 days 365 days 
 
n (%) ARD NNE ARD NNE ARD NNE ARD NNE 
Individual measures           
     ≥5 opioid fills 5525 (7.9%) 0.0008 1215 0.0014 703 0.0044 228 0.0081 124 
     ≥12 MME/day 19926 (28.6%) 0.0001 18197 0.0009 1094 0.0022 456 0.0052 192 
     ≥45 MME/day 7541 (10.8%) 0.0004 2400 0.0020 503 0.0038 260 0.0078 129 
     ≥140 MME/day 1980 (2.8%) 0.0014 712 0.0032 317 0.0090 111 0.0159 63 
     NC MLIP standard: 
      ≥7 opioid fills  
1703 (2.4%) 0.0004 2293 0.0019 513 0.0031 323 0.0088 113 
Combined measures  
(unconditional) 
          
≥5 opioid fills or 
    ≥12 MME/day 
20404 (29.3%) 0.0002 5134 0.0010 971 0.0023 427 0.0053 189 
≥5 opioid fills or 
    ≥45 MME/day 
10545 (15.1%) 0.0005 2034 0.0017 599 0.0035 289 0.0070 143 
≥5 opioid fills or 
     ≥140 MME/day 
6336 (9.1%) 0.0009 1132 0.0019 518 0.0052 193 0.0097 103 
≥7 opioid fills or 
     ≥12 MME/day 
19970 (28.7%) 0.0001 18376 0.0009 1097 0.0022 458 0.0052 192 
≥7 opioid fills or 
     ≥45 MME/day 
8370 (12.0%) 0.0004 2759 0.0019 526 0.0035 285 0.0072 139 
≥7 opioid fills or 
    ≥140 MME/day 
3336 (4.8%) 0.0008 1277 0.0027 371 0.0060 167 0.0123 81 
Combined measures  
(conditional) 
          
≥5 opioid fills and 
    ≥12 MME/day 
5047 (7.2%) 0.0005 2142 0.0012 863 0.0042 239 0.0083 121 
≥5 opioid fills and 
    ≥45 MME/day 
2521 (3.6%) 0.0011 937 0.0024 425 0.0070 144 0.0125 80 
≥5 opioid fills and 
    ≥140 MME/day 
1169 (1.7%) 0.0016 634 0.0020 491 0.0088 114 0.0143 70 
≥7 opioid fills and 
    ≥12 MME/day 
1659 (2.4%) 0.0005 2212 0.0020 497 0.0032 312 0.0091 110 
≥7 opioid fills and 
    ≥45 MME/day 
874 (1.3%) 0.0010 1006 0.0030 334 0.0060 167 0.0161 62 
≥7 opioid fills and 
    ≥140 MME/day 
347 (0.5%) 0.0027 366 0.0023 434 0.0110 91 0.0195 51 
Note: ARD=Absolute risk difference; NNE=Number needed to enroll; MME=Milligram morphine equivalent; NC 
MLIP=North Carolina Medicaid lock-in program. ARD was calculated from Kaplan-Meier survival function models 
by subtracting the probability of experiencing the outcome event at a given time point among those below an opioid 
use measure threshold from the probability of experiencing the outcome event at that same time among those 
meeting the threshold. The NNE was calculated as (1 / ARD) and is interpreted as the number of individuals needed 
to enroll into a hypothetical MLIP program based on a given opioid use criterion in order to have the opportunity to 
prevent one outcome event. 
 
 Based on these findings, a hypothetical MLIP program that used an eligibility criterion of ≥5 
opioid prescription fills in a 60-day period would need to enroll 124 opioid users based on this criterion in 
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order to the have opportunity to prevent one unintentional opioid overdose event.  The NNE values for the 
individual ≥12 MME/day, ≥45 MME/day, and ≥140 MME/day at 365 days of follow-up for the primary 
outcome were 192, 129, and 63, respectively. An opioid use measure’s NNE generally decreased as the 
proportion of the validation sample flagged as high risk based on that measure decreased. However, the 
current NC MLIP criteria of ≥7 opioid fills had nearly twice the NNE as the ≥140 MME/day measure, 
despite flagging roughly the same number of subjects as high risk.  
 Because the absolute risk difference and NNE are a function of underlying prevalence of the 
outcome, NNEs for the rare secondary outcome of unintentional acetaminophen overdose were 
substantially higher than the primary outcome, while NNEs were lower for the other three secondary 
outcomes that were more prevalent than the primary outcome (Appendix Tables 38-41). The NNEs of the 
individual exposure measures for the primary outcome ranged from 63 (≥140 MME/day) to 192 (≥12 
MME/day). The NNE ranges for the unintentional acetaminophen overdose, any drug overdose, opioid 
use disorder diagnosis, and any substance use disorder diagnosis secondary outcomes were 275-909, 31-
56, 10-25, and 4-7, respectively.  
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CHAPTER V: DISCUSSION 
 
5.1 DISSERTATION OBJECTIVES RECAP  
 This dissertation comprised three retrospective cohort studies investigating the North Carolina 
Medicaid Recipient Management Lock-in Program through use of administrative Medicaid claims data 
and data from the state’s PDMP. The NC MLIP is one of at least 46 controlled substance lock-in 
programs operated by state Medicaid programs across the country.147 MLIPs attempt to reduce high-risk 
controlled substance use behaviors by identifying beneficiaries with high utilization of controlled 
substance medication services and restricting their access to a small number of designated providers for 
Medicaid coverage of these services—typically one prescriber and one pharmacy. Despite their high 
prevalence, there exists little rigorous evidence to inform the optimal design of MLIPs and to substantiate 
their effectiveness in achieving their stated public health aims of reducing high-risk and nonmedical use 
of controlled substance medications through enhanced care coordination.  
 The purpose of this dissertation was to provide what is believed to be among the first 
examinations of known limitations to the MLIP policy strategy. The first MLIP limitation of interest was 
the problem of lock-in circumvention. MLIP circumvention occurs when enrollees obtain controlled 
substance medications from non-lock-in providers by paying for them entirely out-of-pocket. MLIP 
circumvention is currently unobservable and unenforceable by MLIP administrators and results in a 
breach in the MLIP’s enhanced care coordination for these high-risk individuals. The second MLIP 
limitation of interest was the lack of literature to support development of MLIP eligibility criteria that 
identify Medicaid beneficiaries at highest risk for adverse clinical outcomes from prescription drug abuse. 
 Aim 1 of this dissertation utilized a longitudinal retrospective cohort of NC MLIP enrollees to 
assess the prevalence of controlled substance circumvention in this population and to isolate the effect of 
MLIP enrollment, as well as patient-level predictors, on the likelihood and extent of engaging in MLIP 
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circumvention behavior. Aim 2 built on this study by investigating MLIP circumvention patterns at the 
prescription level. Aim 2 examined the effect of NC MLIP enrollment, as well as patient-level predictors, 
on three prescription-level outcomes indicative of their risk and abuse potential within the context of 
circumvented and Medicaid-covered behaviors. Aim 3 employed predictive modeling techniques to test 
and validate claims-based measures of high-risk opioid use that were most predictive of overdose events 
and substance use disorders in an NC Medicaid population. 
5.2 SUMMARY OF FINDINGS 
5.2.1 Summary of Findings—Aim 1 
 Out of over 4,400 NC Medicaid beneficiaries who were enrolled in the NC MLIP during its first 
two years of operation, a total of 1,647 MLIP enrollees were included in Aim 1 analyses. This cohort was 
about 40 years of age, on average, and mostly female, White, and residents of metropolitan counties in 
NC. Nearly all subjects had a baseline diagnosis of chronic noncancer pain and there was high mental 
health and physical comorbid burden in the cohort. High opioid utilization was the primary cause of 
MLIP eligibility for these subjects. Nearly all subjects experienced an MLIP enrollment delay. On 
average, the Aim 1 cohort was not subject to the MLIP intervention until nearly six months after first 
demonstrating high risk controlled substance use, as defined by the NC MLIP eligibility criteria. 
 All findings from Aim 1 descriptive, bivariate, and GEE modeling analyses clearly indicated that 
enrollment in the NC MLIP induced subjects to engage in controlled substance circumvention behavior. 
The mean number of circumvented opioids and benzodiazepine prescriptions per-person-per-month 
tripled following MLIP enrollment. When adjusting for policy- and patient-level characteristics, 
enrollment in the NC MLIP was associated with 3.6 times higher likelihood of engaging in circumvention 
in a given month. MLIP enrollment also had similar effects on increases in the extent of circumvention 
behavior within a given person-month. 
 The marked increase in circumvention behavior following MLIP enrollment substantially offset 
what appeared, from NC Medicaid’s perspective, to be a drastic reduction in controlled substance use 
attributed to the MLIP. Looking only at NC Medicaid claims data—which would be the only data source 
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available to NC MLIP administrators to evaluate program outcomes—Medicaid prescription claims for 
opioids and benzodiazepines dropped over 40% after subjects were enrolled in the MLIP, from 2.72 
claims per-person-per-month to 1.39 claims. However, what NC Medicaid could not observe was that 
over half of this decrease in Medicaid claims for controlled substances was offset by an increase in 
controlled substance prescription fills obtained through circumvention. 
 Aside from MLIP enrollment, GEE models from Aim 1 revealed additional factors associated 
with increased controlled substance circumvention behavior. The likelihood and extent of circumvention 
increased roughly 25% during periods in which subjects had demonstrated high-risk controlled substance 
use qualifying them for the MLIP but had not yet been enrolled in the program. Additionally, subjects 
who qualified for the MLIP due to high utilization of benzodiazepines and pharmacies were more likely 
to circumvent. Numerous patient-level characteristics were also associated with circumvention. This 
behavior was more common among MLIP enrollees who were younger, living in areas with high supplies 
of dispensing pharmacies, had anxiety disorder diagnoses, and had a high physical comorbidity burden. 
5.2.2 Summary of Findings—Aim 2  
 A total of 98,243 opioid analgesic prescription fills from 1,646 NC MLIP enrollees were included 
in Aim 2 analyses. Overall, 80% of the prescriptions were paid for using Medicaid coverage, while the 
remaining 20% were obtained through circumvention. Sixty-one percent of opioid prescriptions contained 
Schedule II products, 18% contained a long acting opioid formulation, and the mean prescribed daily 
opioid dose was 79 MME/day.  
 Short acting oral hydrocodone (Vicodin, Norco) and oxycodone (Percocet, Roxicodone) were by 
far the most common opioid products received by subjects through circumvention and Medicaid 
coverage. There were few notable changes in opioid product prevalence before and after MLIP 
enrollment to suggest obvious targeting of specific opioid products for circumvention. The prevalence of 
long acting oxycodone (Oxycontin) among circumvented prescriptions decreased by half after MLIP 
enrollment. However, this finding may have been an artifact of underlying changes in prescribing 
practices in which long acting oxymorphone (Opana ER) gained market share as an alternative to long 
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acting oxycodone.253 Of note, though, methadone was the most commonly circumvented long acting 
opioid product and in the top three of most commonly circumvented Schedule II opioid products. 
However, among Medicaid covered prescriptions, methadone was only the fifth most common long 
acting opioid and not even among the top five most common Schedule II products. 
 The risk profile of opioid prescriptions—characterized by the proportion of prescriptions written 
for Schedule II and long acting opioid products and the mean prescribed MME/day—was comparable 
between circumvented and Medicaid-paid opioid fills before MLIP enrollment. After MLIP enrollment, 
however, opioid prescriptions paid for using NC Medicaid coverage contained Schedule II opioids 30% 
more often, long acting opioids twice as often, and had nearly 50% higher average daily doses of opioids. 
Opioid prescriptions obtained through circumvention did not experience any increase in prescription-level 
risk measures. The proportion of long-acting opioid fills and average daily opioid dose actually decreased 
after MLIP enrollment in the context of circumvention behavior.  
 These trends were confirmed in GLM analysis adjusting for policy- and patient-level 
characteristics. MLIP enrollment had no association with the likelihood of circumventing Schedule II 
opioid products or on the average MME/day of circumvented opioid prescriptions. The likelihood of 
circumventing a long acting opioid decreased 42% following MLIP enrollment. Opioid prescriptions paid 
by subjects using their Medicaid coverage were 30% more likely to contain a Schedule II opioid, twice as 
likely to be written for a long-acting opioid formulation, and had an additional 55 MME prescribed/day 
compared to Medicaid covered opioid prescriptions prior to MLIP enrollment. 
 Although MLIP enrollment was not associated with an increase in risk profile of opioid 
prescriptions obtained through circumvention, GLM models identified a handful of patient-level 
characteristics associated with increased likelihood of circumventing an opioid prescription with a high-
risk attribute: male sex, residence in a border county, depression, and high physical comorbidity burden. 
5.2.3 Summary of Findings—Aim 3 
 Nearly 140,000 adult NC Medicaid beneficiaries were included in Aim 3 analysis investigating 
the performance of potential MLIP eligibility criteria as they are currently applied in the NC MLIP. Half 
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of subjects were used to test opioid exposure measures, and the other half were used to validate optimal 
measures and thresholds identified in the testing phase. The primary outcome of interest was 
unintentional opioid overdose, for which 376 subjects recorded the primary outcome. Secondary 
outcomes were unintentional APAP overdose, an unintentional overdose of any drug, opioid use disorder 
diagnosis, and any substance use disorder diagnosis. 
 Based on survival ROC analysis, no single opioid exposure measure, or combination thereof, 
even reached “fair” discriminatory performance in predicting subjects who experienced a study outcome 
versus those that did not. Measures of number of unique pharmacies used to obtain opioids and average 
daily APAP dosage from opioid/APAP combination products failed as predictors and were excluded from 
further evaluation. Measures of number of opioid prescription fills and average MME/day over a 60-day 
period were on the high end of the “poor” performance with AUCs of 0.67 and 0.68 for the primary 
outcome, respectively. These two measures were further validated using optimal thresholds of ≥5 opioid 
prescription fills and ≥12 MME/day (with alternative high-performing cutpoints at ≥45 MME/day and 
≥140 MME/day). 
 Overall, sensitivity was low for capturing subjects with the primary outcome event using the best 
performing opioid exposure criteria identified in the testing phase. The ≥12 MME/day criterion was 59% 
sensitive, while the alternative mean MME/day cutpoints and the ≥5 opioid fill measure were 16-33% 
sensitive. Specificity of these measures was generally over 90%, except for the ≥12 MME/day criterion 
which was 72% specific for the primary outcome. Despite low sensitivity, the opioid use criteria selected 
for validation were all highly predictive of the study outcomes in bivariate Cox proportional hazard 
modeling. Subjects flagged as high risk based on these measures had 4 to 7-times higher hazard of an 
unintentional opioid overdose compared to those classified as low-risk for that measure. Based on 
bivariate Kaplan-Meier survival models, an MLIP would need to enroll 124, 192, 129, and 63 subjects 
based on thresholds of ≥5 opioid fills, ≥12 MME/day, ≥45 MME/day, and ≥140 MME/day over 60 days, 
respectively, to have the opportunity to prevent one accidental opioid overdose. Improved criterion 
performance across all evaluative methods was largely dictated by a positive relationship with the number 
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of subjects flagged as high risk. The current NC MLIP eligibility criterion of ≥7 opioid fills performed 
demonstrably worse than the optimal opioid use measures selected in Aim 3. 
5.3 POLICY IMPLICATIONS  
 Many stakeholders have tapped MLIPs as a policy tool worthy of serious consideration in 
forthcoming national efforts to mitigate prescription drug abuse behaviors.23,24,130 A bill was even 
introduced in the United States House of Representatives Ways and Means Committee in December 2014 
recommending establishment of a controlled substance lock-in program in Medicare to prevent fraud, 
waste, and abuse of prescription drugs in the Medicare population.254 It is understandable why momentum 
exists behind proliferation of MLIP-type interventions. The national epidemic of prescription drug abuse 
has garnered well-deserved attention as a public health crisis requiring, according to CDC director 
Thomas Frieden, an “all-hands-on-deck approach” to correcting it.255 State Medicaid agencies often 
justify the existence of their MLIPs primarily as a tool for improving public health among patients at 
greatest risk for adverse substance use outcomes.256 However, the available evidence to support the 
effectiveness of MLIPs in achieving desired public health outcomes around prescription drug abuse is 
scant. This dissertation served to reinforce the current lack of understanding about the effectiveness and 
optimal design of MLIPs. Our findings from an evaluation of the NC MLIP elucidated key limitations of 
current MLIP operations that must be further examined and reconciled to achieve the optimal public 
health benefit of the MLIP policy strategy moving forward. 
5.3.1 Policy Implications—MLIP Enrollment Delays 
 The initial purpose of this dissertation was to investigate MLIP circumvention behaviors and the 
performance of MLIP eligibility criteria. However, an additional challenge facing MLIP effectiveness 
was uncovered in the process of conducting Aims 1 and 2—the MLIP enrollment delay. Roughly 95% of 
the over 1,600 NC MLIP enrollees analyzed in Aims 1 and 2 experienced a delay in MLIP enrollment of 
nearly six months, on average, from the time they first became eligible for the program. This meant that 
nearly all NC MLIP enrollees didn’t experience the policy intervention until half a year after they 
exhibited high-risk controlled substance use behavior. Although much work is needed to establish 
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whether and to what extent MLIPs reduce adverse substance use and overdose outcomes, MLIPs are 
incapable of preventing these outcomes if patients are not enrolled in the MLIP until months after they 
were determined to be in need of this intervention. In the Aim 3 validation sample, 57% of unintentional 
opioid overdose events occurred less than 180 days from being flagged as high-risk using a measure of ≥5 
opioid fills in a 60-day period. A MLIP with a six-month enrollment delay would have missed the 
opportunity to prevent these overdoses. Bolstering MLIP effectiveness will require minimizing the time 
between beneficiaries exhibiting high-risk prescription drug use behaviors and enrollment in the MLIP. 
This will likely require enhancing resources dedicated to MLIP administration, as enrollment delays 
appear to primarily be a symptom of inadequate funding and human capital required to keep up with the 
administratively intensive tasks of identifying, notifying, and enrolling MLIP-eligible patients.  
5.3.2 Policy Implications—MLIP Circumvention  
 Aims 1 and 2 provided among the first pieces of rigorous evidence that MLIP circumvention 
behavior undermines the policy’s intended outcomes. Prior MLIP evaluations in the published and grey 
literature measured the effect of MLIP enrollment on controlled substance utilization from Medicaid’s 
perspective—solely using Medicaid claims data. In Aim 1, we observed a 43% reduction in Medicaid 
claims for opioids and benzodiazepines following MLIP enrollment. This finding is in line with those 
reported by previous MLIP evaluations.117-119 However, what prior evidence has failed to capture is the 
extent of controlled substance use taking place outside the scope of the Medicaid program. We found that 
over half of the observed reduction in controlled substance Medicaid prescription claims was offset by an 
increase in circumvented controlled substance prescriptions stemming from NC MLIP enrollment.   
 It is clear from Aim 1 that imposing prescriber and pharmacy access restrictions on NC MLIP 
enrollees caused these high risk patients to more frequently pay for controlled substance prescriptions 
entirely out-of-pocket, obviating the underlying purpose of the policy intervention. It is impossible to 
assess patient motivation behind this circumvention behavior given the limitations of the study data, but it 
likely falls into one of three categories: 1) circumvention to facilitate continued controlled substance 
abuse and/or diversion activities, 2) circumvention as a means to obtain necessary controlled substance 
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therapies in the face of new unintended access barriers caused by MLIP restrictions, or 3) circumvention 
to avoid heightened surveillance of their healthcare use behaviors by Medicaid authorities, even for 
necessary care. Regardless of the circumstances motivating individuals to circumvent Medicaid to obtain 
controlled substances, circumvention behavior poses a non-ignorable threat to MLIP effectiveness.   
 MLIP circumvention fails to prevent access to controlled substance prescriptions among enrollees 
intent on procuring them for abuse or diversion. We have shown that it is feasible and common for high-
risk MLIP enrollees to, in the face of MLIP restrictions, readily obtain prescription medications 
implicated in the vast majority of preventable prescription drug overdose events in the US entirely 
unbeknownst to Medicaid. MLIP circumvention among program enrollees with legitimate medical need 
for opioids and benzodiazepines may be a symptom of unintended barriers to necessary care caused by 
MLIP enrollment. For example, a hypothetical MLIP enrollee may have been forced to pay cash for a 
necessary prescription fill of short-acting opioids to treat legitimate breakthrough pain if they were not 
located within a reasonable distance to their lock-in pharmacy at the time of need. In this scenario, MLIP-
induced circumvention introduces unintended fragmentation in healthcare delivery for high-risk patients 
with legitimate medical need for opioids and benzodiazepines. In addition, MLIP circumvention to obtain 
necessary treatments imposes unnecessary added financial burden on patients with pre-existing financial 
vulnerability. Further research is needed to determine the actual root causes of MLIP circumvention, but 
in any scenario, MLIP circumvention results in a failure to maintain the enhanced care coordination 
between MLIP enrollees and their lock-in providers, which is purported to be the primary mechanism for 
achieving MLIPs’ potential public health benefit.147  
 Aim 2 findings did identify one silver lining to the issue of the MLIP circumvention. Although 
MLIP enrollment caused subjects to circumvent more often, this additional circumvention behavior was 
not any riskier at the prescription-level. The likelihood of a circumvented opioid prescription being 
written for a Schedule II product was not significantly different after MLIP enrollment. The likelihood of 
a circumvention opioid prescription containing a long-acting opioid product decreased and the prescribed 
average daily opioid of circumvented opioid prescriptions decreased after MLIP enrollment. All three of 
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these outcomes reflected an individual prescription’s risk for contributing to adverse substance use and 
overdose outcomes. The highest risk prescriptions—those containing Schedule II opioids, long acting 
opioid formulations, and high daily doses—were more heavily concentrated within the Medicaid program 
after MLIP enrollment. It is possible this trend was driven by cost, in which the high cost of certain 
common Schedule II, long acting, and high dose products, like fentanyl transdermal patches, were too 
cost prohibitive for MLIP enrollees to purchase out of pocket. Regardless, the MLIP’s effect on reducing 
prescription drug abuse outcomes is aided by the fact that the highest risk prescriptions were obtained 
under the purview of a subject’s MLIP providers after MLIP enrollment. 
 However, Aim 2 did indicate a troubling MLIP circumvention trend. Methadone prescriptions 
were among the most commonly circumvented medications both at baseline and after MLIP enrollment. 
Prior literature has shown methadone to be one of the most, if not the most, dangerous prescription opioid 
analgesic in terms of contributing to overdose events.72,209 In North Carolina in 2007, methadone was 
responsible for over 1/3 of all poisoning deaths in the state, causing more fatal overdoses than all other 
prescription opioid products combined.257 The high prevalence of circumvented methadone prescriptions 
is likely due to the structure of the NC Medicaid benefit. Methadone, when indicated for opioid use 
disorder treatment, is only covered for beneficiaries with managed care NC Medicaid coverage.258 
Methadone, when indicated for pain management, however, is covered for beneficiaries with either NC 
Medicaid’s managed care or fee-for-service coverage. Therefore, NC Medicaid fee-for-service 
beneficiaries prescribed methadone for treatment of an opioid use disorder would be forced to pay for 
these prescriptions entirely out-of-pocket, resulting in an elevated prevalence of circumvented methadone 
fills. Further investigation outside the scope of this dissertation is needed to assess whether NC MLIP 
enrollees with fee-for-service coverage experienced access barriers to methadone therapy for opioid 
misuse therapy. Regardless, it is imperative that future efforts to mitigate MLIP circumvention focus on 
establishing greater oversight of methadone use among MLIP enrollees due to its elevated risk for 
overdose outcomes. 
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  Addressing the problem of MLIP circumvention will be necessary for MLIPs to achieve their 
stated public health goals. Strategies to reduce MLIP circumvention could take many forms. First, MLIP 
administrators should provide better education to lock-in providers about their roles in maintaining the 
care coordination network for their MLIP patients. A recent survey of North Carolina pharmacists by the 
dissertation parent project team found that pharmacist providers of MLIP enrollees explicitly requested 
improved communication from MLIP administrators to alleviate what they perceived as a lack of 
knowledge about the MLIP’s purpose and process.259 Provider education could include additional training 
on and/or requirements for providers to use PDMP resources in the course of care delivery to their MLIP 
patients. Standardized use of PDMPs would allow identification of circumvention behavior and give 
providers the opportunity to take steps to correct instances of unnecessary care duplications or report 
suspected diversion activities to program administrators. 
 MLIP circumvention may also be mitigated through patient-centered interventions. First, MLIP 
administrators should consider delivering enhanced education at the time of MLIP enrollment. Currently, 
NC MLIP enrollees receive a letter in the mail 30 days prior to their MLIP enrollment informing them 
that their access to controlled substance-related services is being restricted to a single prescriber and 
pharmacy. This represents a missed opportunity to convey to the underlying purpose behind MLIP 
enrollment as being motivated by a desire for improved quality and not disciplinary in nature. Extending 
the idea of reframing the MLIP as a tool for care quality as opposed to punishment, existing MLIPs could 
serve as platforms for building patient-centered medical home-type programs focused on high quality 
collaborative care, specifically for substance use, pain, and mental health disorders. Indiana and Montana 
currently operate potential exemplar models for collaborative, patient-centered MLIPs that utilize case 
managers and primary care providers as medical home centers whose purpose it is refer MLIP enrollees to 
needed ancillary services, such as substance use or chronic pain treatment, which are covered by 
Medicaid.260,261  
 Our research in Aims 1 and 2 demonstrates the benefit of pursuing integrated data systems in 
evaluating and administering the NC MLIP. To our knowledge, these studies represented the first efforts 
  166 
in the peer-reviewed literature to link administrative claims data with PDMP records. This allowed 
unprecedented observation of comprehensive controlled substance-seeking behaviors among Medicaid 
beneficiaries. If deployed effectively in the healthcare delivery process, this new information would 
greatly enhance prescribers’ and pharmacists’ ability to monitor high-risk controlled substance use 
behaviors, including MLIP circumvention, and take steps correct it, if necessary. For example, 
implementing automated cross-checking of PDMP data and MLIP enrollment records into pharmacies’ 
prescription processing software would provide pharmacists would alert pharmacists to circumvention 
behavior without disrupting existing workflow. Policymakers, payers, and providers must make 
integrated PDMP systems a national priority, both in terms of cooperation with data streams from payers 
and cooperation with data systems across state lines.8,10,25-28  
  
5.3.3 Policy Implications—MLIP Eligibility Criteria 
 In Aim 3, we evaluated the predictive performance of high-risk opioid use criteria. We mimicked 
how these types of measures are currently applied in the NC MLIP to get a sense for how effective this 
MLIP eligibility assessment approach is at enrolling individuals at the greatest risk for relevant public 
health outcomes from prescription drug abuse.  
  Ultimately, our claims-based opioid exposure measures performed poorly at predicting overdose 
and substance use disorder outcomes. The number of unique opioid-dispensing pharmacies, despite being 
included in multiple MLIP programs’ eligibility criteria147, failed to discriminate between subjects 
experiencing the outcomes and those that did not among opioid users in NC Medicaid. Even though the 
measures of number of opioid prescription fills and mean MME/day over a 60-day period were evaluated 
in the validation phase of Aim 3, neither of them proved to be very sensitive both alone or in 
combination. For example, the ≥5 opioid fill criterion flagged 5,525 subjects as high-risk for accidental 
opioid overdose, but it still only captured 26% of the 174 overdose events observed during the study 
period. 
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 This poor performance by our selected high-risk opioid use criteria could be attributable to a few 
underlying causes. First, it is possible there simply exists a low performance ceiling for any claims-based 
measure of high-risk opioid use in predicting prescription drug overdose outcomes. The causes of 
overdose events may be too multifactorial to be captured in the limited scope of administrative claims 
data. Notably, Medicaid claims cannot capture the contributions of illicit drug use to overdose events, 
which has experienced growing prevalence among nonmedical prescription drug users in recent years.262 
As demonstrated in Aim 1, Medicaid claims also fail to capture highly prevalent controlled substance 
circumvention behavior that would contribute to adverse prescription drug abuse outcomes. Also, the 60-
day opioid exposure window we used to simulate NC Medicaid eligibility assessment may have been too 
short for thorough assessment of opioid use risk. Much of the existing literature regarding claims-based 
prescription abuse risk factors employed assessment periods of 90-365 days.140,141,151,155,161,169 This might 
explain why the measures of unique opioid dispensing pharmacies failed to discriminate subjects with 
overdose events in Aim 3. Pharmacy count measures shown to be predictive of relevant public health 
outcomes typically used an assessment period of 6-12 months in prior studies.151,152,157,158,162 Lastly, the 
application of NC MLIP eligibility criteria and the opioid use criteria in Aim 3 analyses did not adjust for 
patient-level characteristics known to be associated with nonmedical opioid use and related outcomes. 
Most of the existing literature examining optimal claims-based measures of high-risk opioid use 
controlled for factors like age, sex, and clinical characteristics, despite this not being standard practice in 
real-world MLIP operations.140,141,144,161 For example, optimal MLIP eligibility criteria may need to 
account for differences between the sexes, age categorizations, and the presence of certain baseline 
clinical diagnoses, particularly mental health conditions. 
 The fact that even the best claims-based measures of high-risk opioid use in Aim 3 performed 
poorly precluded our ability to confidently and definitively recommend specific binary opioid use 
measures in assessing MLIP eligibility. New and actionable evidence for concrete claims-based measures 
of high-risk opioid use is needed before this can take place. Our Aim 3 findings illuminate the large role 
that subjectivity will play when MLIP administrators craft MLIP eligibility criteria. In this situation, two 
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key trade-offs must be considered: 1) Program capacity vs. desired sensitivity, and 2) Rapid vs. thorough 
risk assessment.  
 Aim 3 analyses clearly indicated that the sensitivity of high-risk opioid use criteria in capturing 
subjects who experienced an overdose had a strong positive relationship with the number of subjects 
flagged by that measure. Therefore, MLIP administrators must assess the extent to which they intend the 
MLIP to act as a tool for preventing adverse public health outcomes (favor increased program enrollment 
capacity and high sensitivity) or as a tool primarily for preventing waste and fraudulent use of Medicaid 
resources (favor low program enrollment and high specificity).130 Additionally, MLIP administrators face 
a difficult decision regarding length of the eligibility assessment period. Shorter assessment periods, such 
as North Carolina’s two-month assessment, allows for more rapid identification of high-risk opioid use, 
and therefore timelier enrollment of high-risk beneficiaries in the MLIP. However, the poor performance 
of our 60-day measures, as well as the body of literature using assessment periods of 90 days and greater, 
suggest that claims-based measures of high-risk opioid use may perform better at predicting overdose 
events when assessed over periods of three months or more.  
 Moving forward, existing MLIPs should carefully reevaluate their approaches to assessing MLIP 
eligibility. The high prevalence of this policy strategy across the country means MLIPs are poised to play 
a useful role in the fight against prescription drug abuse in Medicaid. For this to come to fruition, though, 
a concerted effort is needed on behalf of administrators and policymakers to optimize MLIPs for 
achieving public health outcomes. A primary mechanism for optimizing MLIPs is through enrolling 
beneficiaries that stand to benefit the most from the MLIP intervention, and enrolling enough of them to 
have the opportunity to cause meaningful reductions in overdose and substance use disorder outcomes. In 
this spirit, MLIP administrators should prioritize use of MLIP eligibility criteria that maximize sensitivity 
for capturing preventable prescription drug abuse outcomes.  
 MLIP administrators should also explore alternative approaches to assessing eligibility outside of 
the current practice of multiple dichotomous claims-based measures that improve the sensitivity for 
capturing relevant, preventable prescription drug abuse outcomes. More intricate algorithmic approaches 
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may be appropriate, which can assess multiple conditional criteria simultaneously and account for 
relevant patient-level predictors.150 Opioid risk scoring methods may also have added benefit through its 
assessment and weighting of multiple claims-based measures of controlled substance use.168 If claims-
based approaches to assessing MLIP eligibility continue to perform poorly at identifying patients at high 
risk for preventable overdose events, then it may be necessary to rely more heavily on provider referrals. 
Providers’ professional judgment can account for more nuanced risk factors exhibited by patients that 
would not be measurable in claims data, such as illicit substance use or significant history of nonmedical 
controlled substance use in the patient’s household. However, the human element of provider referrals 
could introduce inappropriate biases in identifying MLIP enrollees, so additional processes for 
independent vetting of provider referrals would be necessary to mitigate discriminatory MLIP enrollment 
practices. 
5.3.4 Policy Implications—Call to Action 
 Taken as a whole, this dissertation highlights four necessary steps to achieve optimal public 
health benefit of the MLIP policy strategy in combatting prescription drug abuse: 
1. Foster a unified perception among payers, policymakers, providers, and patients that MLIPs are 
foremost a public health intervention, not a cost-savings intervention.  
2. Protect the integrity of the MLIP’s intended enhanced care coordination by reducing MLIP 
circumvention behavior through, potentially, MLIP provider and enrollee education interventions, 
integration of smarter and cooperative health care data systems into medical and pharmacy 
practice, and medical home-type MLIP designs. 
3. Employ MLIP eligibility criteria that maximize enrollment of—and subsequently, the sensitivity 
for capturing—beneficiaries with the greatest risk for adverse clinical outcomes from high-risk 
prescription drug use. 
4. Build a body of rigorous, scientific evidence for the effectiveness of the MLIP intervention 
strategy in achieving desired public health outcomes. Efforts to reduce circumvention and 
optimize MLIP eligibility criteria will be moot if there is not any clear consensus that the 
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underlying premise of the MLIP policy of restricting access provider access for controlled 
substance services actually reduces prescription drug abuse, diversion, and overdose events 
without presenting unintended barriers to healthcare.  
5.4 LIMITATIONS  
 Findings from this dissertation should be considered in light of several limitations with regard to 
generalizability, study data, and analyses. These results may have limited utility for similar policy 
applications in private payer or other public insurance settings other than Medicaid programs. While it is 
hoped that this dissertation provides new evidence for MLIPs as a general policy strategy, these findings 
only directly generalize to the NC MLIP and the NC Medicaid patient population. These results may not 
apply to other states with varying MLIP designs and patient demography. The use of analytic cohorts in 
Aims 1 and 2 with extended periods of continuous NC Medicaid coverage may not be representative of 
the broader Medicaid population, which is known to experience high enrollment turbulence.212  
 NC CSRS records were not available for the full NC Medicaid population, precluding the 
opportunity to compare circumvention behavior patterns with a control group that did not experience the 
MLIP intervention. The CSRS was unable to observe controlled substance use outside of North 
Carolina’s state boundaries. However, Aims 1 and 2 analyses attempted to control for this by including a 
dummy covariate indicating residence in a border county. The CSRS also failed to capture 6% of 
controlled substance fills, as evidenced by 6% of Medicaid claims lacking a corresponding CSRS record. 
Although these missing CSRS records appeared to be missing at random with respect to key measures, 
this less-than-perfect capture rate likely led to our estimates of circumvention prevalence to be artificially 
low.  
Medicaid prescription claims data provided by NC DMA lacked variables allowing ascertainment 
of unique prescribers. This prevented construction of an indicator of MLIP eligibility due to ≥4 unique 
controlled substance prescribers in Aims 1 and 2 as well as a measure of number of unique opioid 
prescribers in Aim 3 analyses. To address this limitation, proxy measures of number of unique 
community/outpatient pharmacies constructed to attempt to capture the variation in key outcomes 
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explained by high utilization of controlled substance providers. As with any research using administrative 
prescription claims data, we were only able to observe dispensing of medications. Prescription claims data 
does not allow measurement of actual medication use and cannot capture use of substances by study 
subjects that were obtained through routes not captured by these data sources—whether prescription or 
illicit substances. Claims data may also suffer from misclassification of exposures and outcomes, as it 
relies on accurate upstream input from providers administering those services. 
 Estimates produced by statistical models in all dissertation aims can only be interpreted as 
associations between predictors and outcomes and not as causal relationships. These estimates may also 
be biased by variable misspecification or failure to control for unknown and/or unmeasurable 
confounders. Potential unmeasurable confounders included full prescription cost data, household 
controlled substance use patterns, unique prescribers, prescriber skill/training, detailed geospatial 
relationships, education, concomitant prescription and illicit substance use not captured by study data, 
patient frailty, and health beliefs. Secular trends in the prescription drug market and medical practice were 
also not observable. However, we attempted to account for these in Aims 1 and 2 models by controlling 
for historical time. Aim 3 analyses were also limited by the inability to observe unintentional overdose 
outcomes, particularly fatal overdose events, that did not result in contact with the healthcare system and 
subsequently generate Medicaid claims records for treatment. 
5.5 FUTURE RESEARCH 
 This dissertation represented one of the first attempts to establish a peer-reviewed evidence base 
for understanding and bolstering MLIP effectiveness in improving public health outcomes related to 
prescription drug abuse. There exist many rich opportunities to build on the research presented here to 
advance knowledge in this area.   
 Aim 1 provided a population-level view of circumvention behavior after enrollment in the NC 
MLIP. However, it would also be valuable to garner further understanding of the differences between 
groups of MLIP enrollees who exhibit no circumvention behavior and those that exhibit high 
circumvention behavior after MLIP enrollment. For example, a study of circumvention behavior 
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“trajectories” over time using explanatory factor analysis could elucidate greater understanding of patient-
level predictors, and potentially root causes, for not adhering to MLIP restrictions.  
 Additionally, future research should incorporate elements lacking from the present studies due to 
limitations in the study data sources. Linking CSRS data to the full NC Medicaid population would allow 
investigation of Medicaid circumvention behavior as a predictor of preventable overdose outcomes. 
Findings from this research would not only further inform our understanding of the consequences of 
circumvention in the context of MLIPs but also allow circumvention behavior to be employed as a 
potential measure of high-risk behavior in MLIP eligibility criteria applications. Out-of-pocket costs of 
controlled substance medications likely played a role as a predictor of circumvention behavior, but CSRS 
data lacked a payment field to assess this confounder. Further investigation of MLIP circumvention 
should incorporate prescription cost to better understand the role it plays in predicting which prescriptions 
are circumvented and the financial burden placed on low-income Medicaid beneficiaries by 
circumvention. Similarly, the present study data lack geographic characteristics more granular than the 
county-level. A growing body of literature has demonstrated the importance of geographic relationships 
between patients, prescribers, and pharmacies in predicting nonmedical prescription drug use 
patterns.22,263,264 Being able to assess exact distances between patients and providers will allow us to 
recognize and ultimately correct potential geographic barriers to maintaining an MLIP’s enhanced care 
coordination. The momentum behind PDMP and data resource interoperability will provide valuable 
opportunities to research interstate controlled substance use behaviors. This will have special importance 
for fully characterizing circumvention behaviors, because the CSRS data was limited to North Carolina-
specific activity and incapable of capturing prescriptions filled across state lines. 
 Results from Aim 1 and 2 highlight the need to examine the extent to which MLIP enrollment 
may impose undue barriers to care for patients with legitimate need. Engaging in qualitative, primary data 
collection of patient-reported outcomes would provide a valuable chance to identify enrollee motivations 
for engaging in circumvention, whether it be motivated by abuse/diversion intentions or unintended 
barriers to care stemming from MLIP provider restrictions. Additionally, the NC MLIP restrictions only 
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apply to opioid analgesics and benzodiazepines. It is unknown if, and to what extent, MLIP restrictions 
for these two controlled substance medication classes causes “spillover” effects on accessibility and 
utilization of other medication classes not directly regulated by the MLIP. This will be especially 
important to understand for MLIP enrollees with chronic disease, such as those with cardiovascular 
disease, hyperlipidemia, and diabetes, whose overall health outcomes require optimal adherence to non-
controlled medication classes. 
 Much discussion was also presented in this dissertation for the potential role of MLIP provider 
and enrollee educational interventions for reducing MLIP circumvention. Intervention studies will be 
needed to develop, validate, and evaluate such interventions intended to empower lock-in providers with 
the knowledge and tools to monitor and deliver quality care to MLIP enrollees. MLIP enrollee education 
interventions would be designed to clearly convey that the purpose of the MLIP is to deliver higher 
quality care and prevent unnecessary health outcomes from high-risk medication use as well as provide 
enrollees with clear direction for how to navigate the healthcare system when enrolled in the MLIP. 
 Many opportunities also exist to build on the work of Aim 3 in bolstering MLIP eligibility 
assessment methods that identify beneficiaries at the highest risk for adverse clinical outcomes from high-
risk controlled substance use. Logical next steps from Aim 3 would be to investigate varied opioid 
exposure periods beyond two months, which is currently in use in North Carolina. Additional work 
should be done employing advanced predictive modeling techniques. The prescription drug abuse 
literature clearly demonstrates that nonmedical use behaviors and outcomes are multifaceted in their 
origin, which is not currently reflected in state Medicaid agencies’ approach to defining “high-risk” in the 
MLIP context. It may also be useful to conduct these more advanced predictive modeling studies among 
Medicare and privately insured patient populations, not only to broaden external validity to other patient 
populations, but also to capitalize on the vast size of these populations that would improve the quality of 
predictive modeling studies for key outcomes that are relatively rare, like opioid overdose events. Future 
research should also look to alternative data sources, such as electronic medical records, to construct 
measures of high-risk controlled substance use. A recent study from Hylan, et al, used natural language 
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processing techniques in electronic medical record data to construct risk measures with substantially 
higher discriminatory power and sensitivity for predicting problematic opioid use outcomes compared to 
our single claims-based measure criteria.265  
 Lastly, Aim 3 focused on the most pertinent clinical outcomes from high-risk opioid use. A 
natural extension of this study would be to conduct a cost-effectiveness analysis of MLIP interventions, 
accounting for costs of administering the program, costs of controlled substance-related services, and 
costs of downstream adverse outcomes from high-risk opioid use. This would provide a comprehensive 
perspective of the role of MLIPs in the fight against the prescription drug abuse epidemic, by recognizing 
its function as a tool to improve public health outcomes while also acknowledging the importance of 
financial sustainability to MLIP administrators. 
5.6  CONCLUSION  
 Despite these limitations and opportunities for future research, the research presented in this 
dissertation represents one of the first contributions to a body of peer-reviewed evidence for the 
effectiveness and optimal design of MLIPs in preventing prescription drug abuse. Specifically, this is the 
first study, to our knowledge, quantifying the effect of MLIP enrollment on controlled substance 
circumvention behavior through linkage of Medicaid claims and state PDMP data. In Aim 1, enrollment 
in the NC MLIP was associated with a 3.6 times higher likelihood of obtaining a controlled substance 
prescription through circumvention compared to months before MLIP enrollment, controlling for patient 
and policy characteristics. Although the MLIP caused the frequency of circumvention to increase, in Aim 
2 we demonstrated that circumvented opioid prescription use was no riskier at the prescription level after 
subjects were enrolled in the MLIP. In Aim 3, the claims-based opioid use measure approach to assessing 
MLIP eligibility in the NC MLIP was shown to have poor performance in capturing NC Medicaid 
beneficiaries at the highest risk for experiencing preventable overdose outcomes. Findings from this 
dissertation will inform NC MLIP optimizations to improve its public health benefit. On a larger scale, it 
is hoped these findings will also enhance the effectiveness of targeted, comprehensive, and patient-
centered policy interventions across the country intended to combat the prescription drug abuse epidemic.  
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APPENDIX 
 
Appendix Table 1: Examining differences in characteristics of Medicaid controlled substance claims 
captured by the CSRS vs. not captured by the CSRS 
 
Total Captured 
Not 
captured p 
Age in years, mean (SD) 40.4 (10.4) 40.2 (10.4) 42.3 (10.6) 0.000 
Female, % 72.7% 72.6% 73.2% 0.303 
County RUCC score, mean (SD) 2.67 (1.78) 2.66 (1.77) 2.87 (1.92) 0.000 
Charlson score, mean (SD) 1.51 (2.05) 1.50 (2.05) 1.55 (2.04) 0.122 
Schedule II opioid, % 60.5% 60.4% 62.3% 0.003 
Long acting opioid, % 17.7% 17.5% 21.1% 0.000 
Prescribed MME/day, mean (%) 79.7 (132) 79.4 (131) 84.2 (145) 0.007 
 Note: CSRS=Controlled Substances Reporting System; SD=Standard deviation; RUCC=Rural-Urban Continuum 
Code; MME=Milligram morphine equivalent. Higher RUCC score indicates more rural. 
 
Appendix Figure 1: Distribution of captured vs. non-captured controlled substance prescription claims in 
the CSRS across the Aim 1 and 2 study period 
 
Note: CSRS=Controlled Substances Reporting System 
 
Appendix Table 2: NC Medicaid coverage gaps in the Aim 1 analytic cohort 
Month-long 
coverage gaps 
Frequency 
n (%) 
Cumulative 
% 
0 1528 (92.8%) 92.8% 
1 109 (6.6%) 99.4% 
2 10 (0.6%) 100.0% 
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Appendix Table 3: Sensitivity analysis results of generalized estimating equation models of 
circumvention behavior after excluding Aim 1 subjects with any gaps in Medicaid coverage 
 
Any circumvented fill Number of circumvented fills 
Variable RR (95% CI) P-value IRR (95% CI) P-value 
Key independent variable 
       	  MLIP enrollment (Key IV) 3.59 (3.15 , 4.10)	   <0.001 4.50 (3.82 , 5.30) <0.001 
MLIP policy variables         
MLIP enrollment * month 1.00 (0.99 , 1.01)	   0.895 1.01 (1.00 , 1.02) 0.201 
MLIP enrollment delay 1.29 (1.13 , 1.48) <0.001 1.25 (1.06 , 1.48) 0.008 
MLIP enrollment delay * month 1.02 (1.00 , 1.04) 0.035 1.02 (1.00 , 1.05) 0.046 
Month 1.00 (0.99 , 1.01) 0.606 0.98	   (0.97 , 1.00) 0.023	  
MLIP policy period 0.82 (0.73 , 0.92) 0.001 0.87 (0.75 , 1.00) 0.049 
MLIP policy period * month 0.99 (0.98 , 1.00) 0.100 1.00 (0.98 , 1.01) 0.657 
MLIP eligibility route 
        Opioid use 1.01 (0.87, 1.17) 0.902 1.13 (0.95 , 1.35) 0.169 
Benzodiazipine use 1.51 (1.28 , 1.79) <0.001	   1.79 (1.47 , 2.17) <0.001 
Prescriber use 1.10 (1.00 , 1.20) 0.053 1.16 (1.01 , 1.34) 0.042 
No eligibility criteria met 0.95 (0.72 , 1.25) 0.712 1.00 (0.70 , 1.43) 0.988 
Predisposing characteristics	  
        Age 0.993 (0.99, 1.00) <0.001 0.992 (0.99 , 1.00) 0.007 
Female 0.93 (0.86 , 1.02) 0.124 0.88 (0.77	  , 1.00) 0.058 
Race (White referent) 
        Black 0.99 (0.90, 1.10) 0.900 0.96 (0.82 , 1.13) 0.643 
Other 0.99 (0.84 , 1.15) 0.853 0.95 (0.76 , 1.18) 0.630 
Enabling characteristics	  
        Metropolitan residence 1.00 (0.91, 1.09)	   0.969 1.03 (0.90 , 1.17) 0.678 
County pharmacy supply (<10 referent) 
        11-25 1.06 (0.95, 1.19) 0.282 1.05 (0.90 , 1.22) 0.551 
26-50 1.11 (1.00 , 1.24) 0.057 1.09 (0.94 , 1.27) 0.270 
51-100 1.10 (0.98 , 1.24) 0.116 1.07 (0.91 , 1.26) 0.429 
>100 1.25 (1.09	  , 1.43) 0.002 1.37	   (1.10 , 1.70) 0.006 
Border county 0.97 (0.90 , 1.05) 0.440 0.98 (0.87 , 1.11) 0.751 
Need characteristics	  
        Chronic non-cancer pain 1.33 (1.04, 1.70) 0.026 1.46 (1.08 , 1.99) 0.015 
Anxiety disorder 1.14 (1.05 , 1.24) 0.002 1.12 (0.99 , 1.28) 0.077 
Substance abuse disorder 1.02	   (0.94 , 1.09) 0.694	   1.04 (0.93 , 1.17)	   0.466 
Depression 1.08 (1.00 , 1.17) 0.064 1.12 (0.99 , 1.27) 0.063 
Other mental illness 1.03 (0.96 , 1.11) 0.379 1.02 (0.91 , 1.14) 0.729 
Charlson Comorbidity Index score 
        0 (referent) 
        1 1.00	   (0.91, 1.09) 0.998 0.97 (0.85 , 1.11) 0.668 
≥2 1.15 (1.04 , 1.27) 0.007 1.17 (0.99 , 1.37) 0.060 
Prescription drug burden 1.00 (0.99 , 1.00) 0.431 1.00 (0.99 , 1.01) 0.402 
Note: 1,528 subjects were included (119 excluded due to a coverage gap of 1 or 2 months). RR=Relative risk; 
CI=Confidence interval; IRR=Incidence rate ratio; MLIP=Medicaid controlled substance lock-in program 
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Appendix Table 4: Sensitivity analysis comparing generalized estimated equation output from logistic 
versus modified Poisson modeling approach of the Aim 1 binary circumvention outcome 
 
Modified Poisson Logistic regression 
Variable RR (95% CI) P-value OR (95% CI) P-value 
Key independent variable	  
       	  MLIP enrollment (Key IV) 3.55	   (3.13	  , 4.03)	   <0.001	   5.96 (5.05, 7.03) <0.001 
MLIP policy variables        
MLIP enrollment * month 1.00	   (0.99	  , 1.01)	   0.675	   1.00 (0.98 , 1.01) 0.550 
MLIP enrollment delay 1.28	   (1.13	  , 1.46)	   <0.001	   1.33 (1.14 , 1.56) <0.001 
MLIP enrollment delay * month 1.02	   (1.00	  , 1.03) 0.031	   1.03 (1.00 , 1.05) 0.018 
Month 1.00 (0.99	  , 1.01)	   0.766	   1.00 (0.99 , 1.01) 0.845 
MLIP policy period 0.81	   (0.73	  , 0.91)	   <0.001	   0.80 (0.70 , 0.92) 0.001 
MLIP policy period * month 0.99	   (0.98	  , 1.00)	   0.099	   0.98 (0.96 , 1.00) 0.037 
MLIP eligibility route 
       Opioid use 1.01	   (0.87	  , 1.16)	   0.928	   1.01 (0.81 , 1.25) 0.932 
Benzodiazipine use 1.52	   (1.29	  , 1.79)	   <0.001	   2.01 (1.49 , 2.70)	   <0.001 
Prescriber use 1.10	   (1.01	  , 1.21) 0.028	   1.16 (1.02 , 1.32) 0.028 
No eligibility criteria met 0.94 (0.72	  , 1.22) 0.628	   0.91 (0.62 , 1.34) 0.646 
Predisposing characteristics	  
       Age 0.994	   (0.99, 1.00)	   0.001 0.99 (0.99 , 1.00) 0.002 
Female 0.94	   (0.86 , 1.02)	   0.144 0.91 (0.80 , 1.03) 0.147 
Race (White referent) 
       Black 0.99 (0.90	  , 1.10) 0.892	   0.99 (0.85 , 1.15) 0.889 
Other 0.96 (0.82	  , 1.11) 0.551	   0.94 (0.75 , 1.17)	   0.569 
Enabling characteristics	  
       Metropolitan residence 1.01	   (0.93	  , 1.10)	   0.806	   1.02 (0.90 , 1.16) 0.776 
County pharmacy supply (<10 referent) 
       11-25 1.05	   (0.95	  , 1.17)	   0.343	   1.08 (0.92 , 1.26) 0.340 
26-50 1.10	   (0.99	  , 1.22)	   0.071	   1.15 (0.99 , 1.34) 0.072 
51-100 1.07	   (0.96	  , 1.20)	   0.220	   1.11 (0.94 , 1.31) 0.237 
>100 1.22	   (1.07	  , 1.39)	   0.004	   1.34 (1.10 , 1.64)	   0.004 
Border county 1.00	   (0.93	  , 1.07)	   0.925	   0.99 (0.89 , 1.11)	   0.916 
Need characteristics	  
       Chronic non-cancer pain 1.33	   (1.06	  , 1.68)	   0.013	   1.50 (1.10 , 2.04) 0.010 
Anxiety disorder 1.12	   (1.04 , 1.22)	   0.003 1.19 (1.06 , 1.33) 0.003 
Substance abuse disorder 1.01	   (0.94 , 1.08)	   0.874	   1.01 (0.91 , 1.12) 0.855 
Depression 1.07	   (0.99	  , 1.16)	   0.071	   1.11 (0.99 , 1.24) 0.070 
Other mental illness 1.05	   (0.98	  , 1.13)	   0.195	   1.07 (0.96 , 1.19) 0.208 
Charlson Comorbidity Index score 
       0 (referent) 
       1 1.00	   (0.92	  , 1.09)	   0.979	   1.00 (0.88	  , 1.13) 0.995 
≥2 1.14	   (1.03	  , 1.25)	   0.010	   1.21 (1.05 , 1.41) 0.011 
Prescription drug burden 1.00	   (0.99	  , 1.00)	   0.473	   1.00 (0.99 , 1.00) 0.458 
Note: RR=Relative risk; OR=odds ratio; CI=confidence interval; IRR=incidence rate ratio; MLIP=Medicaid lock-in 
program. OR were obtained through generalized estimating equation (GEE) modeling with monthly measures using 
binomial distribution, logit link, and autoregressive (1 month) correlation structure. RR were obtained through GEE 
using Poisson distribution, log link, and autoregressive correlation structure. Both models used robust standard 
errors. 
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Appendix Table 5: Pearson’s correlation coefficients among enabling variables in Aim 1  
 
RUCC 
Metro 
county 
Pharmacy 
supply 
Prescriber 
supply 
Border 
county 
RUCC 1.00 
    Metro county -0.85 1.00 
   Pharmacy supply -0.45 0.35 1.00 
  Prescriber supply -0.42 0.38 0.92 1.00 
 Border county 0.13 -0.26 0.10 -0.01 1.00 
Note: All enabling variables assessed at county level. RUCC=Rural-urban continuum code 
 
Appendix Table 6: Pearson’s correlation coefficients among need variables in Aim 1 
 
Pain 
Anx  
-iety 
Depress
-ion 
Subst. 
use 
Other 
MHI 
Charl
-son 
Rx 
count 
Opioid 
elig. 
Benzo 
elig. 
Doc 
elig. 
Not 
elig. 
Pain 1.00 
          Anxiety 0.10 1.00 
         Depression 0.07 0.28 1.00 
        Subst. use 0.04 0.17 0.16 1.00 
       Other MHI 0.05 0.23 0.24 0.19 1.00 
      Charlson  0.09 0.05 0.12 0.13 0.05 1.00 
     Rx count 0.20 0.24 0.30 0.10 0.22 0.36 1.00 
    Opioid elig. 0.06 -0.09 -0.08 -0.14 -0.12 0.04 0.06 1.00 
   Benzo elig. -0.03 0.10 0.05 0.05 0.07 0.02 -0.04 -0.31 1.00 
  Doc elig. 0.03 -0.01 -0.09 0.00 -0.05 -0.13 -0.24 0.12 0.00 1.00 
 Not elig. -0.09 0.04 0.06 0.13 0.06 -0.02 -0.01 -0.59 -0.04 -0.33 1.00 
Note: Subst.=Substance; MHI=Mental health illness; Rx=Prescription; Elig=Eligibility; Benzo=Benzodiazepine; 
Doc=Prescriber. 
 
Appendix Table 7: Distribution of a categorical county-level pharmacy supply measure in the Aim 1 
cohort 
County 
pharmacy supply 
Frequency 
n (%) 
Cumulative 
% 
10 or less 9144 (17.7%) 17.7% 
11 to 25 12680 (24.5%) 42.1% 
26 to 50 13362 (25.8%) 67.9% 
51 to 100 10186 (19.7%) 87.6% 
Over 100 6426 (12.4%) 100.0% 
Note: County pharmacy supply was variable within subject, so frequency refers to monthly observations 
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Appendix Table 8: Sensitivity analysis results of generalized estimating equation models of 
circumvention behavior when including county-level pharmacy supply, county RUCC score, and 
Charlson score in their original continuous forms 
 
Any circumvented fill Number of circumvented fills 
Variable RR (95% CI) P-value IRR (95% CI) P-value 
Key independent variable	  
       	  MLIP enrollment (Key IV) 3.54	   (3.12	  , 4.02) <0.001 4.39 (3.74 , 5.14) <0.001 
MLIP policy variables         
MLIP enrollment * month 1.00 (0.99 , 1.01) 0.656 1.01 (0.99 , 1.02) 0.282 
MLIP enrollment delay 1.28 (1.13 , 1.46) <0.001 1.25 (1.06 , 1.47) 0.008 
MLIP enrollment delay * month 1.02 (1.00	  , 1.03) 0.033 1.02	   (1.00 , 1.05) 0.038 
Month 1.00 (0.99 , 1.01) 0.763 0.98 (0.97 , 1.00) 0.025 
MLIP policy period 0.81 (0.73 , 0.91) <0.001 0.88 (0.77 , 1.01)	   0.078 
MLIP policy period * month 0.99 (0.98 , 1.00) 0.104 1.00 (0.98 , 1.01) 0.661 
MLIP eligibility route 
        Opioid use 1.01	   (0.87, 1.16) 0.932	   1.11 (0.93 , 1.32) 0.263 
Benzodiazipine use 1.55 (1.31 , 1.82) <0.001 1.83 (1.51 , 2.21) <0.001 
Prescriber use 1.10 (1.01 , 1.21) 0.030 1.18 (1.03 , 1.35) 0.019 
No eligibility criteria met 0.93 (0.71 , 1.21) 0.576 0.96 (0.68 , 1.36) 0.828 
Predisposing characteristics	  
        Age 0.994 (0.99, 1.00) 0.002 0.994 (0.99	  , 1.00) 0.018 
Female 0.94 (0.86 , 1.02) 0.159 0.88 (0.78 , 1.00) 0.058 
Race (White referent) 
        Black 0.99 (0.89, 1.09) 0.802 0.96 (0.82 , 1.12) 0.582 
Other 0.97 (0.84 , 1.13) 0.728 0.92 (0.75 , 1.14) 0.450 
Enabling characteristics	  
        RUCC score 0.99 (0.97, 1.01) 0.415 0.99 (0.96 , 1.02) 0.654 
County pharmacy supply  1.00 (1.00 , 1.00) 0.030 1.00 (1.00 , 1.00) 0.014 
Border county 0.99 (0.92 , 1.06) 0.721 1.00 (0.89 , 1.11) 0.948 
Need characteristics	  
        Chronic non-cancer pain 1.34 (1.07, 1.69) 0.012 1.48 (1.11 , 1.97) 0.007 
Anxiety disorder 1.13 (1.05 , 1.22) 0.002 1.12	   (0.99 , 1.26) 0.079 
Substance abuse disorder 1.01 (0.94 , 1.08) 0.866 1.03 (0.92 , 1.15) 0.624 
Depression 1.07 (0.99 , 1.15) 0.097 1.10 (0.98 , 1.24) 0.094 
Other mental illness 1.05	   (0.97 , 1.12) 0.221	   1.03 (0.93 , 1.15) 0.572 
Charlson Comorbidity Index score 1.03 (1.01 , 1.05) 0.002 1.03 (1.01 , 1.06) 0.019 
Prescription drug burden 1.00 (0.99 , 1.00) 0.424 1.00 (0.99 , 1.00)	   0.368 
Note: RR=Relative risk; CI=Confidence interval; IRR=Incidence rate ratio; MLIP=Medicaid controlled substance 
lock-in program; RUCC=Rural-urban continuum code (RUCC ranges from 1-9 with 1 reflected the most 
metropolitan counties) 
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Appendix Table 9: GLM models for Aim 2 outcomes among circumvented opioid prescription fills, excluding subjects with coverage gaps 
 
Schedule II opioid Long acting opioid Mean MME/day 
Variable RR (95% CI) P-value RR (95% CI) P-value ME (95% CI) P-value 
Key independent variable 
        	      MLIP enrollment 0.95 (0.84, 1.07) 0.406 0.53 (0.36, 0.78) 0.001 0.82  (-8.67, 10.32) 0.865 
MLIP policy variables             
MLIP enrollment * month 1.00 (0.99 , 1.02) 0.507 1.02 (0.98 , 1.06) 0.257 0.42  (-0.41 , 1.25) 0.324 
MLIP enrollment delay 0.99 (0.88 , 1.12) 0.860 0.80 (0.57 , 1.11) 0.177 2.64  (-6.63 , 11.92) 0.576 
MLIP enrollment delay * month 1.00 (0.99 , 1.02) 0.664 1.01 (0.96 , 1.07) 0.676 0.76  (-0.80 , 2.32) 0.340 
Month 1.01 (1.00 , 1.03) 0.055 1.00 (0.96 , 1.04) 0.967 -0.61  (-1.68 , 0.47) 0.272 
MLIP policy period 1.06 (0.93 , 1.19) 0.393 1.42 (1.03 , 1.96) 0.032 -1.33  (-11.22 , 8.55) 0.791 
MLIP policy period * month 0.99 (0.97 , 1.00) 0.059 1.00 (0.95 , 1.05) 0.925 0.16  (-1.13 , 1.44) 0.812 
MLIP eligibility route             
Opioid use 0.96 (0.79 , 1.17) 0.689 0.83 (0.50 , 1.38) 0.473 2.96  (-10.26 , 16.19) 0.661 
Benzodiazepine use 0.90 (0.69 , 1.16) 0.407 0.85 (0.43 , 1.70) 0.656 -1.06  (-21.03 , 18.91) 0.917 
Pharmacy use 1.02 (0.92 , 1.14) 0.675 0.90 (0.67 , 1.21) 0.482 -1.55  (-8.94 , 5.84) 0.681 
No eligibility criteria met 1.04 (0.78 , 1.38) 0.798 0.78 (0.27 , 2.21) 0.639 -3.21  (-21.93 , 15.51) 0.737 
Predisposing characteristics             
Age 1.003 (0.998 , 1.008) 0.199 1.007 (0.992 , 1.021) 0.366 0.39 (0.07 , 0.71) 0.018 
Female 0.80 (0.73 , 0.89) <0.001 0.82 (0.59 , 1.13) 0.233 -9.96  (-19.48 , -0.45) 0.040 
Race (White referent)             
Black 1.09 (0.97 , 1.23) 0.165 0.96 (0.65 , 1.41) 0.820 -1.82  (-9.46 , 5.81) 0.640 
Other 1.11 (0.93 , 1.32) 0.244 0.94 (0.51 , 1.72) 0.840 -5.08  (-17.11 , 6.95) 0.408 
Enabling characteristics             
Metropolitan residence 0.92 (0.82 , 1.03) 0.133 0.86 (0.60 , 1.24) 0.416 -4.12  (-12.90 , 4.67) 0.358 
County pharmacy supply (<10 referent)             
11-25 0.95 (0.83 , 1.09) 0.489 0.86 (0.55 , 1.34) 0.501 -2.96  (-12.88 , 6.96) 0.558 
26-50 0.96 (0.85 , 1.10) 0.574 0.96 (0.62 , 1.49) 0.852 0.58  (-10.32 , 11.49) 0.917 
51-100 1.09 (0.94 , 1.25) 0.243 1.14 (0.72 , 1.80) 0.581 0.03  (-11.19 , 11.25) 0.996 
>100 0.91 (0.75 , 1.11) 0.351 0.81 (0.47 , 1.39) 0.436 -7.90  (-17.09 , 1.30) 0.092 
Border county 0.91 (0.82 , 1.01) 0.073 1.08 (0.80 , 1.46) 0.617 3.13  (-5.24 , 11.49) 0.463 
Need characteristics             
Chronic non-cancer pain 1.23 (0.94 , 1.62) 0.134 4.70 (1.57 , 14.09) 0.006 12.60 (3.86 , 21.35) 0.005 
Anxiety disorder 0.99 (0.90 , 1.10) 0.899 0.90 (0.65 , 1.25) 0.530 -3.10  (-10.81 , 4.61) 0.430 
Substance abuse disorder 1.01 (0.93 , 1.11) 0.780 1.22 (0.90 , 1.64) 0.198 2.68  (-3.78 , 9.13) 0.417 
Depression 1.14 (1.03 , 1.26) 0.009 1.21 (0.89 , 1.65) 0.218 1.44  (-5.68 , 8.55) 0.692 
Other mental illness 0.97 (0.87 , 1.06) 0.477 0.89 (0.67 , 1.20) 0.454 -0.92  (-7.98 , 6.14) 0.799 
Charlson Comorbidity Index (0 referent)             
1 1.03 (0.92 , 1.15) 0.636 0.83 (0.56 , 1.23) 0.352 5.32  (-3.01 , 13.65) 0.211 
≥2 1.12 (0.99 , 1.27) 0.083 1.14 (0.77 , 1.67) 0.516 15.17 (5.73 , 24.61) 0.002 
Prescription drug burden 1.00 (0.99 , 1.00) 0.417 0.99 (0.98 , 1.01) 0.359 -0.51  (-0.86 , -0.16) 0.005 
Note: MME=Milligram morphine equivalent; RR=Relative risk; CI=Confidence interval; ME=Marginal effect; MLIP=Medicaid lock-in program. 117 subjects were excluded from primary analysis due 
Medicare coverage gap(s). GLM predicting the binary outcomes specified a Poisson distribution, log link, and cluster-robust standard errors. GLM predicting the mean MME/day outcome specified a 
log link, inverse Gaussian distribution, and cluster-robust standard errors. All models included 18,204 fills and 1,409 subjects. 
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Appendix Figure 2: Residual distribution for ordinary least squares model of level MME/day outcome 
 
 
Appendix Figure 3: Residual distribution for GLM model of MME/day with inverse Gaussian distribution 
and log link 
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Appendix Table 10: Tabular survival ROC results—opioid fill count/unintentional opioid overdose 
Opioid fill 
count  
cutpoint 
Total subjects 
meeting cutpoint 
n (%) 
Outcome events 
in cutpoint  
n (%) Sensitivity Specificity 
Euclidean 
distance 
≥1 69668 (100.0%) 202 (0.3%) 1.00 0.00 0.00 
≥2 35106 (50.4%) 152 (0.4%) 0.73 0.50 0.43 
≥3* 19166 (27.5%) 117 (0.6%) 0.55 0.73 0.47 
≥4 9712 (13.9%) 80 (0.8%) 0.38 0.86 0.36 
≥5 5611 (8.1%) 60 (1.1%) 0.28 0.92 0.28 
≥6 3316 (4.8%) 41 (1.2%) 0.20 0.95 0.19 
≥7 1654 (2.4%) 20 (1.2%) 0.10 0.98 0.10 
≥8 955 (1.4%) 14 (1.5%) 0.07 0.99 0.07 
≥9 564 (0.8%) 9 (1.6%) 0.04 0.99 0.04 
≥10 324 (0.5%) 6 (1.9%) 0.03 1.00 0.03 
≥11 188 (0.3%) 3 (1.6%) 0.01 1.00 0.01 
≥12 120 (0.2%) 1 (0.8%) 0.00 1.00 0.00 
≥13 63 (0.1%) 0 (0.0%) 0.00 1.00 0.00 
≥14 30 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥15 24 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥16 13 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥17 11 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥18 9 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥20 5 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥21 2 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥22 1 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
*Optimal cutpoint based on joint maximized sensitivity/specificity 
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Appendix Table 11: Tabular survival ROC results—opioid fill count/unintentional acetaminophen 
overdose 
Opioid fill 
count  
cutpoint 
Total subjects 
meeting cutpoint 
n (%) 
Outcome events 
in cutpoint  
n (%) Sensitivity Specificity 
Euclidean 
distance 
≥1 69668 (100.0%) 82 (0.1%) 1.00 0.00 0.00 
≥2* 35106 (50.4%) 54 (0.2%) 0.64 0.50 0.38 
≥3 19166 (27.5%) 37 (0.2%) 0.43 0.73 0.36 
≥4 9712 (13.9%) 23 (0.2%) 0.27 0.86 0.26 
≥5 5611 (8.1%) 18 (0.3%) 0.21 0.92 0.21 
≥6 3316 (4.8%) 14 (0.4%) 0.16 0.95 0.16 
≥7 1654 (2.4%) 10 (0.6%) 0.12 0.98 0.12 
≥8 955 (1.4%) 5 (0.5%) 0.06 0.99 0.06 
≥9 564 (0.8%) 2 (0.4%) 0.02 0.99 0.02 
≥10 324 (0.5%) 2 (0.6%) 0.02 1.00 0.02 
≥11 188 (0.3%) 2 (1.1%) 0.02 1.00 0.02 
≥12 120 (0.2%) 1 (0.8%) 0.01 1.00 0.01 
≥13 63 (0.1%) 0 (0.0%) 0.00 1.00 0.00 
≥14 30 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥15 24 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥16 13 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥17 11 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥18 9 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥20 5 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥21 2 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥22 1 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
*Optimal cutpoint based on joint maximized sensitivity/specificity 
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Appendix Table 12: Tabular survival ROC results—opioid fill count/unintentional overdose, any drug 
Opioid fill 
count  
cutpoint 
Total subjects 
meeting cutpoint 
n (%) 
Outcome events 
in cutpoint  
n (%) Sensitivity Specificity 
Euclidean 
distance 
≥1 69668 (100.0%) 1040 (1.5%) 1.00 0.00 0.00 
≥2 35106 (50.4%) 729 (2.1%) 0.68 0.50 0.40 
≥3* 19166 (27.5%) 511 (2.7%) 0.46 0.73 0.40 
≥4 9712 (13.9%) 323 (3.3%) 0.29 0.86 0.28 
≥5 5611 (8.1%) 200 (3.6%) 0.18 0.92 0.18 
≥6 3316 (4.8%) 134 (4.0%) 0.12 0.95 0.12 
≥7 1654 (2.4%) 76 (4.6%) 0.07 0.98 0.07 
≥8 955 (1.4%) 45 (4.7%) 0.04 0.99 0.04 
≥9 564 (0.8%) 27 (4.8%) 0.03 0.99 0.03 
≥10 324 (0.5%) 16 (4.9%) 0.01 1.00 0.01 
≥11 188 (0.3%) 9 (4.8%) 0.01 1.00 0.01 
≥12 120 (0.2%) 4 (3.3%) 0.00 1.00 0.00 
≥13 63 (0.1%) 2 (3.2%) 0.00 1.00 0.00 
≥14 30 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥15 24 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥16 13 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥17 11 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥18 9 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥20 5 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥21 2 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥22 1 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
*Optimal cutpoint based on joint maximized sensitivity/specificity 
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Appendix Table 13: Tabular survival ROC results—opioid fill count/opioid use disorder 
Opioid fill 
count  
cutpoint 
Total subjects 
meeting cutpoint 
n (%) 
Outcome events 
in cutpoint  
n (%) Sensitivity Specificity 
Euclidean 
distance 
≥1 69668 (100.0%) 2284 (3.3%) 1.00 0.00 0.00 
≥2 35106 (50.4%) 1716 (4.9%) 0.74 0.51 0.44 
≥3* 19166 (27.5%) 1280 (6.7%) 0.54 0.74 0.47 
≥4 9712 (13.9%) 833 (8.6%) 0.35 0.87 0.34 
≥5 5611 (8.1%) 565 (10.1%) 0.24 0.93 0.24 
≥6 3316 (4.8%) 374 (11.3%) 0.16 0.96 0.16 
≥7 1654 (2.4%) 213 (12.9%) 0.09 0.98 0.09 
≥8 955 (1.4%) 123 (12.9%) 0.05 0.99 0.05 
≥9 564 (0.8%) 73 (12.9%) 0.03 0.99 0.03 
≥10 324 (0.5%) 44 (13.6%) 0.02 1.00 0.02 
≥11 188 (0.3%) 34 (18.1%) 0.01 1.00 0.01 
≥12 120 (0.2%) 22 (18.3%) 0.01 1.00 0.01 
≥13 63 (0.1%) 13 (20.6%) 0.01 1.00 0.01 
≥14 30 (0.0%) 6 (20.0%) 0.00 1.00 0.00 
≥15 24 (0.0%) 6 (25.0%) 0.00 1.00 0.00 
≥16 13 (0.0%) 2 (15.4%) 0.00 1.00 0.00 
≥17 11 (0.0%) 1 (9.1%) 0.00 1.00 0.00 
≥18 9 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥20 5 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥21 2 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥22 1 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
*Optimal cutpoint based on joint maximized sensitivity/specificity 
 
Appendix Table 14: Tabular survival ROC results—opioid fill count/any substance use disorder 
Opioid fill 
count  
cutpoint 
Total subjects 
meeting cutpoint 
n (%) 
Outcome events 
in cutpoint  
n (%) Sensitivity Specificity 
Euclidean 
distance 
≥1 69668 (100.0%) 19713 (28.3%) 1.00 0.00 0.00 
≥2* 35106 (50.4%) 12657 (36.1%) 0.62 0.56 0.42 
≥3 19166 (27.5%) 8122 (42.4%) 0.39 0.79 0.35 
≥4 9712 (13.9%) 4617 (47.5%) 0.22 0.90 0.21 
≥5 5611 (8.1%) 2842 (50.7%) 0.13 0.95 0.13 
≥6 3316 (4.8%) 1794 (54.1%) 0.08 0.97 0.08 
≥7 1654 (2.4%) 926 (56.0%) 0.04 0.99 0.04 
≥8 955 (1.4%) 547 (57.3%) 0.03 0.99 0.03 
≥9 564 (0.8%) 337 (59.8%) 0.02 1.00 0.02 
≥10 324 (0.5%) 204 (63.0%) 0.01 1.00 0.01 
≥11 188 (0.3%) 123 (65.4%) 0.01 1.00 0.01 
≥12 120 (0.2%) 76 (63.3%) 0.00 1.00 0.00 
≥13 63 (0.1%) 47 (74.6%) 0.00 1.00 0.00 
≥14 30 (0.0%) 23 (76.7%) 0.00 1.00 0.00 
≥15 24 (0.0%) 20 (83.3%) 0.00 1.00 0.00 
≥16 13 (0.0%) 10 (76.9%) 0.00 1.00 0.00 
≥17 11 (0.0%) 8 (72.7%) 0.00 1.00 0.00 
≥18 9 (0.0%) 6 (66.7%) 0.00 1.00 0.00 
≥20 5 (0.0%) 3 (60.0%) 0.00 1.00 0.00 
≥21 2 (0.0%) 1 (50.0%) 0.00 1.00 0.00 
≥22 1 (0.0%) 1 (100.0%) 0.00 1.00 0.00 
*Optimal cutpoint based on joint maximized sensitivity/specificity 
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Appendix Table 15: Tabular survival ROC results—pharmacy count/unintentional opioid overdose 
Pharmacy 
count  
cutpoint 
Total subjects 
meeting cutpoint 
n (%) 
Outcome events 
in cutpoint  
n (%) Sensitivity Specificity 
Euclidean 
distance 
≥1 69668 (100.0%) 202 (0.3%) 1.00 0.00 0.00 
≥2* 11218 (16.1%) 57 (0.5%) 0.29 0.84 0.27 
≥3 2274 (3.3%) 24 (1.1%) 0.12 0.97 0.12 
≥4 575 (0.8%) 8 (1.4%) 0.04 0.99 0.04 
≥5 156 (0.2%) 2 (1.3%) 0.01 1.00 0.01 
≥6 52 (0.1%) 0 (0.0%) 0.00 1.00 0.00 
≥7 22 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥8 10 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥9 4 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥11 3 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥16 1 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
*Optimal cutpoint based on joint maximized sensitivity/specificity 
 
Appendix Table 16: Tabular survival ROC results—pharmacy count/unintentional acetaminophen 
overdose 
Pharmacy 
count  
cutpoint 
Total subjects 
meeting cutpoint 
n (%) 
Outcome events 
in cutpoint  
n (%) Sensitivity Specificity 
Euclidean 
distance 
≥1 69668 (100.0%) 82 (0.1%) 1.00 0.00 0.00 
≥2* 11218 (16.1%) 18 (0.2%) 0.21 0.84 0.20 
≥3 2274 (3.3%) 8 (0.4%) 0.10 0.97 0.10 
≥4 575 (0.8%) 4 (0.7%) 0.04 0.99 0.04 
≥5 156 (0.2%) 0 (0.0%) 0.00 1.00 0.00 
≥6 52 (0.1%) 0 (0.0%) 0.00 1.00 0.00 
≥7 22 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥8 10 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥9 4 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥11 3 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥16 1 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
*Optimal cutpoint based on joint maximized sensitivity/specificity 
 
Appendix Table 17: Tabular survival ROC results—pharmacy count/unintentional overdose, any drug 
Pharmacy 
count  
cutpoint 
Total subjects 
meeting cutpoint 
n (%) 
Outcome events 
in cutpoint  
n (%) Sensitivity Specificity 
Euclidean 
distance 
≥1 69668 (100.0%) 1040 (1.5%) 1.00 0.00 0.00 
≥2* 11218 (16.1%) 281 (2.5%) 0.27 0.84 0.26 
≥3 2274 (3.3%) 84 (3.7%) 0.08 0.97 0.08 
≥4 575 (0.8%) 25 (4.3%) 0.02 0.99 0.02 
≥5 156 (0.2%) 7 (4.5%) 0.01 1.00 0.01 
≥6 52 (0.1%) 2 (3.8%) 0.00 1.00 0.00 
≥7 22 (0.0%) 1 (4.5%) 0.00 1.00 0.00 
≥8 10 (0.0%) 1 (10.0%) 0.00 1.00 0.00 
≥9 4 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥11 3 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
≥16 1 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
*Optimal cutpoint based on joint maximized sensitivity/specificity 
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Appendix Table 18: Tabular survival ROC results—pharmacy count/opioid use disorder 
Pharmacy 
count  
cutpoint 
Total subjects 
meeting cutpoint 
n (%) 
Outcome events 
in cutpoint  
n (%) Sensitivity Specificity 
Euclidean 
distance 
≥1 69668 (100.0%) 2284 (3.3%) 1.00 0.00 0.00 
≥2* 11218 (16.1%) 825 (7.4%) 0.37 0.85 0.35 
≥3 2274 (3.3%) 304 (13.4%) 0.13 0.97 0.13 
≥4 575 (0.8%) 95 (16.5%) 0.04 0.99 0.04 
≥5 156 (0.2%) 24 (15.4%) 0.01 1.00 0.01 
≥6 52 (0.1%) 7 (13.5%) 0.00 1.00 0.00 
≥7 22 (0.0%) 4 (18.2%) 0.00 1.00 0.00 
≥8 10 (0.0%) 3 (30.0%) 0.00 1.00 0.00 
≥9 4 (0.0%) 1 (25.0%) 0.00 1.00 0.00 
≥11 3 (0.0%) 1 (33.3%) 0.00 1.00 0.00 
≥16 1 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
*Optimal cutpoint based on joint maximized sensitivity/specificity 
 
Appendix Table 19: Tabular survival ROC results—pharmacy count/any substance use disorder 
Pharmacy 
count  
cutpoint 
Total subjects 
meeting cutpoint 
n (%) 
Outcome events 
in cutpoint  
n (%) Sensitivity Specificity 
Euclidean 
distance 
≥1 69668 (100.0%) 19713 (28.3%) 1.00 0.00 0.00 
≥2 11218 (16.1%) 4686 (41.8%) 0.23 0.88 0.22 
≥3 2274 (3.3%) 1196 (52.6%) 0.06 0.98 0.06 
≥4 575 (0.8%) 339 (59.0%) 0.02 1.00 0.02 
≥5 156 (0.2%) 90 (57.7%) 0.00 1.00 0.00 
≥6 52 (0.1%) 30 (57.7%) 0.00 1.00 0.00 
≥7 22 (0.0%) 15 (68.2%) 0.00 1.00 0.00 
≥8 10 (0.0%) 8 (80.0%) 0.00 1.00 0.00 
≥9 4 (0.0%) 4 (100.0%) 0.00 1.00 0.00 
≥11 3 (0.0%) 3 (100.0%) 0.00 1.00 0.00 
≥16 1 (0.0%) 1 (100.0%) 0.00 1.00 0.00 
*Optimal cutpoint based on joint maximized sensitivity/specificity 
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Appendix Table 20: Tabular survival ROC results—mean daily MME/unintentional opioid overdose 
MME/day  
cutpoint 
Total subjects 
meeting cutpoint 
n (%) 
Outcome events 
in cutpoint  
n (%) Sensitivity Specificity 
Euclidean 
distance 
>0 69668 (100.0%) 202 (0.3%) 1.00 0.00 0.00 
≥5 35250 (50.6%) 155 (0.4%) 0.74 0.49 0.43 
≥10* 23122 (33.2%) 132 (0.6%) 0.60 0.67 0.48 
≥20 14950 (21.5%) 106 (0.7%) 0.47 0.79 0.43 
≥30 11131 (16.0%) 87 (0.8%) 0.38 0.84 0.36 
≥40 8426 (12.1%) 75 (0.9%) 0.33 0.88 0.32 
≥60 5659 (8.1%) 60 (1.1%) 0.26 0.92 0.25 
≥80 3897 (5.6%) 49 (1.3%) 0.21 0.94 0.21 
≥100 2965 (4.3%) 43 (1.5%) 0.18 0.96 0.18 
≥125 2399 (3.4%) 40 (1.7%) 0.17 0.97 0.17 
≥150 1983 (2.8%) 35 (1.8%) 0.15 0.97 0.15 
≥175 1703 (2.4%) 28 (1.6%) 0.12 0.98 0.12 
≥200 1441 (2.1%) 22 (1.5%) 0.09 0.98 0.09 
≥250 1061 (1.5%) 15 (1.4%) 0.06 0.98 0.06 
≥300 818 (1.2%) 12 (1.5%) 0.05 0.99 0.05 
≥400 482 (0.7%) 7 (1.5%) 0.03 0.99 0.03 
≥500 273 (0.4%) 4 (1.5%) 0.02 1.00 0.02 
≥1000 38 (0.1%) 1 (2.6%) 0.00 1.00 0.00 
≥2000 5 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
*Optimal cutpoint based on joint maximized sensitivity/specificity 
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Appendix Table 21: Tabular survival ROC results—mean daily MME/unintentional acetaminophen 
overdose 
MME/day  
cutpoint 
Total subjects 
meeting cutpoint 
n (%) 
Outcome events 
in cutpoint  
n (%) Sensitivity Specificity 
Euclidean 
distance 
>0 69668 (100.0%) 82 (0.1%) 1.00 0.00 0.00 
≥5* 35250 (50.6%) 47 (0.1%) 0.56 0.49 0.33 
≥10 23122 (33.2%) 36 (0.2%) 0.41 0.67 0.32 
≥20 14950 (21.5%) 27 (0.2%) 0.30 0.79 0.27 
≥30 11131 (16.0%) 23 (0.2%) 0.25 0.84 0.23 
≥40 8426 (12.1%) 21 (0.2%) 0.23 0.88 0.22 
≥60 5659 (8.1%) 10 (0.2%) 0.11 0.92 0.10 
≥80 3897 (5.6%) 8 (0.2%) 0.08 0.94 0.08 
≥100 2965 (4.3%) 5 (0.2%) 0.05 0.96 0.05 
≥125 2399 (3.4%) 5 (0.2%) 0.05 0.97 0.05 
≥150 1983 (2.8%) 2 (0.1%) 0.02 0.97 0.02 
≥175 1703 (2.4%) 1 (0.1%) 0.01 0.98 0.01 
≥200 1441 (2.1%) 1 (0.1%) 0.01 0.98 0.01 
≥250 1061 (1.5%) 0 (0.0%) 0.00 0.98 0.00 
≥300 818 (1.2%) 0 (0.0%) 0.00 0.99 0.00 
≥400 482 (0.7%) 0 (0.0%) 0.00 0.99 0.00 
≥500 273 (0.4%) 0 (0.0%) 0.00 1.00 0.00 
≥1000 38 (0.1%) 0 (0.0%) 0.00 1.00 0.00 
≥2000 5 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
*Optimal cutpoint based on joint maximized sensitivity/specificity 
 
Appendix Table 22: Tabular survival ROC results—mean daily MME/unintentional overdose, any drug 
MME/day  
cutpoint 
Total subjects 
meeting cutpoint 
n (%) 
Outcome events 
in cutpoint  
n (%) Sensitivity Specificity 
Euclidean 
distance 
>0 69668 (100.0%) 1040 (1.5%) 1.00 0.00 0.00 
≥5 35250 (50.6%) 712 (2.0%) 0.66 0.50 0.39 
≥10* 23122 (33.2%) 545 (2.4%) 0.49 0.67 0.39 
≥20 14950 (21.5%) 413 (2.8%) 0.36 0.79 0.32 
≥30 11131 (16.0%) 332 (3.0%) 0.29 0.84 0.27 
≥40 8426 (12.1%) 272 (3.2%) 0.23 0.88 0.22 
≥60 5659 (8.1%) 191 (3.4%) 0.16 0.92 0.16 
≥80 3897 (5.6%) 150 (3.8%) 0.13 0.95 0.12 
≥100 2965 (4.3%) 114 (3.8%) 0.10 0.96 0.09 
≥125 2399 (3.4%) 98 (4.1%) 0.08 0.97 0.08 
≥150 1983 (2.8%) 87 (4.4%) 0.07 0.97 0.07 
≥175 1703 (2.4%) 75 (4.4%) 0.06 0.98 0.06 
≥200 1441 (2.1%) 63 (4.4%) 0.05 0.98 0.05 
≥250 1061 (1.5%) 44 (4.1%) 0.04 0.99 0.04 
≥300 818 (1.2%) 33 (4.0%) 0.03 0.99 0.03 
≥400 482 (0.7%) 17 (3.5%) 0.01 0.99 0.01 
≥500 273 (0.4%) 11 (4.0%) 0.01 1.00 0.01 
≥1000 38 (0.1%) 3 (7.9%) 0.00 1.00 0.00 
≥2000 5 (0.0%) 0 (0.0%) 0.00 1.00 0.00 
*Optimal cutpoint based on joint maximized sensitivity/specificity 
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Appendix Table 23: Tabular survival ROC results—mean daily MME/opioid use disorder 
MME/day  
cutpoint 
Total subjects 
meeting cutpoint 
n (%) 
Outcome events 
in cutpoint  
n (%) Sensitivity Specificity 
Euclidean 
distance 
>0 69668 (100.0%) 2284 (3.3%) 1.00 0.00 0.00 
≥5 35250 (50.6%) 1634 (4.6%) 0.70 0.50 0.42 
≥10* 23122 (33.2%) 1283 (5.5%) 0.54 0.68 0.43 
≥20 14950 (21.5%) 1011 (6.8%) 0.41 0.79 0.38 
≥30 11131 (16.0%) 822 (7.4%) 0.33 0.85 0.31 
≥40 8426 (12.1%) 691 (8.2%) 0.28 0.89 0.27 
≥60 5659 (8.1%) 504 (8.9%) 0.20 0.92 0.20 
≥80 3897 (5.6%) 397 (10.2%) 0.16 0.95 0.16 
≥100 2965 (4.3%) 334 (11.3%) 0.13 0.96 0.13 
≥125 2399 (3.4%) 287 (12.0%) 0.11 0.97 0.11 
≥150 1983 (2.8%) 256 (12.9%) 0.10 0.97 0.10 
≥175 1703 (2.4%) 224 (13.2%) 0.09 0.98 0.09 
≥200 1441 (2.1%) 194 (13.5%) 0.08 0.98 0.08 
≥250 1061 (1.5%) 152 (14.3%) 0.06 0.99 0.06 
≥300 818 (1.2%) 128 (15.6%) 0.05 0.99 0.05 
≥400 482 (0.7%) 77 (16.0%) 0.03 0.99 0.03 
≥500 273 (0.4%) 45 (16.5%) 0.02 1.00 0.02 
≥1000 38 (0.1%) 8 (21.1%) 0.00 1.00 0.00 
≥2000 5 (0.0%) 1 (20.0%) 0.00 1.00 0.00 
*Optimal cutpoint based on joint maximized sensitivity/specificity 
 
Appendix Table 24: Tabular survival ROC results—mean daily MME/any substance use disorder 
MME/day  
cutpoint 
Total subjects 
meeting cutpoint 
n (%) 
Outcome events 
in cutpoint  
n (%) Sensitivity Specificity 
Euclidean 
distance 
>0 69668 (100.0%) 19713 (28.3%) 1.00 0.00 0.00 
≥5* 35250 (50.6%) 12117 (34.4%) 0.60 0.54 0.39 
≥10 23122 (33.2%) 8965 (38.8%) 0.43 0.72 0.36 
≥20 14950 (21.5%) 6353 (42.5%) 0.29 0.83 0.27 
≥30 11131 (16.0%) 4871 (43.8%) 0.22 0.87 0.21 
≥40 8426 (12.1%) 3770 (44.7%) 0.17 0.91 0.17 
≥60 5659 (8.1%) 2604 (46.0%) 0.12 0.94 0.12 
≥80 3897 (5.6%) 1838 (47.2%) 0.08 0.96 0.08 
≥100 2965 (4.3%) 1415 (47.7%) 0.06 0.97 0.06 
≥125 2399 (3.4%) 1157 (48.2%) 0.05 0.97 0.05 
≥150 1983 (2.8%) 981 (49.5%) 0.04 0.98 0.04 
≥175 1703 (2.4%) 838 (49.2%) 0.04 0.98 0.04 
≥200 1441 (2.1%) 718 (49.8%) 0.03 0.99 0.03 
≥250 1061 (1.5%) 546 (51.5%) 0.02 0.99 0.02 
≥300 818 (1.2%) 421 (51.5%) 0.02 0.99 0.02 
≥400 482 (0.7%) 252 (52.3%) 0.01 1.00 0.01 
≥500 273 (0.4%) 141 (51.6%) 0.01 1.00 0.01 
≥1000 38 (0.1%) 18 (47.4%) 0.00 1.00 0.00 
≥2000 5 (0.0%) 2 (40.0%) 0.00 1.00 0.00 
*Optimal cutpoint based on joint maximized sensitivity/specificity 
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Appendix Table 25: Tabular survival ROC results—mean daily APAP mg/unintentional opioid overdose 
APAP 
mg/day  
cutpoint 
Total subjects 
meeting cutpoint 
n (%) 
Outcome events 
in cutpoint  
n (%) Sensitivity Specificity 
Euclidean 
distance 
>0 69668 (100.0%) 202 (0.3%) 1.00 0.00 0.00 
≥50 66009 (94.7%) 186 (0.3%) 0.93 0.05 0.05 
≥100 60633 (87.0%) 172 (0.3%) 0.86 0.13 0.12 
≥200 41178 (59.1%) 146 (0.4%) 0.71 0.41 0.34 
≥300 30845 (44.3%) 132 (0.4%) 0.63 0.56 0.42 
≥400* 24770 (35.6%) 122 (0.5%) 0.57 0.65 0.44 
≥500 21327 (30.6%) 108 (0.5%) 0.50 0.69 0.41 
≥600 18448 (26.5%) 103 (0.6%) 0.47 0.74 0.41 
≥700 16065 (23.1%) 92 (0.6%) 0.41 0.77 0.37 
≥800 14657 (21.0%) 87 (0.6%) 0.39 0.79 0.35 
≥900 13574 (19.5%) 81 (0.6%) 0.36 0.81 0.33 
≥1000 12133 (17.4%) 72 (0.6%) 0.32 0.83 0.30 
≥1250 9931 (14.3%) 60 (0.6%) 0.27 0.86 0.25 
≥1500 7760 (11.1%) 50 (0.6%) 0.22 0.89 0.21 
≥1750 6121 (8.8%) 40 (0.7%) 0.18 0.91 0.17 
≥2000 4555 (6.5%) 25 (0.5%) 0.11 0.93 0.11 
≥2500 2883 (4.1%) 19 (0.7%) 0.08 0.96 0.08 
≥3000 1649 (2.4%) 10 (0.6%) 0.04 0.98 0.04 
≥3500 894 (1.3%) 5 (0.6%) 0.02 0.99 0.02 
≥4000 376 (0.5%) 1 (0.3%) 0.00 0.99 0.00 
≥5000 124 (0.2%) 1 (0.8%) 0.00 1.00 0.00 
≥6000 35 (0.1%) 1 (2.9%) 0.00 1.00 0.00 
*Optimal cutpoint based on joint maximized sensitivity/specificity 
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Appendix Table 26: Tabular survival ROC results—mean daily APAP mg/unintentional acetaminophen 
overdose 
APAP 
mg/day  
cutpoint 
Total subjects 
meeting cutpoint 
n (%) 
Outcome events 
in cutpoint  
n (%) Sensitivity Specificity 
Euclidean 
distance 
>0 69668 (100.0%) 82 (0.1%) 1.00 0.00 0.00 
≥50 66009 (94.7%) 76 (0.1%) 0.93 0.05 0.05 
≥100 60633 (87.0%) 70 (0.1%) 0.86 0.13 0.12 
≥200 41178 (59.1%) 50 (0.1%) 0.60 0.41 0.29 
≥300* 30845 (44.3%) 45 (0.1%) 0.53 0.56 0.36 
≥400 24770 (35.6%) 35 (0.1%) 0.41 0.64 0.31 
≥500 21327 (30.6%) 32 (0.2%) 0.36 0.69 0.29 
≥600 18448 (26.5%) 28 (0.2%) 0.31 0.74 0.26 
≥700 16065 (23.1%) 26 (0.2%) 0.29 0.77 0.25 
≥800 14657 (21.0%) 24 (0.2%) 0.26 0.79 0.23 
≥900 13574 (19.5%) 23 (0.2%) 0.25 0.81 0.23 
≥1000 12133 (17.4%) 21 (0.2%) 0.23 0.83 0.21 
≥1250 9931 (14.3%) 18 (0.2%) 0.19 0.86 0.18 
≥1500 7760 (11.1%) 13 (0.2%) 0.14 0.89 0.13 
≥1750 6121 (8.8%) 12 (0.2%) 0.13 0.91 0.12 
≥2000 4555 (6.5%) 7 (0.2%) 0.08 0.93 0.07 
≥2500 2883 (4.1%) 7 (0.2%) 0.07 0.96 0.07 
≥3000 1649 (2.4%) 4 (0.2%) 0.04 0.98 0.04 
≥3500 894 (1.3%) 1 (0.1%) 0.01 0.99 0.01 
≥4000 376 (0.5%) 1 (0.3%) 0.01 0.99 0.01 
≥5000 124 (0.2%) 0 (0.0%) 0.00 1.00 0.00 
≥6000 35 (0.1%) 0 (0.0%) 0.00 1.00 0.00 
*Optimal cutpoint based on joint maximized sensitivity/specificity 
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Appendix Table 27: Tabular survival ROC results—mean daily APAP mg/unintentional overdose, any 
drug 
APAP 
mg/day  
cutpoint 
Total subjects 
meeting cutpoint 
n (%) 
Outcome events 
in cutpoint  
n (%) Sensitivity Specificity 
Euclidean 
distance 
>0 69668 (100.0%) 1040 (1.5%) 1.00 0.00 0.00 
≥50 66009 (94.7%) 955 (1.4%) 0.92 0.05 0.05 
≥100 60633 (87.0%) 884 (1.5%) 0.85 0.13 0.12 
≥200 41178 (59.1%) 726 (1.8%) 0.68 0.41 0.33 
≥300* 30845 (44.3%) 609 (2.0%) 0.56 0.56 0.38 
≥400 24770 (35.6%) 532 (2.1%) 0.48 0.65 0.37 
≥500 21327 (30.6%) 464 (2.2%) 0.41 0.70 0.34 
≥600 18448 (26.5%) 422 (2.3%) 0.37 0.74 0.32 
≥700 16065 (23.1%) 392 (2.4%) 0.34 0.77 0.30 
≥800 14657 (21.0%) 355 (2.4%) 0.31 0.79 0.28 
≥900 13574 (19.5%) 332 (2.4%) 0.29 0.81 0.26 
≥1000 12133 (17.4%) 304 (2.5%) 0.26 0.83 0.24 
≥1250 9931 (14.3%) 262 (2.6%) 0.22 0.86 0.21 
≥1500 7760 (11.1%) 206 (2.7%) 0.18 0.89 0.17 
≥1750 6121 (8.8%) 164 (2.7%) 0.14 0.91 0.14 
≥2000 4555 (6.5%) 120 (2.6%) 0.10 0.94 0.10 
≥2500 2883 (4.1%) 83 (2.9%) 0.07 0.96 0.07 
≥3000 1649 (2.4%) 51 (3.1%) 0.04 0.98 0.04 
≥3500 894 (1.3%) 28 (3.1%) 0.02 0.99 0.02 
≥4000 376 (0.5%) 12 (3.2%) 0.01 0.99 0.01 
≥5000 124 (0.2%) 4 (3.2%) 0.00 1.00 0.00 
≥6000 35 (0.1%) 4 (11.4%) 0.00 1.00 0.00 
*Optimal cutpoint based on joint maximized sensitivity/specificity 
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Appendix Table 28: Tabular survival ROC results—mean daily APAP mg/opioid use disorder 
APAP 
mg/day  
cutpoint 
Total subjects 
meeting cutpoint 
n (%) 
Outcome events 
in cutpoint  
n (%) Sensitivity Specificity 
Euclidean 
distance 
>0 69668 (100.0%) 2284 (3.3%) 1.00 0.00 0.00 
≥50 66009 (94.7%) 2048 (3.1%) 0.90 0.05 0.04 
≥100 60633 (87.0%) 1915 (3.2%) 0.84 0.13 0.11 
≥200 41178 (59.1%) 1540 (3.7%) 0.67 0.41 0.33 
≥300 30845 (44.3%) 1342 (4.4%) 0.57 0.56 0.39 
≥400* 24770 (35.6%) 1192 (4.8%) 0.50 0.65 0.39 
≥500 21327 (30.6%) 1058 (5.0%) 0.44 0.70 0.37 
≥600 18448 (26.5%) 964 (5.2%) 0.40 0.74 0.35 
≥700 16065 (23.1%) 886 (5.5%) 0.37 0.78 0.33 
≥800 14657 (21.0%) 814 (5.6%) 0.33 0.79 0.30 
≥900 13574 (19.5%) 758 (5.6%) 0.31 0.81 0.28 
≥1000 12133 (17.4%) 695 (5.7%) 0.28 0.83 0.26 
≥1250 9931 (14.3%) 571 (5.7%) 0.23 0.86 0.22 
≥1500 7760 (11.1%) 439 (5.7%) 0.18 0.89 0.17 
≥1750 6121 (8.8%) 355 (5.8%) 0.14 0.91 0.14 
≥2000 4555 (6.5%) 249 (5.5%) 0.10 0.94 0.10 
≥2500 2883 (4.1%) 143 (5.0%) 0.06 0.96 0.06 
≥3000 1649 (2.4%) 82 (5.0%) 0.03 0.98 0.03 
≥3500 894 (1.3%) 43 (4.8%) 0.02 0.99 0.02 
≥4000 376 (0.5%) 20 (5.3%) 0.01 0.99 0.01 
≥5000 124 (0.2%) 8 (6.5%) 0.00 1.00 0.00 
≥6000 35 (0.1%) 2 (5.7%) 0.00 1.00 0.00 
*Optimal cutpoint based on joint maximized sensitivity/specificity 
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Appendix Table 29: Tabular survival ROC results—mean daily APAP mg/any substance use disorder 
APAP 
mg/day  
cutpoint 
Total subjects 
meeting cutpoint 
n (%) 
Outcome events 
in cutpoint  
n (%) Sensitivity Specificity 
Euclidean 
distance 
>0 69668 (100.0%) 19713 (28.3%) 1.00 0.00 0.00 
≥50 66009 (94.7%) 18493 (28.0%) 0.94 0.05 0.05 
≥100 60633 (87.0%) 17222 (28.4%) 0.88 0.13 0.12 
≥200 41178 (59.1%) 13072 (31.7%) 0.65 0.44 0.34 
≥300* 30845 (44.3%) 10761 (34.9%) 0.52 0.60 0.38 
≥400 24770 (35.6%) 9220 (37.2%) 0.44 0.69 0.36 
≥500 21327 (30.6%) 8226 (38.6%) 0.39 0.74 0.34 
≥600 18448 (26.5%) 7324 (39.7%) 0.34 0.78 0.31 
≥700 16065 (23.1%) 6539 (40.7%) 0.31 0.81 0.28 
≥800 14657 (21.0%) 6048 (41.3%) 0.28 0.83 0.26 
≥900 13574 (19.5%) 5654 (41.7%) 0.26 0.84 0.24 
≥1000 12133 (17.4%) 5103 (42.1%) 0.24 0.86 0.22 
≥1250 9931 (14.3%) 4211 (42.4%) 0.19 0.88 0.18 
≥1500 7760 (11.1%) 3349 (43.2%) 0.15 0.91 0.15 
≥1750 6121 (8.8%) 2670 (43.6%) 0.12 0.93 0.12 
≥2000 4555 (6.5%) 1944 (42.7%) 0.09 0.95 0.09 
≥2500 2883 (4.1%) 1210 (42.0%) 0.05 0.97 0.05 
≥3000 1649 (2.4%) 677 (41.1%) 0.03 0.98 0.03 
≥3500 894 (1.3%) 362 (40.5%) 0.02 0.99 0.02 
≥4000 376 (0.5%) 148 (39.4%) 0.01 1.00 0.01 
≥5000 124 (0.2%) 44 (35.5%) 0.00 1.00 0.00 
≥6000 35 (0.1%) 12 (34.3%) 0.00 1.00 0.00 
*Optimal cutpoint based on joint maximized sensitivity/specificity 
 
  
  196 
Appendix Figure 4: Distribution of log likelihood values from Cox proportional hazard models predicting 
Aim 3 outcomes at varied cutpoints of the pharmacy count measure 
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Appendix Figure 5: Distribution of log likelihood values from Cox proportional hazard models predicting 
Aim 3 outcomes at varied cutpoints of the mean APAP mg/day measure 
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Appendix Table 30: Describing application of selected opioid use criteria in Aim 3 validation sample for 
the secondary unintentional acetaminophen overdose outcome 
 
Criterion met 
(N=69,667) 
Experienced  
outcome event* 
(N=90)    
n 
(% of total 
cohort) n 
(% within 
criterion) Sens.Ŧ Spec. Ŧ 
Individual measures       
     ≥5 opioid fills 5525 (7.9%) 16 (0.3%) 0.176 0.921 
     ≥12 MME/day 19926 (28.6%) 40 (0.2%) 0.413 0.714 
     ≥45 MME/day 7541 (10.8%) 18 (0.2%) 0.176 0.892 
     ≥140 MME/day 1980 (2.8%) 9 (0.5%) 0.087 0.972 
     NC MLIP standard: 
     ≥7 opioid fills  
1703 (2.4%) 5 (0.3%) 0.051 0.976 
Combined criteria  
(unconditional) 
  
≥5 opioid fills or 
    ≥12 MME/day 
20404 (29.3%) 43 (0.2%) 0.445 0.707 
≥5 opioid fills or 
    ≥45 MME/day 
10545 (15.1%) 27 (0.3%) 0.277 0.849 
≥5 opioid fills or 
    ≥140 MME/day 
6336 (9.1%) 21 (0.3%) 0.227 0.909 
≥7 opioid fills or 
    ≥12 MME/day 
19970 (28.7%) 40 (0.2%) 0.413 0.714 
≥7 opioid fills or 
    ≥45 MME/day 
8370 (12.0%) 21 (0.3%) 0.208 0.880 
≥7 opioid fills or 
    ≥140 MME/day 
3336 (4.8%) 12 (0.4%) 0.121 0.952 
Combined measures  
(conditional) 
      ≥5 opioid fills and 
    ≥12 MME/day 
5047 (7.2%) 13 (0.3%) 0.142 0.928 
≥5 opioid fills and 
    ≥45 MME/day 
2521 (3.6%) 7 (0.3%) 0.072 0.964 
≥5 opioid fills and 
    ≥140 MME/day 
1169 (1.7%) 4 (0.3%) 0.039 0.983 
≥7 opioid fills and 
    ≥12 MME/day 
1659 (2.4%) 5 (0.3%) 0.051 0.976 
≥7 opioid fills and 
    ≥45 MME/day 
874 (1.3%) 2 (0.2%) 0.020 0.987 
≥7 opioid fills and 
    ≥140 MME/day 
347 (0.5%) 2 (0.6%) 0.019 0.995 
Note: Sens=Sensitivity; Spec=Specificity; MME=Milligram morphine equivalent; NC MLIP=North Carolina 
Medicaid lock-in program. 
*Reported percentages in the “Experienced outcome event” column refer to the proportion of subjects flagged as 
high risk for that given opioid use criterion in that row. 
Ŧ Reported sensitivities and specificities are time-dependent measures calculated at 365 days of follow-up using 
survival ROC models accounting for time to event. Interpretation of these figures should be per-person-year. 
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Appendix Table 31: Describing application of selected opioid use criteria in Aim 3 validation sample for 
the secondary outcome of an unintentional overdose of any drug 
 
Criterion met 
(N=69,667) 
Experienced  
outcome event* 
(N=1,121)    
n 
(% of total 
cohort) n 
(% within 
criterion) Sens.Ŧ Spec. Ŧ 
Individual measures       
     ≥5 opioid fills 5525 (7.9%) 214 (3.9%) 0.181 0.923 
     ≥12 MME/day 19926 (28.6%) 549 (2.8%) 0.452 0.718 
     ≥45 MME/day 7541 (10.8%) 256 (3.4%) 0.202 0.894 
     ≥140 MME/day 1980 (2.8%) 91 (4.6%) 0.070 0.972 
     NC MLIP standard: 
     ≥7 opioid fills  
1703 (2.4%) 80 (4.7%) 0.067 0.976 
Combined criteria  
(unconditional) 
  
≥5 opioid fills or 
    ≥12 MME/day 
20404 (29.3%) 566 (2.8%) 0.466 0.711 
≥5 opioid fills or 
    ≥45 MME/day 
10545 (15.1%) 356 (3.4%) 0.290 0.852 
≥5 opioid fills or 
    ≥140 MME/day 
6336 (9.1%) 255 (4.0%) 0.213 0.912 
≥7 opioid fills or 
    ≥12 MME/day 
19970 (28.7%) 549 (2.7%) 0.452 0.717 
≥7 opioid fills or 
    ≥45 MME/day 
8370 (12.0%) 282 (3.4%) 0.225 0.882 
≥7 opioid fills or 
    ≥140 MME/day 
3336 (4.8%) 155 (4.6%) 0.125 0.954 
Combined measures  
(conditional) 
      ≥5 opioid fills and 
    ≥12 MME/day 
5047 (7.2%) 197 (3.9%) 0.166 0.930 
≥5 opioid fills and 
    ≥45 MME/day 
2521 (3.6%) 114 (4.5%) 0.091 0.965 
≥5 opioid fills and 
    ≥140 MME/day 
1169 (1.7%) 50 (4.3%) 0.039 0.984 
≥7 opioid fills and 
    ≥12 MME/day 
1659 (2.4%) 80 (4.8%) 0.067 0.977 
≥7 opioid fills and 
    ≥45 MME/day 
874 (1.3%) 54 (6.2%) 0.043 0.988 
≥7 opioid fills and 
    ≥140 MME/day 
347 (0.5%) 16 (4.6%) 0.012 0.995 
Note: Sens=Sensitivity; Spec=Specificity; MME=Milligram morphine equivalent; NC MLIP=North Carolina 
Medicaid lock-in program. 
*Reported percentages in the “Experienced outcome event” column refer to the proportion of subjects flagged as 
high risk for that given opioid use criterion in that row. 
Ŧ Reported sensitivities and specificities are time-dependent measures calculated at 365 days of follow-up using 
survival ROC models accounting for time to event. Interpretation of these figures should be per-person-year. 
  
  200 
Appendix Table 32: Describing application of selected opioid use criteria in Aim 3 validation sample for 
the secondary opioid use disorder outcome 
 
Criterion met 
(N=69,667) 
Experienced  
outcome event* 
(N=2,241)    
n 
(% of total 
cohort) n 
(% within 
criterion) Sens.Ŧ Spec. Ŧ 
Individual measures       
     ≥5 opioid fills 5525 (7.9%) 557 (10.1%) 0.243 0.928 
     ≥12 MME/day 19926 (28.6%) 1142 (5.7%) 0.485 0.722 
     ≥45 MME/day 7541 (10.8%) 606 (8.0%) 0.248 0.898 
     ≥140 MME/day 1980 (2.8%) 243 (12.3%) 0.097 0.974 
     NC MLIP standard: 
     ≥7 opioid fills  
1703 (2.4%) 216 (12.7%) 0.094 0.978 
Combined criteria  
(unconditional) 
  
≥5 opioid fills or 
    ≥12 MME/day 
20404 (29.3%) 1186 (5.8%) 0.504 0.716 
≥5 opioid fills or 
    ≥45 MME/day 
10545 (15.1%) 856 (8.1%) 0.361 0.857 
≥5 opioid fills or 
    ≥140 MME/day 
6336 (9.1%) 637 (10.1%) 0.275 0.917 
≥7 opioid fills or 
    ≥12 MME/day 
19970 (28.7%) 1145 (5.7%) 0.486 0.722 
≥7 opioid fills or 
    ≥45 MME/day 
8370 (12.0%) 694 (8.3%) 0.287 0.887 
≥7 opioid fills or 
    ≥140 MME/day 
3336 (4.8%) 398 (11.9%) 0.166 0.957 
Combined measures  
(conditional) 
      ≥5 opioid fills and 
    ≥12 MME/day 
5047 (7.2%) 513 (10.2%) 0.223 0.934 
≥5 opioid fills and 
    ≥45 MME/day 
2521 (3.6%) 307 (12.2%) 0.127 0.968 
≥5 opioid fills and 
    ≥140 MME/day 
1169 (1.7%) 163 (13.9%) 0.066 0.985 
≥7 opioid fills and 
    ≥12 MME/day 
1659 (2.4%) 213 (12.8%) 0.092 0.979 
≥7 opioid fills and 
    ≥45 MME/day 
874 (1.3%) 128 (14.6%) 0.053 0.989 
≥7 opioid fills and 
    ≥140 MME/day 
347 (0.5%) 61 (17.6%) 0.024 0.996 
Note: Sens=Sensitivity; Spec=Specificity; MME=Milligram morphine equivalent; NC MLIP=North Carolina 
Medicaid lock-in program. 
*Reported percentages in the “Experienced outcome event” column refer to the proportion of subjects flagged as 
high risk for that given opioid use criterion in that row. 
Ŧ Reported sensitivities and specificities are time-dependent measures calculated at 365 days of follow-up using 
survival ROC models accounting for time to event. Interpretation of these figures should be per-person-year. 
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Appendix Table 33: Describing application of selected opioid use criteria in Aim 3 validation sample for 
the secondary outcome of any substance use disorder 
 
Criterion met 
(N=69,667) 
Experienced  
outcome event* 
(N=19,820)    
n 
(% of total 
cohort) n 
(% within 
criterion) Sens.Ŧ Spec. Ŧ 
Individual measures       
     ≥5 opioid fills 5525 (7.9%) 2801 (50.7%) 0.132 0.950 
     ≥12 MME/day 19926 (28.6%) 7930 (39.8%) 0.371 0.760 
     ≥45 MME/day 7541 (10.8%) 3293 (43.7%) 0.149 0.914 
     ≥140 MME/day 1980 (2.8%) 956 (48.3%) 0.043 0.979 
     NC MLIP standard: 
     ≥7 opioid fills  
1703 (2.4%) 981 (57.6%) 0.046 0.987 
Combined criteria  
(unconditional) 
  
≥5 opioid fills or 
    ≥12 MME/day 
20404 (29.3%) 8177 (40.1%) 0.383 0.756 
≥5 opioid fills or 
    ≥45 MME/day 
10545 (15.1%) 4801 (45.5%) 0.222 0.887 
≥5 opioid fills or 
    ≥140 MME/day 
6336 (9.1%) 3156 (49.8%) 0.148 0.940 
≥7 opioid fills or 
    ≥12 MME/day 
19970 (28.7%) 7958 (39.8%) 0.372 0.760 
≥7 opioid fills or 
    ≥45 MME/day 
8370 (12.0%) 3763 (45.0%) 0.171 0.908 
≥7 opioid fills or 
    ≥140 MME/day 
3336 (4.8%) 1734 (52.0%) 0.079 0.969 
Combined measures  
(conditional) 
      ≥5 opioid fills and 
    ≥12 MME/day 
5047 (7.2%) 2554 (50.6%) 0.120 0.954 
≥5 opioid fills and 
    ≥45 MME/day 
2521 (3.6%) 1293 (51.3%) 0.059 0.976 
≥5 opioid fills and 
    ≥140 MME/day 
1169 (1.7%) 601 (51.4%) 0.027 0.989 
≥7 opioid fills and 
    ≥12 MME/day 
1659 (2.4%) 953 (57.4%) 0.044 0.987 
≥7 opioid fills and 
    ≥45 MME/day 
874 (1.3%) 511 (58.5%) 0.023 0.993 
≥7 opioid fills and 
    ≥140 MME/day 
347 (0.5%) 203 (58.5%) 0.009 0.997 
Note: Sens=Sensitivity; Spec=Specificity; MME=Milligram morphine equivalent; NC MLIP=North Carolina 
Medicaid lock-in program. 
*Reported percentages in the “Experienced outcome event” column refer to the proportion of subjects flagged as 
high risk for that given opioid use criterion in that row. 
Ŧ Reported sensitivities and specificities are time-dependent measures calculated at 365 days of follow-up using 
survival ROC models accounting for time to event. Interpretation of these figures should be per-person-year. 
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Appendix Table 34: Bivariate Cox proportional hazard model results estimating the hazard of an 
unintentional acetaminophen overdose for each opioid use criterion 
 Criterion met 
(N=69,667) 
  
  
n (%) Hazard ratio 95% CI LL 
Individual measures       
     ≥5 opioid fills 5525 (7.9%) 2.39** (1.39 , 4.10) -975.6 
     ≥12 MME/day 19926 (28.6%) 1.78** (1.17 , 2.69) -976.2 
     ≥45 MME/day 7541 (10.8%) 1.79* (1.07 , 3.00) -977.5 
     ≥140 MME/day 1980 (2.8%) 3.27*** (1.64 , 6.50) -975.5 
     NC MLIP standard: 
     ≥7 opioid fills  
1703 (2.4%) 2.21 (0.90 , 5.46) -978.5 
Combined criteria  
(unconditional) 
  
≥5 opioid fills or 
    ≥12 MME/day 
20404 (29.3%) 1.97*** (1.30 , 2.98) -974.7 
≥5 opioid fills or 
    ≥45 MME/day 
10545 (15.1%) 2.17*** (1.38 , 3.40) -974.7 
≥5 opioid fills or 
    ≥140 MME/day 
6336 (9.1%) 2.84*** (1.75 , 4.64) -972.5 
≥7 opioid fills or 
    ≥12 MME/day 
19970 (28.7%) 1.77** (1.17 , 2.68) -976.2 
≥7 opioid fills or 
    ≥45 MME/day 
8370 (12.0%) 1.96** (1.20 , 3.19) -976.5 
≥7 opioid fills or 
    ≥140 MME/day 
3336 (4.8%) 2.75*** (1.50 , 5.05) -975.5 
Combined measures  
(conditional)       
≥5 opioid fills and 
    ≥12 MME/day 
5047 (7.2%) 2.04* (1.13 , 3.67) -1865.6 
≥5 opioid fills and 
    ≥45 MME/day 
2521 (3.6%) 2.00 (0.92 , 4.32) -1863.6 
≥5 opioid fills and 
    ≥140 MME/day 
1169 (1.7%) 2.36 (0.86 , 6.42) -1874.5 
≥7 opioid fills and 
    ≥12 MME/day 
1659 (2.4%) 2.27 (0.92 , 5.59) -1881.2 
≥7 opioid fills and 
    ≥45 MME/day 
874 (1.3%) 1.59 (0.39 , 6.47) -1877.4 
≥7 opioid fills and 
    ≥140 MME/day 
347 (0.5%) 3.89 (0.96 , 15.82) -1883.1 
Note: CI=Confidence interval; LL=Log likelihood; MME=Milligram morphine equivalent; NC MLIP=North 
Carolina Medicaid lock-in program. All hazard ratio estimates reported in this table were statistically significant at 
p<0.001. *p<0.05; **p<0.01; ***p<0.001 
  
  203 
Appendix Table 35: Bivariate Cox proportional hazard model results estimating the hazard of any 
overdose event for each opioid use criterion 
 Criterion met 
(N=69,667) 
  
  
n (%) Hazard ratio 95% CI LL 
Individual measures       
     ≥5 opioid fills 5525 (7.9%) 2.64 (2.28 , 3.07) -12127.9 
     ≥12 MME/day 19926 (28.6%) 2.15 (1.91 , 2.41) -12114.7 
     ≥45 MME/day 7541 (10.8%) 2.14 (1.86 , 2.46) -12144.9 
     ≥140 MME/day 1980 (2.8%) 2.64 (2.13 , 3.27) -12163.9 
     NC MLIP standard: 
     ≥7 opioid fills  
1703 (2.4%) 2.95 (2.35 , 3.70) -12161.9 
Combined criteria  
(unconditional) 
  
≥5 opioid fills or 
    ≥12 MME/day 
20404 (29.3%) 2.21 (1.97 , 2.49) -12107.8 
≥5 opioid fills or 
    ≥45 MME/day 
10545 (15.1%) 2.38 (2.10 , 2.70) -12113.8 
≥5 opioid fills or 
    ≥140 MME/day 
6336 (9.1%) 2.79 (2.43 , 3.21) -12109.2 
≥7 opioid fills or 
    ≥12 MME/day 
19970 (28.7%) 2.14 (1.90 , 2.41) -12115.3 
≥7 opioid fills or 
    ≥45 MME/day 
8370 (12.0%) 2.19 (1.91 , 2.50) -12138.1 
≥7 opioid fills or 
    ≥140 MME/day 
3336 (4.8%) 2.92 (2.46 , 3.46) -12135.0 
Combined measures  
(conditional)       
≥5 opioid fills and 
    ≥12 MME/day 
5047 (7.2%) 2.61 (2.24 , 3.04) -12133.8 
≥5 opioid fills and 
    ≥45 MME/day 
2521 (3.6%) 2.73 (2.25 , 3.31) -12154.4 
≥5 opioid fills and 
    ≥140 MME/day 
1169 (1.7%) 2.40 (1.81 , 3.19) -12180.0 
≥7 opioid fills and 
    ≥12 MME/day 
1659 (2.4%) 3.02 (2.41 , 3.79) -12160.6 
≥7 opioid fills and 
    ≥45 MME/day 
874 (1.3%) 3.64 (2.77 , 4.79) -12164.3 
≥7 opioid fills and 
    ≥140 MME/day 
347 (0.5%) 2.52 (1.54 , 4.12) -12189.1 
Note: CI=Confidence interval; LL=Log likelihood; MME=Milligram morphine equivalent; NC MLIP=North 
Carolina Medicaid lock-in program. All hazard ratio estimates reported in this table were statistically significant at 
p<0.001. 
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Appendix Table 36: Bivariate Cox proportional hazard model results estimating the hazard of an opioid 
use disorder diagnosis for each opioid use criterion 
 Criterion met 
(N=69,667) 
  
  
n (%) Hazard ratio 95% CI LL 
Individual measures       
     ≥5 opioid fills 5525 (7.9%) 3.83 (3.48 , 4.22) -24198.8 
     ≥12 MME/day 19926 (28.6%) 2.40 (2.21 , 2.61) -24282.8 
     ≥45 MME/day 7541 (10.8%) 2.80 (2.55 , 3.07) -24296.4 
     ≥140 MME/day 1980 (2.8%) 3.85 (3.37 , 4.40) -24352.1 
     NC MLIP standard: 
     ≥7 opioid fills  
1703 (2.4%) 4.28 (3.72 , 4.92) -24350.2 
Combined criteria  
(unconditional) 
  
≥5 opioid fills or 
    ≥12 MME/day 
20404 (29.3%) 2.52 (2.32 , 2.74) -24257.8 
≥5 opioid fills or 
    ≥45 MME/day 
10545 (15.1%) 3.28 (3.01 , 3.57) -24166.9 
≥5 opioid fills or 
    ≥140 MME/day 
6336 (9.1%) 3.91 (3.57 , 4.28) -24156.4 
≥7 opioid fills or 
    ≥12 MME/day 
19970 (28.7%) 2.41 (2.22 , 2.62) -24281.5 
≥7 opioid fills or 
    ≥45 MME/day 
8370 (12.0%) 3.05 (2.79 , 3.33) -24241.8 
≥7 opioid fills or 
    ≥140 MME/day 
3336 (4.8%) 4.13 (3.70 , 4.60) -24251.8 
Combined measures  
(conditional)       
≥5 opioid fills and 
    ≥12 MME/day 
5047 (7.2%) 3.77 (3.41 , 4.16) -24224.3 
≥5 opioid fills and 
    ≥45 MME/day 
2521 (3.6%) 4.03 (3.57 , 4.54) -24307.9 
≥5 opioid fills and 
    ≥140 MME/day 
1169 (1.7%) 4.31 (3.68 , 5.06) -24382.8 
≥7 opioid fills and 
    ≥12 MME/day 
1659 (2.4%) 4.32 (3.75 , 4.97) -24350.6 
≥7 opioid fills and 
    ≥45 MME/day 
874 (1.3%) 4.62 (3.86 , 5.52) -24398.9 
≥7 opioid fills and 
    ≥140 MME/day 
347 (0.5%) 5.30 (4.11 , 6.84) -24440.5 
Note: CI=Confidence interval; LL=Log likelihood; MME=Milligram morphine equivalent; NC MLIP=North 
Carolina Medicaid lock-in program. All hazard ratio estimates reported in this table were statistically significant at 
p<0.001. 
  
  205 
Appendix Table 37: Bivariate Cox proportional hazard model results estimating the hazard of any 
substance use disorder diagnosis for each opioid use criterion 
 Criterion met 
(N=69,667) 
  
  
n (%) Hazard ratio 95% CI LL 
Individual measures       
     ≥5 opioid fills 5525 (7.9%) 2.27 (2.18 , 2.36) -212631.5 
     ≥12 MME/day 19926 (28.6%) 1.68 (1.63 , 1.73) -212680.0 
     ≥45 MME/day 7541 (10.8%) 1.63 (1.57 , 1.69) -213002.0 
     ≥140 MME/day 1980 (2.8%) 1.73 (1.63 , 1.85) -213175.2 
     NC MLIP standard: 
     ≥7 opioid fills  
1703 (2.4%) 2.60 (2.44 , 2.77) -212968.8 
Combined criteria  
(unconditional) 
  
≥5 opioid fills or 
    ≥12 MME/day 
20404 (29.3%) 1.72 (1.68 , 1.77) -212610.5 
≥5 opioid fills or 
    ≥45 MME/day 
10545 (15.1%) 1.91 (1.85 , 1.97) -212619.8 
≥5 opioid fills or 
    ≥140 MME/day 
6336 (9.1%) 2.18 (2.10 , 2.27) -212619.3 
≥7 opioid fills or 
    ≥12 MME/day 
19970 (28.7%) 1.69 (1.64 , 1.73) -212670.5 
≥7 opioid fills or 
    ≥45 MME/day 
8370 (12.0%) 1.75 (1.69 , 1.81) -212868.0 
≥7 opioid fills or 
    ≥140 MME/day 
3336 (4.8%) 2.11 (2.01 , 2.22) -212932.0 
Combined measures  
(conditional)       
≥5 opioid fills and 
    ≥12 MME/day 
5047 (7.2%) 2.22 (2.13 , 2.32) -212709.6 
≥5 opioid fills and 
    ≥45 MME/day 
2521 (3.6%) 2.03 (1.91 , 2.14) -213045.8 
≥5 opioid fills and 
    ≥140 MME/day 
1169 (1.7%) 1.90 (1.75 , 2.06) -213193.5 
≥7 opioid fills and 
    ≥12 MME/day 
1659 (2.4%) 2.58 (2.42 , 2.75) -212981.8 
≥7 opioid fills and 
    ≥45 MME/day 
874 (1.3%) 2.43 (2.22 , 2.65) -213142.3 
≥7 opioid fills and 
    ≥140 MME/day 
347 (0.5%) 2.25 (1.96 , 2.59) -213240.8 
Note: CI=Confidence interval; LL=Log likelihood; MME=Milligram morphine equivalent; NC MLIP=North 
Carolina Medicaid lock-in program. All hazard ratio estimates reported in this table were statistically significant at 
p<0.001. 
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Appendix Figure 6: Kaplan-Meier survival function plots of time to an unintentional acetaminophen 
overdose event, by individual high risk opioid use measure criteria  
 
Note: p-values refer to a statistical test for the hypothesis that the survivor functions are equal  
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Appendix Figure 7: Kaplan-Meier survival function plots of time to an unintentional acetaminophen 
overdose event, by unconditional combination high risk opioid use measure criteria  
 
Note: p-values refer to a statistical test for the hypothesis that the survivor functions are equal  
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Appendix Figure 8: Kaplan-Meier survival function plots of time to an unintentional acetaminophen 
overdose event, by conditional combination high risk opioid use measure criteria  
 
Note: p-values refer to a statistical test for the hypothesis that the survivor functions are equal  
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Appendix Figure 9: Kaplan-Meier survival function plots of time to any unintentional overdose event, by 
individual high risk opioid use measure criteria  
 
Note: p-values refer to a statistical test for the hypothesis that the survivor functions are equal  
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Appendix Figure 10: Kaplan-Meier survival function plots of time to any unintentional overdose event, 
by unconditional combined high risk opioid use measure criteria  
 
Note: p-values refer to a statistical test for the hypothesis that the survivor functions are equal  
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Appendix Figure 11: Kaplan-Meier survival function plots of time to any unintentional overdose event, 
by conditional combined high risk opioid use measure criteria  
 
Note: p-values refer to a statistical test for the hypothesis that the survivor functions are equal  
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Appendix Figure 12: Kaplan-Meier survival function plots of time to an opioid use disorder diagnosis, by 
individual high risk opioid use measure criteria  
 
Note: p-values refer to a statistical test for the hypothesis that the survivor functions are equal  
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Appendix Figure 13: Kaplan-Meier survival function plots of time to an opioid use disorder diagnosis, by 
unconditional combined high risk opioid use measure criteria  
 
Note: p-values refer to a statistical test for the hypothesis that the survivor functions are equal  
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Appendix Figure 14: Kaplan-Meier survival function plots of time to an opioid use disorder diagnosis, by 
conditional combined high risk opioid use measure criteria  
 
Note: p-values refer to a statistical test for the hypothesis that the survivor functions are equal  
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Appendix Figure 15: Kaplan-Meier survival function plots of time to any substance use disorder 
diagnosis, by individual high risk opioid use measure criteria  
 
Note: p-values refer to a statistical test for the hypothesis that the survivor functions are equal  
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Appendix Figure 16: Kaplan-Meier survival function plots of time to any substance use disorder 
diagnosis, by unconditional combined high risk opioid use measure criteria  
 
Note: p-values refer to a statistical test for the hypothesis that the survivor functions are equal  
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Appendix Figure 17: Kaplan-Meier survival function plots of time to any substance use disorder 
diagnosis, by conditional combined high risk opioid use measure criteria  
 
Note: p-values refer to a statistical test for the hypothesis that the survivor functions are equal  
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Appendix Table 38: Kaplan-Meier estimates of unintentional acetaminophen overdose event, by opioid 
use criterion, represented as absolute risk differences and numbers needed to enroll 
   Follow-up time 
Criterion met 
(N=69,667) 30 days 90 days 180 days 365 days 
 
n (%) ARD NNE ARD NNE ARD NNE ARD NNE 
Individual measures           
     ≥5 opioid fills 5525 (7.9%) 0.0003 3924 0.0004 2549 0.0002 5977 0.0023 442 
     ≥12 MME/day 19926 (28.6%) 0.0000 40721 0.0002 5834 0.0003 3974 0.0011 909 
     ≥45 MME/day 7541 (10.8%) 0.0002 6637 0.0005 2096 0.0002 5803 0.0012 820 
     ≥140 MME/day 1980 (2.8%) -0.0001 - 0.0007 1460 0.0003 3957 0.0036 275 
     NC MLIP standard: 
      ≥7 opioid fills  
1703 (2.4%) 0.0005 2150 0.0015 660 0.0011 921 0.0019 526 
Combined measures  
(unconditional) 
          
≥5 opioid fills or 
    ≥12 MME/day 
20404 (29.3%) 0.0001 10782 0.0002 4371 0.0003 3386 0.0013 767 
≥5 opioid fills or 
    ≥45 MME/day 
10545 (15.1%) 0.0003 3369 0.0006 1721 0.0003 2915 0.0017 593 
≥5 opioid fills or 
     ≥140 MME/day 
6336 (9.1%) 0.0002 4862 0.0005 2075 0.0002 4516 0.0028 356 
≥7 opioid fills or 
     ≥12 MME/day 
19970 (28.7%) 0.0000 41528 0.0002 5883 0.0002 4018 0.0011 914 
≥7 opioid fills or 
     ≥45 MME/day 
8370 (12.0%) 0.0003 3865 0.0007 1476 0.0004 2830 0.0014 700 
≥7 opioid fills or 
    ≥140 MME/day 
3336 (4.8%) 0.0002 5754 0.0009 1095 0.0005 2121 0.0028 364 
Combined measures  
(conditional) 
          
≥5 opioid fills and 
    ≥12 MME/day 
5047 (7.2%) 0.0001 14551 0.0002 4095 0.0000 24600 0.0018 564 
≥5 opioid fills and 
    ≥45 MME/day 
2521 (3.6%) -0.0001 - 0.0000 74565 -0.0004 - 0.0018 565 
≥5 opioid fills and 
    ≥140 MME/day 
1169 (1.7%) -0.0001 - 0.0005 1977 0.0001 12605 0.0023 436 
≥7 opioid fills and 
    ≥12 MME/day 
1659 (2.4%) 0.0005 2080 0.0016 640 0.0011 882 0.0020 503 
≥7 opioid fills and 
    ≥45 MME/day 
874 (1.3%) -0.0001 - 0.0008 1222 0.0004 2536 0.0010 1028 
≥7 opioid fills and 
    ≥140 MME/day 
347 (0.5%) -0.0001 - 0.0026 380 0.0022 453 0.0048 210 
Note: ARD=Absolute risk difference; NNE=Number needed to enroll; MME=Milligram morphine equivalent; NC 
MLIP=North Carolina Medicaid lock-in program. ARD was calculated from Kaplan-Meier survival function models 
by subtracting the probability of experiencing the outcome event at a given time point among those below an opioid 
use measure threshold from the probability of experiencing the outcome event at that same time among those 
meeting the threshold. The NNE was calculated as (1 / ARD) and is interpreted as the number of individuals needed 
to enroll into a hypothetical MLIP program based on a given opioid use criterion in order to have the opportunity to 
prevent one outcome event. 
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Appendix Table 39: Kaplan-Meier estimates of any unintentional overdose event, by opioid use criterion, 
represented as absolute risk differences and numbers needed to enroll 
   Follow-up time 
Criterion met 
(N=69,667) 30 days 90 days 180 days 365 days 
 
n (%) ARD NNE ARD NNE ARD NNE ARD NNE 
Individual measures           
     ≥5 opioid fills 5525 (7.9%) 0.0039 254 0.0093 108 0.0158 63 0.0295 34 
     ≥12 MME/day 19926 (28.6%) 0.0014 724 0.0044 226 0.0088 114 0.0178 56 
     ≥45 MME/day 7541 (10.8%) 0.0021 468 0.0057 177 0.0098 102 0.0208 48 
     ≥140 MME/day 1980 (2.8%) 0.0014 730 0.0070 144 0.0155 65 0.0322 31 
     NC MLIP standard: 
      ≥7 opioid fills  
1703 (2.4%) 0.0068 147 0.0103 97 0.0175 57 0.0379 26 
Combined measures  
(unconditional) 
          
≥5 opioid fills or 
    ≥12 MME/day 
20404 (29.3%) 0.0016 628 0.0049 205 0.0092 109 0.0184 54 
≥5 opioid fills or 
    ≥45 MME/day 
10545 (15.1%) 0.0026 380 0.0072 139 0.0121 83 0.0232 43 
≥5 opioid fills or 
     ≥140 MME/day 
6336 (9.1%) 0.0034 293 0.0091 110 0.0164 61 0.0314 32 
≥7 opioid fills or 
     ≥12 MME/day 
19970 (28.7%) 0.0014 728 0.0044 227 0.0088 114 0.0177 56 
≥7 opioid fills or 
     ≥45 MME/day 
8370 (12.0%) 0.0024 408 0.0059 170 0.0104 96 0.0212 47 
≥7 opioid fills or 
    ≥140 MME/day 
3336 (4.8%) 0.0039 254 0.0086 117 0.0171 58 0.0359 28 
Combined measures  
(conditional) 
          
≥5 opioid fills and 
    ≥12 MME/day 
5047 (7.2%) 0.0036 280 0.0085 117 0.0156 64 0.0294 34 
≥5 opioid fills and 
    ≥45 MME/day 
2521 (3.6%) 0.0045 224 0.0085 117 0.0153 65 0.0333 30 
≥5 opioid fills and 
    ≥140 MME/day 
1169 (1.7%) 0.0026 381 0.0072 138 0.0140 71 0.0281 36 
≥7 opioid fills and 
    ≥12 MME/day 
1659 (2.4%) 0.0070 142 0.0107 93 0.0182 55 0.0394 25 
≥7 opioid fills and 
    ≥45 MME/day 
874 (1.3%) 0.0088 114 0.0137 73 0.0210 48 0.0522 19 
≥7 opioid fills and 
    ≥140 MME/day 
347 (0.5%) 0.0041 245 0.0096 105 0.0134 75 0.0310 32 
Note: ARD=Absolute risk difference; NNE=Number needed to enroll; MME=Milligram morphine equivalent; NC 
MLIP=North Carolina Medicaid lock-in program. ARD was calculated from Kaplan-Meier survival function models 
by subtracting the probability of experiencing the outcome event at a given time point among those below an opioid 
use measure threshold from the probability of experiencing the outcome event at that same time among those 
meeting the threshold. The NNE was calculated as (1 / ARD) and is interpreted as the number of individuals needed 
to enroll into a hypothetical MLIP program based on a given opioid use criterion in order to have the opportunity to 
prevent one outcome event. 
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Appendix Table 40: Kaplan-Meier estimates of opioid use disorder diagnosis, by opioid use criterion, 
represented as absolute risk differences and numbers needed to enroll 
   Follow-up time 
Criterion met 
(N=69,667) 30 days 90 days 180 days 365 days 
 
n (%) ARD NNE ARD NNE ARD NNE ARD NNE 
Individual measures           
     ≥5 opioid fills 5525 (7.9%) 0.0138 73 0.0296 34 0.0523 19 0.0900 11 
     ≥12 MME/day 19926 (28.6%) 0.0028 356 0.0107 93 0.0211 47 0.0404 25 
     ≥45 MME/day 7541 (10.8%) 0.0049 203 0.0163 61 0.0310 32 0.0591 17 
     ≥140 MME/day 1980 (2.8%) 0.0127 79 0.0318 31 0.0532 19 0.1002 10 
     NC MLIP standard: 
      ≥7 opioid fills  
1703 (2.4%) 0.0146 68 0.0374 27 0.0684 15 0.1161 9 
Combined measures  
(unconditional) 
          
≥5 opioid fills or 
    ≥12 MME/day 
20404 (29.3%) 0.0034 298 0.0117 86 0.0222 45 0.0424 24 
≥5 opioid fills or 
    ≥45 MME/day 
10545 (15.1%) 0.0082 122 0.0208 48 0.0371 27 0.0664 15 
≥5 opioid fills or 
     ≥140 MME/day 
6336 (9.1%) 0.0132 76 0.0296 34 0.0514 19 0.0893 11 
≥7 opioid fills or 
     ≥12 MME/day 
19970 (28.7%) 0.0028 352 0.0108 93 0.0211 47 0.0405 25 
≥7 opioid fills or 
     ≥45 MME/day 
8370 (12.0%) 0.0060 167 0.0184 54 0.0349 29 0.0643 16 
≥7 opioid fills or 
    ≥140 MME/day 
3336 (4.8%) 0.0133 75 0.0325 31 0.0589 17 0.1041 10 
Combined measures  
(conditional) 
          
≥5 opioid fills and 
    ≥12 MME/day 
5047 (7.2%) 0.0132 76 0.0289 35 0.0522 19 0.0897 11 
≥5 opioid fills and 
    ≥45 MME/day 
2521 (3.6%) 0.0124 81 0.0306 33 0.0576 17 0.1048 10 
≥5 opioid fills and 
    ≥140 MME/day 
1169 (1.7%) 0.0160 62 0.0361 28 0.0626 16 0.1185 8 
≥7 opioid fills and 
    ≥12 MME/day 
1659 (2.4%) 0.0147 68 0.0375 27 0.0694 14 0.1177 8 
≥7 opioid fills and 
    ≥45 MME/day 
874 (1.3%) 0.0155 65 0.0418 24 0.0734 14 0.1308 8 
≥7 opioid fills and 
    ≥140 MME/day 
347 (0.5%) 0.0190 53 0.0575 17 0.0811 12 0.1555 6 
Note: ARD=Absolute risk difference; NNE=Number needed to enroll; MME=Milligram morphine equivalent; NC 
MLIP=North Carolina Medicaid lock-in program. ARD was calculated from Kaplan-Meier survival function models 
by subtracting the probability of experiencing the outcome event at a given time point among those below an opioid 
use measure threshold from the probability of experiencing the outcome event at that same time among those 
meeting the threshold. The NNE was calculated as (1 / ARD) and is interpreted as the number of individuals needed 
to enroll into a hypothetical MLIP program based on a given opioid use criterion in order to have the opportunity to 
prevent one outcome event. 
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Appendix Table 41: Kaplan-Meier estimates of any substance use disorder diagnosis, by opioid use 
criterion, represented as absolute risk differences and numbers needed to enroll 
   Follow-up time 
Criterion met 
(N=69,667) 30 days 90 days 180 days 365 days 
 
n (%) ARD NNE ARD NNE ARD NNE ARD NNE 
Individual measures           
     ≥5 opioid fills 5525 (7.9%) 0.0872 11 0.1625 6 0.2187 5 0.2567 4 
     ≥12 MME/day 19926 (28.6%) 0.0380 26 0.0813 12 0.1163 9 0.1518 7 
     ≥45 MME/day 7541 (10.8%) 0.0339 30 0.0759 13 0.1102 9 0.1530 7 
     ≥140 MME/day 1980 (2.8%) 0.0362 28 0.0792 13 0.1262 8 0.1821 5 
     NC MLIP standard: 
      ≥7 opioid fills  
1703 (2.4%) 0.1066 9 0.2014 5 0.2627 4 0.3144 3 
Combined measures  
(unconditional) 
          
≥5 opioid fills or 
    ≥12 MME/day 
20404 (29.3%) 0.0410 24 0.0867 12 0.1224 8 0.1586 6 
≥5 opioid fills or 
    ≥45 MME/day 
10545 (15.1%) 0.0580 17 0.1146 9 0.1573 6 0.1972 5 
≥5 opioid fills or 
     ≥140 MME/day 
6336 (9.1%) 0.0793 13 0.1511 7 0.2035 5 0.2437 4 
≥7 opioid fills or 
     ≥12 MME/day 
19970 (28.7%) 0.0383 26 0.0821 12 0.1172 9 0.1528 7 
≥7 opioid fills or 
     ≥45 MME/day 
8370 (12.0%) 0.0451 22 0.0938 11 0.1321 8 0.1744 6 
≥7 opioid fills or 
    ≥140 MME/day 
3336 (4.8%) 0.0692 14 0.1362 7 0.1916 5 0.2416 4 
Combined measures  
(conditional) 
          
≥5 opioid fills and 
    ≥12 MME/day 
5047 (7.2%) 0.0837 12 0.1565 6 0.2137 5 0.2511 4 
≥5 opioid fills and 
    ≥45 MME/day 
2521 (3.6%) 0.0624 16 0.1271 8 0.1798 6 0.2300 4 
≥5 opioid fills and 
    ≥140 MME/day 
1169 (1.7%) 0.0488 20 0.0936 11 0.1563 6 0.2165 5 
≥7 opioid fills and 
    ≥12 MME/day 
1659 (2.4%) 0.1056 9 0.1991 5 0.2604 4 0.3120 3 
≥7 opioid fills and 
    ≥45 MME/day 
874 (1.3%) 0.0841 12 0.1769 6 0.2319 4 0.3001 3 
≥7 opioid fills and 
    ≥140 MME/day 
347 (0.5%) 0.0780 13 0.1530 7 0.1947 5 0.2847 4 
Note: ARD=Absolute risk difference; NNE=Number needed to enroll; MME=Milligram morphine equivalent; NC 
MLIP=North Carolina Medicaid lock-in program. ARD was calculated from Kaplan-Meier survival function models 
by subtracting the probability of experiencing the outcome event at a given time point among those below an opioid 
use measure threshold from the probability of experiencing the outcome event at that same time among those 
meeting the threshold. The NNE was calculated as (1 / ARD) and is interpreted as the number of individuals needed 
to enroll into a hypothetical MLIP program based on a given opioid use criterion in order to have the opportunity to 
prevent one outcome event.  
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